

1  
2                   IN THE UNITED STATES DISTRICT COURT  
3                   FOR THE NORTHERN DISTRICT OF OHIO  
4                   EASTERN DIVISION

5  
6                   IN RE: NATIONAL PRESCRIPTION           MDL No. 2804  
7                   OPIATE LITIGATION                   Case No. 17-md-2804

8                   This document relates to:               Judge Dan  
9   Aaron Polster

10                   The County of Cuyahoga v. Purdue  
11                   Pharma, L.P., et al.

12                   Case No. 17-OP-45005

13                   City of Cleveland, Ohio vs. Purdue  
14                   Pharma, L.P., et al.

15                   Case No. 18-OP-45132

16                   The County of Summit, Ohio,  
17                   et al. v. Purdue Pharma, L.P.,  
18                   et al.

19                   Case No. 18-OP-45090

20   VOLUME II  
21   Videotaped Deposition of Kyle J. Wright  
22   Washington, D.C.  
23   March 4, 2019

24   9:09 a.m.

25                   Reported by: Bonnie L. Russo  
26                   Job No. 3249543

<p style="text-align: right;">Page 269</p> <p>1 Videotaped Deposition of Kyle J. Wright held 2 at: 3 4 5 6 7 Williams &amp; Connolly, LLP 8 725 12th Street, N.W. 9 Washington, D.C. 10 11 12 Pursuant to Notice, when were present on behalf 13 of the respective parties: 14 15 16 17 18 19 20 21 22 23 24 25</p>	<p style="text-align: right;">Page 271</p> <p>1 APPEARANCES (CONTINUED): 2 On behalf of Purdue Pharma, L.P. DEBRA D. O'GORMAN, ESQ. 3 DECHERT, LLP Three Bryant Park 4 1095 Avenue of the Americas New York, New York 10036 5 212-698-3593 debra.ogorman@dechert.com 6 7 On behalf of Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. 8 JEFFREY A. BARKER, ESQ. O'MELVENY &amp; MYERS, LLP 9 610 Newport Center Drive, 17th Floor Newport Beach, California 92660 10 949-823-7963 jbarker@omm.com 11 -and- RAYMOND KRNEVIC, ESQ. 12 (Via Teleconference) TUCKER ELLIS, LLP 13 950 Main Avenue Suite 1100 14 Cleveland, Ohio 44113 216-592-5000 15 raymond.krnevic@tuckerellis.com 16 17 On behalf of Walmart, Inc. 18 NEAL J. STEPHENS, ESQ. JONES DAY 18 1755 Embarcadero Road Palo Alto, California 94303 19 650-739-3939 nstephens@jonesday 20 -and- PATRICK J. BEISELL, ESQ. 21 (By Teleconference) JONES DAY 22 77 West Wacker Chicago, Illinois 60601 23 312-269-4066 pbeisell@jonesday.com 24 25</p>
<p style="text-align: right;">Page 270</p> <p>1 APPEARANCES: 2 On behalf of the Witness: 3 DAVID LEE TAYMAN, ESQ. TAYMAN LANE CHAVERRI, LLP 4 1875 Eye Street, N.W. Fifth Floor 5 Washington, D.C. 20006 202-695-8147 6 ddayman@tlclawfirm.com 7 On behalf of the U.S. Department of Justice: JAMES R. BENNETT, II, ESQ. 8 UNITED STATES ATTORNEY'S OFFICE 801 West Superior Avenue 9 Suite 400 Cleveland, Ohio 44113 10 216-622-3988 james.bennett4@usdoj.gov 11 12 On behalf of Cuyahoga County: HUNTER J. SHKOLNIK, ESQ. 13 NAPOLI SHKOLNIK, PLLC 360 Lexington Avenue, 11th Floor 14 New York, New York 10017 212-397-1000 15 sshkolnik@napolilaw.com 16 On behalf of Summit County: DONALD A. MIGLIORI, ESQ. 17 KAITLYN EEKHOFF, ESQ. MOTLEY RICE, LLC 18 28 BridgeSide Boulevard Mt. Pleasant, South Carolina 29464 19 843-216-9241 dmigliori@motleyrice.com 20 keekhoff@motleyrice.com 21 On behalf of Plaintiffs: PAUL FARRELL, JR., ESQ. (Via Teleconference) 22 GREENE KETCHUM BAILEY FARRELL &amp; TWEEL, LLP 23 419 11th Street Huntington, West Virginia 25701 24 304-525-9115 25</p>	<p style="text-align: right;">Page 272</p> <p>1 APPEARANCES (CONTINUED): 2 On behalf of Par Pharmaceuticals: AMY M. VANNI, ESQ. 3 McCARTER &amp; ENGLISH 1600 Market Street, Suite 3900 4 Philadelphia, Pennsylvania 19103 215-979-3848 5 avanni@mccarter.com 6 7 On behalf of Cardinal Health, Inc.: 8 ENU MAINIGI, ESQ. COLLEEN McNAMARA, ESQ. 9 JENNIFER WICHT, ESQ. BRAD MASTERS, ESQ. 9 WILLIAMS &amp; CONNOLLY, LLP 725 12th Street, N.W. 10 Washington, D.C. 20005 202-434-5000 11 emainigi@wc.com cmcnamara@wc.com 12 jwicht@wc.com bmasters@wc.com 13 14 On behalf of CVS Indiana, LLC and CVS Rx Services, Inc.: 15 ANTHONY M. RUIZ, ESQ. ZUCKERMAN SPAEDER, LLP 16 1800 M Street, N.W. Suite 1000 17 Washington D.C. 20036 202-778-1800 18 aruiz@zuckerman.com 19 20 On behalf of AmerisourceBergen Drug Corporation: 21 SHANNON McCLURE, ESQ. 21 REED SMITH, LLP Three Logan Square, Suite 3100 22 1717 Arch Street Philadelphia, Pennsylvania 19103 23 215-241-7910 smclure@reedsmith.com 24 25</p>

<p>1 APPEARANCES (CONTINUED):  2 On behalf of Henry Schein, Inc.:  3 BRANDAN MONTMINY, ESQ.  3 (By Teleconference)  4 LOCKE LORD, LLP  4 2200 Ross Avenue  5 Suite 2800  5 Dallas, Texas 75201  5 214-740-8554  6 brandan.montminy@lockelord.com  7  8 On behalf of McKesson Corporation:  8 GEOFFREY E. HOBART, ESQ.  9 ANDREW STANNER, ESQ.  9 MEGHAN MONAGHAN, ESQ.  10 COVINGTON &amp; BURLING, LLP  10 One CityCenter  10 850 Tenth Street, N.W.  11 Washington, D.C. 20001  11 202-662-6000  12 ghobart@cov.com  12 astanner@cov.com  13 mmonaghan@cov.com  13 -and-  14 CHRISTOPHER K. EPPICH, ESQ.  14 COVINGTON &amp; BURLING, LLP  15 1999 Avenue of the Stars  15 Los Angeles, California 90067  16 424-332-4764  16 ceppich@cov.com  17  18 On behalf of Allergan Finance, LLC:  18 JENNIFER LEVY, ESQ.  19 CATIE VENTURA, ESQ.  19 KIRKLAND &amp; ELLIS, LLP  20 655 Fifteenth Street, N.W.  20 Washington, D.C. 20005  21 202-879-5907  21 jennifer.levy@kirkland.com  22 catie.ventura@kirkland.com  23  24  25</p>	<p>Page 273</p> <p>1 ALSO PRESENT:  1 David Cohen, Special Master  2 Renee A. Bacchus, Esq., United States  2 Department of Justice, United States Attorney's  3 Office  3 Robert E. Chandler, Esq., United States  4 Department of Justice, Civil Division  4 David M. Finkelstein, Esq., United States  5 Department of Justice, Civil Fraud Section  5 Mariama C. Spears, Esq., United States  6 Department of Justice, Drug Enforcement  6 Administration  7 Natalie A. Waites, United States Department of  7 Justice, Civil Fraud Section  8 Chelsea Thompson, Napoli Shkolnik, PLLC  8 Jodie Klockenga, Napoli Shkolnik, PLLC (Via  9 Teleconference)  9 Mike Fuller, Motley Rice  10 Daniel Russo, Videographer  10 Solomon Francis, IT Specialist  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25</p>
<p>1 APPEARANCES (CONTINUED):  2 On behalf of Mallinckrodt and Spec Gx, LLC:  2 ANDREW O'CONNOR, ESQ.  3 WILLIAM DAVISON, ESQ.  3 ROPES &amp; GRAY, LLP  4 Prudential Tower  4 800 Boylston Street  5 Boston, Massachusetts 02199  5 617-951-7000  6 andrew.o'connor@ropesgray.com  6 william.davison@ropesgray.com  7  8 On behalf of H.D. SMITH:  8 WILLIAM E. PADGETT, ESQ.  8 BARNESES &amp; THORNBURG, LLP  9 11 South Meridian Street  9 Indianapolis, Indiana 46204  10 317-236-1313  10 william.padgett@btlaw.com  11  12 On behalf of HBC:  12 ROBERT M. BARNES, ESQ.  12 (Via Teleconference)  13 MARCUS &amp; SHAPIRA, LLP  13 One Oxford Centre, 35th Floor  14 301 Grant Street  14 Pittsburgh, Pennsylvania 15219  15 412-338-5224  15 rbarnes@marcus-shapira.com  16  16 On behalf of Walgreen Co. and Walgreen Eastern  16 Co., Inc.:  17 LESTER C. HOUTZ, ESQ.  17 BARTLIT BECK, LLP  17 1801 Wewatta Street  18 Suite 1200  18 Denver, Colorado 80202  20 303-592-3197  20 lester.houtz@bartlitbeck.com  21  21 On behalf of Prescription Supply, Inc.  22 ZACHARY MARTIN, ESQ.  22 (Via Teleconference)  23 FOX ROTHSCHILD, LLP  23 Stone Manor Corporate Center  24 2700 Kelly Road, Suite 300  24 Warrington, Pennsylvania 18976  25 215-918-3680  25 zmartin@foxrothschild.com</p>	<p>Page 274</p> <p>1 C O N T E N T S  2 EXAMINATION OF KYLE J. SMITH PAGE  3 BY MR. MIGLIORI 278  4 BY MR. SHKOLNIK 383  5 BY MS. MAINIGI 478  6 BY MR. EPPICH 535  7  8 EXHIBITS  9 Exhibit 30 Letter dated 9-27-06 322  9 CAH_MDL_PRIORPROD_DEA07_00837645-648  10  10 Exhibit 31 Letter dated 12-27-07 343  11 CAH_MDL_PRIORPROD_DEA07_01053067-068  12 Exhibit 32 Draft Summary of the 356  12 HDMA DEA Meeting  13 October 16 and 17, 2007  13 HDS-MDL-00622468-472  14  14 Exhibit 33 Effective Controls Against 362  15 Diversion of Controlled  15 Substances  16 10-16-07  16 ECAH_001_000454261-320  17  17 Exhibit 34 Industry Compliance 370  18 Guidelines  18 CAH_MDL2804_00988458-472  19  19 Exhibit 35 Drug Enforcement 386  20 Administration's Office of  20 Diversion Control  21 CAH 019076-120  22 Exhibit 36 Claimant's Request for 401  22 Production of Documents to  22 Plaintiff  22 HDS_MDL_00002032-2045  24  24 Exhibit 37 NWDA Suspicious Order 415  25 Monitoring System  25 CAH_MDL2804_01465723-734</p>

3 (Pages 273 - 276)

Veritext Legal Solutions

www.veritext.com

888-391-3376

<p>1 EXHIBITS (CONTINUED):  2 Exhibit 38 Request Number 03-1134-F 429  3 CAH_MDL2804_02203353-357  4 Exhibit 39 Chemical Handler's Manual 437  5 January 2004  6 WAGMDL00395965-033  7 Exhibit 40 Letter date stamped 9-4-08 442  8 US-DEA-00005987-6045  9 Exhibit 41 Inventory Data 459  10 License Agreement  11 TEVA_MDL_A_03448408-418  12 Exhibit 42 Inventory Data 467  13 License Agreement  14 PPLPC004000320062-072  15 Exhibit 43 First Amendment 472  16 Inventory Data License  17 Agreement  18 PPLPC034001042114-115  19 Exhibit 44 IMS Health Data 473  20 Sharing Agreement  21 PPLPC031001277089-092  22 Exhibit 45 (SKIPPED)  23 Exhibit 46 21 U.S.C.A. Section 823 495  24 Exhibit 47 21 C.F.R. Section 1301.74 495  25 Exhibit 48 United States vs. 527  26 S463,407.72  27 Opinion  28 Exhibit 49 ARCOS 539  29 Automation of Reports and  30 Consolidated Orders System  31 Exhibit 50 (SKIPPED)  32 Exhibit 51 E-Mail Chain 551  33 dated 8-14-08  34 MCK_WVA_000088-89  35 (Exhibits included with transcript.)</p>	Page 277	Page 279
<p>1 PROCEEDINGS  2  3 THE VIDEOGRAPHER: Good morning.  4 We going on the record at 9:09 a.m.  5 on March 4th, 2019.  6 This begins Media Unit No. 1, Volume  7 II, of the continued recorded video deposition  8 of Kyle Wright.  9 We are now on the record.  10 You may proceed, Counsel.  11 MR. MIGLIORI: Thank you.  12 EXAMINATION BY COUNSEL FOR SUMMIT COUNTY  13 PLAINTIFFS  14 BY MR. MIGLIORI:  15 Q. Good morning.  16 A. Good morning.  17 Q. My name is Don Migliori. I'm here  18 on behalf of Summit County and -- and the  19 plaintiffs generally in the multidistrict  20 litigation.  21 With me is Hunter Shkolnik.  22 A. Morning.  23 Q. This morning we'll be asking you  24 some questions as a follow-up to our day  25 together on Thursday. Okay?</p>	Page 278	Page 280
<p>1 A. Okay.  2 Q. Before we get started, do you have  3 any questions or concerns, anything we need to  4 know about?  5 A. No.  6 Q. Okay. Sir, could you tell us again  7 what you were doing from 1995 to 2005 at DEA.  8 A. I was a diversion investigator  9 assigned to the Dallas field division. I  10 covered a myriad of assignments and  11 investigations, basically culminating in -- in  12 two facets: the methamphetamine problem along  13 the Texas-Oklahoma border, and actually I was  14 engaged in an Internet investigation just prior  15 to being transferred to D.C.  16 Q. Okay. And that Internet  17 investigation what -- what type of  18 investigation was that?  19 A. It was a -- a Internet Hydrocodone  20 investigation.  21 Q. Was it specific to the field where  22 you were located in Dallas, or was it outside  23 of the Dallas area?  24 A. The actual pharmacies were located  25 within the jurisdictional or operational area    1 of the Dallas field division with ties to other  2 areas of the country.  3 Q. So fair to say that, from 1995 when  4 you first started at the DEA through 2005, you  5 had no responsibilities with respect to the  6 drug enforcement agency headquarter operations?  7 A. That would be correct.  8 Q. And while you were in the Dallas  9 field office, primarily your responsibilities  10 involved investigations relative to  11 methamphetamines and pseudoephedrine, correct?  12 MS. MCCLURE: Objection. Misstates  13 the witness's testimony.  14 BY MR. MIGLIORI:  15 Q. Go ahead. You an answer.  16 A. That would be correct.  17 Q. Okay. So as you know, counsel  18 showed you the notice of deposition for today  19 and then also showed you Exhibit No. 2.  20 Do you have the exhibit book in  21 front of you?  22 A. Yes, sir.  23 Q. So I'm going to project on the  24 screen what we're talking about. But you have  25 it in front of you. And if you have any</p>		

<p style="text-align: right;">Page 281</p> <p>1 questions or if not sure where I'm referring 2 to, please -- please just let me know. 3         Exhibit 2, as was explained to you, 4 is the authorization for you to testify here 5 today. 6         Do you understand that? 7         A. Yes, sir. 8         Q. And that authorization was provided 9 by the United States Department of Justice. 10 And the purpose of that authorization is to 11 identify five areas where you are, in fact, 12 authorized to give testimony for this case. 13         Do you see that? 14         A. Yes, sir. 15         Q. And we'll go through those in a 16 minute. 17         But on the second page is a list of 18 the areas that you are not authorized to speak 19 on, and it's letter A through M. 20         Do you see that? 21         A. Yes, sir. 22         Q. Okay. So just for context, I want 23 to make sure that we're clear of why you're 24 here and what you're allowed to speak on based 25 on your authorization from the Department of</p>	<p style="text-align: right;">Page 283</p> <p>1         THE WITNESS: Yes, sir. 2         BY MR. MIGLIORI: 3         Q. Okay. The third is your personal 4 recollection of practices and procedures 5 relating to ARCOS data and suspicious order 6 reports. 7         MR. BENNETT: Objection. I think 8 you missed a word. You said "your." You -- I 9 think you didn't tell him "your practices and 10 procedures." 11         MR. MIGLIORI: Okay. There are two 12 yours in there. I'll repeat it. 13         MR. BENNETT: Correct. 14         BY MR. MIGLIORI: 15         Q. Your personal recollection of your 16 practices and procedures relating to ARCOS data 17 and suspicious order reports. 18         Do you understand that that's and 19 that has been your authorization to speak here 20 today and -- and last week? 21         MS. MAINIGI: Objection. Form. 22         THE WITNESS: Yes, sir. 23         BY MR. MIGLIORI: 24         Q. And -- and the reason I'm asking is, 25 when you are giving your testimony in this</p>
<p style="text-align: right;">Page 282</p> <p>1 Justice. Okay? 2         MS. MAINIGI: Objection. 3         THE WITNESS: Yes, sir. 4         BY MR. MIGLIORI: 5         Q. The first area that you're 6 authorized to speak about is your general 7 employment history with the DEA. 8         You have already given us a pretty 9 complete description of your general employment 10 history with the DEA, correct? 11         A. Yes, sir. 12         Q. And that started in 1995, and you 13 retired in 2017; is that correct? 14         A. Yes, sir. 15         Q. And you're currently retired and 16 have been for approximately two years, correct? 17         A. Yes, sir. 18         Q. All right. The second area you're 19 authorized to speak on is your general duties 20 in your various positions held in the DEA. 21         Do you feel like you've given us a 22 general -- I think the word was used several 23 times -- high-level description of your various 24 positions held at the DEA? 25         MS. MAINIGI: Objection. Form.</p>	<p style="text-align: right;">Page 284</p> <p>1 case, you understand that you're here giving us 2 your factual background and experience with the 3 DEA based on this authority. 4         Did you understand that? 5         MS. MAINIGI: Objection. 6         MS. McClure: Objection. 7         THE WITNESS: Yes, sir. 8         BY MR. MIGLIORI: 9         Q. And that you weren't here speaking 10 for the G -- the DEA across the board as an 11 official representative of the DEA today. 12         You understood that, correct? 13         MS. MAINIGI: Objection. 14         THE WITNESS: Yes, sir. 15         BY MR. MIGLIORI: 16         Q. And you weren't authorized to speak 17 on behalf of the DEA for the years that you 18 were employed at the DEA; that is you were 19 limited to your personal recollection of your 20 practices. 21         Did you understand that? 22         MS. MAINIGI: Objection. 23         THE WITNESS: Yes, sir. 24         BY MR. MIGLIORI: 25         Q. The fourth area where you've been</p>

<p style="text-align: right;">Page 285</p> <p>1 authorized to speak is your personal 2 recollection of your interaction with 3 registrants when a distributor terminated its 4 relationship with a customer due to the risk of 5 diversion -- diversion.</p> <p>6 When speaking about that topic, that 7 is the termination of a distributor in 8 relationship to a customer, you understood that 9 any testimony that you provided last week or 10 will provide today is your personal your 11 personal relect -- interact -- strike -- your 12 personal recollection of your interactions.</p> <p>13 Do you understand and appreciate 14 that limitation?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: Yes, sir.</p> <p>17 BY MR. MIGLIORI:</p> <p>18 Q. And the final area that the 19 Department of Justice has authorized you to 20 give testimony in this case is your personal 21 recollection regarding DEA's interpretation and 22 enforcement of and practices relating to 21 USC 23 823 and 21 CFR 1301.74 to the extent covered by 24 the foregoing authorized specific topics.</p> <p>25 Did you understand that, whenever</p>	<p style="text-align: right;">Page 287</p> <p>1 these topics that we've -- we've identified 2 here, he would have a position, at least 3 relative these -- to these topics, as you said, 4 three or four tears higher than you in the flow 5 chart within DEA headquarters, correct?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: That would be correct.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. The same for Mr. Mapes; Mr. Mapes 10 was your direct supervisor, correct?</p> <p>11 A. Yes, sir.</p> <p>12 Q. And to the extent that Mr. Mapes may 13 testify in this case, he would have his own 14 authority under this process to testify, and he 15 would be above you in terms of role and 16 responsibility in the area of distributor 17 initiative and briefing, correct?</p> <p>18 MS. MAINIGI: Objection.</p> <p>19 THE WITNESS: I apologize. I got a 20 little lost in that question.</p> <p>21 MR. MIGLIORI: I may have too. I'll 22 start over.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. Mr. Mapes was your direct 25 supervisor, correct?</p>
<p style="text-align: right;">Page 286</p> <p>1 you spoke about the DEA's interpretation of the 2 obligations under the Controlled Substances 3 Act, that you were giving your personal 4 recollection of the DEA's interpretation?</p> <p>5 MS. MAINIGI: Objection.</p> <p>6 THE WITNESS: Yes, sir.</p> <p>7 BY MR. MIGLIORI:</p> <p>8 Q. The defendants in this case have 9 noticed the depositions of Mr. Rannazzisi.</p> <p>10 Just for purposes of -- of clarity, 11 what was Mr. Rannazzisi's role in relationship 12 to you in the years you were in the DEA?</p> <p>13 A. Mr. Rannazzisi was the deputy 14 assistant administrator. And he was about 15 three to four tiers above myself and 16 supervisor.</p> <p>17 Q. Okay. So you reported directly to 18 him, or did you report to him through 19 Mr. Mapes?</p> <p>20 MS. McClure: Objection. Form.</p> <p>21 THE WITNESS: I would have reported 22 to him through Mr. Mapes.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. Okay. And so, to the extent that 25 Mr. Rannazzisi has testimony that's related to</p>	<p style="text-align: right;">Page 288</p> <p>1 A. Yes, sir.</p> <p>2 Q. All right. And to the extent that 3 he is speaking on these topics that we've 4 enumerated, he would be the person above you, 5 that is a decision maker above you, on these 6 topics, correct --</p> <p>7 MS. MAINIGI: Objection.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 -- during the relevant years?</p> <p>10 MS. MAINIGI: Excuse me.</p> <p>11 Objection.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. MIGLIORI:</p> <p>14 Q. Okay. Now, the Justice Department 15 in Exhibit 2 specifically said there is some 16 thing that you are not authorized to talk 17 about. That's on Page 2 of -- of Exhibit 2 18 introduced by defense counsel Thursday. And 19 I'll just go through some of them.</p> <p>20 You are not authorized and have not 21 testified here about information regarding any 22 specific DEA investigation or activity, 23 correct?</p> <p>24 MS. MAINIGI: Objection.</p> <p>25 MS. McClure: Objection.</p>

1        THE WITNESS: Correct. 2        BY MR. MIGLIORI: 3        Q. And you are not authorized and you 4        weren't giving any testimony in this case 5        relative to classified and classifiable 6        information that you may have encountered while 7        at the DEA, correct? 8        MS. MAINIGI: Objection. 9        THE WITNESS: Correct. 10      BY MR. MIGLIORI: 11      Q. You are not authorized and you are 12     not speaking in this deposition as to 13     information that would reveal the internal 14     deliberative process within the United States 15     Department of Justice, including the DEA, the 16     United States Attorney's Off -- U.S. Attorney's 17     Office and/or any federal departments or 18     agencies, correct? 19      MS. MAINIGI: Objection. 20      THE WITNESS: Correct. 21      BY MR. MIGLIORI: 22      Q. You are not authorized and you did 23     not testify on Thursday and will not testify 24     today about any information that could reveal 25     investigative or intelligence gathering and	Page 289 1        aware of concerning any proposed agency action, 2        correct? 3        MS. MAINIGI: Objection. 4        THE WITNESS: Correct. 5        BY MR. MIGLIORI: 6        Q. I know it may seem a little tedious, 7        but counsel showed this to you without going 8        through those elements. And so I just want to 9        make sure we understand. 10      You're here to tell us your 11     experience at the DEA, correct? 12      MS. MAINIGI: Objection. 13      MR. STEPHENS: Object to form. 14      (Reporter clarification.) 15      MR. MIGLIORI: I'll repeat the -- 16     what we said off the record last time. We're 17     -- I'll accept one objection as for everybody, 18     unless there's some other reason to make the 19     court reporter crazy. 20      THE WITNESS: Yes, sir. 21      BY MR. MIGLIORI: 22      Q. All right. So when counsel last 23     week asked you questions about your impressions 24     of what was right or what was wrong or what was 25     blessed or not blessed, those were your
Page 290 1        dissemination techniques whose effectiveness 2        would thereby be impaired, correct? 3        MS. MAINIGI: Objection. 4        MR. MIGLIORI: Letter H. 5        THE WITNESS: Correct. 6        BY MR. MIGLIORI: 7        Q. You are not authorized and you are 8        not giving any expert testimony related to the 9        nonpublic facts or information acquired as part 10      of your performance of your official duties at 11      the DEA, correct? 12      MS. MAINIGI: Objection. 13      THE WITNESS: Correct. 14      BY MR. MIGLIORI: 15      Q. You are not authorized and you are 16      not going to offer any personal opinions 17      regarding nonpublic facts or information 18      acquired as part of your performance of your 19      official duties, correct? 20      MS. MAINIGI: Objection. 21      THE WITNESS: Correct. 22      BY MR. MIGLIORI: 23      Q. And finally, you are not authorized 24      you did not speak and you will not speak on any 25      nonpublic recommendations you made or you are	Page 292 1        recollections of your interpretations of what 2        happened in the past, correct? 3        MS. MAINIGI: Objection. 4        THE WITNESS: Yes, sir. 5        BY MR. MIGLIORI: 6        Q. And so the defendants have noticed 7        what's called a 30(b)(6) witness. That is 8        they've actually sent out a notice asking the 9        government to produce the person to speak on 10      behalf of the Drug Enforcement Agency in this 11      litigation. 12      To date have you been asked to serve 13      as that person that will speak on behalf of the 14      DEA in a 30(b)(6) deposition? 15      MS. MAINIGI: Objection to form. 16      MR. BENNETT: And objection to the 17      extent that it calls for any communications 18      with counsel, either the general counsel's 19      office at DEA or the Department of Justice. 20      But otherwise you can answer. 21      THE WITNESS: God, I hope not. 22      BY MR. MIGLIORI: 23      Q. Okay. And, in fact, we believe that 24      there is somebody else designated to speak on 25      behalf of the Drug Enforcement Agency in that

<p style="text-align: right;">Page 293</p> <p>1 capacity.</p> <p>2 But as you sit here today, you have</p> <p>3 not -- you don't have any understanding that</p> <p>4 that is a role that you're supposed to be</p> <p>5 playing, correct?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 Don, I don't know if you need to</p> <p>8 have a running commentary about what's</p> <p>9 happening as part of your questioning.</p> <p>10 MR. MIGLIORI: Okay. That's -- I</p> <p>11 got your objection. You can -- you can note</p> <p>12 that.</p> <p>13 THE WITNESS: Yes, sir.</p> <p>14 MR. MIGLIORI: All right.</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. So we're here about the role that</p> <p>17 you did play and your recollection of the role</p> <p>18 that you played primarily with respect to the</p> <p>19 period of time from 2005 on at the DEA.</p> <p>20 In 2000 --</p> <p>21 MS. McCLURE: Objection to the</p> <p>22 commentary for the record.</p> <p>23 MS. MAINIGI: Is -- is that -- was</p> <p>24 that a question? And are you starting another</p> <p>25 question?</p>	<p style="text-align: right;">Page 295</p> <p>1 MR. MIGLIORI: Go ahead.</p> <p>2 THE WITNESS: Yes, sir.</p> <p>3 BY MR. MIGLIORI:</p> <p>4 Q. All right. So counsel showed you</p> <p>5 some PowerPoints.</p> <p>6 And in 2005 -- this is Exhibit No.</p> <p>7 10 -- you testified to having participated --</p> <p>8 MR. BENNETT: Counsel, can we let</p> <p>9 him find it --</p> <p>10 MR. MIGLIORI: Sure.</p> <p>11 MR. BENNETT: -- find it. It's not</p> <p>12 in the book.</p> <p>13 MR. MIGLIORI: Oh, I apologize.</p> <p>14 MR. BENNETT: Did you find it?</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. Do you have it?</p> <p>17 A. Exhibit No. 10.</p> <p>18 Q. Okay. Counsel showed you Exhibit</p> <p>19 No. 10, which on the cover of the PowerPoint</p> <p>20 attachment says the Internet Pharmacy Data</p> <p>21 Meeting with the Amerisource --</p> <p>22 AmerisourceBergen DEA headquarters, August</p> <p>23 10th, 2005.</p> <p>24 Are we on the same page?</p> <p>25 A. Same as displayed?</p>
<p style="text-align: right;">Page 294</p> <p>1 MR. MIGLIORI: No. I'm about to go</p> <p>2 into the question.</p> <p>3 Are we going to do this the whole</p> <p>4 thing?</p> <p>5 You can -- you can put it --</p> <p>6 anything you want on the record, and we can</p> <p>7 argue about it later.</p> <p>8 MS. MAINIGI: Well, we may have to</p> <p>9 call the special master and argue about it now.</p> <p>10 But go ahead.</p> <p>11 MR. MIGLIORI: That's -- that's not</p> <p>12 how this works.</p> <p>13 MS. MAINIGI: Well, I think it is.</p> <p>14 BY MR. MIGLIORI:</p> <p>15 Q. In 2005 you started in Washington,</p> <p>16 D.C., correct?</p> <p>17 A. Correct.</p> <p>18 Q. Everything that you've testified to</p> <p>19 prior to 2005 is based on information that you</p> <p>20 would have learned from others about the</p> <p>21 history of the diversion program in Washington,</p> <p>22 D.C., correct?</p> <p>23 MS. MAINIGI: Objection. Form.</p> <p>24 Misstates his testimony. His testimony speaks</p> <p>25 for itself.</p>	<p style="text-align: right;">Page 296</p> <p>1 Q. Yes.</p> <p>2 A. Okay. Yes, sir.</p> <p>3 Q. All right. Now, this is a</p> <p>4 PowerPoint that you helped put together for</p> <p>5 purposes of distributor briefings, correct?</p> <p>6 Was that your testimony?</p> <p>7 MS. McCLURE: Objection. Asked and</p> <p>8 answered.</p> <p>9 THE WITNESS: Correct.</p> <p>10 BY MR. MIGLIORI:</p> <p>11 Q. Counsel didn't go through with you</p> <p>12 all of the pages. So I want to take some time</p> <p>13 to do that now. Okay?</p> <p>14 There was testimony that these were</p> <p>15 -- that there were concerns at this time in</p> <p>16 2005 about Internet pharmacies, correct?</p> <p>17 A. Correct.</p> <p>18 MS. MAINIGI: Correct.</p> <p>19 BY MR. MIGLIORI:</p> <p>20 Q. But Internet pharmacies were not the</p> <p>21 only concern you had in 2005, was it?</p> <p>22 MS. MAINIGI: Objection. Misstates</p> <p>23 his testimony.</p> <p>24 THE WITNESS: No.</p> <p>25 BY MR. MIGLIORI:</p>

<p style="text-align: right;">Page 297</p> <p>1 Q. What other concerns in 2005 did you 2 have relative to the Controlled Substances Act 3 and the registrants when you were doing these 4 briefings?</p> <p>5 MS. MAINIGI: Objection.</p> <p>6 THE WITNESS: I'll try to say it in 7 a nutshell: to maintain, oversee and protect 8 the closed system of distribution at all 9 levels.</p> <p>10 BY MR. MIGLIORI:</p> <p>11 Q. Was that the role of the Drug 12 Enforcement Agency, as you understood it in 13 your experience?</p> <p>14 A. Yes, sir.</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 BY MR. MIGLIORI:</p> <p>17 Q. And, in fact, this PowerPoint 18 presentation has some general slides that 19 relates to that mission, correct?</p> <p>20 MS. MAINIGI: Objection. The 21 document speaks for itself.</p> <p>22 THE WITNESS: Correct.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. I want to show you the slide that 25 says "Issues to Consider."</p>	<p style="text-align: right;">Page 299</p> <p>1 pharmacy?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: They could.</p> <p>4 BY MR. MIGLIORI:</p> <p>5 Q. Do they apply to all registrants in 6 the closed system of distribution for 7 controlled substances?</p> <p>8 MS. MAINIGI: Objection.</p> <p>9 THE WITNESS: Yes, sir, they could.</p> <p>10 BY MR. MIGLIORI:</p> <p>11 Q. What's the importance of looking at 12 things like the payment method?</p> <p>13 Why is that important?</p> <p>14 MS. McCLURE: Objection.</p> <p>15 THE WITNESS: I'm sorry. I didn't 16 hear the --</p> <p>17 BY MR. MIGLIORI:</p> <p>18 Q. Why would looking at the payment 19 method be an important issue to consider as an 20 example?</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: Most people at this 23 time were covered by insurance. And when 24 insurance -- insurances, in our experience, 25 felt that if they were paying too frequently,</p>
<p style="text-align: right;">Page 298</p> <p>1 Did you help prepare this slide?</p> <p>2 A. Correct.</p> <p>3 Q. What does this slide represent?</p> <p>4 A. From past cases, experiences, 5 issues. This -- these -- these are items that 6 could be encountered, not inclusive, not every 7 one of them. But they are some items to look 8 at conducting your business from distributor to 9 pharmacy or practitioner. There could be tails 10 that there might be some amiss or awry.</p> <p>11 Q. Does this only apply to Internet 12 sales?</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 THE WITNESS: Absolutely not.</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. So when you have issues to consider, 17 like the frequency of order or size of order or 18 range of products purchased, were those applied 19 to the more traditional relationship of 20 distributor to pharmacy?</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: They absolutely could.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. Do they apply to the relationship 25 between a distributor and a chain retail</p>	<p style="text-align: right;">Page 300</p> <p>1 they wouldn't authorize payment. A reflection 2 of addiction is to pay cash.</p> <p>3 BY MR. MIGLIORI:</p> <p>4 Q. Is there a term for that kind of 5 issue?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 BY MR. MIGLIORI:</p> <p>8 Q. In the DEA is that referred to as 9 a -- a red flag?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 MS. McCLURE: Objection.</p> <p>12 THE WITNESS: I said "tails." You 13 could say red flag, yes.</p> <p>14 BY MR. MIGLIORI:</p> <p>15 Q. Okay. What about percentage of 16 controlled to noncontrolled substances; why is 17 that important?</p> <p>18 MS. McCLURE: Objection.</p> <p>19 THE WITNESS: We had some 20 benchmarks. And I -- truly a benchmark, there 21 are variables in those -- in those benchmarks.</p> <p>22 But the amount of controlled versus 23 noncontrolled, noncontrolled products would be 24 like your geriatric product, your diabetes, 25 your heart medications. All those things</p>

<p style="text-align: right;">Page 301</p> <p>1   constituted a greater bulk of business, in our 2   experience and observations, as compared to 3   controlled substances.</p> <p>4       If there was a outside of that 5   pattern, look at it, see if it -- there's some 6   justification to it. There potentially could 7   be. But it's a tail or a red flag.</p> <p>8       BY MR. MIGLIORI:</p> <p>9       Q.   Were these tails or red flags 10   understood and appreciated at the time of this 11   presentation?</p> <p>12       That is, in your experience, was 13   this something that was appreciated in the 14   industry?</p> <p>15       MR. STEPHENS: Objection.</p> <p>16       MS. MAINIGI: Objection to form. No 17   foundation.</p> <p>18       THE WITNESS: In my interchange with 19   them doing these briefings, yes.</p> <p>20       BY MR. MIGLIORI:</p> <p>21       Q.   Were these red flags or tails 22   appreciated when you started in 1995 in dealing 23   with field investigations for pseudoephedrine 24   and methamphetamines?</p> <p>25       MS. MAINIGI: Objection to form.</p>	<p style="text-align: right;">Page 303</p> <p>1   Controlled Substances Act, as you understood it 2   in your experience?</p> <p>3       MS. MAINIGI: Objection.</p> <p>4       THE WITNESS: Absolutely.</p> <p>5       BY MR. MIGLIORI:</p> <p>6       Q.   And was that true when the Act was 7   enacted in the early 1970s?</p> <p>8       MS. MAINIGI: Objection.</p> <p>9       THE WITNESS: Yes, sir.</p> <p>10       BY MR. MIGLIORI:</p> <p>11       Q.   Was it certainly true as of the time 12   that you started at the DEA in 1995?</p> <p>13       MS. MAINIGI: Objection.</p> <p>14       THE WITNESS: Yes, sir.</p> <p>15       BY MR. MIGLIORI:</p> <p>16       Q.   You give some examples of cases, 17   supreme court cases and others, that relate to 18   Internet pharmacies. And then you have a 19   section in your PowerPoint presentation. This 20   is your August -- again, your August 2005 21   distributor briefing. And here you have a 22   slide that says "Suspicious Orders." 23       Can you read that?</p> <p>24       MS. MAINIGI: Objection.</p> <p>25       MR. MIGLIORI: I'm sorry. They're</p>
<p style="text-align: right;">Page 302</p> <p>1       MR. STEPHENS: Objection.</p> <p>2       THE WITNESS: Yes, sir.</p> <p>3       BY MR. MIGLIORI:</p> <p>4       Q.   These weren't new issues in 2005 5   when you're giving these briefings, were they?</p> <p>6       MS. MAINIGI: Objection.</p> <p>7       THE WITNESS: No, sir.</p> <p>8       BY MR. MIGLIORI:</p> <p>9       Q.   And these weren't limited to 10   Internet sales, were they?</p> <p>11       MS. MAINIGI: Objection.</p> <p>12       THE WITNESS: Yes, sir -- no. I'm 13   sorry. No, they were not limited to just 14   Internet.</p> <p>15       BY MR. MIGLIORI:</p> <p>16       Q.   The next page -- I don't think you 17   saw this last week either. It says "DEA 18   Distributor Registrations" and gives the 19   citation.</p> <p>20       And then it says: "Is a 21   registration in the public interest? 22   Maintenance of effective controls against 23   diversion of particular controlled substances 24   into other than legitimate medical channels."</p> <p>25       Is that part of the purpose for the</p>	<p style="text-align: right;">Page 304</p> <p>1   not numbered.</p> <p>2       THE WITNESS: You want me to read 3   this?</p> <p>4       MR. MIGLIORI: If you don't mind.</p> <p>5       THE WITNESS: Reporting a suspicious 6   order to DEA does not, emphasis on not, relieve 7   the distributor of the responsibility to 8   maintain effective controls against diversion.</p> <p>9       BY MR. MIGLIORI:</p> <p>10       Q.   What's the importance of that?</p> <p>11       MS. MAINIGI: Objection.</p> <p>12       THE WITNESS: There's 13   accountability. There's a responsibility not 14   to let -- if you go back to what you said at 15   823, maintain effective controls, medical 16   channels. Don't let it out there.</p> <p>17       BY MR. MIGLIORI:</p> <p>18       Q.   Does that only relate to Internet 19   sales?</p> <p>20       MS. MAINIGI: Objection.</p> <p>21       THE WITNESS: No, sir.</p> <p>22       BY MR. MIGLIORI:</p> <p>23       Q.   Does that apply to the sale of all 24   controlled substances within the closed system?</p> <p>25       MS. MAINIGI: Objection.</p>

<p style="text-align: right;">Page 305</p> <p>1        THE WITNESS: It the covers all 2        controls.</p> <p>3        BY MR. MIGLIORI:</p> <p>4        Q. I'm going to just flash it on the 5        screen now. We'll get back to it later. But 6        Exhibit 26, if you remember, counsel gave you 7        what's called an ingredient limit report.</p> <p>8        Do you remember seeing that 9        document?</p> <p>10      A. Yes, sir.</p> <p>11      Q. Does submitting that report on a 12     monthly basis satisfy the requirement in this 13     PowerPoint slide that we just read?</p> <p>14      MS. MAINIGI: Objection. Outside of 15     the scope.</p> <p>16      BY MR. MIGLIORI:</p> <p>17      Q. In your experience?</p> <p>18      MS. MAINIGI: Objection. Form. 19     Objection. Outside of the scope.</p> <p>20      THE WITNESS: No, sir.</p> <p>21      BY MR. MIGLIORI:</p> <p>22      Q. Why not?</p> <p>23      A. It doesn't tell me what you've done, 24     why you drew this conclusion. It's just they 25     exceeded a limit. What does -- what is your</p>	<p style="text-align: right;">Page 307</p> <p>1        MS. MAINIGI: Objection. 2        THE WITNESS: Correct.</p> <p>3        BY MR. MIGLIORI:</p> <p>4        Q. This report, Exhibit 26, was just 5        that -- those sales or purchases that were made 6        that were in excess of the benchmarks, correct?</p> <p>7        MS. MAINIGI: Object to form. Lacks 8        foundation. He said he'd never even seen the 9        report before.</p> <p>10      THE WITNESS: I'm sorry, sir. Could 11     you --</p> <p>12      MR. MIGLIORI: Sure.</p> <p>13      THE WITNESS: -- restate that</p> <p>14     question.</p> <p>15      BY MR. MIGLIORI:</p> <p>16      Q. Is Exhibit 26 a subset of the 17     transactions submitted to ARCOS?</p> <p>18      MS. MAINIGI: Objection. 19      THE WITNESS: Yes, sir.</p> <p>20      BY MR. MIGLIORI:</p> <p>21      Q. And by its description, it's the 22     excess purchases over benchmark for the month, 23     correct?</p> <p>24      MS. MAINIGI: Objection. 25      MS. McCLURE: Objection.</p>
<p style="text-align: right;">Page 306</p> <p>1        limit? Why did you set that limit? What is 2        your experience behind that limit?</p> <p>3        Q. Is everything in Exhibit 26, the 4        ingredient limit report, in excess of 5        benchmarks?</p> <p>6        MS. MAINIGI: Objection.</p> <p>7        THE WITNESS: Now that I found the 8        document, could you please repeat the question.</p> <p>9        BY MR. MIGLIORI:</p> <p>10      Q. Sure. I'm sorry.</p> <p>11      Is everything that's in this 12     ingredient limit report, Exhibit No. 26, in 13     excess of the set benchmarks?</p> <p>14      MS. MAINIGI: Objection.</p> <p>15      BY MR. MIGLIORI:</p> <p>16      Q. Is this an excessive purchase 17     report?</p> <p>18      MS. MAINIGI: Objection.</p> <p>19      THE WITNESS: This would be an 20     example of what we called Excessive Purchase 21     Reports.</p> <p>22      BY MR. MIGLIORI:</p> <p>23      Q. So the ARCOS data that you got 24     monthly was data of all transactions for the 25     month, correct?</p>	<p style="text-align: right;">Page 308</p> <p>1        THE WITNESS: Correct.</p> <p>2        BY MR. MIGLIORI:</p> <p>3        Q. Are these reported, as you 4        understood it in your experience, at the time 5        that they're discovered?</p> <p>6        MS. McCLURE: Objection.</p> <p>7        MS. MAINIGI: Objection. Outside 8        the scope. And objection to form.</p> <p>9        BY MR. MIGLIORI:</p> <p>10      Q. In your experience.</p> <p>11      A. No, sir.</p> <p>12      MS. McCLURE: Same objections.</p> <p>13      MS. MAINIGI: Same objections.</p> <p>14      BY MR. MIGLIORI:</p> <p>15      Q. For Suspicious Order Reporting, in 16     your experience was it compliant to submit a 17     report on a monthly basis?</p> <p>18      MS. MAINIGI: Objection. Form. 19     Objection foundation.</p> <p>20      THE WITNESS: I don't understand the 21     question. I'm sorry.</p> <p>22      BY MR. MIGLIORI:</p> <p>23      Q. Sure. I'll -- we'll go to the -- 24     I'll show you through the slide. 25     I'll -- I'll strike the question.</p>

<p style="text-align: right;">Page 309</p> <p>1        The next slide on the PowerPoint  2    from exhibit -- I think this was 10 -- states:  3    "The basic obligation of the Controlled  4    Substances Act," right, "that a registrant is  5    required to design and operate a system to  6    identify suspicious orders," correct?</p> <p>7        MS. MAINIGI: Objection.  8        THE WITNESS: Correct.  9        BY MR. MIGLIORI:</p> <p>10      Q. And the next point on your slide  11    from August of 2005 says: The -- "Report  12    suspicious orders to DEA when discovered."  13        In your experience, in your history,  14    "when discovered" means what to you?</p> <p>15        MS. MAINIGI: Objection. Form.  16    Objection. Calls for a legal conclusion.  17        MS. McCLURE: Objection. Outside  18    the scope.</p> <p>19        MR. MIGLIORI: Go ahead.  20        THE WITNESS: If you're going --  21    when you just determine that it's suspicious.  22        BY MR. MIGLIORI:</p> <p>23      Q. Does that mean gather them  24    and report them on a monthly basis?</p> <p>25        MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 311</p> <p>1        MS. MAINIGI: Objection.  2        THE WITNESS: If it is deemed  3    suspicious, you should resolve that suspicion  4    before fulfilling that order. Because  5    otherwise now you're letting the product go out  6    to do its damage.</p> <p>7        BY MR. MIGLIORI:</p> <p>8        Q. The next slide talks about the DEA  9    cannot tell a distributor if an order is  10   legitimate or not.  11        Do you recall that in your  12    presentation in the distributor briefings?</p> <p>13        A. Repeatedly.  14        Q. Was that true when you first got to  15    the DEA, in your experience, in 1995?</p> <p>16        MS. MAINIGI: Objection.  17        THE WITNESS: Yes, sir.  18        BY MR. MIGLIORI:</p> <p>19        Q. Did it remain true through to your  20    retirement in 2017?  21        MS. MAINIGI: Objection.  22        THE WITNESS: Yes, sir.  23        BY MR. MIGLIORI:</p> <p>24        Q. In your experience, did you express  25    that ever to registrants when asked?</p>
<p style="text-align: right;">Page 310</p> <p>1        THE WITNESS: No, sir. It says  2    "when discovered."</p> <p>3        BY MR. MIGLIORI:</p> <p>4        Q. On Exhibit 26, counsel referred to  5    this as Excessive Purchase Reports.</p> <p>6        Are purchases the same as orders?</p> <p>7        MS. MAINIGI: Objection.</p> <p>8        THE WITNESS: These are consummated  9    or completed sales. They're gone. They're  10   done.</p> <p>11        BY MR. MIGLIORI:</p> <p>12      Q. And what's a suspicious order?</p> <p>13        MS. McCLURE: Objection.</p> <p>14        THE WITNESS: Order is I have  15   submitted a request to you; it's in your hands;  16   you determine to sell it or not, fulfill it or  17   not. It's an order.</p> <p>18        BY MR. MIGLIORI:</p> <p>19        Q. If an order is determined to be --  20   or suspected to be suspicious, is it to be  21   consummated, to use your term; is the sale to  22   be consummated and sent out the door?</p> <p>23        MS. MAINIGI: Objection.</p> <p>24        BY MR. MIGLIORI:</p> <p>25        Q. In your experience?</p>	<p style="text-align: right;">Page 312</p> <p>1        MS. MAINIGI: Objection.  2        THE WITNESS: Yes, sir.</p> <p>3        BY MR. MIGLIORI:</p> <p>4        Q. Why is that true?</p> <p>5        MS. MAINIGI: Objection.</p> <p>6        THE WITNESS: They had the  7    registration. They understand control  8    substances. They've more fact than I do  9    in making that decision to fulfill or not  10   fulfill an order.</p> <p>11        I cannot draw the conclusions that  12   they can. And I can't bless or run your  13   business.</p> <p>14        BY MR. MIGLIORI:</p> <p>15        Q. What is your understanding, in your  16   experience, of who or in whom the Controlled  17   Substances Act puts that obligation?</p> <p>18        MS. MAINIGI: Objection.</p> <p>19        THE WITNESS: In these particular  20   areas, the onus of responsibility is upon the  21   industry.</p> <p>22        BY MR. MIGLIORI:</p> <p>23        Q. And the language of the act that's  24   the registrant?</p> <p>25        A. Yes, sir.</p>

Page 313	Page 315
<p>1 Q. And registrants include 2 distributors, correct?</p> <p>3 A. Correct.</p> <p>4 Q. A registrant includes pharmacies, 5 correct?</p> <p>6 A. Correct.</p> <p>7 Q. Including chain pharmacies, correct?</p> <p>8 A. Correct.</p> <p>9 Q. And pharmaceutical manufacturers are 10 also DEA registrants, correct?</p> <p>11 A. Correct.</p> <p>12 Q. And so these provisions would apply 13 to all of those groups, correct, in your 14 experience and your -- to your understanding?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: It would apply to all 17 DEA registrants.</p> <p>18 BY MR. MIGLIORI:</p> <p>19 Q. You give some examples of 20 pharmacies, and then you give a summary. And I 21 want to ask you whether this applies only to 22 Internet sales or to the industry as a whole. 23 Okay? I'll go through each one.</p> <p>24 MS. MAINIGI: Objection.</p> <p>25 BY MR. MIGLIORI:</p>	<p>1 Q. The next page of the summary says: 2 "A pattern of drugs being distributed to 3 pharmacies who are diverting controlled 4 substances demonstrates the lack of effective 5 controls against diversion by the distributor." 6 Does that apply only to Internet 7 pharmacies, or was that industrywide? 8 MS. MAINIGI: Objection.</p> <p>9 THE WITNESS: Industrywide. 10 BY MR. MIGLIORI:</p> <p>11 Q. "The DEA registration of the 12 distributor could be revoked under public 13 interest grounds."</p> <p>14 Does that apply only to Internet 15 pharmacies, or does that apply industrywide? 16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: Across the board. 18 BY MR. MIGLIORI:</p> <p>19 Q. Did you make that clear during these 20 briefings, that it applied across the board? 21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: To the best of my 23 recollection, yes.</p> <p>24 BY MR. MIGLIORI:</p> <p>25 Q. Summary says: "Any distributor</p>
Page 314	Page 316
<p>1 Q. "Prescriptions not written in the 2 usual course of professional practice are not 3 valid."</p> <p>4 Does that only apply to Internet 5 sales, or does that apply to all sales within 6 the system?</p> <p>7 MS. MAINIGI: Objection.</p> <p>8 THE WITNESS: To all sales.</p> <p>9 BY MR. MIGLIORI:</p> <p>10 Q. "Drugs dispensed pursuant to invalid 11 prescriptions are not for legitimate medical 12 purpose. The drugs are diverted."</p> <p>13 Is that limited only to Internet 14 sales, or is that industrywide?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: Across the scope.</p> <p>17 BY MR. MIGLIORI:</p> <p>18 Q. The last bullet says: "Not limited 19 to Internet pharmacies."</p> <p>20 Is that -- is that something that -- 21 is that a message that you had throughout these 22 distributor briefings?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Correct.</p> <p>25 BY MR. MIGLIORI:</p>	<p>1 who's selling controlled substances that are 2 being dispensed outside the course of 3 professional practice must stop immediately." 4 Does that apply to industry or to 5 Internet sales only?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: To industry.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. "And the DEA cannot guarantee that 10 past failure to maintain effective controls 11 against diversion will not result in action 12 against a distributor."</p> <p>13 First off, what does that mean?</p> <p>14 A. If your practice has had a potential 15 investigation or potential problems of 16 diversion, attending this briefing, becoming 17 knowledgeable, didn't make that go away.</p> <p>18 Q. So when you were at these briefings, 19 I think you testified to presenting some 20 information from data in -- from the ARCOS 21 database.</p> <p>22 Do you recall saying that last week?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Yes, sir.</p> <p>25 BY MR. MIGLIORI:</p>

<p style="text-align: right;">Page 317</p> <p>1 Q. And the data that you would look at, 2 was that data provided by that company that was 3 at the briefing?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 THE WITNESS: Absolutely.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. So the data you were looking at was 8 whatever that that company was providing to 9 you, that is to the ARCOS database, the origin 10 of it was the -- the registrant, correct?</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 THE WITNESS: Absolutely.</p> <p>13 BY MR. MIGLIORI:</p> <p>14 Q. And at these briefings, you used 15 some of that data to point out to some of these 16 companies anomalies or tails that suggested 17 concerns that you might have about potential 18 suspicious orders, correct?</p> <p>19 MS. MAINIGI: Objection.</p> <p>20 THE WITNESS: Correct.</p> <p>21 BY MR. MIGLIORI:</p> <p>22 Q. That wasn't based on, in your 23 experience, reviewing other people's data, was it?</p> <p>25 MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 319</p> <p>1 the meeting, if you were not there, there's no 2 other record of, to your knowledge, correct?</p> <p>3 MS. MAINIGI: Objection.</p> <p>4 THE WITNESS: No, sir.</p> <p>5 BY MR. MIGLIORI:</p> <p>6 Q. No, that's not correct; or no, 7 you -- you -- you didn't...</p> <p>8 MS. MAINIGI: Objection.</p> <p>9 THE WITNESS: There would be no 10 other communication.</p> <p>11 BY MR. MIGLIORI:</p> <p>12 Q. All right. But I think you 13 testified -- well, let me just ask you.</p> <p>14 To your knowledge, were all of the 15 major distributors provided a briefing in 2005 16 or 2006?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 MR. STEPHENS: Object to form.</p> <p>19 THE WITNESS: That would have been 20 our priority, yes.</p> <p>21 BY MR. MIGLIORI:</p> <p>22 Q. Did you also send letters to the 23 registrants around this period of time?</p> <p>24 MS. MAINIGI: Objection.</p> <p>25 THE WITNESS: I don't recall.</p>
<p style="text-align: right;">Page 318</p> <p>1 THE WITNESS: No, sir.</p> <p>2 BY MR. MIGLIORI:</p> <p>3 Q. And then at -- at least at the end 4 of these slides, it has you and your direct 5 supervisor, Michael Mapes, listed.</p> <p>6 There were times when Mr. Mapes 7 presented this briefing to registrants or 8 distributors without you, correct?</p> <p>9 A. There may have been occasion. Yes, 10 sir.</p> <p>11 Q. And, in fact, I think in Exhibit 12 12 the Cardinal presentation of this information, 13 which counsel showed you, it was Michael Mapes 14 and Vickie Seeger from OD presenting, correct?</p> <p>15 This was in August 22nd of 2005?</p> <p>16 That's in the first paragraph here.</p> <p>17 I'm sorry. It's right in the middle of the 18 first paragraph.</p> <p>19 A. Yes, sir.</p> <p>20 Q. Who is Vickie Seeger?</p> <p>21 A. She was a -- she was a staff 22 coordinator. And my recollection is that she 23 worked in liaison and policy. But I'm not 24 definitive on that.</p> <p>25 Q. So what was verbally communicated at</p>	<p style="text-align: right;">Page 320</p> <p>1 BY MR. MIGLIORI:</p> <p>2 Q. Are you familiar with letters that 3 are referred to as dear-registrant letters --</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 BY MR. MIGLIORI:</p> <p>6 Q. -- from your supervisor, Joe 7 Rannazzisi?</p> <p>8 MS. McClure: Objection. Misstates 9 the record.</p> <p>10 THE WITNESS: Not particularly.</p> <p>11 MR. MIGLIORI: All right. Let me --</p> <p>12 (Deposition Exhibit 30 was marked 13 for identification.)</p> <p>14 MR. MIGLIORI: Let me show you 15 Exhibit No. 30.</p> <p>16 MS. MAINIGI: Counsel, do you have a 17 copy?</p> <p>18 MR. MIGLIORI: Yes.</p> <p>19 This one is September 27th.</p> <p>20 MR. BENNETT: Counsel, do you happen 21 to have one more copy?</p> <p>22 MR. MIGLIORI: I have literally one 23 more copy.</p> <p>24 MR. BENNETT: Thank you.</p> <p>25 MR. MIGLIORI: It's Exhibit 30.</p>

<p style="text-align: right;">Page 321</p> <p>1 MR. BENNETT: Thank you.    2 BY MR. MIGLIORI:    3 Q. Take a moment to look at this.    4 Have you reviewed it?    5 A. I have reviewed it.    6 Q. Have you seen that before?    7 A. Yes.    8 Q. Okay. And did you play any role --    9 first of all, in September of 2006 were you    10 still then in the headquarters in Washington,    11 D.C. of the Drug Enforcement Administration?    12 A. Yes, sir.    13 Q. And did you play a role in -- in    14 forming this letter of Mr. Joe Rannazzisi?    15 I'll show you the signature on the    16 last page.    17 MS. McCLURE: Objection.    18 THE WITNESS: None whatsoever.    19 BY MR. MIGLIORI:    20 Q. H okay. Ad you seen it though when    21 it went out or roughly around the time that it    22 had gone out?    23 MS. MAINIGI: Objection.    24 THE WITNESS: I only saw it after it    25 was published and sent out and only in passing.</p>	<p style="text-align: right;">Page 323</p> <p>1 prescription drug abuse problem our nation    2 currently faces."    3 Did you understand that this was not    4 a new program but a summary or -- or    5 reiteration of what the obligations are under    6 the Controlled Substances Act?    7 MS. MAINIGI: Objection.    8 THE WITNESS: Yes, sir.    9 BY MR. MIGLIORI:    10 Q. In giving background, your    11 supervisor wrote: "As each of you is    12 undoubtedly aware, the abuse, nonmedical use of    13 controlled prescription drugs, is a serious and    14 growing health problem in this country."    15 Was that consistent with and    16 supportive of your efforts in the distributor    17 initiative?    18 MS. MAINIGI: Objection.    19 THE WITNESS: Yes, sir.    20 BY MR. MIGLIORI:    21 Q. "DEA has an obligation to combat    22 this problem as one of the agency's core    23 functions is to prevent the diversion of    24 controlled substances into illicit channels.    25 Congress assigned DEA to carry out this</p>
<p style="text-align: right;">Page 322</p> <p>1 BY MR. MIGLIORI:    2 Q. And in your experience and to your    3 knowledge, was this part of the effort within    4 your department to make sure that registrants    5 understood and appreciated what their    6 obligations were under the Controlled    7 Substances Act?    8 MS. MAINIGI: Objection. Absolutely    9 no foundation. He said he never saw it before    10 it went out and saw it in passing after.    11 BY MR. MIGLIORI:    12 Q. Go ahead.    13 A. It supports the efforts that were    14 trying to be done cross the board in the    15 agency.    16 Q. Did it support, in your experience,    17 the efforts that you were trying to accomplish    18 with the distributor initiative?    19 MS. MAINIGI: Objection.    20 THE WITNESS: It did.    21 BY MR. MIGLIORI:    22 Q. If you look in the first paragraph,    23 it says: "The purpose of the letter is to    24 reiterate the responsibilities of controlled    25 substance distributors in view of the</p>	<p style="text-align: right;">Page 324</p> <p>1 function through enforcement of the Controlled    2 Substances Act and DEA regulations to implement    3 the Act."    4 Is that consistent with the message    5 that you were trying to deliver in your    6 experience in the distributor briefings?    7 MS. MAINIGI: Objection.    8 THE WITNESS: Yes, sir.    9 BY MR. MIGLIORI:    10 Q. That is your role was enforcement of    11 the provisions of the Controlled Substances    12 Act, correct?    13 MS. MAINIGI: Objection.    14 THE WITNESS: Correct.    15 BY MR. MIGLIORI:    16 Q. The obligations of a registrant were    17 the focus of what you, as a distributor    18 initiative, were trying to monitor and enforce,    19 correct?    20 MS. MAINIGI: Objection.    21 THE WITNESS: Correct.    22 BY MR. MIGLIORI:    23 Q. "The Controlled Substances Act was    24 designed by congress to combat diversion by    25 providing for a closed system of drug</p>

<p style="text-align: right;">Page 325</p> <p>1 distribution in which all legitimate handlers 2 of controlled substances must obtain a DEA 3 registration and, as a condition of maintaining 4 such registration, must take reasonable steps 5 to ensure that their registration is not being 6 utilized as a source of diversion."</p> <p>7       Was that consistent with the 8 message, in your experience, that you were 9 trying to get across through the distributor 10 initiative?</p> <p>11       MS. MAINIGI: Objection. 12       THE WITNESS: Yes, sir. 13       BY MR. MIGLIORI: 14       Q. That is, if a company wanted the 15 benefits of having a DEA registration for the 16 distribution and sale of controlled substance, 17 there were certain obligations that came with 18 that privilege, correct? 19       MS. MAINIGI: Objection. 20       THE WITNESS: Yes, sir. 21       BY MR. MIGLIORI: 22       Q. It says here that: "Distributors 23 are, of course, one of the key components of 24 the distribution chain. If the closed system 25 is to function properly, as congress</p>	<p style="text-align: right;">Page 327</p> <p>1 has a substantial and detrimental effect on the 2 health and general welfare of the American 3 people."</p> <p>4       Is that consistent with the message 5 that you delivered, in your experience, in the 6 distributor initiative?</p> <p>7       MS. MAINIGI: Objection. 8       THE WITNESS: Yes, sir. 9       BY MR. MIGLIORI: 10       Q. Mr. Rannazzisi talks about the 11 statutory scheme and legal duties of 12 distributors as DEA registrants. And he says: 13 "Although most distributors are already well 14 aware of the following legal principles, they 15 are reiterated here as additional background 16 for this discussion.</p> <p>17       In your presentation of the 18 distributor initiative, did you reiterate legal 19 principles that most distributors were already 20 well aware of?</p> <p>21       MS. MAINIGI: Objection. 22       THE WITNESS: Yes, sir. 23       BY MR. MIGLIORI: 24       Q. "The CSA uses a concept of 25 registration as a primary means by which</p>
<p style="text-align: right;">Page 326</p> <p>1 envisioned, distributors must be vigilant in 2 deciding whether prospective customer can be 3 trusted to deliver the controlled substance 4 only for lawful purposes."</p> <p>5       Is that consistent with the message 6 you tried to deliver in the distributor 7 initiative?</p> <p>8       MS. MAINIGI: Objection. 9       THE WITNESS: Yes, sir. 10       BY MR. MIGLIORI: 11       Q. The Controlled Substances Act puts 12 the obligation on who to make sure that the 13 customer that receives controlled substances is 14 the intend and appropriate customer?</p> <p>15       MS. MAINIGI: Objection. 16       THE WITNESS: The onus of 17 responsibility is upon the registrant. 18       BY MR. MIGLIORI: 19       Q. Is it upon the DEA? 20       MR. STEPHENS: Objection. 21       THE WITNESS: No, sir. 22       BY MR. MIGLIORI: 23       Q. "This responsibility is critical as 24 congress has expressly declared that the 25 illegal distribution of controlled substances</p>	<p style="text-align: right;">Page 328</p> <p>1 manufacturers, distributors and practitioners 2 are given legal authority to handle controlled 3 substance. Registration also serves as the 4 primary incentive for compliance with the 5 regulatory requirements of the CSA and" DS -- 6 "DEA regulations as congress gave DEA the 7 authority under the ACT to revoke and suspend 8 registrations for failure to comply with these 9 requirements."</p> <p>10       Was one of the enforcement 11 mechanisms of the DEA, in your experience, the 12 revocation and suspension of registrations when 13 companies, in fact, did not comply with the 14 provisions of the Controlled Substances Act?</p> <p>15       MS. MAINIGI: Objection. 16       THE WITNESS: Yes, sir. 17       BY MR. MIGLIORI: 18       Q. And did you make that known in your 19 distributor initiative briefings that one of 20 the consequences of failing to comply with the 21 CSA was a potential suspension or revocation of 22 registration?</p> <p>23       MS. MAINIGI: Objection. 24       THE WITNESS: Yes, sir. 25       BY MR. MIGLIORI:</p>

<p style="text-align: right;">Page 329</p> <p>1 Q. All right. I'm not going to go 2 through the whole rest of it. But in the -- 3 right in the middle of this page, there is the 4 operative language I think in two days nobody 5 has actually asked you about. It's this box 6 here -- here.</p> <p>7 It says: "The registrant shall 8 design and operate a system to disclose to the 9 registrant suspicious orders of controlled 10 substances. The registrant shall inform the 11 field division of the administration in his 12 area of suspicious orders when discovered by 13 the registrant. Suspicious orders include 14 orders of unusual size, orders deviating 15 substantially from a normal pattern, and orders 16 of unusual frequency."</p> <p>17 Is that the operative language, in 18 your experience, of the Controlled Substances 19 Act when you were giving the distributor 20 initiative briefings?</p> <p>21 MS. MAINIGI: Objection. 22 THE WITNESS: Yes, sir. 23 BY MR. MIGLIORI: 24 Q. And that was in existence when you 25 got to the DEA in 1995, correct?</p>	<p style="text-align: right;">Page 331</p> <p>1 Q. Independent of that obligation, was 2 there an -- was there also a concurrent 3 obligation for registrants to know their 4 customer?</p> <p>5 MS. MAINIGI: Objection. 6 THE WITNESS: Yes, sir. 7 BY MR. MIGLIORI: 8 Q. This letter says: "Thus, in 9 addition to reporting all suspicious orders, a 10 distributor has a statutory responsibility to 11 exercise due diligence to avoid filling 12 suspicious orders that might be diverted into 13 other than legitimate medical, scientific and 14 industrial channels. Failure to exercise such 15 due diligence could, as circumstances warrant, 16 provide a statutory basis for revocation of 17 suspension of a distributor's registration. 18 What is due diligence? 19 MS. MAINIGI: Objection. 20 MS. McCLURE: Objection to the 21 commentary in the record prior to asking the 22 question. 23 BY MR. MIGLIORI: 24 Q. In your understanding, what does 25 "due diligence" mean in this context?</p>
<p style="text-align: right;">Page 330</p> <p>1 MS. MAINIGI: Objection. 2 THE WITNESS: Yes, sir. 3 Q. And that was in existence as the 4 operative language when you retired in 2017, 5 correct?</p> <p>6 MS. MAINIGI: Objection. 7 THE WITNESS: Yes, sir. 8 BY MR. MIGLIORI: 9 Q. Was it enough simply to be compliant 10 with the Controlled Substances Act, in your 11 experience, in your understanding, to just 12 monitor whether or not an order was suspicious 13 or deviated in size, frequency or pattern from 14 prior orders?</p> <p>15 MS. MAINIGI: Objection. 16 THE WITNESS: No, sir. 17 BY MR. MIGLIORI: 18 Q. What else was required?</p> <p>19 MS. MAINIGI: Objection. 20 THE WITNESS: If you deemed an order 21 suspicious, resolve that conflict. In that 22 resolution of resolving the conflict, if it did 23 not meet the criteria of a legitimate order, 24 take the appropriate action.</p> <p>25 BY MR. MIGLIORI:</p>	<p style="text-align: right;">Page 332</p> <p>1 MS. MAINIGI: Objection. 2 THE WITNESS: Meeting your 3 requirements, obligations, responsibilities as 4 stipulated by both the CSA and the CFR. 5 BY MR. MIGLIORI: 6 Q. Did those responsibilities to 7 conduct due diligence exist when you got to the 8 DEA in 1995?</p> <p>9 MS. MAINIGI: Objection. 10 THE WITNESS: Yes, sir. 11 BY MR. MIGLIORI: 12 Q. Again, Mr. Rannazzisi goes on to say 13 in the next paragraph: "A distributor may not 14 simply rely on the fact that the person placing 15 the suspicious order is a DEA registrant and 16 turn a blind eye to the suspicious 17 circumstances. Again, to maintain effective 18 controls against diversion, as Section 823(e) 19 requires, the distributor should exercise due 20 care in confirming the legitimacy of all orders 21 prior to filling."</p> <p>22 MS. McCLURE: Objection to the 23 extent that that portion that you've read is 24 not up on the record. So to the extent that 25 misstates the document from which you are</p>

<p style="text-align: right;">Page 333</p> <p>1 reading, the document speaks for itself.  2 MR. MIGLIORI: I have no idea what  3 you just said.  4 You're saying because it's not on  5 the screen.  6 MS. MAINIGI: She's saying you  7 didn't read it right.  8 MR. MIGLIORI: I didn't read it  9 right or --  10 MS. McCLURE: To the extent -- to  11 the extent you didn't, objection.  12 MR. MIGLIORI: Let me ask the  13 question.  14 Is it the way I read it or the fact  15 that it wasn't on the screen?  16 I couldn't make heads or tails.  17 MS. McCLURE: We couldn't determine  18 where you were reading from on the screen. It  19 was not visible to us.  20 MR. MIGLIORI: Fair enough. I'll  21 fix it.  22 MS. McCLURE: So to the extent you  23 didn't read it correctly --  24 MR. MIGLIORI: Thank you.  25 MS. McCLURE: -- I object.</p>	<p style="text-align: right;">Page 335</p> <p>1 registrant's obligations under the Controlled  2 Substances Act?  3 MS. MAINIGI: Objection.  4 THE WITNESS: Yes, sir.  5 BY MR. MIGLIORI:  6 Q. There was some questions last week  7 about testimony you gave in the past concerning  8 whether the CSA requires documentation.  9 Do you remember that questioning?  10 MS. MAINIGI: Objection.  11 THE WITNESS: Yes, sir.  12 BY MR. MIGLIORI:  13 Q. Now, counsel -- strike that.  14 Your answer, as I recall, was that  15 the CSA does not specifically require  16 documentation in its provisions; is that true?  17 MS. MAINIGI: Objection. His answer  18 under oath last week speaks for itself.  19 BY MR. MIGLIORI:  20 Q. Go ahead.  21 A. Yes, sir.  22 Q. But in prior testimony, you spoke  23 about best practices relative to documentation,  24 correct?  25 MS. MAINIGI: Objection.</p>
<p style="text-align: right;">Page 334</p> <p>1 MR. MIGLIORI: I'll fix it.  2 I have to do this again.  3 BY MR. MIGLIORI:  4 Q. Mr. Rannazzisi says: "In a similar  5 vein, given the requirement under Section  6 823(e) that a distributor maintain effective  7 controls against diversion, a distributor may  8 not simply rely on the fact that the person  9 placing a suspicious order is a DEA registrant  10 and turn a blind eye to the suspicious  11 circumstances. Again, to maintain effective  12 controls against diversion, as Section 823(e)  13 requires, the distributor should exercise due  14 care in confirming the legitimacy of all orders  15 prior to filling."</p> <p>16 Was that consistent with the  17 messages that you were giving in the  18 distributor initiative briefings?</p> <p>19 MS. MAINIGI: Objection.  20 THE WITNESS: Yes, sir.  21 BY MR. MIGLIORI:  22 Q. And would failure -- in your  23 experience, would failure to exercise the due  24 care in confirming the legitimacy of all orders  25 prior to filling be a violation of the</p>	<p style="text-align: right;">Page 336</p> <p>1 What prior testimony?  2 BY MR. MIGLIORI:  3 Q. Do you believe that documentation is  4 necessary for good best practices in complying  5 with the Controlled Substances Act?  6 MS. MAINIGI: Objection. Misstates  7 his prior testimony. Vague. Ambiguous.  8 BY MR. MIGLIORI:  9 Q. Go ahead.  10 A. Yes, sir.  11 Q. Why?  12 A. If you can't show me what you've  13 done, explained or give -- besides -- you've  14 got to document everything that you do. It  15 shows what you did.  16 When I do an investigation, I have  17 to document what I did. It shows what I did.  18 When the IRS audited me about 12 years ago, I  19 was about -- I had to come up with paper I  20 didn't know I had.  21 Everything is critical. Best  22 practices -- business operated in our system --  23 everybody should -- best practices. This is  24 why I did what I did, as a company, as a  25 decision.</p>

<p style="text-align: right;">Page 337</p> <p>1 Q. Is that a message that you gave 2 during your distributor initiative briefings? 3 MS. MAINIGI: Objection. 4 THE WITNESS: Absolutely. 5 BY MR. MIGLIORI: 6 Q. In Mr. Rannazzisi's letter on the 7 last paragraph of this page, it says: 8 "Depending on the circumstances, the failure to 9 keep or furnish required records might also be 10 the basis for civil fines or criminal penalties 11 under the CSA as provided in 21 USC 842."</p> <p>12 Was that consistent with the 13 messages that you gave during the distributor 14 initiative briefings? 15 MS. MAINIGI: Objection. 16 THE WITNESS: Yes, sir. 17 BY MR. MIGLIORI: 18 Q. Page 3 of Mr. Rannazzisi's letter 19 goes into circumstances that might be 20 indicative of diversion. And the first one is 21 "Ordering excessive quantities of limited 22 variety of controlled substances. Example, 23 ordering only phentermine, Hydrocodone or 24 alprazolam while ordering few, if any, other 25 drugs."</p>	<p style="text-align: right;">Page 339</p> <p>1 MS. MAINIGI: Objection. 2 THE WITNESS: Yes, sir. 3 BY MR. MIGLIORI: 4 Q. Can you explain that? 5 How does that work, in your 6 experience? 7 MS. MAINIGI: Objection. 8 THE WITNESS: What is their purpose. 9 Who is their clientele. Is there any 10 speciality that they're going to be involved 11 in. What's their business model and role. 12 Who do they want to reach out to as a customer 13 base themselves. What products are they going 14 to be needing. Project to them quantities they 15 potentially may be ordering. 16 BY MR. MIGLIORI: 17 Q. Does the obligation for a registrant 18 to know the customer exist outside of actually 19 placing orders? 20 MS. MAINIGI: Objection. 21 THE WITNESS: How can you understand 22 what the customers needs if you don't know 23 their potential needs? 24 BY MR. MIGLIORI: 25 Q. So is it fair --</p>
<p style="text-align: right;">Page 338</p> <p>1 Is that a message that you were 2 delivering during the distributor initiative 3 meetings? 4 MS. MAINIGI: Objection. 5 THE WITNESS: Yes, sir. It was. 6 BY MR. MIGLIORI: 7 Q. "Ordering a limited variety of 8 controlled substances and quantities 9 disproportionate to the quantity of 10 noncontrolled medications ordered," was that a 11 message you were delivering in your distributor 12 initiatives? 13 MS. MAINIGI: Objection. 14 THE WITNESS: Yes, sir. 15 BY MR. MIGLIORI: 16 Q. Are these concepts that are 17 consistent with the obligation to know your 18 customer under the Controlled Substances Act? 19 MS. MAINIGI: Objection. 20 THE WITNESS: Yes, sir. 21 BY MR. MIGLIORI: 22 Q. Are the obligations to know your 23 customer on the Controlled Substances Act also 24 applicable when a new client is brought on 25 board for a registrant?</p>	<p style="text-align: right;">Page 340</p> <p>1 A. Especially in the context of control 2 substances. If it's labeled "controlled," it's 3 a dangerous product. Has potential to cause 4 harm. If that's the case, you're not trying 5 to -- know your customer. Know what they want 6 to do. 7 Q. Is that a requirement of the 8 Controlled Substances Act? 9 MS. MAINIGI: Objection. 10 THE WITNESS: Protect the legitimate 11 medical need. It's the obligation that you are 12 required to fulfill. 13 BY MR. MIGLIORI: 14 Q. And was that consistent with the 15 message that you delivered during the 16 distributor initiative briefings that you were 17 involved in, in your experience, in 2005 and 18 2006? 19 MS. MAINIGI: Objection. 20 THE WITNESS: Yes, sir. 21 BY MR. MIGLIORI: 22 Q. And was that a new concept in 2005, 23 or did that exist when you got to DEA in 1995? 24 MS. MAINIGI: Objection. 25 THE WITNESS: It existed in 1995</p>

<p style="text-align: right;">Page 341</p> <p>1 when I came on board.</p> <p>2 MR. MIGLIORI: All right. Why don't</p> <p>3 we take a break.</p> <p>4 THE VIDEOGRAPHER: We are going off</p> <p>5 the record.</p> <p>6 This is the end of Media Unit No. 1.</p> <p>7 The time is 10:23.</p> <p>8 (A short recess was taken.)</p> <p>9 THE VIDEOGRAPHER: We are going back</p> <p>10 on the record.</p> <p>11 This is the start of Media Unit No.</p> <p>12 2.</p> <p>13 The time is 10:42.</p> <p>14 You may proceed, Counsel.</p> <p>15 MR. MIGLIORI: Thank you.</p> <p>16 (Deposition Exhibit 31 was marked</p> <p>17 for identification.)</p> <p>18 MR. MIGLIORI: I want to show you</p> <p>19 what I've marked as Exhibit 31.</p> <p>20 BY MR. MIGLIORI:</p> <p>21 Q. Mr. Wright, I'm showing you what's</p> <p>22 been marked as Exhibit 31. This is a two-page</p> <p>23 letter, if you look on the second page, it's</p> <p>24 again signed by Joseph T. Rannazzisi.</p> <p>25 In December of 2007, was he still</p>	<p style="text-align: right;">Page 343</p> <p>1 MS. MAINIGI: Objection.</p> <p>2 THE WITNESS: I do not know.</p> <p>3 BY MR. MIGLIORI:</p> <p>4 Q. Okay. You'll notice that the same</p> <p>5 language is in this December 27th, 2007 letter.</p> <p>6 It says: "The purpose of this</p> <p>7 letter is to reiterate the responsibilities of</p> <p>8 the controlled substance manufacturers and</p> <p>9 distributors to inform DEA of suspicious orders</p> <p>10 in accordance with 21 CFR 1301.74(b)."</p> <p>11 Based on your recollection of this</p> <p>12 letter, did you understand that to be the</p> <p>13 purpose of sending this out to registrants like</p> <p>14 Cardinal Health?</p> <p>15 MS. MAINIGI: Objection. He's</p> <p>16 testified he didn't have a recollection of</p> <p>17 the -- of the letter. And there's been no</p> <p>18 foundation.</p> <p>19 MR. MIGLIORI: All right. You can</p> <p>20 just -- you don't have to give that much</p> <p>21 information. I got it with --</p> <p>22 MS. MAINIGI: I am actually just</p> <p>23 allowing you --</p> <p>24 MR. MIGLIORI: Three or four words.</p> <p>25 MS. MAINIGI: -- to correct your</p>
<p style="text-align: right;">Page 342</p> <p>1 your -- your boss?</p> <p>2 MS. McCLURE: Object to form.</p> <p>3 THE WITNESS: He was still the</p> <p>4 deputy assistant administrator of diversion</p> <p>5 control.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. This is another letter.</p> <p>8 Have you ever -- did you have a</p> <p>9 chance to review it?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 THE WITNESS: Yes, sir.</p> <p>12 BY MR. MIGLIORI:</p> <p>13 Q. Are you familiar with this letter?</p> <p>14 MS. MAINIGI: Objection.</p> <p>15 THE WITNESS: Only in the context</p> <p>16 that it was sent out.</p> <p>17 BY MR. MIGLIORI:</p> <p>18 Q. Do you know to whom this was sent?</p> <p>19 MS. MAINIGI: Objection.</p> <p>20 THE WITNESS: This exhibit</p> <p>21 specifically to Cardinal Health. But this went</p> <p>22 out to -- industrywide.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. And did it go out to all</p> <p>25 registrants, to your knowledge?</p>	<p style="text-align: right;">Page 344</p> <p>1 question, Counsel.</p> <p>2 MR. MIGLIORI: I appreciate that.</p> <p>3 THE WITNESS: Yes, sir.</p> <p>4 BY MR. MIGLIORI:</p> <p>5 Q. Here in the second paragraph, it</p> <p>6 says: "In addition to and not in lieu of the</p> <p>7 general requirement under 21 USC 823 that</p> <p>8 manufacturers and distributors maintain</p> <p>9 effective controls against diversion, DEA</p> <p>10 regulations require all manufacturers and</p> <p>11 distributors to report suspicious orders of</p> <p>12 controlled substances. The title 21 CFR</p> <p>13 1301.74(b) specifically requires that the</p> <p>14 registrant design and operate a system to</p> <p>15 disclose to the registrant suspicious orders of</p> <p>16 controlled substances."</p> <p>17 That's the same language we've seen</p> <p>18 throughout your presentation.</p> <p>19 It's about the general obligations</p> <p>20 under Controlled Substances Act, correct?</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: Correct, sir.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. "The regulation clearly indicates</p> <p>25 that it is the sole responsibility of the</p>

<p style="text-align: right;">Page 345</p> <p>1 registrant to design and operate such a 2 system."</p> <p>3 Was that message consistent with the 4 message that you delivered to the distributors 5 in your briefings with them in 2005, 2006 6 and -- and on?</p> <p>7 MS. MAINIGI: Objection.</p> <p>8 THE WITNESS: Yes, sir. It was.</p> <p>9 BY MR. MIGLIORI:</p> <p>10 Q. And it says: "Accordingly, DEA does 11 not approve or otherwise endorse any specific 12 system for reporting suspicious orders."</p> <p>13 Is that consistent with the 14 messaging that you had in your distributor 15 initiative briefings?</p> <p>16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: Yes, sir. It was.</p> <p>18 BY MR. MIGLIORI:</p> <p>19 Q. In your experience, do you recall 20 actually talking to registrants and telling 21 them that the DEA does not approve or otherwise 22 endorse a specific system for reporting 23 suspicious orders?</p> <p>24 MS. MAINIGI: Objection.</p> <p>25 THE WITNESS: Repeatedly.</p>	<p style="text-align: right;">Page 347</p> <p>1 Q. If the industry or registrant 2 standard was to ship a suspicious order without 3 performing due diligence, would that standard 4 have been compliant with federal law, in your 5 experience and your understanding?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: No, sir.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. Would it have been compliant to 10 report suspicious orders after sale on a 11 monthly basis?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 THE WITNESS: No, sir.</p> <p>14 BY MR. MIGLIORI:</p> <p>15 Q. Mr. Rannazzisi says: "The 16 registration also requires that the registrant 17 inform the local DEA division office of 18 suspicious orders when discovered by the 19 registrant."</p> <p>20 Is that a message that you delivered 21 in your distributor initiative briefings?</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 THE WITNESS: Yes, sir.</p> <p>24 BY MR. MIGLIORI:</p> <p>25 Q. Was that true in 1995, in your</p>
<p style="text-align: right;">Page 346</p> <p>1 BY MR. MIGLIORI:</p> <p>2 Q. And in doing that, was that 3 something that was true in 1995 when you first 4 began with the DEA in the Dallas field office?</p> <p>5 MS. MAINIGI: Objection.</p> <p>6 THE WITNESS: Yes, sir.</p> <p>7 BY MR. MIGLIORI:</p> <p>8 Q. "Past communications with DEA, 9 whether implicit or explicit, that could be 10 construed as approval of a particular system 11 for reporting suspicious orders should no 12 longer be taken to mean that the DEA approves a 13 specific system."</p> <p>14 Do you remember delivering that 15 message in your own experience during the 16 distributor initiative meetings?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 THE WITNESS: Yes, sir.</p> <p>19 BY MR. MIGLIORI:</p> <p>20 Q. Would that have applied to the 21 Excessive Purchase Reports, Exhibit 26, that 22 counsel for Cardinal showed you last week?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Yes, sir.</p> <p>25 BY MR. MIGLIORI:</p>	<p style="text-align: right;">Page 348</p> <p>1 experience, when you got to the DEA?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: Yes, sir.</p> <p>4 BY MR. MIGLIORI:</p> <p>5 Q. That is reporting suspicious orders 6 when discovered by the registrant, is actually 7 part of the language of the Controlled 8 Substances Act, correct, in your -- to your 9 understanding?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 THE WITNESS: Yes, sir.</p> <p>12 BY MR. MIGLIORI:</p> <p>13 Q. So that goes back to the enactment, 14 in your understanding, of the Controlled 15 Substances Act and did not start in 2005 when 16 you did these briefings, correct?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 THE WITNESS: Yes, sir.</p> <p>19 BY MR. MIGLIORI:</p> <p>20 Q. Filling a month --</p> <p>21 MS. MAINIGI: Can I ask a question 22 of the government: Is this all of fair game 23 for questioning so we and ask similar 24 questions?</p> <p>25 MR. BENNETT: When it's about his</p>

<p style="text-align: right;">Page 349</p> <p>1 personal knowledge on the suspicious orders and 2 ARCOS data, practices and procedures, which is 3 No. 3.</p> <p>4 MS. MAINIGI: Back to 1970?</p> <p>5 MR. BENNETT: Huh?</p> <p>6 MS. MAINIGI: Back to 1970, James?</p> <p>7 MR. MIGLIORI: It's based on his --</p> <p>8 MR. BENNETT: If he has -- if he has 9 any personal knowledge, yes.</p> <p>10 MS. MAINIGI: I see. You think he 11 has personal knowledge back then?</p> <p>12 MR. MIGLIORI: Oh, you can save the 13 argument.</p> <p>14 MR. BENNETT: I don't have a 15 position on that.</p> <p>16 MR. MIGLIORI: Save the argument. 17 That's my time you're using for that.</p> <p>18 MS. MAINIGI: I'll give you a 19 minute.</p> <p>20 MR. MIGLIORI: Thank you. You're 21 sweet.</p> <p>22 BY MR. MIGLIORI:</p> <p>23 Q. "Registrants are reminded that their 24 responsibility does not end merely with the 25 filling of a suspicious orders report."</p>	<p style="text-align: right;">Page 351</p> <p>1 Q. And did that independent analysis of 2 suspicious orders requirement exist in '95, in 3 your experience, when you got to DEA?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 THE WITNESS: The requirement of 6 this statute existed.</p> <p>7 BY MR. MIGLIORI:</p> <p>8 Q. So the -- it existed in 1995 when 9 you got to the DEA, in your experience, 10 correct?</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. MIGLIORI:</p> <p>14 Q. All right. Mr. Rannazzisi then goes 15 into the concepts of -- well, orders of unusual 16 size, orders deviating substantially from a 17 normal pattern, and orders of unusual 18 frequency.</p> <p>19 Those are also in the statute, 20 correct?</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: Yes, sir.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. If orders deviate in size, are they, 25 on the face of the statute, potentially</p>
<p style="text-align: right;">Page 350</p> <p>1 Was that a message that you 2 delivered in your distributor briefings?</p> <p>3 MS. MAINIGI: Objection.</p> <p>4 THE WITNESS: Yes, sir.</p> <p>5 BY MR. MIGLIORI:</p> <p>6 Q. Was that true in 1995 when you got 7 to the DEA?</p> <p>8 MS. MAINIGI: Objection.</p> <p>9 THE WITNESS: Yes, sir.</p> <p>10 BY MR. MIGLIORI:</p> <p>11 Q. Mr. Rannazzisi says: Registrants 12 must conduct an independent analysis of 13 suspicious orders prior to completing a sale to 14 determine whether the controlled substances are 15 likely to be diverted from legitimate channels. 16 Reporting an order as suspicious will not 17 absolve the registrant of responsibility if the 18 registrant knew or should have known that the 19 controlled substances were being diverted."</p> <p>20 Was that a message that you 21 delivered in your distributor initiative 22 briefings?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Yes, sir.</p> <p>25 BY MR. MIGLIORI:</p>	<p style="text-align: right;">Page 352</p> <p>1 suspicious orders?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: Yes, sir.</p> <p>4 BY MR. MIGLIORI:</p> <p>5 Q. "These criteria are disjunctive and 6 are not all-inclusive."</p> <p>7 First of all, is that a message that 8 you delivered in the distributor -- distributor 9 initiative briefings?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 THE WITNESS: Yes, sir.</p> <p>12 BY MR. MIGLIORI:</p> <p>13 Q. And what does that mean, that 14 they're disjunctive?</p> <p>15 A. It isn't limited to just this. It 16 isn't -- these are the primary things to start 17 looking at. Think. Why?</p> <p>18 Q. So an order may be suspicious if it 19 only deviates substantially from a normal 20 pattern, in your understanding of the 21 obligations under the Controlled Substances 22 Act, correct?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Yes, sir.</p> <p>25 BY MR. MIGLIORI:</p>

<p style="text-align: right;">Page 353</p> <p>1 Q. It doesn't require that it also be 2 of unusual frequency or unusual size; any one 3 or any three or all three could -- could exist 4 for it to be potentially a suspicious order, 5 correct?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: Correct.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. The language says "that suspicious 10 orders include orders of unusual size."</p> <p>11 Is an order of unusual size, on its 12 face, suspicious?</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 THE WITNESS: It could certainly be.</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. And to determine whether it's 17 suspicious, what is required, in your 18 understanding?</p> <p>19 MS. MAINIGI: Objection.</p> <p>20 THE WITNESS: Legitimate medical 21 necessity. Why is there a certain particular 22 reason for a substantial increase in size?</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. Who determines that?</p> <p>25 MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 355</p> <p>1 such reports suspicious order reports."</p> <p>2 Is that consistent with the message 3 that you delivered in the distributor 4 initiative briefings?</p> <p>5 MS. MAINIGI: Objection.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. What's your answer?</p> <p>8 A. Yes, sir.</p> <p>9 Q. And was that true in 1995 when you 10 got to the DEA?</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 THE WITNESS: The statute this the 13 requirement, yes.</p> <p>14 MS. MAINIGI: Objection.</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. So Exhibit 26, this excessive 17 purchase report or this ingredient limit report 18 that counsel showed you last week, as you 19 understand it, would not be a suspicious order 20 report even if it were labeled as such, based 21 on your understanding, correct?</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 THE WITNESS: Correct.</p> <p>24 BY MR. MIGLIORI:</p> <p>25 Q. Did you deliver this message to the</p>
<p style="text-align: right;">Page 354</p> <p>1 THE WITNESS: It'd have to be the 2 registrant who has received the order.</p> <p>3 BY MR. MIGLIORI:</p> <p>4 Q. Is that a message you delivered in 5 the distributor briefings?</p> <p>6 MS. MAINIGI: Object to form.</p> <p>7 James, I -- I hope that -- well, 8 I'll save it.</p> <p>9 THE WITNESS: Yes, sir.</p> <p>10 BY MR. MIGLIORI:</p> <p>11 Q. And was that true in 1995 when you 12 got to DEA?</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 THE WITNESS: Yes, sir.</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. On the second page of his letter, 17 Mr. Rannazzisi writes: "When reporting an 18 order as suspicious, registrants must be clear 19 in their communications with DEA that the" 20 registrant -- "registrant is actually 21 characterizing an order as suspicious. Daily, 22 weekly or monthly reports submitted by a 23 registrant indicating excessive purchases do 24 not comply with the requirement to report 25 suspicious orders even if the registrant calls</p>	<p style="text-align: right;">Page 356</p> <p>1 HDA or the HDMA as well?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 BY MR. MIGLIORI:</p> <p>4 Q. And by "you" I mean in the 5 distributor initiative briefings.</p> <p>6 Did you ever speak to the HDMA?</p> <p>7 A. I don't recall specifically. I 8 probably did. We reached out to many 9 organizations every chance we had to get this 10 message out.</p> <p>11 MR. MIGLIORI: Let me show you 12 Exhibit 32.</p> <p>13 (Deposition Exhibit 32 was marked 14 for identification.)</p> <p>15 BY MR. MIGLIORI:</p> <p>16 Q. Exhibit 32 is a document produced 17 I'll show you the Bates number: HSI-MDL 18 00622468. I'll present to you that it's a 19 Henry Schein document produced in this 20 litigation.</p> <p>21 And what I have highlighted on the 22 screen -- well, the -- the title of it is 23 "Draft Summary of the HDMA DEA meeting," 24 October 16th and 17th, 2007, "Not For External 25 Distribution.</p>

<p style="text-align: right;">Page 357</p> <p>1        And then under the subparagraph 2    "Suspicious Orders," your name appears. 3        Why don't you take a look at it, and 4    then I'll ask you about it. 5        Does reviewing this document refresh 6    your recollection at all as to whether or not 7    you may have been present at a presentation to 8    the HDMA? 9        A. It does. 10      Q. This document says, under 11    "Suspicious Orders": "Kyle Wright joined the 12    meeting and provided DEA's presentation on 13    suspicious orders. Mr. Wright highlighted 14    DEA's position that whole distributors should 15    conduct a more aggressive form of customer due 16    diligence in addition to reporting." 17      Do you recall giving that message? 18      MS. MAINIGI: Objection. 19      THE WITNESS: Yes, sir. 20      BY MR. MIGLIORI: 21      Q. And it says: "DEA also wants 22    distributors to assess orders and stop them 23    before they are filled if there" -- if there's 24    a reason to be suspicious and expects wholesale 25    distributors to thoroughly evaluate orders, the</p>	<p style="text-align: right;">Page 359</p> <p>1        BY MR. MIGLIORI: 2        Q. And why was it important to 3    encourage distributor employees going to the 4    dispensing sites to actually look at the 5    physical locations? 6        MS. MAINIGI: Objection. 7        THE WITNESS: It would help them 8    resolve the business model of that customer. 9        BY MR. MIGLIORI: 10      Q. Help me understand how that relates 11    to obligations under Controlled Substances Act, 12    if at all. 13      MS. MAINIGI: Objection. 14      THE WITNESS: If a customer is in a 15    sparsely populated area and is ordering, 16    conduct business the same as a 17    well-established, suburban area, what's the 18    draw? Why? 19      If the -- if the potential customer 20    is in a impoverished or blighted area of town 21    and is doing business commensurate with a 22    well-established other, how can that be? 23      These are tails, again, that is 24    drawing it. 25      BY MR. MIGLIORI:</p>
<p style="text-align: right;">Page 358</p> <p>1    dispensers themselves, and the dispensers' 2    customers." 3        Was that the message that you were 4    delivering at the HDMA conference with the DEA 5    in October of 2007? 6        MS. MAINIGI: Objection. 7        THE WITNESS: Yes, sir. 8        BY MR. MIGLIORI: 9        Q. And was that consistent with the 10    messages that you delivered in the distributor 11    initiative briefings? 12        MS. MAINIGI: Objection. 13        THE WITNESS: Yes, sir. 14        BY MR. MIGLIORI: 15        Q. Kyle went so far as to discuss 16    having a distributor's employee take a look at 17    the dispensing site's physical location and 18    watch for suspicious activity. Kyle also noted 19    that the DEA wants to expand the drug subject 20    to ARCOS reporting to include all controlled 21    substances." 22        Do you recall delivering that 23    message to the HDMA? 24        MS. MAINIGI: Objection. 25        THE WITNESS: Yes, sir.</p>	<p style="text-align: right;">Page 360</p> <p>1        Q. Do you recall how that message was 2    received at the HDMA conference? 3        MS. MAINIGI: Objection. 4        Foundation. 5        THE WITNESS: I think they 6    understood that -- what we were trying to 7    convey to them. 8        BY MR. MIGLIORI: 9        Q. Were you -- do you recall being 10    asked about DEA's role with respect to this 11    higher level of due diligence? 12        MS. MAINIGI: Objection. 13        THE WITNESS: Yes. 14        BY MR. MIGLIORI: 15        Q. What do you recall? 16        A. We were not trying to lead or get 17    industry involved in enforcement. There were 18    limits to their capabilities. We understood 19    that. We weren't trying to drive them in that 20    direction. 21        But on the basis of understanding 22    who their customer was, there were certain 23    obligations that they could do and perform. 24        Q. Did that include on-site 25    inspections?</p>

<p style="text-align: right;">Page 361</p> <p>1 MS. MAINIGI: Objection to form.  2 THE WITNESS: It wasn't a compulsory  3 requirement. It was a suggested requirement to  4 help resolve the legitimacy of the orders in  5 the business.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. The minutes go on to say: "When  8 asked, if these customers weren't DEA  9 registrants, what steps did the DEA take to  10 evaluate them before registration, Kyle made it  11 clear that the DEA didn't have the resources to  12 inspect or otherwise follow up on all  13 registrants. A copy of Kyle's presentation is  14 attached. Kyle also offered to act as an  15 information conduit in the event that any  16 distributor terminated a pharmacy or clinic  17 customer based on suspicious orders."</p> <p>18 Do you recall having that  19 interaction about DEA resources?</p> <p>20 A. Yes, sir.</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 BY MR. MIGLIORI:</p> <p>23 Q. And did D -- DEA, in your  24 experience, have the resources to do the  25 policing of all individual orders that may be</p>	<p style="text-align: right;">Page 363</p> <p>1 Q. And does it appear to be, as you  2 flip through it, the same as we discussed in  3 Exhibit 10, the AmerisourceBergen?</p> <p>4 A. It contains the -- most, if not all,  5 the material.</p> <p>6 Q. It has the same section on  7 suspicious orders that we talked about earlier,  8 correct?</p> <p>9 This is a page that ends with Bates  10 No. 1 -- ending in 8158. You can look on the  11 screen too.</p> <p>12 We discussed this in the  13 AmerisourceBergen presentation, correct?</p> <p>14 MS. MAINIGI: Objection.</p> <p>15 THE WITNESS: Correct, sir.</p> <p>16 BY MR. MIGLIORI:</p> <p>17 Q. My -- my question is simply it  18 appears to be the same one even with the  19 examples of the pharmacies and the summary  20 on -- on the last page?</p> <p>21 A. Yes, sir.</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 BY MR. MIGLIORI:</p> <p>24 Q. And again, I'm not sure if I asked  25 you this, but relative to the summary of this</p>
<p style="text-align: right;">Page 362</p> <p>1 suspicious?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: That would be  4 relatively impossible for us to do.</p> <p>5 BY MR. MIGLIORI:</p> <p>6 Q. And under the CSA, in your -- to  7 your understanding, who had the sole  8 responsibility to do that?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 THE WITNESS: The industry, the  11 registrant.</p> <p>12 MR. MIGLIORI: Let me show you  13 Exhibit 33.</p> <p>14 MR. EPPICH: Don, before we move to  15 Exhibit 33, what's the Bates on Exhibit 32?</p> <p>16 MR. MIGLIORI: On 32? HSI-MDL  17 00622468.</p> <p>18 Exhibit 33.</p> <p>19 (Deposition Exhibit 33 was marked  20 for identification.)</p> <p>21 BY MR. MIGLIORI:</p> <p>22 Q. Does this appear to be the  23 presentation that was made at the HDMA  24 conference?</p> <p>25 A. Yes, sir.</p>	<p style="text-align: right;">Page 364</p> <p>1 presentation, these points, these principals,  2 existed in 1995 when you got to the DEA,  3 correct?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 THE WITNESS: Yes, sir.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. I do want to bring your attention --  8 attached to it seems to be a PowerPoint  9 presentation with notes underneath them, like  10 speaking notes. We haven't seen anything like  11 this yet.</p> <p>12 Are you familiar with these speaking  13 notes?</p> <p>14 Would they have been notes that you  15 put together?</p> <p>16 MS. MCCLURE: Object to form.</p> <p>17 Compound.</p> <p>18 BY MR. MIGLIORI:</p> <p>19 Q. Just so we can illustrate what I'm  20 talking about, if you turn to Page 16 of the  21 PowerPoint presentation, it seems to be a  22 duplicate of the larger presentation in front  23 of it, but underneath there are notes  24 underneath the PowerPoint slides. I'm on Page  25 16, "Suspicious Orders."</p>

<p style="text-align: right;">Page 365</p> <p>1 MS. MAINIGI: Objection.</p> <p>2 MS. McClURE: Don, for the record,</p> <p>3 who applied the highlighting that we now see on</p> <p>4 this?</p> <p>5 MR. MIGLIORI: I did.</p> <p>6 MS. McClURE: It's not on the</p> <p>7 original?</p> <p>8 MR. MIGLIORI: That's correct.</p> <p>9 MS. McClURE: Thank you.</p> <p>10 MR. MIGLIORI: But I did not do the</p> <p>11 all caps.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. MIGLIORI:</p> <p>14 Q. Okay. So do you recall working off</p> <p>15 of notes like that when you gave these</p> <p>16 briefings?</p> <p>17 A. For recall.</p> <p>18 MS. MAINIGI: Objection.</p> <p>19 BY MR. MIGLIORI:</p> <p>20 Q. Go ahead. Repeat your answer.</p> <p>21 A. For recall.</p> <p>22 Q. And so under this particular slide</p> <p>23 on Page 16 of the suspicious orders where it</p> <p>24 talks about reporting a suspicious order, "The</p> <p>25 DEA does not relieve the distributor of the</p>	<p style="text-align: right;">Page 367</p> <p>1 slide on the -- that?</p> <p>2 A. "Suspicious orders versus excessive</p> <p>3 purchases. Orders are before sales."</p> <p>4 Q. Is that a message that you were</p> <p>5 delivering in your distributor briefings?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: Yes, sir.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. And why did you make a note, or was</p> <p>10 there a note there for you to recall making</p> <p>11 that point?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 Foundation. He's already said he doesn't even</p> <p>14 recall whether he made these notes.</p> <p>15 MR. MIGLIORI: All right. That's</p> <p>16 about ten word. But you can get it down to</p> <p>17 four, and we'll be in good shape.</p> <p>18 MS. MAINIGI: I don't think I need</p> <p>19 to. Because you're trying to put words in his</p> <p>20 mouth for this entire bit of testimony.</p> <p>21 MR. MIGLIORI: Who asked for</p> <p>22 leading?</p> <p>23 MS. MAINIGI: I --</p> <p>24 BY MR. MIGLIORI:</p> <p>25 Q. Can you answer that question, or do</p>
<p style="text-align: right;">Page 366</p> <p>1 responsibility to maintain effective controls</p> <p>2 against diversion," underneath it says, in all</p> <p>3 caps, "VERY" and then in lower case "Important</p> <p>4 Concept."</p> <p>5 Is that your note?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: I don't recall.</p> <p>8 BY MR. MIGLIORI:</p> <p>9 Q. Is it a note that you would have</p> <p>10 taken an instruction from for recall as you</p> <p>11 were giving the presentation?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 THE WITNESS: Yes, sir.</p> <p>14 BY MR. MIGLIORI:</p> <p>15 Q. Is it a concept that you would have</p> <p>16 emphasized as a very important concept?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 THE WITNESS: Yes, sir.</p> <p>19 BY MR. MIGLIORI:</p> <p>20 Q. If you turn to the next page -- it's</p> <p>21 the last one I'll ask you about -- there's a</p> <p>22 note underneath the side on "Suspicious Orders"</p> <p>23 that discuss the requirement to design and</p> <p>24 operate a system to identify suspicious orders.</p> <p>25 Could you read the note under the</p>	<p style="text-align: right;">Page 368</p> <p>1 you want me to repeat it?</p> <p>2 A. Order --</p> <p>3 Q. I'm happy to repeat it.</p> <p>4 A. Order before. Was the sale is</p> <p>5 completed. It's a sale. Order is I'm</p> <p>6 requesting it. The distinction had to be made</p> <p>7 clear.</p> <p>8 Q. Is there a distinction being made</p> <p>9 between suspicious order reporting and</p> <p>10 excessive purchase reporting?</p> <p>11 MS. MAINIGI: Objection. No</p> <p>12 foundation this witness wrote this note.</p> <p>13 THE WITNESS: As previously stated,</p> <p>14 the excessive purchase -- it was already done.</p> <p>15 It was -- the sale was completed. Suspicious</p> <p>16 order is before the order is completed.</p> <p>17 BY MR. MIGLIORI:</p> <p>18 Q. Was this excessive purchase</p> <p>19 reporting compliant, to your understanding,</p> <p>20 with the Controlled Substances Act obligations</p> <p>21 for a registrant at the time of this</p> <p>22 presentation in 2007?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: No, sir. It was not.</p> <p>25 BY MR. MIGLIORI:</p>

<p style="text-align: right;">Page 369</p> <p>1 Q. Was excessive purchase reporting, to 2 your understanding of the DEA obligations, 3 compliant with the -- with the -- strike that. 4       Was excessive purchase reporting 5 compliant with the obligations under the 6 Controlled Substances Act, to your 7 understanding, when you got to the DEA in 1995? 8       MS. MAINIGI: Objection. 9       THE WITNESS: No, sir. 10      BY MR. MIGLIORI: 11      Q. And when you gave your briefings in 12 2007, did you make a point to distinguish 13 orders from sales relative to the obligations 14 to report suspicious orders? 15      MS. MAINIGI: Objection. 16      THE WITNESS: Yes, sir. 17      BY MR. MIGLIORI: 18      Q. The issue came up when counsel was 19 talking to you last week about documentation of 20 due diligence. 21      Do you recall that? 22      A. Yes, sir. 23      Q. Now, we've been talking a little bit 24 about the HDMA. 25      Do you know who the members of the</p>	<p style="text-align: right;">Page 371</p> <p>1       BY MR. MIGLIORI: 2      Q. Were retail chain pharmacies part of 3 the HDMA, to your knowledge? 4       MS. MAINIGI: Objection. 5       THE WITNESS: I don't recall. 6      BY MR. MIGLIORI: 7      Q. Okay. Were manufacturers of 8 controlled substances members of the HDMA, to 9 your knowledge? 10      MS. MAINIGI: Objection. 11      THE WITNESS: I don't recall. I 12 don't believe so. 13      BY MR. MIGLIORI: 14      Q. On the covering page of this 15 document, in talking about -- oh, I'll -- 16 I'll -- let me give the full title. It's 17 called "The Industry Compliance Guidelines: 18 Reporting Suspicious Orders and Preventing 19 Diversion of Controlled Substances." 20      Were you aware that the HDMA, in 21 November of 2008, published a guidance for 22 distributors relative to suspicious orders and 23 preventing diversion? 24      MS. MAINIGI: Objection. 25      THE WITNESS: No, sir.</p>
<p style="text-align: right;">Page 370</p> <p>1 HDMA are? 2       MS. MAINIGI: Objection. 3       THE WITNESS: (No response.) 4       MR. MIGLIORI: This is Exhibit No. 5 34. 6       (Deposition Exhibit 34 was marked 7 for identification.) 8       MS. McClURE: Can you read the Bates 9 number into the record for the -- 10      MR. MIGLIORI: Happy to. 11      MS. MAINIGI: -- attorneys and 12 people on the phone. 13      MR. MIGLIORI: This is Cardinal 14 Health document CAH_MDL 280400988458. It's 15 called the "Industry Compliance Guidelines, 16 Healthcare Distribution Management Association, 17 HDMA." 18      THE WITNESS: It was an association 19 of distributors, to my understanding, mostly, 20 in which they would get together, either 21 independently on their own and with the 22 department of -- or drug enforcement to discuss 23 matters, litigation, proposed rule making, a 24 variety of things that would affect their 25 business or had an interest in their business.</p>	<p style="text-align: right;">Page 372</p> <p>1       BY MR. MIGLIORI: 2      Q. I'm going to read from this cover 3 introduction. It says: "At the center of a 4 sophisticated supply chain, distributors are 5 uniquely situated to perform the due diligence 6 in order to help support the security of the 7 controlled substances they deliver to their 8 customers." 9       Do you agree with that statement? 10      MS. MAINIGI: Objection. 11      BY MR. MIGLIORI: 12      Q. That distributors are uniquely 13 situated to perform the due diligence? 14      MS. MAINIGI: Objection. 15      THE WITNESS: Yes, sir. 16      BY MR. MIGLIORI: 17      Q. The HDMA wrote: "Due diligence can 18 provide a greater level of assurance that those 19 who purchase controlled substance from 20 distributors intend to dispense them for 21 legally acceptable purposes." 22       Do you agree with that statement of 23 the HDMA? 24      MS. MAINIGI: Objection. 25      THE WITNESS: Yes, sir.</p>

<p style="text-align: right;">Page 373</p> <p>1        BY MR. MIGLIORI:</p> <p>2        Q. And it says: "Such due diligence 3 can reduce the possibility that controlled 4 substances within the supply chain will reach 5 locations they are not intended to reach."</p> <p>6        Do you agree with that statement of 7 the HDMA?</p> <p>8        MS. MAINIGI: Objection.</p> <p>9        THE WITNESS: Yes, sir.</p> <p>10      BY MR. MIGLIORI:</p> <p>11      Q. I want to have you turn to Page 415, 12 if you look at the top-right corner. There's a 13 discussion in the guidance about the "Know Your 14 Customer Due Diligence."</p> <p>15      And it says: "Before opening an 16 account for a new customer, the distributor 17 should obtain background information on the 18 customer and the customer's business, review 19 that information carefully and, where 20 appropriate, verify the information and 21 independently investigate the potential 22 customer."</p> <p>23      Do you agree with that statement of 24 the Healthcare -- of the HDMA?</p> <p>25      MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 375</p> <p>1        an Order of Interest Shipment," the HDMA wrote: 2        "If an order meets or exceeds a distributor's 3 threshold, as defined in the distributor's 4 monitoring system, or as otherwise 5 characterized by the distributor as an order of 6 interest, the distributor should not ship to 7 the customer in fulfillment of that order any 8 units of the specific drug code product as to 9 which the order met or exceed a threshold or as 10 to which the order was otherwise characterized 11 as an order of interest."</p> <p>12      Do you agree with that guidance?</p> <p>13      MS. MAINIGI: Objection.</p> <p>14      BY MR. MIGLIORI:</p> <p>15      Q. Was that consistent with your then 16 understanding of the requirements under the 17 CSA?</p> <p>18      MS. MAINIGI: Objection.</p> <p>19      THE WITNESS: An order of interest 20 would be a suspicious order. Anything that 21 drew attention, identified anomalies should be 22 looked at.</p> <p>23      BY MR. MIGLIORI:</p> <p>24      Q. Once identified, what were the 25 obligations of that registrant, in your</p>
<p style="text-align: right;">Page 374</p> <p>1        THE WITNESS: I do, sir.</p> <p>2        BY MR. MIGLIORI:</p> <p>3        Q. Was that a good due diligence 4 practice in 2008?</p> <p>5        MR. BENNETT: Objection.</p> <p>6        MS. MAINIGI: Objection.</p> <p>7        THE WITNESS: It's a good start.</p> <p>8        BY MR. MIGLIORI:</p> <p>9        Q. And --</p> <p>10      MS. MCCLURE: Don, for the purposes 11 of the record, I'm just going to confirm that 12 the highlighting that you're displaying in this 13 document is again your own and not contained in 14 the original, correct?</p> <p>15      MR. MIGLIORI: Correct. That's true 16 for every document that you'll see from me 17 today.</p> <p>18      BY MR. MIGLIORI:</p> <p>19      Q. Due diligence for a new customer was 20 also required in 1995 when you got to the DEA, 21 correct?</p> <p>22      MS. MAINIGI: Objection.</p> <p>23      THE WITNESS: Yes, sir.</p> <p>24      BY MR. MIGLIORI:</p> <p>25      Q. On Page 9 of 15, under "Suspend/Stop</p>	<p style="text-align: right;">Page 376</p> <p>1        experience, or to your understanding?</p> <p>2        MS. MAINIGI: Objection.</p> <p>3        THE WITNESS: If you deem it 4 suspicious, you report.</p> <p>5        BY MR. MIGLIORI:</p> <p>6        Q. When do you report it?</p> <p>7        A. When discovered.</p> <p>8        Q. If you turn to Page 11 of 15, 9 there's a reference here by the HDMA about 10 documentation. In 2008, the HDMA guidance on 11 document says: "All investigations should be 12 fully documented, and all records of the 13 investigation should be retained in an 14 appropriate location with the firm, such as 15 with other records relating to the particular 16 customer."</p> <p>17      Do you agree with that statement of 18 the HDMA in 2008?</p> <p>19      MS. MAINIGI: Objection.</p> <p>20      THE WITNESS: I do, sir.</p> <p>21      BY MR. MIGLIORI:</p> <p>22      Q. Is that something that you told 23 registrants when you briefed them in your 24 distributor briefings?</p> <p>25      MS. MAINIGI: Objection.</p>

<p style="text-align: right;">Page 377</p> <p>1       THE WITNESS: Most certainly was.    2       BY MR. MIGLIORI:    3       Q. And did you believe that to be the    4 appropriate procedure or policy in 1995 when    5 you got to the DEA and were in the field in    6 Dallas?    7       MS. MAINIGI: Objection.    8       THE WITNESS: Yes, sir.    9       BY MR. MIGLIORI:    10      Q. The HDMA wrote: "At a minimum,    11 documentation should include the names, titles    12 and other relevant identification of the    13 representative of the customer contacted,    14 example given: pharmacist in charge, dates of    15 contact, full description of questions asked    16 and requests for information made by the    17 distributor and of information provided by the    18 customer."    19       Do you agree with that guidance from    20 the HDMA to its distributor members in 2008?    21       MS. MAINIGI: Objection.    22       THE WITNESS: I certainly do.    23       BY MR. MIGLIORI:    24       Q. And would that have been what you    25 would expect in 1995 of registrant</p>	<p style="text-align: right;">Page 379</p> <p>1       BY MR. MIGLIORI:    2       Q. It goes on to say: "The    3 documentation should include a clear statement    4 of the final conclusion of the investigation,    5 including why the order investigated was or was    6 not determined to be suspicious."    7       Do you agree with that statement of    8 the HDMA?    9       MS. MAINIGI: Objection.    10      THE WITNESS: Yes, sir.    11      Q. And would that have been appropriate    12 guidance in 1995 when you got to the DEA?    13       MS. MAINIGI: Objection.    14       THE WITNESS: Yes, sir.    15       BY MR. MIGLIORI:    16       Q. Finally: "That statement should be    17 signed and dated by the reviewer. Copies of    18 any written information provided by the    19 customer should also be retained as part of the    20 documentation of the investigation."    21       Was that good guidance by the HDMA    22 in 2008?    23       MS. MAINIGI: Objection.    24       MR. BENNETT: Objection.    25       THE WITNESS: Yes, sir.</p>
<p style="text-align: right;">Page 378</p> <p>1       distributors?    2       MS. MAINIGI: Objection.    3       THE WITNESS: Yes, sir.    4       BY MR. MIGLIORI:    5       Q. In fact, have you ever looked at the    6 standard operating procedures of any of the    7 registrant distributors in your experience at    8 the DEA?    9       MR. BENNETT: Objection.    10      MS. MAINIGI: Objection.    11      MR. BENNETT: I don't want you to    12 talk about specific investigations. You can    13 talk generally though.    14      THE WITNESS: As I'm -- would you    15 please repeat the question.    16      BY MR. MIGLIORI:    17      Q. Sure.    18      Are you familiar with any standard    19 operating procedures of any of the distributor    20 registrants?    21      First "yes" or "no."    22      MS. MAINIGI: Objection.    23      THE WITNESS: No.    24      MR. MIGLIORI: Okay. Made that    25 quick.</p>	<p style="text-align: right;">Page 380</p> <p>1       BY MR. MIGLIORI:    2       Q. And would that have been appropriate    3 guidance in 1995 when you got to the DEA?    4       MS. MAINIGI: Objection.    5       THE WITNESS: Yes, sir.    6       BY MR. MIGLIORI:    7       Q. Let me just bring you to the Page 14    8 of 15 under "Additional Recommendations."    9       The HDMA, on page 14 of 15, lists    10 under "Additional Recommendations" the third    11 bullet point. Well, it says: "It is    12 recommended that a distributor include in its    13 system provisions for," the third bullet point,    14 "periodic review of the distributor system for    15 monitoring for suspicious orders, including the    16 system design and the thresholds to determine    17 whether a revision should be developed. For    18 example, if the FDA approves a new controlled    19 substance or a new indication for use for an    20 existing controlled substance, or if the DEA    21 makes new information available regarding a    22 drug or concern, provisions to the thresholds    23 may be needed."    24       Do you agree with the guidance of    25 the HDMA in 2008 that periodic review of the</p>

<p style="text-align: right;">Page 381</p> <p>1 Suspicious Order Monitoring System is 2 appropriate?</p> <p>3 MS. MAINIGI: Objection.</p> <p>4 THE WITNESS: Yes, sir.</p> <p>5 BY MR. MIGLIORI:</p> <p>6 Q. Would that have been appropriate in 7 1995 when you got to the DEA?</p> <p>8 Would that have been appropriate 9 guidance?</p> <p>10 MS. McCLURE: Objection.</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. MIGLIORI:</p> <p>14 Q. Why?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: The means of criminal 17 activity was always changing; didn't stay 18 constant. Means of -- of trying to obtain 19 these narcotic drugs illicitly was always 20 changing. The drugs themselves, the 21 combinations of those drugs.</p> <p>22 There's -- can't predict what the 23 drug is today is going to be the same drug of 24 abuse. Opana was a regional drug through the 25 Midwest that stayed consistent for a little</p>	<p style="text-align: right;">Page 383</p> <p>1 on the record.</p> <p>2 This is the start of Media Unit No.</p> <p>3 3.</p> <p>4 The time is 11:54.</p> <p>5 You may proceed, Counsel.</p> <p>6 EXAMINATION BY COUNSEL FOR CUYAHOGA COUNTY</p> <p>7 PLAINTIFFS</p> <p>8 BY MR. SHKOLNIK:</p> <p>9 Q. Good morning, Mr. Wright.</p> <p>10 My name's Hunter Shkolnik. I 11 introduced myself last Thursday when your first 12 day of your deposition began.</p> <p>13 You and I have never met before that 14 Thursday occasion; am I correct?</p> <p>15 A. No, sir. Not to the best of my 16 recollection.</p> <p>17 Q. And let me reintroduce myself and 18 why I'm here. I represent Cuyahoga County as 19 well as -- as various plaintiffs in this 20 litigation. And Cuyahoga County is one of the 21 cases going to trial this coming October in the 22 opioid litigation.</p> <p>23 You, sir, during your years at DEA, 24 did you ever -- or were you ever assigned to 25 the region that would encompass Ohio, Cuyahoga</p>
<p style="text-align: right;">Page 382</p> <p>1 over a year and quickly died out because it 2 just didn't have the desired effect.</p> <p>3 Things were going to come up and 4 arise and change. The system had to be adapted 5 to detect these changes.</p> <p>6 BY MR. MIGLIORI:</p> <p>7 Q. What was your understanding of whose 8 responsibility it was to periodically review 9 and make those changes?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 THE WITNESS: The registrants'.</p> <p>12 BY MR. MIGLIORI:</p> <p>13 Q. Did that responsibility, in your 14 experience, go back to 1995 when you got to the 15 DEA?</p> <p>16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: Yes, sir.</p> <p>18 MR. MIGLIORI: Want to take a break?</p> <p>19 Let's take a break.</p> <p>20 THE VIDEOGRAPHER: We are going off 21 the record.</p> <p>22 This is the end of Media Unit No. 2.</p> <p>23 The time is 11:31.</p> <p>24 (A short recess was taken.)</p> <p>25 THE VIDEOGRAPHER: We are going back</p>	<p style="text-align: right;">Page 384</p> <p>1 County, when you were working in the field?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: No, sir.</p> <p>4 BY MR. SHKOLNIK:</p> <p>5 Q. Did you ever have occasion to work 6 any investigations in Ohio, specifically 7 Cuyahoga County or, for that matter, Summit 8 County, which is adjoining it?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 MR. BENNETT: Objection. Don't 11 speak about specific investigation.</p> <p>12 But you can answer generally.</p> <p>13 THE WITNESS: Not to my 14 recollection.</p> <p>15 BY MR. SHKOLNIK:</p> <p>16 Q. Now, you -- you've been asked 17 questions on Thursday and again this morning 18 about attending and -- and a present -- and 19 presentations at a pharmaceutical industry 20 conference in Houston September 11th and 12th, 21 2007.</p> <p>22 Do you actually have recollection of 23 attending that conference with Mr. Mapes and 24 doing any presentations?</p> <p>25 MS. MAINIGI: Objection.</p>

<p style="text-align: right;">Page 385</p> <p>1 MR. STEPHENS: Objection.</p> <p>2 THE WITNESS: The dates? Repeat</p> <p>3 those --</p> <p>4 BY MR. SHKOLNIK:</p> <p>5 Q. September 11th and 12th of 2007 in</p> <p>6 Houston, Texas?</p> <p>7 MS. MCCLURE: Objection. Asked and</p> <p>8 answered.</p> <p>9 MR. SHKOLNIK: Not by me.</p> <p>10 THE WITNESS: Vaguely, yes.</p> <p>11 BY MR. SHKOLNIK:</p> <p>12 Q. And -- and would I be correct in</p> <p>13 stating that that was not just attend by</p> <p>14 distributors, that conference in Houston in</p> <p>15 2007, correct?</p> <p>16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: Correct.</p> <p>18 BY MR. SHKOLNIK:</p> <p>19 Q. And that was what we would call a</p> <p>20 pharmaceutical industry conference, meaning you</p> <p>21 would have various levels of the pharmaceutical</p> <p>22 industry, and registrants in particular,</p> <p>23 pharmacy, pharmacy chains, manufacturers and</p> <p>24 distributors that were in attendance, correct?</p> <p>25 MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 387</p> <p>1 Q. And also attached to it is a portion</p> <p>2 of a -- of one of the PowerPoints presented at</p> <p>3 that conference. We can go into details in a</p> <p>4 little bit.</p> <p>5 But it is a -- a PowerPoint</p> <p>6 presentation, correct?</p> <p>7 A. It is, sir.</p> <p>8 Q. And that is not -- withdraw that.</p> <p>9 If we could just briefly go through</p> <p>10 35.</p> <p>11 On -- on the first page at the</p> <p>12 bottom it says "1 of 24." We -- we see that</p> <p>13 there are a list of attendees.</p> <p>14 MR. SHKOLNIK: How I do zoom this</p> <p>15 out. Here we go.</p> <p>16 BY MR. SHKOLNIK:</p> <p>17 Q. Okay. We have a list of attendees</p> <p>18 that were here. I want to just go through this</p> <p>19 and see if this helps refresh your recollect as</p> <p>20 to who some of the attendees are.</p> <p>21 We have here Actavis --</p> <p>22 MS. MAINIGI: Is that a question, or</p> <p>23 what -- what is it?</p> <p>24 MR. SHKOLNIK: It's all -- it's all</p> <p>25 of the above. I hope you like it.</p>
<p style="text-align: right;">Page 386</p> <p>1 THE WITNESS: Correct.</p> <p>2 MR. SHKOLNIK: And I'd like to hand</p> <p>3 you what I've marked as Exhibit No. -- I</p> <p>4 believe it's 35.</p> <p>5 I can give you this.</p> <p>6 (Deposition Exhibit 35 was marked</p> <p>7 for identification.)</p> <p>8 MR. SHKOLNIK: Unlike my colleagues,</p> <p>9 I only have limited numbers of copies. So I</p> <p>10 apologize.</p> <p>11 MS. MAINIGI: Could you read the</p> <p>12 Bates number for the record.</p> <p>13 MR. SHKOLNIK: I will.</p> <p>14 Cardinal Health 019076.</p> <p>15 BY MR. SHKOLNIK:</p> <p>16 Q. And sir, I've just handed you what</p> <p>17 I've marked as Exhibit No. 35. And it appears</p> <p>18 to -- and -- and if -- if I understand it</p> <p>19 correctly, it is a list of attendees at the</p> <p>20 13th pharmaceutical industry conference in</p> <p>21 Houston, Texas, September 11th, 2000 --</p> <p>22 September 12, 2007.</p> <p>23 Do you have that in front of you,</p> <p>24 sir?</p> <p>25 A. I do, sir.</p>	<p style="text-align: right;">Page 388</p> <p>1 MS. MAINIGI: Objection.</p> <p>2 BY MR. SHKOLNIK:</p> <p>3 Q. Actavis was there; am I correct,</p> <p>4 sir?</p> <p>5 MS. MAINIGI: Objection.</p> <p>6 MR. BENNETT: Objection.</p> <p>7 THE WITNESS: Yes, sir.</p> <p>8 BY MR. SHKOLNIK:</p> <p>9 Q. Actavis Mid-Atlantic, LLC, also had</p> <p>10 a -- had a person there; am I correct?</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 MS. MCCLURE: Objection.</p> <p>13 MR. BENNETT: Object to the form.</p> <p>14 MR. SHKOLNIK: I don't think --</p> <p>15 MR. BENNETT: Counsel, I just --</p> <p>16 just so the record's clear, are you asking him</p> <p>17 whether the document says that or whether he --</p> <p>18 MR. SHKOLNIK: Okay. I'll --</p> <p>19 MR. BENNETT: -- remembers?</p> <p>20 MR. SHKOLNIK: I'll rephrase it.</p> <p>21 That's a --</p> <p>22 MR. BENNETT: Thank you, sir.</p> <p>23 BY MR. SHKOLNIK:</p> <p>24 Q. According to the document, the --</p> <p>25 the attendee list, it suggests that Actavis and</p>

Page 389	Page 391
<p>1 Actavis Mid-Atlantic was in attendance, if you 2 see Page 2.</p> <p>3 A. Yes, sir.</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 BY MR. SHKOLNIK:</p> <p>6 Q. It -- it also suggests that, whether 7 they were actually physically there or -- and 8 attending, they were registered, also 9 AmerisourceBergen had a group of registered 10 participants at that conference, correct?</p> <p>11 MS. McCLURE: Objection.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. SHKOLNIK:</p> <p>14 Q. And if we turn to Page No. 4, we 15 have more AmerisourceBergen as well as 16 AmerisourceBergen Specialty Group represent -- 17 representatives who were registered at that 18 pharmaceutical conference in -- in Houston, 19 correct?</p> <p>20 MS. McCLURE: Objection.</p> <p>21 THE WITNESS: Yes, sir.</p> <p>22 BY MR. SHKOLNIK:</p> <p>23 Q. And when you go to these type of 24 conferences, is it common to get a list of the 25 attendees so you know who was registered and</p>	<p>1 MR. O'CONNOR: Objection.</p> <p>2 THE WITNESS: Correct, sir.</p> <p>3 BY MR. SHKOLNIK:</p> <p>4 Q. And if we go to the next page, which 5 I'm looking at is Page 10, we -- we -- we also 6 have FedEx Custom Critical and FedEx Freight as 7 a registered attendee at the conference in 8 Houston.</p> <p>9 Does it say that?</p> <p>10 A. Yes, sir.</p> <p>11 Q. Now, FedEx was one of the -- was an 12 entity that actually participated in the 13 distribution process of controlled substances, 14 was it not?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 Foundation.</p> <p>17 MR. EPPICH: Objection.</p> <p>18 THE WITNESS: Yes, sir.</p> <p>19 BY MR. SHKOLNIK:</p> <p>20 Q. And they were -- they actually had a 21 registration where they could distribute for 22 manufacturers, couldn't they?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: Yes, sir.</p> <p>25 BY MR. SHKOLNIK:</p>
Page 390	Page 392
<p>1 who'd be participating?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: It was a very common 4 practice.</p> <p>5 BY MR. SHKOLNIK:</p> <p>6 Q. And if we go to Page 6, it looks 7 like we have Cardinal Health represented in the 8 house that day as well, correct?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 BY MR. SHKOLNIK:</p> <p>11 Q. Or at least registered.</p> <p>12 A. Correct, sir.</p> <p>13 Q. And if we go to Page 7, we have 14 Cephalon registered and potentially in the 15 house for the presentation by at least three 16 people, correct?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 THE WITNESS: Correct, sir.</p> <p>19 BY MR. SHKOLNIK:</p> <p>20 Q. And if we go to the next page, Page 21 8, we have, again, Cephalon and Cephalon doing 22 business as Anesta Corp., also registered 23 attendee at the Houston pharmaceutical 24 conference where the presentation was made, 25 correct?</p>	<p>1 Q. And then if we go to the next page, 2 we have H.D. Smith as a registrant on Page 11, 3 correct?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 MR. EPPICH: Object.</p> <p>6 BY MR. SHKOLNIK:</p> <p>7 Q. When I say "registered," I mean 8 registered attendee at the conference.</p> <p>9 Correct?</p> <p>10 A. Yes, sir.</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 BY MR. SHKOLNIK:</p> <p>13 Q. If we go to the next page, we have 14 Henry Schein also registered by a couple of 15 people, both regulatory affairs people, for -- 16 as attendees at the conference, correct?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 THE WITNESS: Yes, sir.</p> <p>19 BY MR. SHKOLNIK:</p> <p>20 Q. And if we could go now to Page 15, 21 we have Mallinckrodt Davidian, and we have 22 McKesson as registered attendees at the 23 pharmaceutical conference in Houston, correct.</p> <p>24 MR. EPPICH: Objection.</p> <p>25 THE WITNESS: Yes, sir.</p>
	32 (Pages 389 - 392)

<p style="text-align: right;">Page 393</p> <p>1 BY MR. SHKOLNIK:</p> <p>2 Q. If we go to the next page, we</p> <p>3 actually have McKesson's Medical Surgical,</p> <p>4 Incorporated, as a registered attendee for the</p> <p>5 conference, correct?</p> <p>6 MR. EPPICH: Objection.</p> <p>7 MR. SHKOLNIK: Sorry. Go back to</p> <p>8 that. I apologize.</p> <p>9 THE WITNESS: Yes, sir.</p> <p>10 BY MR. SHKOLNIK:</p> <p>11 Q. And if we go to the next page, 17,</p> <p>12 we have Mylan Laboratories also as a registered</p> <p>13 attendee for the conference, correct?</p> <p>14 MR. EPPICH: Objection.</p> <p>15 THE WITNESS: Yes, sir.</p> <p>16 MR. SHKOLNIK: Going to skip ahead.</p> <p>17 BY MR. SHKOLNIK:</p> <p>18 Q. If we could go to Page 20, we have</p> <p>19 Purdue and Qualitest Pharmaceuticals both as</p> <p>20 registered attendees at this conference,</p> <p>21 correct?</p> <p>22 MR. O'CONNOR: Objection.</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 MS. McCLURE: Objection.</p> <p>25 THE WITNESS: (No response.)</p>	<p style="text-align: right;">Page 395</p> <p>1 BY MR. SHKOLNIK:</p> <p>2 Q. And we have Watson Laboratories also</p> <p>3 attending as a -- or a registered attendee at</p> <p>4 the conference, correct?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 THE WITNESS: Yes, sir.</p> <p>7 BY MR. SHKOLNIK:</p> <p>8 Q. Now, would it be fair to say that,</p> <p>9 when these pharmaceutical companies, chain</p> <p>10 pharmacies, manufacturers and distributors were</p> <p>11 attending this conference and -- and you and/or</p> <p>12 Mr. Mapes presenting there or Mr. Mapes</p> <p>13 presenting there, was the goal to try to get</p> <p>14 out your information to as many people as you</p> <p>15 possibly could at a forum such as this where so</p> <p>16 many people were -- or so many registrants were</p> <p>17 attending?</p> <p>18 MS. MAINIGI: Objection.</p> <p>19 THE WITNESS: Absolutely.</p> <p>20 BY MR. SHKOLNIK:</p> <p>21 Q. I mean, if you want to get the word</p> <p>22 out from the DEA perspective, you want to go to</p> <p>23 where the registrants are so that you could</p> <p>24 really hit as many or get as many to hear the</p> <p>25 word that you're -- that you're -- you're --</p>
<p style="text-align: right;">Page 394</p> <p>1 BY MR. SHKOLNIK:</p> <p>2 Q. And if we could go to Page 23, we</p> <p>3 even have Walgreens here --</p> <p>4 MR. STEPHENS: Objection.</p> <p>5 BY MR. SHKOLNIK:</p> <p>6 Q. -- as a attendee registrant at this</p> <p>7 conference, correct?</p> <p>8 MR. STEPHENS: Objection.</p> <p>9 MR. SHKOLNIK: I knew that was</p> <p>10 coming.</p> <p>11 BY MR. SHKOLNIK:</p> <p>12 Q. Am I correct, sir?</p> <p>13 A. Yes, sir.</p> <p>14 Q. So would -- would I be -- oh, and I</p> <p>15 think I've got one more here. Oh, I do.</p> <p>16 If we could just go to the last</p> <p>17 page. We've Walgreen Company again. And</p> <p>18 actually, they even had their lawyer there</p> <p>19 attending the -- as a registrant --</p> <p>20 MR. STEPHENS: Same objection.</p> <p>21 BY MR. SHKOLNIK:</p> <p>22 Q. -- for the conference, Mr. Pinon,</p> <p>23 correct?</p> <p>24 MR. STEPHENS: Objection.</p> <p>25 THE WITNESS: Yes, sir.</p>	<p style="text-align: right;">Page 396</p> <p>1 you're sort of preaching.</p> <p>2 You want them to get it, and this</p> <p>3 was a good places to do it, correct?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 MR. BENNETT: Objection. Form.</p> <p>6 THE WITNESS: Yes, sir.</p> <p>7 BY MR. SHKOLNIK:</p> <p>8 Q. I mean I'm not -- I'm not using the</p> <p>9 word "preaching" in a derogatory way.</p> <p>10 You were trying to get the word out</p> <p>11 to the industry that you had a problem with</p> <p>12 respect to sales and distribution of controlled</p> <p>13 substances, and these companies had to do</p> <p>14 something, and they had to act, correct?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 Mr. Shkolnik, if you could -- I</p> <p>17 don't know what foundation you have that you</p> <p>18 are trying to put all these words in this</p> <p>19 witness's mouth.</p> <p>20 MR. SHKOLNIK: Please, you know, do</p> <p>21 you have an objection to form?</p> <p>22 MS. MAINIGI: He's not even said</p> <p>23 that --</p> <p>24 MR. SHKOLNIK: Do you have an</p> <p>25 objection to form? Say it.</p>

<p>1 MS. MAINIGI: I've an objection to 2 form. And I -- 3 MR. SHKOLNIK: Okay. Could we go 4 off the record. We're going to call Special 5 Master Cohen. 6 MS. MAINIGI: I'm fine with that. 7 MR SHKOLNIK. On. That -- that -- 8 that's good. 9 THE VIDEOGRAPHER: We -- we are 10 going off the record. The time is 12:06. 11 (A short recess was taken.) 12 (Whereupon, Special Master Cohen was 13 called.) 14 (Discussion off the record.) 15 SPECIAL MASTER COHEN: Who right now 16 is doing the questioning, and who is stating 17 objections? 18 MS. MAINIGI: Hunter is doing the 19 questioning. And I'm stating the objection. 20 And the problem that we are having 21 -- and I'm happy to read the question -- is 22 this witness has indicated he actually has no 23 idea whether he was at this meeting, number 24 one. Number two, he's actually previously 25 testified under oath that he was not at the</p>	Page 397	<p>1 If we could go back to that. 2 MS. MAINIGI: I -- I'm looking for 3 it. I -- I think we keep talking, so it goes 4 further and further back. 5 MR. SHKOLNIK: Maybe the court 6 reporter -- could you pull that up? 7 (Discussion held off the record.) 8 (The record was read as requested.) 9 SPECIAL MASTER COHEN: All right. 10 So look, this is how this needs to go forward. 11 I said it before that an objection needs to be 12 one word with an explanation, and the 13 explanation can be about ten words or less. So 14 an appropriate objection would be, "Objection. 15 Form." 16 When it's time to decide whether 17 that colloquy is allowed in as evidence, and if 18 -- if it ever comes up that counsel designates 19 that colloquy, then the court will look at the 20 objection and may well decide that the form was 21 shitty and that the question was inappropriate 22 and that the response isn't allowed in. But 23 the only thing that needs to happen is that 24 somebody needs to register an objection. 25 I always think that, when counsel is</p>	Page 399
<p>1 meeting. 2 I think he's trying to be as helpful 3 as he can to the plaintiffs' counsel, which we 4 all understood why. 5 And so, despite all of that, Mr. 6 Shkolnik is building into his questioning all 7 of these assumptions. He's not asking a 8 straight question. He's basically taking a 9 page and then asking a question at the end of 10 his self-serving statements. 11 MR. SHKOLNIK: I'm cross-examining 12 the witness. I think we're allowed to do that. 13 MS. MAINIGI: And so I think -- so I 14 put in an objection. It has been object to 15 form the entire morning when Mr. Migliori was 16 questioning. 17 And Mr. Shkolnik has just now 18 started questioning and is loading up all of 19 his questions with just is garbage. 20 MR. SHKOLNIK: David, could we just 21 read the question and then -- 22 SPECIAL MASTER COHEN: Yeah. Go 23 ahead. 24 MR. SHKOLNIK: -- and then the 25 speech that came at the end of it.</p>	Page 398	<p>1 inside of a deposition like this, that they are 2 at odds, but sometimes it actually does some 3 good for questioning counsel to think about 4 what the objection is and think to themselves, 5 "Hmm, you know what? That really wasn't such a 6 good-formed question. Maybe I'll reask it." 7 But that isn't relevant to what you 8 were calling me for. The point is that an 9 objection has to be extremely succinct, in the 10 form of a word and a very brief explanation so 11 that a reviewing court knows what the basis for 12 the objection is. And that's it. 13 MR. SHKOLNIK: Thank you. 14 MS. MAINIGI: David, that's fine. 15 SPECIAL MASTER COHEN: And you can 16 have an opportunity for whatever you want to 17 call it, redirect, to clean things up or ask 18 additional questions. And that's how that is 19 addressed. 20 MS. MAINIGI: David, that's fine. 21 And we'll follow that. But it doesn't work 22 perfectly, your solution, in the case of a 23 witness who can be easily influenced and who is 24 a consultant for the plaintiffs. 25 SPECIAL MASTER COHEN: You can make</p>	Page 400

<p style="text-align: right;">Page 401</p> <p>1 that argument later.</p> <p>2 MS. MAINIGI: Okay. I will.</p> <p>3 MR. SHKOLNIK: Thank you very much.</p> <p>4 SPECIAL MASTER COHEN: Anything</p> <p>5 else?</p> <p>6 MR. SHKOLNIK: No. Thank you.</p> <p>7 SPECIAL MASTER COHEN: Okay.</p> <p>8 THE VIDEOGRAPHER: We are going back</p> <p>9 on the record.</p> <p>10 The 12 -- the time is 12:12.</p> <p>11 You may proceed, Counsel.</p> <p>12 BY MR. SHKOLNIK:</p> <p>13 Q. So, Mr. Wright, was I correct in</p> <p>14 stating that one of the reasons to go to a -- a</p> <p>15 industry conference is to try to get the word</p> <p>16 out to as many registrants as possible in one</p> <p>17 location?</p> <p>18 MS. MAINIGI: Objection.</p> <p>19 THE WITNESS: Yes, sir.</p> <p>20 MR. SHKOLNIK: I'm going to hand you</p> <p>21 a document which I marked as Exhibit 36.</p> <p>22 (Deposition Exhibit 36 was marked</p> <p>23 for identification.)</p> <p>24 BY MR. SHKOLNIK:</p> <p>25 Q. And it is, again, a document from</p>	<p style="text-align: right;">Page 403</p> <p>1 something, there's an official recognition that</p> <p>2 there was attendance by DEA, if you know?</p> <p>3 MR. BENNETT: Objection to form.</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 MR. SHKOLNIK: I'll rephrase it.</p> <p>6 BY MR. SHKOLNIK:</p> <p>7 Q. Are you familiar with this type of</p> <p>8 notice being given out by DEA?</p> <p>9 A. Yes, sir.</p> <p>10 Q. And is -- is this something that's</p> <p>11 utilized when DEA attends such -- something</p> <p>12 such as a conference or has a meeting that it</p> <p>13 wants to give notice of?</p> <p>14 MS. MAINIGI: Objection.</p> <p>15 MS. McCLURE: Form.</p> <p>16 BY MR. SHKOLNIK:</p> <p>17 Q. You can answer.</p> <p>18 A. Yes, sir.</p> <p>19 Q. And here it -- it -- it says that</p> <p>20 there are a number of people in attendance, and</p> <p>21 Mr. Mapes was one of the people, and it was --</p> <p>22 the topic was -- and it says a PowerPoint slide</p> <p>23 presentation.</p> <p>24 And it says Mr. Mapes, Michael</p> <p>25 Mapes, "Suspicious Orders"; am I correct?</p>
<p style="text-align: right;">Page 402</p> <p>1 the Houston conference September 11, 12, 2007.</p> <p>2 This is HDS_MDL Bates No. 2033. So it's a</p> <p>3 document produced by I believe H.D. Smith in</p> <p>4 this case.</p> <p>5 And -- and attached to this document</p> <p>6 is a PowerPoint which I don't think we've</p> <p>7 looked at yet in your deposition as well as</p> <p>8 a -- a printout from the Office of Diversion</p> <p>9 Control outlining the pharmaceutical industry</p> <p>10 conference attendees by DEA; am I correct?</p> <p>11 MS. MAINIGI: Objection.</p> <p>12 THE WITNESS: Yes, sir.</p> <p>13 BY MR. SHKOLNIK:</p> <p>14 Q. And if we could turn to what would</p> <p>15 be Bates numbered at the bottom 2035. This</p> <p>16 type of notice -- it -- at the top it says --</p> <p>17 MR. BENNETT: Hang on a second,</p> <p>18 Counsel. He's going to try to find it.</p> <p>19 MR. SHKOLNIK: Yeah. I'm going to</p> <p>20 try to -- it says "Office of Diversion</p> <p>21 Control," to help you find it.</p> <p>22 Thank you.</p> <p>23 BY MR. SHKOLNIK:</p> <p>24 Q. This type of notice is -- is common</p> <p>25 for DEA that, if you -- if you attend</p>	<p style="text-align: right;">Page 404</p> <p>1 MS. MAINIGI: Objection.</p> <p>2 THE WITNESS: Yes, sir.</p> <p>3 BY MR. SHKOLNIK:</p> <p>4 Q. And if we could turn now to the next</p> <p>5 page that's Bates No. 2036, if we could zoom in</p> <p>6 on that.</p> <p>7 This actually -- this DEA notice</p> <p>8 also gives a -- a synopsis of what Mr. Mapes</p> <p>9 presented to the conference in Houston, this</p> <p>10 pharmaceutical conference that was attended by</p> <p>11 the individuals we -- I'm sorry -- the --</p> <p>12 withdraw that.</p> <p>13 This notice give a synopsis of Mr.</p> <p>14 Mapes's presentation; am I correct?</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: Yes, sir.</p> <p>17 BY MR. SHKOLNIK:</p> <p>18 Q. And if I'm reading it correctly --</p> <p>19 MR. SHKOLNIK: And that's my</p> <p>20 highlight on the document, just in case anyone</p> <p>21 questions it.</p> <p>22 BY MR. SHKOLNIK:</p> <p>23 Q. Toward the bottom middle section it</p> <p>24 says: In 21 CFR Section 1301.74. Other</p> <p>25 security controls include making a good faith</p>

<p style="text-align: right;">Page 405</p> <p>1 inquiry, report suspicious orders, report 2 significant losses."</p> <p>3 He also quoted 21 CFR 1301.74(b): 4 "Registrant shall design and operate a system 5 to disclose to the registrant suspicious orders 6 of controlled substances. The registrant shall 7 inform the field diversion office of the 8 administration in his area of suspicious orders 9 when discovered by the registrant."</p> <p>10 That was your understanding of what 11 the rule was while you were working in 12 Washington from 2005 to your retirement, 13 correct?</p> <p>14 MS. MAINIGI: Objection. 15 THE WITNESS: Yes, sir. 16 BY MR. SHKOLNIK: 17 Q. And -- and just so -- so I -- I 18 understand it, was that also your understanding 19 from before getting to Washington in 2005 when 20 you were working out in the field?</p> <p>21 MS. MAINIGI: Objection. 22 THE WITNESS: Yes, sir. 23 BY MR. SHKOLNIK: 24 Q. This doesn't represent any -- from 25 your perspective, this did not represent any</p>	<p style="text-align: right;">Page 407</p> <p>1 MS. MAINIGI: Objection. 2 THE WITNESS: It wasn't uncommon but 3 not necessarily done all the time. 4 BY MR. SHKOLNIK: 5 Q. Now, if we can now go to what's 6 Bates numbered 252 in this PowerPoint -- I'm 7 sorry -- in this exhibit numbered -- I think 8 it's 36. 9 And here we have -- I think we may 10 have seen a version of this earlier, but I'm 11 not sure. But I just want to ask you a few 12 questions. 13 If I read this correctly: 14 "Suspicious orders." Once again, Title 21 CFR 15 1301.74(b). "Requires registrant to design and 16 operate a system to disclose suspicious orders 17 of controlled substances to DEA." 18 That was your understanding in 2005, 19 correct, sir? 20 MS. MAINIGI: Objection. 21 THE WITNESS: Yes, sir. 22 BY MR. SHKOLNIK: 23 Q. That was your understanding straight 24 through your retirement in 2017, correct, sir? 25 MS. MAINIGI: Objection.</p>
<p style="text-align: right;">Page 406</p> <p>1 change in any law or regulation at DEA. 2 Fair statement? 3 MS. MAINIGI: Objection. 4 THE WITNESS: Yes, sir. 5 BY MR. SHKOLNIK: 6 Q. Now, by the way, it also has another 7 paragraph that talks about that a Mr. 8 Zimmerman, who I think is referred to as -- as 9 vice president corporate security regulatory 10 affairs at AmerisourceBergen, also spoke at 11 this conference. And if I'm reading it 12 correctly -- please tell me if I'm not reading 13 it correctly. 14 "Mr. Zimmerman stressed the 15 importance of knowing your customer and 16 providing due diligence investigations on all 17 new retail and wholesale accounts with the 18 exception of retail chain pharmacies included 19 in new account setup processes and new account 20 questionnaire." 21 I mean was it common that industry 22 people would speak alongside DEA people, from 23 your experience, when you attended conferences 24 like this? 25 MS. McClure: Object to form.</p>	<p style="text-align: right;">Page 408</p> <p>1 THE WITNESS: Yes, sir. 2 BY MR. SHKOLNIK: 3 Q. Now, if we go to the second 4 paragraph of Mr. Mapes's PowerPoint slide, it 5 says: "The requirement is to report suspicious 6 orders, not suspicious sales after the fact." 7 Did I read that correctly, sir? 8 MS. MAINIGI: Objection. 9 THE WITNESS: Yes, sir. 10 BY MR. SHKOLNIK: 11 Q. Now, what is the difference between 12 a suspicious order versus a suspicious sales 13 after the fact, if you could -- your 14 understanding? 15 MS. MAINIGI: Objection. 16 THE WITNESS: A suspicious order is 17 the order placed. I send you a request. I 18 want to order 1,500 widgets. You get this, and 19 you say that it -- that's excess -- or it's 20 suspicious, it's whatever -- 21 Q. Uh-huh. 22 A. -- and you can't fulfill it. Maybe 23 you don't even have it in stock. But if you 24 deem it's suspicious, you report it. 25 A sale --</p>

<p style="text-align: right;">Page 409</p> <p>1 Q. Thank you.</p> <p>2 A. A sale says this is completed. It's</p> <p>3 already out. It has been fulfilled. It has</p> <p>4 been delivered. And the potential harm or</p> <p>5 damage is now there.</p> <p>6 Q. So you really can't pull it back at</p> <p>7 that point once it's out into the market, is</p> <p>8 what you're saying?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 THE WITNESS: No.</p> <p>11 BY MR. SHKOLNIK:</p> <p>12 Q. So when Mr. Mapes is -- is -- is</p> <p>13 telling this group of attendees at the</p> <p>14 pharmaceutical conference "The requirement is</p> <p>15 to report suspicious orders, not suspicious</p> <p>16 sales after the fact," from your understanding,</p> <p>17 what was he telling those industry</p> <p>18 representatives that were in attendance in</p> <p>19 Houston in 2007?</p> <p>20 MS. McCLURE: Objection.</p> <p>21 Foundation.</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 Foundation.</p> <p>24 THE WITNESS: Don't let the drugs</p> <p>25 get on the street.</p>	<p style="text-align: right;">Page 411</p> <p>1 -- of that when you were working with Mr. Mapes</p> <p>2 during that time frame?</p> <p>3 MS. MAINIGI: Objection.</p> <p>4 THE WITNESS: This was incorporated</p> <p>5 in other presentations, this very statement.</p> <p>6 BY MR. SHKOLNIK:</p> <p>7 Q. And what was the significance of</p> <p>8 that statement?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 THE WITNESS: The onus of</p> <p>11 responsibility lies with the registrant.</p> <p>12 BY MR. SHKOLNIK:</p> <p>13 Q. So that would be either the</p> <p>14 manufacturer selling to a distributor,</p> <p>15 distributor selling to a pharmacy, whichever in</p> <p>16 line you're -- is -- is occurring?</p> <p>17 MS. MAINIGI: Objection.</p> <p>18 BY MR. SHKOLNIK:</p> <p>19 Q. Is that a fair statement?</p> <p>20 MS. MAINIGI: Objection.</p> <p>21 THE WITNESS: That's correct, sir.</p> <p>22 BY MR. SHKOLNIK:</p> <p>23 Q. And -- and you were asked some</p> <p>24 questions the other day by counsel about</p> <p>25 visibility. And I think the questions focused</p>
<p style="text-align: right;">Page 410</p> <p>1 BY MR. SHKOLNIK:</p> <p>2 Q. Was that the -- was that the word</p> <p>3 that the DEA was trying to get out to man --</p> <p>4 withdraw that.</p> <p>5 From your recollection and</p> <p>6 understanding, was that the word that your</p> <p>7 group at DEA and DEA at the time was trying to</p> <p>8 get out to industry?</p> <p>9 MS. MAINIGI: Objection.</p> <p>10 MR. SHKOLNIK: You knew the</p> <p>11 objection was coming.</p> <p>12 THE WITNESS: This was the</p> <p>13 difference between the old system of Excessive</p> <p>14 and the new system Suspicious. Excessive it</p> <p>15 was reporting after the sale. Suspicious was</p> <p>16 to catch them before it went out.</p> <p>17 BY MR. SHKOLNIK:</p> <p>18 Q. And -- and if we could turn, if you</p> <p>19 would, to Bates No. 254.</p> <p>20 A. Okay.</p> <p>21 Q. In this slide that -- in Mr. Mapes's</p> <p>22 presentation, "The responsibility for making</p> <p>23 the decision ship" -- "ship rests with the</p> <p>24 supplier."</p> <p>25 What was your understanding of -- of</p>	<p style="text-align: right;">Page 412</p> <p>1 on who would have visibility of what, would it</p> <p>2 be manufacturer to distributor, distributor to</p> <p>3 pharmacy.</p> <p>4 Do you recall those questions the</p> <p>5 other day?</p> <p>6 MS. MAINIGI: Objection.</p> <p>7 THE WITNESS: I do, sir.</p> <p>8 BY MR. SHKOLNIK:</p> <p>9 Q. And one of the -- the -- sort of the</p> <p>10 gist of what you were being asked is, "Well,</p> <p>11 does a manufacturer see what's at the</p> <p>12 pharmacist? Does a distributor see what's --</p> <p>13 do they see everything? Who sees what?"</p> <p>14 Is that a fair statement from the</p> <p>15 questions you were asked?</p> <p>16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: Yes, sir.</p> <p>18 BY MR. SHKOLNIK:</p> <p>19 Q. And is it your understanding that,</p> <p>20 generally speaking, there may not be situations</p> <p>21 -- there may be situations where a manufacturer</p> <p>22 doesn't know what a pharmacy is doing, correct?</p> <p>23 MS. MAINIGI: Objection.</p> <p>24 THE WITNESS: That'd be correct.</p> <p>25 BY MR. SHKOLNIK:</p>

<p style="text-align: right;">Page 413</p> <p>1 Q. And there are situations where only 2 a distributor may have certain information 3 about a pharmacy, correct? 4 MS. MAINIGI: Objection. 5 THE WITNESS: Yes, sir. 6 BY MR. SHKOLNIK: 7 Q. But there are also situations -- 8 withdraw that. 9 Were you aware of situations back 10 when you were -- at the agency that 11 manufacturers, distributors and pharmacies 12 actually shared the data up and down the stream 13 through sharing agreements? 14 Were you aware of that? 15 A. No, sir. 16 MS. MAINIGI: Objection. 17 BY MR. SHKOLNIK: 18 Q. And just -- the other day you were 19 asked questions about the issue of -- of 20 shipping and -- and not -- when this idea of do 21 not ship comes into -- comes into play. 22 Do you recall that? 23 A. Yes, sir. 24 MS. MAINIGI: Objection. 25 BY MR. SHKOLNIK:</p>	<p style="text-align: right;">Page 415</p> <p>1 Q. And there was no sea change in 2000 2 time frame, mid 2000s, in terms of changing of 3 the regulations in that regard, correct? 4 MS. MAINIGI: Objection. 5 THE WITNESS: Yes, sir. 6 MR. SHKOLNIK: In fact, I'm going to 7 mark as Exhibit No. 30 -- was the last one 37? 8 MR. BENNETT: 37. 9 THE REPORTER: We were up to 37. 10 MR. SHKOLNIK: Okay. The next 11 exhibit's going to be 38. I'm going to hand 12 you -- 13 (Discussion held off the 14 stenographic record.) 15 MR. SHKOLNIK: Going to hand you a 16 document marked as Exhibit No. 37. 17 (Deposition Exhibit 37 was marked 18 for identification.) 19 MR. SHKOLNIK: It is Bates numbered 20 Cardinal 2804_01465723, dated June 21, 1993. 21 And it's entitled "NWDA Suspicious Order 22 Monitoring System." 23 BY MR. SHKOLNIK: 24 Q. When you were at DEA, was it part of 25 your job to try to determine what was -- what</p>
<p style="text-align: right;">Page 414</p> <p>1 Q. And -- and would I be correct in 2 stating that there -- from all the years that 3 you were at DEA, there were regulations in 4 place that dealt with the obligations of a 5 registrant not to ship if there was a 6 suspicious order that they could identify, 7 correct? 8 MS. MAINIGI: Objection. 9 THE WITNESS: Yes, sir. 10 BY MR. SHKOLNIK: 11 Q. I mean that was not a new phenomenon 12 in 2005, '6, '7, was it, sir? 13 MS. MAINIGI: Objection. 14 THE WITNESS: No, sir. 15 BY MR. SHKOLNIK: 16 Q. And that obligation was on -- was in 17 place for whether it was a pharmacy, whether it 18 was a chain pharmacy, whether it was a 19 distributor, whether it was a manufacturer; if 20 they identified a suspicious order, the 21 obligation was on them to decide if they should 22 ship it or not, correct? 23 MS. MAINIGI: Objection. 24 THE WITNESS: Yes, sir. 25 BY MR. SHKOLNIK:</p>	<p style="text-align: right;">Page 416</p> <p>1 was the regulatory requirements that -- that -- 2 that you were working under in terms of the 3 controlled substance monitoring? 4 MS. MAINIGI: Objection. 5 MR. SHKOLNIK: I'll rephrase that. 6 BY MR. SHKOLNIK: 7 Q. When you were working another DEA at 8 the field office and again in -- in D.C., did 9 -- did -- did; you try to become aware of what 10 the regulations were? 11 MS. MAINIGI: Objection. 12 THE WITNESS: Absolutely. 13 BY MR. SHKOLNIK: 14 Q. I mean that was part of your job to 15 know what you were trying to enforce, correct? 16 MS. MAINIGI: Objection. 17 THE WITNESS: Yes, sir. 18 BY MR. SHKOLNIK: 19 Q. And if -- if we could turn -- have 20 you ever heard of the National Wholesale 21 Druggists Association? 22 A. Vaguely. 23 Q. And -- and what was your 24 understanding of it? 25 MS. MAINIGI: Objection.</p>

<p style="text-align: right;">Page 417</p> <p>1       THE WITNESS: Another industry 2 organization sharing their issues specifically 3 dealing with government proposed legislation 4 and other issues.</p> <p>5       BY MR. SHKOLNIK:</p> <p>6       Q. And if we could just look at Page 1 7 of Exhibit No. 37. This -- this is entitled 8 "The NWDA Suspicious Order Monitoring System."</p> <p>9       Were you aware that -- that the 10 National Wholesale Druggists Association had 11 promulgated its own policy for its members 12 regarding the Suspicious Order Monitoring 13 System -- Systems?</p> <p>14       MS. MAINIGI: Objection.</p> <p>15       THE WITNESS: No, sir.</p> <p>16       BY MR. SHKOLNIK:</p> <p>17       Q. Were you aware that in 1993 that 18 industry with -- that -- that -- that the 19 industry group for chain pharmacies and 20 pharmacies was promulgating any rules for their 21 organization members regarding monitoring for 22 suspicious orders?</p> <p>23       MS. MAINIGI: Objection.</p> <p>24       THE WITNESS: No, sir.</p> <p>25       BY MR. SHKOLNIK:</p>	<p style="text-align: right;">Page 419</p> <p>1       that they should report immediately if they 2 identify a order of unusual size or deviation, 3 that that was a recommendation to the industry, 4 the -- the wholesale druggist industry, back in 5 the '90s?</p> <p>6       Would that surprise you?</p> <p>7       MS. MAINIGI: Objection.</p> <p>8       THE WITNESS: Yes, sir.</p> <p>9       BY MR. SHKOLNIK:</p> <p>10       Q. Okay. Why is -- why would it 11 surprise you, sir?</p> <p>12       MS. MAINIGI: Objection.</p> <p>13       THE WITNESS: Because, in my field 14 experience, I did not see this in practice.</p> <p>15       BY MR. SHKOLNIK:</p> <p>16       Q. Would -- would you have -- from -- 17 from your experience, would you have -- would 18 you have liked to have seen this in practice in 19 the industry, this recommendation?</p> <p>20       MS. MAINIGI: Objection.</p> <p>21       THE WITNESS: Yes, sir. I would 22 have welcomed it.</p> <p>23       BY MR. SHKOLNIK:</p> <p>24       Q. And then it goes on to say: "The 25 submission of a monthly printout of</p>
<p style="text-align: right;">Page 418</p> <p>1       Q. If we could turn to Page 7, Bates 2 number ending in 730, it says "Single 3 Suspicious Orders."</p> <p>4       "Single orders of unusual size or 5 deviations must be reported immediately."</p> <p>6       Were you aware that members of the 7 National Wholesale -- I'm sorry -- the National 8 -- got to make sure I get it right -- Wholesale 9 Druggist Association were aware in 1993 that 10 they were being guided that they should report 11 orders of unusual size or deviation 12 immediately?</p> <p>13       Were you aware of that?</p> <p>14       A. No, sir.</p> <p>15       MS. MAINIGI: Objection.</p> <p>16       BY MR. SHKOLNIK:</p> <p>17       Q. Was that consistent with your 18 understanding of what was being -- of what the 19 regulations were when you were in DEA, 95 20 through your retirement?</p> <p>21       MS. MAINIGI: Objection.</p> <p>22       THE WITNESS: Yes, sir.</p> <p>23       BY MR. SHKOLNIK:</p> <p>24       Q. Does it -- would it be surprising to 25 you that -- that a recommendation such as this,</p>	<p style="text-align: right;">Page 420</p> <p>1       after-the-fact sales will not relieve a 2 registrant from the responsibility of reporting 3 these single excessive or suspicious orders."</p> <p>4       Were you aware that was a 5 recommendation being made to industry before 6 you even started at DEA in '95?</p> <p>7       MS. MAINIGI: Objection.</p> <p>8       THE WITNESS: No, sir.</p> <p>9       BY MR. SHKOLNIK:</p> <p>10       Q. Did you see any of these wholesale 11 chain pharmacies or wholesale pharmacy members 12 implementing this type of responsibility 13 regarding suspicious orders in -- withdraw 14 that.</p> <p>15       Did you observe pharmacies, chain 16 pharmacies, following this recommendation while 17 you were at DEA out in the field and again in 18 D.C.?</p> <p>19       MS. MAINIGI: Objection.</p> <p>20       THE WITNESS: No, sir.</p> <p>21       BY MR. SHKOLNIK:</p> <p>22       Q. Would you have liked to have seen 23 them comply with this recommendation by the -- 24 the Wholesale Druggists Association while you 25 were working at DEA?</p>

<p>1       Would you have like that, sir?</p> <p>2       MS. MAINIGI: Objection.</p> <p>3       THE WITNESS: Very much.</p> <p>4       BY MR. SHKOLNIK:</p> <p>5       Q. Why?</p> <p>6       MS. MAINIGI: Objection.</p> <p>7       THE WITNESS: This is reiterating</p> <p>8       what we were emphasizing at the time.</p> <p>9       BY MR. SHKOLNIK:</p> <p>10      Q. When --</p> <p>11      A. This would have -- if it had come on</p> <p>12      and been utilized, we may not have been steeped</p> <p>13      in the endemic problem that we were</p> <p>14      experiencing at the time. It could have</p> <p>15      effectively kept it down to a lower level and</p> <p>16      potentially fewer problems, addictions and</p> <p>17      deaths.</p> <p>18      Q. And -- and by the way, the last</p> <p>19      sentence, the DEA interpreted orders to mean</p> <p>20      prior to shipment.</p> <p>21      Wasn't that something that you were</p> <p>22      telling everybody from 2005 until your</p> <p>23      retirement in 2017, that that's what -- that</p> <p>24      was your recommendation?</p> <p>25      MS. MAINIGI: Objection.</p>	Page 421	<p>1       Fair statement?</p> <p>2       MS. MAINIGI: Objection.</p> <p>3       THE WITNESS: Yes, sir.</p> <p>4       BY MR. SHKOLNIK:</p> <p>5       Q. Looking at that document, sir, were</p> <p>6       they being honest with you where -- any</p> <p>7       registrant that was a member of that</p> <p>8       organization, if they said to you, sir, "This</p> <p>9       is new, we didn't know about it before," would</p> <p>10      they have been honest with you --</p> <p>11      MR. BENNETT: Objection.</p> <p>12      MS. MAINIGI: Objection.</p> <p>13      BY MR. SHKOLNIK:</p> <p>14      Q. -- based on what we just read?</p> <p>15      A. No, sir.</p> <p>16      MR. SHKOLNIK: Okay. I'm going to</p> <p>17      mark for Exhibit -- Exhibit No. 38 a document</p> <p>18      from 1984.</p> <p>19      Did I tell you '34? '84. Sorry.</p> <p>20      '84. It's in your copy? Okay. I'm sorry.</p> <p>21      We're not changing the markings on</p> <p>22      this one then. Good thing I had someone else</p> <p>23      here.</p> <p>24      BY MR. SHKOLNIK:</p> <p>25      Q. If we can go to Bates numbered 5732</p>	Page 423
<p>1       THE WITNESS: Yes, sir.</p> <p>2       BY MR. SHKOLNIK:</p> <p>3       Q. Did you know that they were being</p> <p>4       told that by the their agents -- by their own</p> <p>5       lobbying group, trade association, that that</p> <p>6       was the definition back in 1993?</p> <p>7       MS. MAINIGI: Objection.</p> <p>8       THE WITNESS: No, sir. I did not.</p> <p>9       BY MR. SHKOLNIK:</p> <p>10      Q. Did any of the registrants that you</p> <p>11      met with, sir, ever tell you that they had a</p> <p>12      trade organization that recommended that orders</p> <p>13      should be reported immediately and orders meant</p> <p>14      before shipment?</p> <p>15      Did anyone ever -- any of these</p> <p>16      people you met with ever say, "We knew about</p> <p>17      this back in 1993"?</p> <p>18      MS. MAINIGI: Objection.</p> <p>19      THE WITNESS: No, sir.</p> <p>20      BY MR. SHKOLNIK:</p> <p>21      Q. In fact, they were telling you, sir,</p> <p>22      "This is new to us. We didn't even know about</p> <p>23      this."</p> <p>24      Isn't that what they were really</p> <p>25      saying? "This is a sea change to us."</p>	Page 422	<p>1       in that last exhibit.</p> <p>2       A. Excuse me. What page?</p> <p>3       Q. Bates number is 5732 at the bottom.</p> <p>4       I'll show you a document -- a letter</p> <p>5       that was sent to nation -- the vice</p> <p>6       president --</p> <p>7       MR. BENNETT: Counsel, can you give</p> <p>8       me one second.</p> <p>9       MR. SHKOLNIK: Sure.</p> <p>10      MR. BENNETT: Thank you, Counsel.</p> <p>11      We're good.</p> <p>12      BY MR. SHKOLNIK:</p> <p>13      Q. I'm going to show -- just read from</p> <p>14      this letter that was sent in 1984 from DEA.</p> <p>15      And it's diversion operation section chief, Mr.</p> <p>16      Tom Gitchel.</p> <p>17      Do you know that name at all?</p> <p>18      MS. MAINIGI: Objection.</p> <p>19      BY MR. SHKOLNIK:</p> <p>20      Q. May have been before your time.</p> <p>21      A. Oh, I heard his name many a time.</p> <p>22      Q. Okay. This is a letter he wrote to</p> <p>23      the Wholesale Druggist Association where he</p> <p>24      said in his letter: "As previously discussed,</p> <p>25      an after-the-fact computer printout of sales</p>	Page 424

<p style="text-align: right;">Page 425</p> <p>1 data does not relieve a registrant of its 2 responsibility to report excessive or 3 suspicious orders when discovered. I'm 4 enclosing a copy of your draft with my pen and 5 ink changes."</p> <p>6 Were you aware that the members of 7 the National Wholesale Druggists Association, 8 as far back as '84, was advised by the DEA that 9 these monthly after-the-fact reports did not 10 relieve them of their responsibility to report 11 excessive or suspicious orders when discovered?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 BY MR. SHKOLNIK:</p> <p>14 Q. Were you aware of that when -- when 15 you were at DEA?</p> <p>16 MS. MAINIGI: Objection.</p> <p>17 THE WITNESS: No, sir.</p> <p>18 BY MR. SHKOLNIK:</p> <p>19 Q. In all the times that you had 20 meetings with registrants, pharmacy chains, at 21 any time did anyone ever say to you, "By the 22 way, we already knew about this requirement to 23 report way back in '84. And there's nothing 24 new about what you're telling us in 2005 and 25 2006 and 2007"?</p>	<p style="text-align: right;">Page 427</p> <p>1 Isn't that you -- what you were 2 hearing from industry in 2005 on when you told 3 them that their obligation was to investigate, 4 report and don't ship?</p> <p>5 Isn't -- wasn't that their response 6 to you?</p> <p>7 MS. MAINIGI: Objection.</p> <p>8 THE WITNESS: Yes, sir.</p> <p>9 BY MR. SHKOLNIK:</p> <p>10 Q. And -- and you were asked to -- to 11 read your testimony from a -- a trial by 12 counsel the other day where -- where your 13 testimony was that there -- there was a change 14 in -- in -- in circumstances.</p> <p>15 Did anyone before you testified in 16 that trial ever show you the 1984 document, 17 this 1993 document?</p> <p>18 Did anyone ever show those to you 19 before you testified in preparation for your 20 testimony?</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: No, sir.</p> <p>23 BY MR. SHKOLNIK:</p> <p>24 Q. Would you have liked to have had 25 that as preparation for your testimony to know</p>
<p style="text-align: right;">Page 426</p> <p>1 Did they ever say that?</p> <p>2 MS. MAINIGI: Objection.</p> <p>3 THE WITNESS: No, sir.</p> <p>4 BY MR. SHKOLNIK:</p> <p>5 Q. Would you have liked to have known 6 that they knew about it for decades by the time 7 you told them this in 2005, '6, '7 and so on?</p> <p>8 MS. MAINIGI: Objection.</p> <p>9 THE WITNESS: Yes, sir.</p> <p>10 BY MR. SHKOLNIK:</p> <p>11 Q. Why?</p> <p>12 Why would you have liked to have 13 known that?</p> <p>14 MS. MAINIGI: Objection.</p> <p>15 THE WITNESS: Because it would have 16 shown institutional knowledge of the 17 requirements, the regulation, that we weren't 18 throwing something new or startling at them; 19 that we were simply trying to enforce the 20 regulations that had existed already.</p> <p>21 BY MR. SHKOLNIK:</p> <p>22 Q. And would it be fair to say you 23 repeatedly were met with the response that, 24 "This is new. You're changing the rules on 25 us"?</p>	<p style="text-align: right;">Page 428</p> <p>1 what DEA had told the people in industry going 2 back to '84?</p> <p>3 Wouldn't that have helped you, sir?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 THE WITNESS: It certainly would 6 have.</p> <p>7 BY MR. SHKOLNIK:</p> <p>8 Q. Would you have liked to have had 9 counsel show that to you when you were being 10 confronted with your testimony from 2011 the 11 other day?</p> <p>12 MR. BENNETT: Objection to form.</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 MR. BENNETT: I'm sorry. Were you 15 talk defense counsel?</p> <p>16 MR. SHKOLNIK: Oh, yeah.</p> <p>17 MR. BENNETT: I withdraw my 18 objection. I thought you were talking about 19 me.</p> <p>20 MR. SHKOLNIK: That was good.</p> <p>21 MS. MAINIGI: I think he was talking 22 about defense counsel too.</p> <p>23 MR. SHKOLNIK: Yes, I was.</p> <p>24 BY MR. SHKOLNIK:</p> <p>25 Q. Would you have liked to have had</p>

Page 429	Page 431
<p>1 that -- those documents presented to you at the 2 same time?</p> <p>3 A. Yes, sir.</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 MR. SHKOLNIK: I'm going to give you 6 a document I'm marking as Exhibit 36.</p> <p>7 MR. BENNETT: I'm sorry. Would this 8 be 38?</p> <p>9 MR. SHKOLNIK: 38. I'm sorry. I'm 10 horrible with exhibits. That's why I need 11 other people doing this.</p> <p>12 (Deposition Exhibit 38 was marked 13 for identification.)</p> <p>14 BY MR. SHKOLNIK:</p> <p>15 Q. I'm going to show you a document 16 from -- let me see -- 1996 so this is after you 17 were at DEA. If you could take a look at it. 18 It's from Department of Justice to 19 Cardinal Health, Bates number is 2203353.</p> <p>20 MR. STEPHENS: Counsel, is this 38 21 or 39?</p> <p>22 MR. SHKOLNIK: This is 38, am I 23 correct? 38.</p> <p>24 MR. BENNETT: Counsel, may I've one 25 second?</p>	<p>1 this copy of the manual was -- according to 2 what we have here, was sent to Cardinal Health. 3 And it says: "The" registrant -- "registrants 4 are required to inform DEA of suspicious orders 5 in accordance with 21 CFR 1301.74(b). DEA 6 field offices are not to approve or disapprove 7 supplier shipments of controlled substance." 8 That was your understanding of the 9 rules that you worked under back when you were 10 at DEA, correct?</p> <p>11 MS. McCLURE: Objection. Misstates 12 prior testimony.</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 THE WITNESS: Yes, sir.</p> <p>15 BY MR. SHKOLNIK:</p> <p>16 Q. And -- and a manual like this is 17 something you had to -- you had to act in 18 accordance with; am I correct?</p> <p>19 MS. MAINIGI: Objection.</p> <p>20 THE WITNESS: Or receive special --</p> <p>21 BY MR. SHKOLNIK:</p> <p>22 Q. Dispensation?</p> <p>23 A. Yes, sir.</p> <p>24 Q. Okay. And then it says: "The 25 responsibility for making the decision to ship</p>
Page 430	Page 432
<p>1 MR. SHKOLNIK: Sure.</p> <p>2 MR. BENNETT: Thank you, counsel. 3 We're okay.</p> <p>4 BY MR. SHKOLNIK:</p> <p>5 Q. If you could just take a look at 6 Bates No. 3355. It's a -- it's a cover of a 7 manual that says "Diversion Investigator 8 Manual."</p> <p>9 Were you familiar with this manual 10 at all, sir?</p> <p>11 A. Yes, sir.</p> <p>12 Q. And -- and I'm going to -- let's 13 turn to Bates numbered 3356, if we -- if we 14 could.</p> <p>15 And it's -- the top of the page it 16 says "DEA Sensitive." And then when we go down 17 the page, there's a section that says: 18 "Requirement to report suspicious orders."</p> <p>19 So was it your understanding that 20 this manual was in effect when -- when you went 21 out in the field for DEA?</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 THE WITNESS: Yes, sir.</p> <p>24 BY MR. SHKOLNIK:</p> <p>25 Q. And -- and here this -- apparently</p>	<p>1 substance" -- I'm sorry. I'm sorry. 2 "DEA field offices are not to 3 approve or disapprove supplier shipments of 4 controlled substances. The responsibility for 5 making the decision to ship rests with the 6 supplier."</p> <p>7 That's what you at DEA, from your 8 recollection, is what you were telling people 9 back in 1996 and forward, correct?</p> <p>10 MS. MAINIGI: Objection.</p> <p>11 THE WITNESS: Yes, sir.</p> <p>12 BY MR. SHKOLNIK:</p> <p>13 Q. And down at the bottom it says: 14 "Registrants who routinely report suspicious 15 orders yet fill these orders with reason to 16 believe they are destined for illicit market 17 are expressing an attitude of 18 irresponsibility."</p> <p>19 Did you recall that being the -- 20 the -- the position of DEA while you were with 21 them from '96 right through to your retirement?</p> <p>22 MS. MAINIGI: Objection.</p> <p>23 BY MR. SHKOLNIK:</p> <p>24 Q. Basically your understanding?</p> <p>25 A. Yes, sir.</p>

<p style="text-align: right;">Page 433</p> <p>1 Q. If we could just turn to the next 2 page. 3 MR. SHKOLNIK: And by the way, just 4 so the record's clear, this is my highlighting. 5 This didn't come from DEA like this or 6 Cardinal. 7 BY MR. SHKOLNIK: 8 Q. "The supplier can determine whether 9 the order is excessive by checking their own 10 sales and establishing the average amount of 11 controlled substances shipped to the 12 registrants of the same apparent size in a 13 particular geographic area. 14 Was that your -- your understanding 15 while you were at DEA? 16 MS. MAINIGI: Objection. 17 THE WITNESS: Yes, sir. 18 BY MR. SHKOLNIK: 19 Q. And it goes on to say: "If the 20 customer exceeds the threshold, the request 21 should be viewed as suspicious. This activity 22 over extended periods of time would lead a 23 reasonable person to believe the controlled 24 substance are possibly being diverted." 25 Was that your understanding when you</p>	<p style="text-align: right;">Page 435</p> <p>1 MS. MAINIGI: Objection. 2 BY MR. SHKOLNIK: 3 Q. That we just looked at, sir? 4 A. It does, sir. 5 Q. And are you familiar with something 6 called the "Chemical Handlers Manual"?</p> <p>7 A. Yes, sir. 8 Q. You say that with a sigh. 9 How do you know about that document? 10 A. Many long hours enforcing it. 11 Q. Okay. And -- and is your 12 understanding that the Chemical Handlers Manual 13 was -- was utilized by some of the registrants 14 or many registrants as a manner in which they 15 thought they would be in compliance with the 16 regulations?</p> <p>17 MS. MAINIGI: Objection. 18 THE WITNESS: Yes, sir. 19 BY MR. SHKOLNIK: 20 Q. And if -- if -- if I'm not mistaken, 21 you were shown what we -- was referred to as 22 a -- I think it's a -- an ingredient list 23 report. I don't remember the exact exhibit 24 number. The thick compilation that you have 25 there.</p>
<p style="text-align: right;">Page 434</p> <p>1 were at DEA? 2 MS. MAINIGI: Objection. 3 THE WITNESS: Yes, sir. 4 BY MR. SHKOLNIK: 5 Q. And was that something that, when 6 you were going out and having these 7 presentations, you were impressing upon the 8 registrants that's you presented to? 9 MS. MAINIGI: Objection. 10 BY MR. SHKOLNIK: 11 Q. Correct? 12 A. Yes, sir. 13 Q. And this was not something new in 14 2005 forward; this is -- this was clearly in 15 place back in 1996, correct, sir? 16 MS. MAINIGI: Objection. 17 THE WITNESS: Correct. 18 BY MR. SHKOLNIK: 19 Q. And from what we saw from other 20 documents, even earlier, correct? 21 MS. MAINIGI: Objection. 22 THE WITNESS: Yes, sir. 23 BY MR. SHKOLNIK: 24 Q. And the 1984 letter from DEA says 25 that, does it not?</p>	<p style="text-align: right;">Page 436</p> <p>1 MR. BENNETT: 26. 2 BY MR. SHKOLNIK: 3 Q. Number -- Exhibit 26. 4 Were -- were -- were you under the 5 impression that documents like that were being 6 generated based upon an interpretation of the 7 Chemical Handlers Manual? 8 MS. MAINIGI: Objection. 9 THE WITNESS: No, I did not. 10 BY MR. SHKOLNIK: 11 Q. Did -- none of the manufacturers, to 12 your knowledge, ever told -- I'm sorry -- 13 manufacturers, distributors or pharmacies ever 14 suggested that they were basing their analyses 15 on the Chemical Handlers Manual? 16 MS. MAINIGI: Objection. 17 THE WITNESS: No, sir. 18 BY MR. SHKOLNIK: 19 Q. To your knowledge, sir -- withdraw 20 that. 21 Mr. Wright, was the Chemical 22 Handlers Manual the -- the -- the criteria set 23 forth in the manual, in terms of the 24 determining suspicious orders or not, did that 25 apply to opioids?</p>

<p style="text-align: right;">Page 437</p> <p>1 MS. MAINIGI: Objection.  2 MR. SHKOLNIK: I'm sorry. I put the  3 sticker on the wrong one. Let me give you a  4 copy.  5 I'm going to withdraw the question.  6 Let me just withdraw that.  7 MS. MAINIGI: What was the answer?  8 Did we have an answer?  9 MR. SHKOLNIK: I withdrew the  10 question. There was no answer.  11 MS. MAINIGI: Oh, he didn't answer  12 the question.  13 MR. SHKOLNIK: No. I can't withdraw  14 it if he answered it.  15 (Deposition Exhibit 39 was marked  16 for identification.)  17 BY MR. SHKOLNIK:  18 Q. I've handed you a copy of the 2004  19 Chemical Handlers Manual.  20 Do you recall ever seeing that  21 actual manual before?  22 MS. McCLURE: Counsel, for the  23 record, can you please read the Bates number.  24 MR. SHKOLNIK: Yes. This copy is  25 from Walgreens 395965 dated January 2004.</p>	<p style="text-align: right;">Page 439</p> <p>1 THE WITNESS: Okay.  2 BY MR. SHKOLNIK:  3 Q. Let's try that again. I'll read it  4 slow.  5 "When a regulated person suspects  6 that an order may be intended for illicit  7 purposes, good practice requires that every  8 reasonable effort be made to resolve those  9 suspicions."  10 Was that your understanding of the  11 requirement of registrants?  12 MS. MAINIGI: Objection.  13 THE WITNESS: No, sir.  14 MR. SHKOLNIK: Oh, okay.  15 THE WITNESS: Regulated was not a  16 registrant.  17 BY MR. SHKOLNIK:  18 Q. Ah.  19 What's a regulated?  20 A. Regulated meant that they were  21 downstream. We could not regulate every  22 7-Eleven in town. We -- our system couldn't  23 accommodate that because this was the only  24 product that they were selling. So they were  25 not registrants. They were regulated. The</p>
<p style="text-align: right;">Page 438</p> <p>1 MR. STEPHENS: What's the exhibit  2 number?  3 MR. SHKOLNIK: 39.  4 BY MR. SHKOLNIK:  5 Q. Have you ever seen this before?  6 A. Yes, sir.  7 Q. Okay. If we could turn to Page 10  8 of the Chemical Handlers Manual, Exhibit 39.  9 I'm going to read one paragraph from the --  10 from the 2000 -- I'm sorry -- from the 2004  11 version of it.  12 "When a regulated person suspects an  13 order may be intended for illicit purposes,  14 good practice requires that every reasonable  15 effort made to resolve those" suspicious --  16 "those suspicions."  17 Was -- was that your understanding  18 of a requirement of registrants when -- when  19 you were at DEA?  20 MR. TAYMAN: What page are you at?  21 MS. MAINIGI: Yeah. You said 10.  22 MR. SHKOLNIK: Oh, 19. I'm sorry.  23 19.  24 THE WITNESS: 19?  25 MR. SHKOLNIK: Yeah. 19.</p>	<p style="text-align: right;">Page 440</p> <p>1 registrants above them would be the suppliers.  2 Q. So in -- when it says "In addition  3 to making required reports, transactions should  4 not be completed until the customer is able to  5 eliminate the suspicions," what does that mean?  6 MS. MAINIGI: Objection.  7 MR. BENNETT: Objection.  8 THE WITNESS: The --  9 BY MR. SHKOLNIK:  10 Q. I'm sorry.  11 Do you understand what that means?  12 A. Yes, sir.  13 Q. Okay. What does that mean?  14 MS. MAINIGI: Objection.  15 MR. BENNETT: Objection.  16 Counsel, are you asking his  17 understanding of what this --  18 MR. SHKOLNIK: Yeah. His  19 understanding, not DEA's.  20 MR. BENNETT: Then I withdraw the  21 objection.  22 THE WITNESS: Don't let the product  23 get into illicit markets or systems.  24 BY MR. SHKOLNIK:  25 Q. "The distributor may have to forgo</p>

<p>1 some transactions."</p> <p>2 Did you -- did you have an</p> <p>3 understanding as to what that meant?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 MS. McCLURE: Objection.</p> <p>6 THE WITNESS: Yes.</p> <p>7 BY MR. SHKOLNIK:</p> <p>8 Q. What did that mean to you, sir?</p> <p>9 A. Don't let it get into the system.</p> <p>10 Q. That was something known long before</p> <p>11 even 2004 while you were at DEA, correct?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 THE WITNESS: Yes, sir.</p> <p>14 BY MR. SHKOLNIK:</p> <p>15 Q. Are you familiar with an action</p> <p>16 brought by DEA against Novelty Distributors,</p> <p>17 Inc.?</p> <p>18 MS. McCLURE: Objection.</p> <p>19 BY MR. SHKOLNIK:</p> <p>20 Q. I'm not going to ask about any</p> <p>21 specific investigation but the case in -- in</p> <p>22 particular.</p> <p>23 A. I do recall that litigation.</p> <p>24 Q. I don't want to know any details,</p> <p>25 but were you involved in that or just aware of?</p>	<p>Page 441</p> <p>1 Date of the opinion on the order is</p> <p>2 September 3, 2008.</p> <p>3 BY MR. SHKOLNIK:</p> <p>4 Q. Says: "Fundamental to its</p> <p>5 obligation to maintain effective controls</p> <p>6 against diversion, a distributor must review</p> <p>7 every order and identify suspicious"</p> <p>8 transaction -- "transactions. Further, it must</p> <p>9 do so prior to shipping the products. Indeed,</p> <p>10 a distributor has an affirmative duty to forgo</p> <p>11 a transaction if, upon investigation, it is</p> <p>12 unable to determine that the proposed</p> <p>13 transaction is for legitimate purposes."</p> <p>14 And it's referencing the Chemical</p> <p>15 Handlers Manual for 2002.</p> <p>16 Is this -- in this opinion, is this</p> <p>17 consistent with what we just looked at in the</p> <p>18 2004 Chemical Handlers Manual?</p> <p>19 MS. MAINIGI: Objection.</p> <p>20 THE WITNESS: Yes, sir.</p> <p>21 BY MR. SHKOLNIK:</p> <p>22 Q. "Respondents procedure of</p> <p>23 post-transaction review is incompatible with</p> <p>24 its obligation to identify and forgo suspicious</p> <p>25 transactions."</p>
<p>1 A. I was only aware.</p> <p>2 Q. Okay. Did -- did you ever become</p> <p>3 aware of the fact that Novelty Drugs -- the</p> <p>4 decision not -- with -- withdraw that.</p> <p>5 (Deposition Exhibit 40 was marked</p> <p>6 for identification.)</p> <p>7 BY MR. SHKOLNIK:</p> <p>8 Q. I'm going to hand you a document I</p> <p>9 marked as Exhibit 40, a copy of it. December</p> <p>10 -- I'm sorry. September 2008 letter from</p> <p>11 Department of Justice. And attached to it is</p> <p>12 the decision in Novelty Distributors, Inc.,</p> <p>13 revocation of registration.</p> <p>14 Were -- were you --</p> <p>15 MR. BENNETT: Give me one second,</p> <p>16 Counsel.</p> <p>17 MR. SHKOLNIK: Yeah.</p> <p>18 BY MR. SHKOLNIK:</p> <p>19 Q. If we could turn to Page No. 39. I</p> <p>20 think I actually got that one right too.</p> <p>21 In the Novelty Distributors, Inc.,</p> <p>22 case there is a -- I'm going to read a section</p> <p>23 of it.</p> <p>24 MR. SHKOLNIK: Yeah. Good idea. I</p> <p>25 think I said it was 2008.</p>	<p>Page 442</p> <p>1 Was that your understanding of what</p> <p>2 -- of -- of the state of the regulations</p> <p>3 while you were at DEA?</p> <p>4 MS. MAINIGI: Objection.</p> <p>5 THE WITNESS: Yes, sir.</p> <p>6 BY MR. SHKOLNIK:</p> <p>7 Q. You're aware -- sir, are you aware</p> <p>8 that AmerisourceBergen had a DEA-issued order</p> <p>9 to show cause and immediate suspension order</p> <p>10 issued against it in 2007 for -- for shipping</p> <p>11 suspicious orders?</p> <p>12 Were you aware of that?</p> <p>13 MS. McCLURE: Objection. Same</p> <p>14 objection.</p> <p>15 MS. MAINIGI: Objection.</p> <p>16 THE WITNESS: Yes, sir.</p> <p>17 BY MR. SHKOLNIK:</p> <p>18 Q. If -- if AmerisourceBergen in 2007</p> <p>19 was shipping suspicious orders without doing a</p> <p>20 due diligence investigation before shipping, if</p> <p>21 that was the case, was that after you started</p> <p>22 doing those presentations telling the -- the</p> <p>23 registrants that they shouldn't be shipping</p> <p>24 without doing due diligence?</p> <p>25 MS. McCLURE: Objection.</p>

<p style="text-align: right;">Page 445</p> <p>1 MS. MAINIGI: And, Mr. Bennett, are 2 you allowing questions on specific -- 3 MR. BENNETT: If 2007 is after 2005? 4 MR. SHKOLNIK: Yeah. 5 MS. MAINIGI: Well, he's referencing 6 the ABDC investigation. So I was -- 7 MR. BENNETT: I thought he said 8 "immediate suspension order." 9 MS. MAINIGI: Well, it sounds like 10 he's asking him to draw upon -- 11 MR. SHKOLNIK: Well -- 12 MS. MAINIGI: -- something from the 13 investigation -- 14 MR. BENNETT: I don't -- 15 MS. MAINIGI: -- order to answer 16 that question. 17 MR. BENNETT: Sure. And if -- if -- 18 MS. MAINIGI: If he -- if he needs 19 to know if 2008 is before 2007, that's fine. 20 But I would like -- 21 MR. SHKOLNIK: Okay. You know 22 something? No. Let's go off the record if 23 you're going to have a conversation. All 24 right? 25 MS. MAINIGI: I --</p>	<p style="text-align: right;">Page 447</p> <p>1 go on the record first. 2 THE VIDEOGRAPHER: We are on the 3 record. 4 MS. MAINIGI: Okay. Thank you. 5 MR. BENNETT: The answer is that the 6 witness is not authorized to talk about any 7 specific investigations. 8 To the extent that the question 9 called for information about a specific 10 investigation, Mr. Wright's not authorized to 11 answer that question. 12 I did not understand the question to 13 have called for information about a specific 14 investigation. 15 MR. SHKOLNIK: And it wasn't. 16 MR. BENNETT: But if it -- if it 17 does, Mr. Wright, you are instructed that you 18 cannot talk about any specifics of the 19 AmerisourceBergen investigation. However, if 20 there is a publicly-filed document that you're 21 aware of, you may talk about the contents of 22 that but not the investigation. 23 Do you understand? 24 THE WITNESS: I understand. 25 MR. SHKOLNIK: Just so the record is</p>
<p style="text-align: right;">Page 446</p> <p>1 MR. SHKOLNIK: I thought we had 2 this -- I thought we had this ruling already 3 once. 4 MS. MAINIGI: No, we didn't. 5 MR. SHKOLNIK: We did. Let's go off 6 the record, please. 7 If you want to have a discussion, 8 we'll do it off the record, not on my time. 9 MS. MAINIGI: Fine. Let's go back 10 on the record, and DOJ can make their -- 11 MR. SHKOLNIK: Off -- off video. 12 MS. MAINIGI: No. We're -- we're on 13 the record. 14 MR. SHKOLNIK: No, no. I'm not -- 15 MS. MAINIGI: We're going to let DOJ 16 answer the question. 17 MR. SHKOLNIK: You're not going to 18 have a discussion. 19 MS. MAINIGI: I'm not having a 20 discussion. You're right. 21 So let's go back on the record, 22 please. 23 MR. BENNETT: So the answer is that 24 the witness is not -- 25 MS. MAINIGI: Well, hang on. Let's</p>	<p style="text-align: right;">Page 448</p> <p>1 clear, this was brought up by counsel on -- 2 this issue was brought up by counsel on direct. 3 BY MR. SHKOLNIK: 4 Q. So my question -- just to help 5 refresh your recollection very clear -- if 6 AmerisourceBergen suspension order was issued 7 in 2007 for violating the Controlled Substances 8 Act and allowing diversion in 2007, would that 9 have been after you had already told industry 10 that they were not to ship if they had 11 suspicious orders? 12 MS. McClure: Objection. Form. 13 Foundation misstates prior testimony. 14 Speculative. 15 MS. MAINIGI: Objection. 16 BY MR. SHKOLNIK: 17 Q. It's a simple -- simple date. 18 A. Yes, sir. 19 Q. And if there was a immediate 20 suspension order against Cardinal Health Auburn 21 facility in November of 2007 for violating the 22 Controlled Substances Act related to shipping 23 without completing due diligence, would that 24 have been after you had already told them that 25 they were not allowed to do that?</p>

1 MS. MAINIGI: Objection. 2 BY MR. SHKOLNIK: 3 Q. When I say "you," I mean you at part 4 of the presentations. 5 MS. MAINIGI: Objection. 6 THE WITNESS: Yes, sir. 7 BY MR. SHKOLNIK: 8 Q. And -- and that -- that was from 9 your experience, correct, sir? 10 MS. MAINIGI: Objection. 11 THE WITNESS: Yes, sir. 12 BY MR. SHKOLNIK: 13 Q. And if, on December 7, 2007, an 14 order to show cause and immediate suspension 15 order was issued to Cardinal Health Lakeland 16 facility for failure to -- to main [sic] 17 effective controls against diversion of 18 hydrocodone, that was after you had already 19 told them, meaning you -- you and Mr. Mapes as 20 part of the presentations to the big 21 distributors, that -- that they shouldn't be 22 shipping absent the due diligence, correct, 23 sir? 24 MS. MAINIGI: Objection. 25 THE WITNESS: Yes, sir.	Page 449	1 BY MR. SHKOLNIK: 2 Q. That would have meant they rejected 3 the recommendations and the guidance given by 4 DEA, correct? 5 MS. MAINIGI: Objection. 6 THE WITNESS: They weren't adhering 7 to the recommendations. 8 BY MR. SHKOLNIK: 9 Q. If a DEA issued an order to show 10 cause against Cardinal Health's Stafford, Texas 11 distribution center on January 30th, 2008, for 12 failure to maintain effective controls against 13 diversion of hydrocodone, that was now three 14 years after you already started telling the big 15 three distributors, "You can't ship without due 16 diligence," correct? 17 MS. MAINIGI: Objection. 18 THE WITNESS: Yes, sir. 19 BY MR. SHKOLNIK: 20 Q. And that would have meant they 21 didn't follow the recommendations you and 22 Mr. Mapes and the rest of the team were giving 23 at these presentations. 24 Fair statement? 25 MS. MAINIGI: Objection.	Page 451
1 BY MR. SHKOLNIK: 2 Q. Even if it was a sea change in the 3 field of distributors and manufacturers, this 4 do-not-ship requirement, even assume that that 5 was correct, they still did it after you told 6 them, correct? 7 MS. MAINIGI: Objection. 8 THE WITNESS: Yes, sir. 9 BY MR. SHKOLNIK: 10 Q. They apparently weren't taking the 11 advice you were giving. 12 Fair statement? 13 MS. MAINIGI: Objection. 14 THE WITNESS: Yes, sir. 15 BY MR. SHKOLNIK: 16 Q. If the DEA issued an order to show 17 cause and an immediate suspension order against 18 Cardinal Health's Swedesboro, New Jersey, 19 distribution center for failure to maintain 20 effective controls against diversion of 21 Hydrocodone, December 7, 2007, that was after 22 you had already told them, "You're not supposed 23 to ship without doing due diligence," correct? 24 MS. MAINIGI: Objection. 25 THE WITNESS: Yes, sir.	Page 450	1 MR. BENNETT: And I am going to 2 object to the extent that he's asking you about 3 any specific investigation and interpretation 4 of what they were or were not doing after your 5 presentation. 6 But to the extent it's in a public 7 document or it's asking about timing, you may 8 answer. 9 BY MR. SHKOLNIK: 10 Q. Just as to timing. 11 A. Yes, sir. 12 Q. And if -- if May 2008 McKesson 13 agreed to a \$13 million civil penalty and 14 entered into an administrative MOA with DEA for 15 failure to maintain compliance program designed 16 to detect and prevent diversion of controlled 17 substances, inform DEA of suspicious orders in 18 violation -- I'm sorry -- as required by 21 CFR 19 1301.74, that was more than three years after 20 you started telling the big three, "Do due 21 diligence. Don't ship," correct? 22 MR. EPPICH: Object to the form. 23 BY MR. SHKOLNIK: 24 Q. Just for the timing standpoint. 25 MR. EPPICH: Object to the form.	Page 452

<p style="text-align: right;">Page 453</p> <p>1 Foundation.</p> <p>2 THE WITNESS: Yes, sir.</p> <p>3 BY MR. SHKOLNIK:</p> <p>4 Q. If in December 2016 Cardinal Health</p> <p>5 agreed to pay \$34 million as a civil penalty</p> <p>6 for failure to report suspicious orders and</p> <p>7 meet its obligations under CSA as it relates to</p> <p>8 shipping without doing due diligence, that was</p> <p>9 11 years after you first brought in the big</p> <p>10 three and told them what the rules are,</p> <p>11 correct?</p> <p>12 MS. MAINIGI: Objection.</p> <p>13 THE WITNESS: Yes, sir.</p> <p>14 BY MR. SHKOLNIK:</p> <p>15 Q. In 2017, January 5th of 2017,</p> <p>16 McKesson entered into an administrative MOA</p> <p>17 with DEA pay -- to pay 150 million civil</p> <p>18 penalty for failure to identify and report</p> <p>19 suspicious orders in its facilities in</p> <p>20 Colorado, Illinois, New Jersey, Wisconsin,</p> <p>21 Florida, Maryland, Nebraska, Michigan,</p> <p>22 Massachusetts, California, Ohio and Cal --</p> <p>23 and -- and West Sacramento, California.</p> <p>24 That was now 12 years after you</p> <p>25 first sat them down and said, "You can't ship</p>	<p style="text-align: right;">Page 455</p> <p>1 (A lunch recess was taken.)</p> <p>2 THE VIDEOGRAPHER: We are going back</p> <p>3 on the record.</p> <p>4 This is the start of Media Unit No.</p> <p>5 4.</p> <p>6 The time is 2:31.</p> <p>7 You may proceed, Counsel.</p> <p>8 MR. BENNETT: For the record, while</p> <p>9 we took our lunch break, it's my understanding</p> <p>10 that there was an ex parte communication with</p> <p>11 the Special Master to discuss how long the</p> <p>12 lunch break was.</p> <p>13 That's the second time that this has</p> <p>14 happened during the deposition that there was a</p> <p>15 communication about the deposition without the</p> <p>16 government being present.</p> <p>17 I would object to that. And I would</p> <p>18 respectfully request that, any time the special</p> <p>19 master is contacted regarding a deposition</p> <p>20 involving the government witnesses, that the</p> <p>21 government be included in that conversation.</p> <p>22 MS. MAINIGI: I understand your</p> <p>23 position. Let me state for the record what</p> <p>24 happened.</p> <p>25 I reached out to David Cohen, who is</p>
<p style="text-align: right;">Page 454</p> <p>1 without doing due diligence."</p> <p>2 Fair statement?</p> <p>3 MR. EPPICH: Object to the form.</p> <p>4 THE WITNESS: Yes, sir.</p> <p>5 BY MR. SHKOLNIK:</p> <p>6 Q. And Walgreens, the chains pharmacy,</p> <p>7 they had had an immediate suspension order</p> <p>8 issued to them in 2011 and 2012 and agreed to</p> <p>9 an MOA and paid \$80 million in 2013.</p> <p>10 MR. STEPHENS: Object to form.</p> <p>11 BY MR. SHKOLNIK:</p> <p>12 Q. That would have been almost seven</p> <p>13 years after you first started telling industry,</p> <p>14 "You can't ship without doing due diligence,"</p> <p>15 correct?</p> <p>16 MR. STEPHENS: Object to form.</p> <p>17 THE WITNESS: Yes, sir.</p> <p>18 MR. SHKOLNIK: All right. I'm going</p> <p>19 to change topics.</p> <p>20 Can we just take a -- just a</p> <p>21 couple-minute break?</p> <p>22 THE VIDEOGRAPHER: We are going off</p> <p>23 the record.</p> <p>24 This is the end of Media Unit No. 3.</p> <p>25 The time is 1:08.</p>	<p style="text-align: right;">Page 456</p> <p>1 actually in D.C. here somewhere, for the</p> <p>2 purpose of setting up such a conference.</p> <p>3 Because it was clear that everyone was choosing</p> <p>4 to act unilaterally perhaps as to how much time</p> <p>5 the lunch break was actually going to be and</p> <p>6 that for whatever reason we would not reach</p> <p>7 agreement on that.</p> <p>8 I called him to set up a time</p> <p>9 quickly for us to speak.</p> <p>10 He said "What is the dispute about</p> <p>11 so that I know."</p> <p>12 I told him. I told him the</p> <p>13 government position. I told him the</p> <p>14 plaintiffs' position that it was 45 minutes,</p> <p>15 government position that there was a hard stop</p> <p>16 for the witness at 5:00; that it was -- and</p> <p>17 they only wanted 45 minutes.</p> <p>18 And I said, "Do you want me to</p> <p>19 gather the parties?"</p> <p>20 And he basically said, "I -- I don't</p> <p>21 have time for this. Hour and 15 minutes."</p> <p>22 So I understand your position</p> <p>23 that -- but it -- it was not intended to be</p> <p>24 some sort of ex parte conversation. I think he</p> <p>25 was trying to go ahead to whatever his other</p>

<p style="text-align: right;">Page 457</p> <p>1 issue was or -- I think he's here for AG 2 meetings, if what I saw from his e-mail trails 3 to the larger community last night, while at 4 the same time be responsive to us while this 5 deposition is going.</p> <p>6 MR. BENNETT: And again, whether 7 it's a call to schedule a call or a call to 8 talk substantively, we believe we should be 9 involved in that conversation. Maybe it would 10 be better to send an e-mail and copy all of us, 11 if you're trying to set up a call.</p> <p>12 But either way about it, we want to 13 be involved in any conversations with the 14 special master regarding our witness 15 depositions.</p> <p>16 MS. MAINIGI: Noted.</p> <p>17 MR. SHKOLNIK: And just so the 18 record's clear, we were not involved as well. 19 We were in the other room and were not 20 contacted.</p> <p>21 Ready to start?</p> <p>22 MS. MAINIGI: Yes.</p> <p>23 MR. TAYMAN: Okay. Hunter, can I 24 just say on the record -- I just want to put on 25 record what we talked about before we went on</p>	<p style="text-align: right;">Page 459</p> <p>1 starting now. 2 (Deposition Exhibit 41 was marked 3 for identification.) 4 BY MR. SHKOLNIK: 5 Q. Mr. Wright, I'm going to hand you a 6 document I've marked as Exhibit 41. The 7 document is TEVA_MDL 034408. And it's -- the 8 title is "Inventory Data License Agreement." 9 Mr. Wright, I'm going to hand you 10 a -- a -- a -- this document, and I'm going to 11 ask you a few questions about it. 12 This is a document that was produced 13 us to by Teva. And it's entitled "Inventory 14 Data License Made Between and entered on July 15 1, 2001, by and between Walgreen on behalf of 16 itself" as -- "and Cephalon, Inc." 17 Are you -- you're aware, are you 18 not, that Walgreen and Cephalon are both 19 registrants, are you not? 20 A. Yes, sir. 21 Q. Were you ever aware, while you were 22 at DEA, that there were written agreements 23 between Cephalon and Walgreens to provide 24 inventory data electronically from Walgreens to 25 the manufacturer Cephalon regarding its</p>
<p style="text-align: right;">Page 458</p> <p>1 the record, that we have a hard stop at 5:00. 2 And we're not able to continue to tomorrow. 3 And once the plaintiff -- the 4 plaintiffs and the defendants coordinate an 5 figure out what they need, once we see where we 6 are today, Mr. Wright will reasonably 7 participate in -- in -- in rescheduling 8 whatever time remains at that point. 9 MS. MAINIGI: And thank you for 10 that. 11 I'll just note for the record that, 12 until we came back from lunch, it was not known 13 to us that Mr. Wright did, in fact, have a hard 14 stop at 5:00. We heard different things 15 communicated over the lunch break. 16 But I do wish, in retrospect, we had 17 been aware at the morning time or last week 18 that Mr. Wright had a hard top at 5:00 so we 19 could have began the day -- begun the day at 20 8:00, for example, instead of 9:00 or 21 something. 22 But we understand. And -- and we 23 will collectively figure out how to work around 24 that. 25 MR. SHKOLNIK: Okay. My time is</p>	<p style="text-align: right;">Page 460</p> <p>1 products? 2 MR. BENNETT: I remind the witness 3 not to discuss any specific investigations. So 4 if this -- if you're aware unrelated to a 5 specific investigation, you can answer. 6 THE WITNESS: No, sir. 7 BY MR. SHKOLNIK: 8 Q. If we read under the first 9 paragraph -- I'm sorry -- the second paragraph, 10 it says "Whereas, Cephalon desires a license 11 from Walgreen, certain inventory data, as 12 further described herein, the data relating to 13 Cephalon products and Walgreens' desire to 14 license such data to Cephalon on terms and 15 conditions herein." 16 And I'm going to jump down to 17 Paragraph 1.2, where it says a description of 18 the data: "All data supplied to Cephalon shall 19 be in electronic format and contain the 20 elements described in Exhibit B attached hereto 21 or made a part hereof. Walgreen shall supply 22 data as frequently as set forth in Exhibit B, 23 and in any event, Walgreen shall supply the 24 data no later than five business days following 25 the end of the applicable period, provided that</p>

<p style="text-align: right;">Page 461</p> <p>1 Walgreen has received the license fee from 2 Cephalon as provided herein."</p> <p>3 Were you aware of inventory data 4 being exchanged within five days between 5 Walgreens Distribution and Pharmacies and 6 Cephalon?</p> <p>7 MS. MAINIGI: Objection.</p> <p>8 MR. STEPHENS: Objection.</p> <p>9 THE WITNESS: No, sir.</p> <p>10 BY MR. SHKOLNIK:</p> <p>11 Q. During -- at any point in time 12 during the -- those years that you were in 13 Washington, D.C., and doing those presentations 14 regarding Suspicious Order, Monitoring did 15 anyone ever tell you that Cephalon was 16 providing -- I'm sorry -- Walgreens was 17 providing store- and distributor-level data 18 directly up to Cephalon regarding its opioid 19 products?</p> <p>20 A. I've --</p> <p>21 MS. MAINIGI: Objection.</p> <p>22 THE WITNESS: I have no 23 recollection.</p> <p>24 BY MR. SHKOLNIK:</p> <p>25 Q. Would you -- from -- from your</p>	<p style="text-align: right;">Page 463</p> <p>1 MS. McCLURE: Objection. 2 THE WITNESS: Yes, sir. 3 BY MR. SHKOLNIK: 4 Q. And -- and you didn't know that they 5 were -- that there was actually sales agree -- 6 I mean there were agreements where the pharmacy 7 would sell that data right up to the 8 manufacturer so they could have it in their 9 possession. 10 Fair statement? 11 MS. MAINIGI: Objection. 12 THE WITNESS: Yes, sir. 13 BY MR. SHKOLNIK: 14 Q. And -- and, in fact, we've such 15 information as EDI 852 transactions. 16 Do you know what EDI 852s are? 17 A. It's -- EDI is the format -- 18 electronic format that it is transmitted under. 19 And it's the character strings take -- you 20 know, certain elements go in a certain block. 21 Q. And -- and were you aware that -- 22 that, in this industry, that EDI data was 23 available? 24 MS. MAINIGI: Objection. 25 THE WITNESS: No, sir.</p>
<p style="text-align: right;">Page 462</p> <p>1 understanding, would -- would it have been 2 helpful to -- would it have been helpful to you 3 doing your job if you had been provided 4 information that a manufacturer such as 5 Cephalon was actually getting the -- the sales 6 data from the pharmacy through the distributor 7 up to the -- I'm sorry. Withdraw that. 8 Would it have been helpful to you, 9 back when you were working at DEA, to have the 10 information that the manufacturers were 11 actually purchasing the sales data from the 12 pharmacies directly?</p> <p>13 MS. MAINIGI: Objection.</p> <p>14 THE WITNESS: It would have been 15 insightful.</p> <p>16 BY MR. SHKOLNIK:</p> <p>17 Q. Early -- on Thursday you were asked 18 by counsel for the manufacturers questions 19 about visibility.</p> <p>20 And -- and I think you gave your 21 answers as best as you could from your 22 recollection about either your knowledge or 23 lack of knowledge of visibility between 24 manufacturers and pharmacies, correct?</p> <p>25 MS. MAINIGI: Objection.</p>	<p style="text-align: right;">Page 464</p> <p>1 BY MR. SHKOLNIK: 2 Q. Here we -- we -- we show that 3 "Walgreens shall provide" the vendor -- 4 "Walgreens shall provide vendor with EDI 852 5 transactions for all products with summary 6 transmitted to vendor on a weekly basis in a 7 manner mutually agreed upon. Each transmission 8 will include information set forth below." 9 And it says: "on hand," "on order," 10 "quantity withdrawn," "lost billing," and 11 "receipts." 12 You weren't aware that Walgreens was 13 actually selling that up to the manufacturer 14 Cephalon, correct? 15 MS. MAINIGI: Objection. 16 THE WITNESS: No, sir. 17 BY MR. SHKOLNIK: 18 Q. Would that be an example of -- using 19 the terminology that was used on Thursday -- 20 visibility? 21 MS. MAINIGI: Objection. 22 MR. EPPICH: Objection. 23 THE WITNESS: Yes, sir. 24 BY MR. SHKOLNIK: 25 Q. And then it goes and says:</p>

<p style="text-align: right;">Page 465</p> <p>1 "Walgreens was providing the vendor EDI 867 2 transactions for all products which included 3 the information set forth below transmitted on 4 a weekly basis and its distributor stock sales 5 and who it was shipped to."</p> <p>6       And it says: "Each data point 7 included will provide at the level of each 8 Walgreens distribution center and by product 9 NDC."</p> <p>10      So if I'm reading that correctly, 11 Walgreens is selling the data of its sales to 12 its stores right up to the manufacturers here, 13 according to this agreement, correct?</p> <p>14      MR. STEPHENS: Object to form. 15      MS. MAINIGI: Objection. 16      THE WITNESS: It appears so. 17      BY MR. SHKOLNIK: 18      Q. "Provide vendor store direct" -- 19 "vendor store direct purchase data from 20 wholesale on a weekly basis." 21      It's also suggesting that it's 22 providing on a weekly basis its wholesale 23 numbers directly to the manufacturer, correct? 24      MS. MAINIGI: Objection. 25      THE WITNESS: Yes, sir.</p>	<p style="text-align: right;">Page 467</p> <p>1       Q. But Actiq was one of the C2s, was it 2 not?</p> <p>3       A. I -- 4            MS. MAINIGI: Objection. 5            THE WITNESS: -- don't recall, sir. 6            MR. SHKOLNIK: Now, I'm going to -- 7 I'm going to mark as Exhibit 42 another 8 inventory license. 9            (Deposition Exhibit 42 was marked 10 for identification.) 11            BY MR. SHKOLNIK: 12            Q. This is an inventory license. It -- 13 unfortunately, we weren't provided the signed 14 ones. But just want to ask some questions 15 about this document. 16            It's from 2012. "Walgreen and 17 Purdue Pharma Inventory Data License." 18            And again, this is a document, if 19 we're reading at 1. -- 1.2: "All data supplied 20 to vendors shall be in electronic format and 21 contain the elements described in Exhibit B 22 attached hereto and made part hereof. 23 Walgreens shall use commercially reasonable 24 efforts to supply the data no" longer -- "no 25 later than five days following the end of each</p>
<p style="text-align: right;">Page 466</p> <p>1      BY MR. SHKOLNIK: 2      Q. Once again, that's an example of 3 visibility between a manufacturer and a -- a 4 wholesale chain distributor and pharmacy, is it 5 not, sir? 6      MS. MAINIGI: Objection. 7      THE WITNESS: Yes, sir. 8      BY MR. SHKOLNIK: 9      Q. If we can go back one page, they 10 give an example of the products that they were 11 reporting on from Walgreens up to the 12 manufacturer. It says "Actiq." 13      That's a -- an opioid, is it not, 14 sir? 15      MS. MAINIGI: Objection. 16      THE WITNESS: Yes, sir. 17      BY MR. SHKOLNIK: 18      Q. Fentora? 19      Are -- are any of these other -- are 20 -- are these controlled substances, to your 21 knowledge, that we have a list of here? 22      MS. MAINIGI: Objection. 23      THE WITNESS: I'm not familiar with 24 the -- the rest of these, no. 25      BY MR. SHKOLNIK:</p>	<p style="text-align: right;">Page 468</p> <p>1      calendar week." 2      And then I'm going to jump to the 3 attachment. 4      MS. McCLURE: Is that a question? 5      MR. SHKOLNIK: No. I'll get there. 6      And I'm going to keep reading. 7      MS. McCLURE: Object to the 8 commentary on the record with a -- not a 9 question. 10     MR. SHKOLNIK: Thank you. 11     Can I finish my question? 12     MS. McCLURE: If there is one. 13     MR. SHKOLNIK: I'll get to it, if 14 you -- if you don't mind. 15     BY MR. SHKOLNIK: 16     Q. And this is the list of products 17 that's referred to in the Exhibit B in the 18 paragraph I was just reading before I was 19 interrupted. 20     Dilaudid and OxyContin, those are 21 Schedule II products, are they not? 22     MS. MAINIGI: Objection. 23     MS. McCLURE: Objection. 24     MR. SHKOLNIK: Let me restate the 25 question. I'm sorry.</p>

<p style="text-align: right;">Page 469</p> <p>1        BY MR. SHKOLNIK:</p> <p>2        Q. Those are controlled substances, are</p> <p>3        they not?</p> <p>4        MS. MAINIGI: Objection.</p> <p>5        MS. McCLURE: Objection.</p> <p>6        THE WITNESS: Yes, sir.</p> <p>7        BY MR. SHKOLNIK:</p> <p>8        Q. And OxyContin is a product that is</p> <p>9        manufactured by Purdue, is it not?</p> <p>10       MS. MAINIGI: Objection.</p> <p>11       THE WITNESS: Yes, sir.</p> <p>12       BY MR. SHKOLNIK:</p> <p>13       Q. If this was a contract that was</p> <p>14       entered into between Walgreens and Purdue, this</p> <p>15       would be an example of Purdue getting data</p> <p>16       directly from the pharmacy right up to the</p> <p>17       company for visibility purposes, would it not?</p> <p>18       MS. MAINIGI: Objection.</p> <p>19       MS. McCLURE: Same objection.</p> <p>20       MR. STEPHENS: Object to form.</p> <p>21       THE WITNESS: Yes, sir.</p> <p>22       BY MR. SHKOLNIK:</p> <p>23       Q. And under Exhibit B format, it</p> <p>24       suggests that datasets are inventory available,</p> <p>25       demand quantity, quantity on order, quantity</p>	<p style="text-align: right;">Page 471</p> <p>1        manufacturer, Purdue, pursuant to a license</p> <p>2        with the pharmacy Walgreens, correct?</p> <p>3        MS. MAINIGI: Objection.</p> <p>4        MS. McCLURE: Objection.</p> <p>5        THE WITNESS: Yes, sir.</p> <p>6        MR. SHKOLNIK: I'm going to show you</p> <p>7        Exhibit No. 43.</p> <p>8        I apologize again. This is another</p> <p>9        unsigned contract that neither Walgreen or</p> <p>10       Purdue provided us. But it appears to be the</p> <p>11       amendment of the last contract.</p> <p>12       (Deposition Exhibit 43 was marked</p> <p>13       for identification.)</p> <p>14       BY MR. SHKOLNIK:</p> <p>15       Q. This document, if I'm reading it</p> <p>16       correctly, says: "First Amendment Inventory</p> <p>17       Data License Agreement." And the data of this</p> <p>18       is March 2015 between Walgreen and Purdue. And</p> <p>19       it's now including a new product that they</p> <p>20       would be providing data on. And it says</p> <p>21       Hysingla.</p> <p>22       Are you familiar with Hysingla?</p> <p>23       MS. MAINIGI: Objection.</p> <p>24       THE WITNESS: No, sir. I'm not.</p> <p>25       BY MR. SHKOLNIK:</p>
<p style="text-align: right;">Page 470</p> <p>1        sold.</p> <p>2        If that type of information was</p> <p>3        provided by Walgreen up to the manufacturer,</p> <p>4        Purdue on those Schedule II products,</p> <p>5        OxyContin, that would be a way of having</p> <p>6        visibility down to the store level by</p> <p>7        Walgreens, would it not?</p> <p>8        MS. MAINIGI: Objection.</p> <p>9        MS. McCLURE: Objection.</p> <p>10       THE WITNESS: It appears so. Yes,</p> <p>11       sir.</p> <p>12       BY MR. SHKOLNIK:</p> <p>13       Q. And then on Dataset 2, it would also</p> <p>14       include retail sales quantity.</p> <p>15       So that would be evidence of data at</p> <p>16       the store level going all the way up to the</p> <p>17       manufacturer on the movement of OxyContin,</p> <p>18       correct?</p> <p>19       MS. MAINIGI: Objection.</p> <p>20       MS. McCLURE: Objection.</p> <p>21       THE WITNESS: Yes, sir.</p> <p>22       BY MR. SHKOLNIK:</p> <p>23       Q. That would be what would one -- one</p> <p>24       might call visibility of the sales of OxyContin</p> <p>25       at the store level right up to the</p>	<p style="text-align: right;">Page 472</p> <p>1        Q. Are you familiar with something -- a</p> <p>2        data source called IMS or IMS Health?</p> <p>3        A. Yes, sir.</p> <p>4        Q. What's your understanding of IMS</p> <p>5        Health or IMS?</p> <p>6        MS. MAINIGI: Objection.</p> <p>7        BY MR. SHKOLNIK:</p> <p>8        Q. In terms of data.</p> <p>9        MS. MAINIGI: Objection.</p> <p>10       THE WITNESS: It's a data aggregate</p> <p>11       company that provides high-level and low-level</p> <p>12       or granular transaction information.</p> <p>13       And we had -- DEA had high-level</p> <p>14       data output, in other words, how much a certain</p> <p>15       product was moving, but nothing specific as to</p> <p>16       who or what.</p> <p>17       BY MR. SHKOLNIK:</p> <p>18       Q. Did you know that the pharma -- that</p> <p>19       -- that the pharmacy chains and the</p> <p>20       distributors could purchase the -- the -- the</p> <p>21       data regarding the movement of prescriptions</p> <p>22       right down to the store level --</p> <p>23       MS. MAINIGI: Objection.</p> <p>24       BY MR. SHKOLNIK:</p> <p>25       Q. -- from IMS?</p>

<p style="text-align: right;">Page 473</p> <p>1 MS. MAINIGI: Objection.    2 MS. McCLURE: Objection.    3 THE WITNESS: I don't know if they    4 could or not, no.    5 MR. SHKOLNIK: I'm going to hand you    6 what I'm marking as Exhibit No. 44, was that, I    7 think.    8 (Deposition Exhibit 44 was marked    9 for identification.)    10 MR. SHKOLNIK: Once again, this is    11 another unsigned contract provided to us by    12 Purdue. And this -- this is an unsigned    13 agreement between Purdue and Walgreen for    14 access to IMF -- IMS Health data sharing.    15 BY MR. SHKOLNIK:    16 Q. And I would like to turn your    17 attention to the Bates No. 791. And if we    18 could go to the section entitled "AMA/AOA    19 Third-Party Data" where -- where it says: "The    20 AMA/AOA data, any fields of information    21 specific to identifiable physician, where    22 identified by name or other identifier,    23 collectively, shall be treated by IMS and    24 Walgreens as derived from American Medical    25 Association, physician professional data."</p>	<p style="text-align: right;">Page 475</p> <p>1 Were you aware that IMS could    2 provide the physician prescribing level data as    3 it flowed through the pharmacies by way of the    4 IMS database?    5 Were you aware of that?    6 A. Yes, sir.    7 MS. MAINIGI: Objection.    8 MS. McCLURE: Objection.    9 BY MR. SHKOLNIK:    10 Q. Did you know that the manufacturers    11 were purchasing that data and having that?    12 MS. MAINIGI: Objection.    13 MS. McCLURE: Objection.    14 THE WITNESS: No, sir.    15 BY MR. SHKOLNIK:    16 Q. Would that be an -- if they had that    17 data, would that be another example of    18 visibility between manufacturer through    19 distribution right down to the store level and,    20 in fact, down to the prescription level?    21 MS. MAINIGI: Objection.    22 MS. McCLURE: Objection.    23 THE WITNESS: Yes, sir.    24 BY MR. SHKOLNIK:    25 Q. Would that help, sir -- based on</p>
<p style="text-align: right;">Page 474</p> <p>1 Were you aware that -- that the    2 manufacturer Purdue was purchasing directly    3 from chain pharmacies the actual information    4 regarding the prescriptions of the individual    5 physicians --    6 MR. EPPICH: Object to form.    7 BY MR. SHKOLNIK:    8 Q. -- at the store level?    9 MS. McCLURE: Same objection.    10 MR. EPPICH: And object to the    11 characterization of the document.    12 THE WITNESS: No, sir.    13 BY MR. SHKOLNIK:    14 Q. Did you know that IMS could provide    15 physician-level data flowing through the    16 pharmacies?    17 MS. MAINIGI: Objection.    18 BY MR. SHKOLNIK:    19 Q. Through IMS?    20 Did you know that?    21 MS. MAINIGI: Objection.    22 THE WITNESS: I got lost in the    23 question.    24 BY MR. SHKOLNIK:    25 Q. Sure.</p>	<p style="text-align: right;">Page 476</p> <p>1 your understanding of the way things were,    2 would that help in getting the manufacturers,    3 the distributors, as well as the pharmacies to    4 do adequate due diligence regarding suspicious    5 orders if they had all that data available to    6 them?    7 MS. MAINIGI: Objection.    8 MR. EPPICH: Object to form.    9 THE WITNESS: Yes, sir.    10 BY MR. SHKOLNIK:    11 Q. If they had used that data for that    12 purpose, correct, sir?    13 MR. EPPICH: Object to form.    14 MS. MAINIGI: Objection.    15 THE WITNESS: Yes, sir.    16 BY MR. SHKOLNIK:    17 Q. To your knowledge, when you were    18 doing your -- your work at DEA, did any -- any    19 of the registrants you work with ever tell you    20 they were using all that data together to help    21 comply with their Suspicious Order Monitoring    22 obligations under the Act?    23 MR. EPPICH: Object to form.    24 MS. MAINIGI: Objection.    25 MR. BENNETT: Objection.</p>

<p style="text-align: right;">Page 477</p> <p>1 You may not talk about any specific 2 investigations or interviews that you had. 3 But you can answer it generally if 4 it's outside of a specific investigation. 5 THE WITNESS: And the question was? 6 MR. SHKOLNIK: Could you read that 7 question back, please. I'll never get it -- 8 get it a second time. 9 (The record was read as requested.) 10 THE WITNESS: No, sir. 11 MS. MAINIGI: May I ask the 12 videographer how much time is left before we 13 reach 3:30? 14 THE VIDEOGRAPHER: You've got run 15 time of 3:32:30 so far. 16 MS. MAINIGI: Okay. I think we're 17 done. 18 Go off the record, please. 19 MR. SHKOLNIK: No. Wait -- wait a 20 second. We had -- wasn't there -- there was a. 21 THE VIDEOGRAPHER: Well, that -- you 22 -- I mean you guys have to work that out -- 23 MR. SHKOLNIK: You -- you -- you 24 guys were having a discussion. 25 MS. MAINIGI: We're at 3:32. I</p>	<p style="text-align: right;">Page 479</p> <p>1 whether you two had ever met. 2 Do you recall him asking you that 3 question? 4 A. Yes. 5 Q. Okay. And you told him you have 6 never met him before, correct? 7 A. Maybe I'll no recollection. 8 Q. Okay. Now, Mr. Migliori, have you 9 met Mr. Migliori before? 10 A. Yes, ma'am. 11 Q. And on how many occasions have you 12 met Mr. Migliori? 13 MR. MIGLIORI: I'm going to object 14 on the scope. On this question I will not tell 15 him not to answer. But I'm going to -- I'm 16 warning that this is getting into the ruling 17 that was already issued. 18 MS. MAINIGI: I think the door was 19 opened so -- by Mr. Shkolnik. 20 BY MS. MAINIGI: 21 Q. How many times have you met with 22 Mr. Migliori? 23 A. One time, to the best of my 24 recollection. 25 Q. You've only met Mr. Migliori one</p>
<p style="text-align: right;">Page 478</p> <p>1 don't think our discussion was longer than two 2 minutes. 3 MR. SHKOLNIK: Oh, actually timed it 4 over here. 5 MS. MAINIGI: Let's go off the 6 record, please. 7 THE VIDEOGRAPHER: We are going off 8 the record. 9 The time is 2:53. 10 (A short recess was taken.) 11 THE VIDEOGRAPHER: We are going back 12 on the record. 13 The time is 3:07. 14 You may proceed, Counsel. 15 FURTHER EXAMINATION BY COUNSEL FOR 16 CARDINAL HEALTH, INC. 17 BY MS. MAINIGI: 18 Q. Good afternoon, Mr. Wright. 19 You just were questioned by Mr. 20 Hunter Shkolnik. 21 Do you remember that? 22 A. Yes, ma'am. 23 Q. And one of the questions Mr. 24 Shkolnik asked you at the beginning of his 25 testimony -- or his questioning of you was</p>	<p style="text-align: right;">Page 480</p> <p>1 time. 2 That's your testimony under oath? 3 A. Except for the days here. 4 Q. Okay. And other individuals from 5 Motley Rice, have you met with them? 6 A. No, ma'am. 7 Q. The only -- 8 A. Now -- 9 Q. I'm sorry. Go ahead. Go ahead. 10 A. I've had a couple of telephone -- 11 I've had some telephone conferences. But I've 12 not physically met with anyone from Motley Rice 13 except for him. 14 Q. Okay. Thank you for completing 15 that. 16 In terms of -- well, the meeting 17 with Mr. Migliori, when was, that 18 approximately, what month; do you remember? 19 A. It was late last year. 20 Q. Was he the first person from Motley 21 Rice that you spoke with? 22 MR. TAYMAN: Objection. 23 MR. BENNETT: Objection. 24 MR. TAYMAN: Privileged and 25 confidential.</p>

<p style="text-align: right;">Page 481</p> <p>1 I'm going to direct you not the 2 answer. 3 We don't control the privilege. 4 MS. MAINIGI: I know that. I don't 5 know why that would be privileged and 6 confidential. But I can't -- I can't change 7 how you're directing him not to answer the 8 question. 9 BY MS. MAINIGI: 10 Q. Who else from -- you mentioned 11 telephone calls with Motley Rice. 12 Were those with Mr. Migliori? 13 A. He had occasion to be in -- in some 14 of those but not all. 15 Q. How many phone calls, approximately, 16 have you had with Motley Rice? 17 A. Four. 18 Q. And approximately how long did each 19 last? 20 A. None of them lasted more than an 21 hour. 22 Q. And those -- 23 A. The last two were only half an hour. 24 Q. Were all of those calls -- and I 25 don't know -- want to know the details, but</p>	<p style="text-align: right;">Page 483</p> <p>1 identify you from Motley Rice as someone he has 2 met with for the purpose of consulting, but he 3 can't -- I'd -- you're -- you're -- 4 MR. MIGLIORI: Yes. You're right. 5 MS. MAINIGI: -- forbidding him, 6 Mr. Migliori, from identifying anyone else from 7 Motley Rice? 8 MR. MIGLIORI: That's correct. 9 MS. MAINIGI: Okay. Well, I guess 10 we'll take that up with the Special Master 11 Cohen. 12 BY MS. MAINIGI: 13 Q. Did you meet with Ms. Singer from 14 Motley Rice? 15 MR. MIGLIORI: Do not answer. 16 MR. TAYMAN: Objection. Privileged. 17 Confidential. 18 Direct you not to answer. 19 BY MS. MAINIGI: 20 Q. Did you meet to Ms. Singer by 21 telephone? 22 MR. MIGLIORI: Same objection. 23 MR. TAYMAN: Objection. 24 BY MS. MAINIGI: 25 Q. Your in-person meeting with</p>
<p style="text-align: right;">Page 482</p> <p>1 were all of those calls related to your 2 consulting arrangement with Motley Rice? 3 MR. TAYMAN: Objection to the extent 4 it calls for the content of the call. 5 But otherwise You can answer. 6 THE WITNESS: Yes. 7 BY MS. MAINIGI: 8 Q. Who else from Motley Rice was on 9 those telephone calls? 10 MR. MIGLIORI: Objection. 11 MR. TAYMAN: Objection. 12 MR. MIGLIORI: Don't answer. 13 MR. TAYMAN: Direct you not to 14 answer. 15 MS. MAINIGI: Why is that 16 privileged? 17 MR. MIGLIORI: It's the privilege 18 under the rule for -- 19 MS. MAINIGI: But -- 20 MR. MIGLIORI: -- for consultancy 21 experts. You happened to learn by happenstance 22 of the existence of it. I gave you latitude 23 about how little it was. But content on the 24 and who he spoke with a far beyond the rule. 25 MS. MAINIGI: So he's able to</p>	<p style="text-align: right;">Page 484</p> <p>1 Mr. Migliori that took place late last year, 2 how long did that meeting last? 3 MR. MIGLIORI: Objection. 4 Do not answer. 5 We're -- we're done with that. 6 That's going to be my running objection. 7 MS. MAINIGI: Okay. We'll -- we'll 8 figure out if on the next break we go ahead and 9 stop and call David Cohen. 10 BY MS. MAINIGI: 11 Q. So you were retained, as you 12 testified before, by Mr. Migliori and Motley 13 Rice to represent or consult for Summit County, 14 correct? 15 MR. MIGLIORI: Objection. 16 Don't answer. 17 MR. TAYMAN: Objection. 18 MS. MAINIGI: He's already answered 19 that. 20 MR. MIGLIORI: No. First of all, 21 it's been asked and answered. It's beyond the 22 spoke. I don't know how Hunter opened the door 23 for it. But it's beyond the scope of this type 24 of questioning. 25 MS. MAINIGI: Well, actually.</p>

<p style="text-align: right;">Page 485</p> <p>1        MR. MIGLIORI: And we can have David 2 resolve the issue. But David's already let you 3 go as far as you can go. 4        MS. MAINIGI: I don't think so. 5 Because Mr. Shkolnik opened the door to this. 6        MR. SHKOLNIK: I didn't open any 7 door. 8        MR. MIGLIORI: He can't open a door 9 for my relationship. 10      MS. MAINIGI: Okay. Well, the -- I 11 disagree. But we'll keep on going, and then 12 we'll come back. 13      MR. MIGLIORI: And you can use all 14 of your time doing that, but -- 15      BY MS. MAINIGI: 16      Q. Did you meet with -- between last 17 week's testimony that you provided under oath 18 and today's testimony that you are providing 19 under oath, did you meet with your attorney? 20      MR. TAYMAN: Objection to the extent 21 that -- don't -- 22      BY MS. MAINIGI: 23      Q. "Yes" or "no"?</p> <p>24      MR. TAYMAN: You can't tell her the 25 content of any meeting. But you can tell her</p>	<p style="text-align: right;">Page 487</p> <p>1 and today? 2      A. Yes, ma'am. 3      Q. Okay. Did you speak to anyone else 4 about this matter between last Thursday and 5 today? 6      A. No, ma'am. 7      Q. Okay. You testified that the 8 Excessive Purchase System had been in place 9 since at least 1995 when you joined the DEA, 10 correct? 11      A. Excessive? 12      Q. Yes. 13      A. Yes, ma'am. 14      Q. Okay. And the Excessive Purchase 15 Reports were the accepted practice for many 16 years, correct? 17      A. Yes, ma'am. 18      Q. And these reports were blessed by 19 DEA headquarters and field offices, correct? 20      MR. BENNETT: Objection. 21      You can answer. 22      THE WITNESS: To my understanding. 23 Because that's all I was provided, ma'am. 24      BY MS. MAINIGI: 25      Q. Well, you understood, when you were</p>
<p style="text-align: right;">Page 486</p> <p>1 about the existence of a meeting. 2      THE WITNESS: I'm sorry. Could you 3 repeat your question for me, please. 4      BY MS. MAINIGI: 5      Q. Sure. 6      Do you remember testifying last 7 Thursday here in this room? 8      A. Okay. Thank you. 9      Yes, ma'am. 10     Q. Okay. And then your back, of 11 course, today. 12     Between then and now, did you meet 13 with your attorney? 14     I don't need to know what you talk 15 about; I just -- "yes" or "no," did you meet 16 with your attorney? 17     A. No, ma'am. 18     Q. Okay. Did you speak to your 19 attorney by telephone between last Thursday and 20 today? 21     A. Yes, ma'am. 22     Q. Okay. How long did you speak to 23 your attorney for, sir? 24     A. Five minutes. 25     Q. Five minutes between last Thursday</p>	<p style="text-align: right;">Page 488</p> <p>1 at the DEA field office, that it was the 2 practice for registrants to send in Excessive 3 Purchase Reports, correct? 4      A. That's all I ever saw. That's all I 5 ever got on my desk. I saw no other variation 6 of that. 7      Q. Did you ever ask anybody, when you 8 were in the field office, whether there were 9 other variations? 10     A. No, ma'am. 11     Q. Okay. And when you got to 12 headquarters, you were aware that the practice 13 was to -- for registrants to send in Excessive 14 Purchase Reports, correct? 15     A. Yes, ma'am. 16     Q. And, in fact, the DEA told 17 registrants during inspections that your system 18 is working, correct? 19     MR. BENNETT: Objection. 20     THE WITNESS: I do not know what 21 other investigators were -- were telling or 22 whatever, approving. 23     I know that these were accepted 24 reports. They were received by many field 25 office nationwide. Got that through training.</p>

<p style="text-align: right;">Page 489</p> <p>1 When we got together, we'd talk about work and 2 things like this, so -- 3 BY MS. MAINIGI: 4 Q. And prior for 2005, you personally, 5 in your experience, never told any registrant 6 that there was anything improper or illegal 7 about the practice of submitting excesses -- 8 Excessive Purchase Reports, correct? 9 A. Yes, ma'am. 10 Q. And to the best of your knowledge, 11 in your experience, nobody at DEA told any 12 registrant there was anything improper or 13 illegal about the practice of submitting 14 Excessive Purchase Reports, correct? 15 A. Yes, ma'am. 16 Q. A colleague pointed out to me that 17 your very polite response may -- it may not be 18 totally clear. 19 When you say "yes, ma'am" -- when 20 you say "yes, ma'am" -- 21 A. You don't want me to be polite? 22 Q. I do want you to be polite. 23 When you say "yes, ma'am," that 24 means you're agreeing with my statement; is 25 that right?</p>	<p style="text-align: right;">Page 491</p> <p>1 Q. So you weren't person making 2 decisions about what did or did not comply with 3 regulations and statutes? 4 MR. MIGLIORI: Objection. 5 THE WITNESS: No, ma'am. 6 BY MS. MAINIGI: 7 Q. That would have been the office of 8 legal counsel at DEA, correct? 9 A. Among one of many. 10 Q. Now, if you, as one of the employees 11 of DEA, knew facts that indicated that 12 registrants were failing to maintain effective 13 controls against diversion, you would have 14 tried to take some sort of action, correct? 15 MR. MIGLIORI: Objection. Form. 16 Foundation. 17 THE WITNESS: I would have tried -- 18 I would have begun looking into it to -- to 19 explore it. I -- "action" is a very broad 20 word. 21 BY MS. MAINIGI: 22 Q. To your knowledge, no one from DEA 23 told registrants to submit anything other than 24 Excessive Purchase Reports until the 2005, 2007 25 time frame we've been talking about, correct?</p>
<p style="text-align: right;">Page 490</p> <p>1 MR. MIGLIORI: Objection. 2 BY MS. MAINIGI: 3 Q. So let's -- let's -- let's make sure 4 the record is clear. I -- let me do -- I 5 apologize. Let -- let -- let me try to make 6 sure that the record is clear. 7 To the best of your knowledge, 8 Mr. Wright, in your experience, do you agree 9 that no one at DEA told a registrant that there 10 was anything improper or illegal about the 11 practice of submitting Excessive Purchase 12 Reports prior to 2005? 13 A. To the best of my knowledge, no. 14 Q. DEA would not have blessed a 15 practice that did not comply with the 16 regulation, correct? 17 MR. MIGLIORI: Objection. Scope. 18 MR. BENNETT: Objection. 19 MR. MIGLIORI: Authority. 20 THE WITNESS: I was never at that 21 level to say what DEA would approve or not 22 approve. Never. Everything I did got stamped, 23 spented and folded and mutilated 20 different 24 ways. 25 BY MS. MAINIGI:</p>	<p style="text-align: right;">Page 492</p> <p>1 A. To the best of my knowledge. 2 Q. To the best of your knowledge, that 3 is a correct statement? 4 A. Yes, ma'am. 5 Q. Okay. And I believe you testified 6 to this before, but the DEA continued to accept 7 those Excessive Purchase Reports even after the 8 distributor initiative briefings that you 9 discussed with Mr. Migliori began, correct? 10 MR. MIGLIORI: Objection. Beyond 11 the scope. 12 MR. BENNETT: Objection. 13 MS. MAINIGI: Let me -- let me 14 withdraw the question. And I'll -- I'll -- let 15 me break it up a little bit for you. Okay? 16 THE WITNESS: Thank you. 17 BY MS. MAINIGI: 18 Q. You testified that the distributor 19 briefings began towards the end of 2005 and 20 actually continued for several more years 21 thereafter, correct? 22 A. Yes, ma'am. 23 Q. And, in fact, I recall you 24 discussing with Mr. Migliori the concept of 25 doing one of the distributor briefings with --</p>

<p style="text-align: right;">Page 493</p> <p>1 with the trade association HDMA. I think it 2 was at the end of 2007.</p> <p>3 Do you remember that?</p> <p>4 A. Yes, ma'am.</p> <p>5 Q. And I believe you testified last 6 week that there were some distributor briefings 7 that took place even after 2007, correct?</p> <p>8 A. Yes, ma'am.</p> <p>9 Q. So there was a period of time where 10 a number of the one-on-one distributor 11 briefings were happening, correct?</p> <p>12 A. Yes, ma'am.</p> <p>13 Q. Okay. And I believe you told me 14 last week that, even after the distributor 15 briefings began at the end of 2005, to your 16 knowledge the DEA continued to accept Excessive 17 Order Reports from registrants for some period 18 of time after the briefings began.</p> <p>19 A. Only for those that have not been 20 briefed, not accepting or maybe more from those 21 that have been -- the -- the distributor 22 briefing or whatever had been given to.</p> <p>23 There's -- there had to be a 24 transition time. We couldn't just fall on top 25 of everybody all at once.</p>	<p style="text-align: right;">Page 495</p> <p>1 Do you remember that discussion?</p> <p>2 A. Yes, ma'am.</p> <p>3 Q. And you're familiar with the statute 4 and the regulations that are at issue here, 5 correct?</p> <p>6 A. Yes, ma'am.</p> <p>7 Q. Would you like me to put them in 8 front of you, or do you feel like you're 9 sufficiently aware of them?</p> <p>10 A. Oh, I would rather have them in 11 front of me.</p> <p>12 MS. MAINIGI: Okay.</p> <p>13 THE WITNESS: I -</p> <p>14 MS. MAINIGI: Let's do that.</p> <p>15 THE WITNESS: After a few years --</p> <p>16 MS. MAINIGI: Understood.</p> <p>17 46 is the statute, sir.</p> <p>18 (Deposition Exhibit 46 was marked 19 for identification.)</p> <p>20 MS. MAINIGI: And 47 is the 21 regulation, sir.</p> <p>22 (Deposition Exhibit 47 was marked 23 for identification.)</p> <p>24 BY MS. MAINIGI:</p> <p>25 Q. Now, the -- this is just a reference</p>
<p style="text-align: right;">Page 494</p> <p>1 Q. That's right.</p> <p>2 Because it would have been -- it -- 3 it took a while for the registrants to build 4 out essentially a new system, correct?</p> <p>5 A. I don't know if "build out." But 6 they had to employ and -- and start it. But it 7 wasn't fair for brief -- Company A and Company 8 B hadn't been briefed, and make them -- Company 9 B change.</p> <p>10 Q. Do you recall saying to any company 11 after a briefing that you would no longer 12 accept Excessive Order Reports from that 13 company starting from some date certain?</p> <p>14 A. I never recall giving anybody a 15 hard, fast date of transition.</p> <p>16 Q. Okay. Do you recall ever sending 17 out a letter to a company telling them you were 18 no longer going to accept Excessive Order 19 Reports from that company?</p> <p>20 A. I don't have any recollection of 21 ever doing that.</p> <p>22 Q. Now, there was some discussion about 23 the due diligence that a company may perform in 24 determining whether an order is suspicious or 25 not.</p>	<p style="text-align: right;">Page 496</p> <p>1 for you if -- if you need the statute or the 2 regulation.</p> <p>3 I believe, when you spoke of best 4 practice -- when you spoke of the due diligence 5 that may be performed, you spoke of it in terms 6 of best practices, correct?</p> <p>7 A. Yes, ma'am.</p> <p>8 Q. So the due diligence that got 9 referenced in your discussion this morning, 10 that is not required by the statute or the 11 regulation, correct?</p> <p>12 MR. BENNETT: Objection.</p> <p>13 THE WITNESS: It is not mentioned 14 specifically.</p> <p>15 BY MS. MAINIGI:</p> <p>16 Q. It is, in your mind, a best 17 practice, correct?</p> <p>18 A. I don't see how it can be -- it's a 19 little more than best practice. I know it's 20 not stipulated. But I don't see how you can do 21 the assessments without going through some of 22 those -- those processes.</p> <p>23 Q. And it is the documentation of -- 24 whatever due diligence is done by a company, 25 that may be a best practice, but it is not</p>

<p style="text-align: right;">Page 497</p> <p>1 required by statute or regulation, correct?</p> <p>2 MR. BENNETT: Objection.</p> <p>3 MR. SHKOLNIK: Objection to form.</p> <p>4 THE WITNESS: Yes, ma'am.</p> <p>5 BY MS. MAINIGI:</p> <p>6 Q. When you did your distributor</p> <p>7 briefings, you did not note in your distributor</p> <p>8 briefings the documentation of due diligence,</p> <p>9 did you?</p> <p>10 A. No, ma'am.</p> <p>11 MR. BENNETT: Mr. Wright, do you</p> <p>12 need to supplement your answer?</p> <p>13 THE WITNESS: I'm not changing my</p> <p>14 answer.</p> <p>15 MR. BENNETT: Okay.</p> <p>16 BY MS. MAINIGI:</p> <p>17 Q. There was testimony this morning</p> <p>18 about a September 11th, 2007 DEA conference.</p> <p>19 Do you recall that?</p> <p>20 A. In Houston.</p> <p>21 Q. That's correct.</p> <p>22 Do you recall that discussion back</p> <p>23 and forth with you and Mr. Migliori?</p> <p>24 A. Yes, ma'am.</p> <p>25 Q. It might have even been</p>	<p style="text-align: right;">Page 499</p> <p>1 Q. And that was not necessarily a</p> <p>2 pleasant experience for you, correct?</p> <p>3 A. No, ma'am.</p> <p>4 Q. That -- the date of your testimony</p> <p>5 was in the year 2011, correct?</p> <p>6 A. Yes, ma'am.</p> <p>7 Q. And 2011 is certainly closer in time</p> <p>8 to 2007 than 2019 is, correct?</p> <p>9 A. Yes, ma'am.</p> <p>10 Q. So in 2011 your memory about whether</p> <p>11 you attended that conference might be a bit</p> <p>12 better; don't you agree?</p> <p>13 A. Yes, ma'am.</p> <p>14 Q. Okay. Let's take a look at your</p> <p>15 testimony at Page 368, lines 10 through 14.</p> <p>16 MR. SHKOLNIK: Can we have the date</p> <p>17 of the transcript so we know which one you're</p> <p>18 talking about.</p> <p>19 MS. MAINIGI: Page 368, pages --</p> <p>20 lines 10 to 14. And the trial testimony date</p> <p>21 is August 12th, 2011.</p> <p>22 THE WITNESS: Okay.</p> <p>23 BY MS. MAINIGI:</p> <p>24 Q. At Page 368, lines 10 through 14,</p> <p>25 have you had a chance to review your testimony?</p>
<p style="text-align: right;">Page 498</p> <p>1 Mr. Shkolnik. I -- I may have gotten that</p> <p>2 wrong.</p> <p>3 But in any case, with the plaintiffs</p> <p>4 you discussed the concept of whether you</p> <p>5 attended the DEA conference on September 11th,</p> <p>6 2007, correct?</p> <p>7 A. Yes, ma'am.</p> <p>8 Q. And I believe your testimony was</p> <p>9 that you couldn't remember, but you thought</p> <p>10 maybe you had.</p> <p>11 Do you remember that?</p> <p>12 A. I've been to Houston several times.</p> <p>13 And I just can't recall if it was in connection</p> <p>14 with this or not.</p> <p>15 Q. Okay. And Mr. Migliori or</p> <p>16 Mr. Shkolnik plaintiffs' counsel walked you</p> <p>17 through the deck or PowerPoint associated with</p> <p>18 that DEA conference, correct?</p> <p>19 A. Yes, ma'am.</p> <p>20 Q. Now, I think in front of you you've</p> <p>21 your trial testimony in the binder.</p> <p>22 A. Okay. Thank you.</p> <p>23 Q. And you recall testifying at the</p> <p>24 H.D. Smith trial, correct?</p> <p>25 A. Unfortunately, yes, ma'am.</p>	<p style="text-align: right;">Page 500</p> <p>1 A. Yes, ma'am.</p> <p>2 Q. Okay. Does it appear to you,</p> <p>3 Mr. Wright, upon reflection, that you did not</p> <p>4 attend the September 11, 2007, DEA conference?</p> <p>5 A. According to this statement that I</p> <p>6 made, no, I did not.</p> <p>7 Q. And when did you make the statement?</p> <p>8 A. This was 2011.</p> <p>9 Q. What was the statement you made</p> <p>10 Mr. Wright?</p> <p>11 A. Oh, you want me to read it verbatim?</p> <p>12 Q. Or you can -- you can paraphrase it.</p> <p>13 Whatever you wish.</p> <p>14 MR. MIGLIORI: Objection. Form.</p> <p>15 THE WITNESS: "Question: Did you</p> <p>16 attend the DEA distributor conference in</p> <p>17 Houston September 11th or 12th of 2007?</p> <p>18 "Answer: To the best of my</p> <p>19 recollection, no, I did not."</p> <p>20 BY MS. MAINIGI:</p> <p>21 Q. So sitting here today, just to be</p> <p>22 clear, Mr. Wright, to the best of your</p> <p>23 recollection sitting here today, did you attend</p> <p>24 the September 11th, 2007, DEA conference?</p> <p>25 A. In Houston, Texas.</p>

<p style="text-align: right;">Page 501</p> <p>1 Q. Yes.</p> <p>2 A. Apparently to previous testimony, I</p> <p>3 did not.</p> <p>4 Q. Okay. Based on prior documents that</p> <p>5 you reviewed, is it clear that Mr. Mapes</p> <p>6 attended that conference?</p> <p>7 MR. BENNETT: Objection. Form.</p> <p>8 THE WITNESS: It appears so.</p> <p>9 BY MS. MAINIGI:</p> <p>10 Q. And sitting here today, you don't</p> <p>11 recall having a discussion with Mr. Mapes about</p> <p>12 what he specifically said or discussed at that</p> <p>13 conference, do you?</p> <p>14 A. I -- I only snicker because I - how</p> <p>15 many thousands of things did I talk to him</p> <p>16 about. I -- I do not know. I would not know.</p> <p>17 BY MS. MAINIGI:</p> <p>18 Q. And so, when you were asked a series</p> <p>19 of questions by plaintiffs' counsel about what</p> <p>20 might have been said at the conference or what</p> <p>21 got said at the conference, the September 11th,</p> <p>22 2007 conference, that was speculation on your</p> <p>23 part, correct?</p> <p>24 MR. SHKOLNIK: Objection to form.</p> <p>25 THE WITNESS: I don't think it would</p>	<p style="text-align: right;">Page 503</p> <p>1 Q. Okay. Now, you also got asked a</p> <p>2 number of questions -- well, let's back up.</p> <p>3 You were shown also copies of</p> <p>4 various letters to registrants from Joe</p> <p>5 Rannazzisi in the 2006 and 2007 time period,</p> <p>6 correct?</p> <p>7 A. Yes, ma'am.</p> <p>8 Q. And you've testified that you didn't</p> <p>9 see Mr. Rannazzisi's letters before they went</p> <p>10 out, correct?</p> <p>11 A. Yes, ma'am.</p> <p>12 Q. You did not see them, right?</p> <p>13 A. No, ma'am. I did not.</p> <p>14 Q. Okay. And I believe you said this</p> <p>15 morning that you saw Mr. Rannazzisi's letter</p> <p>16 after the fact in passing, correct?</p> <p>17 MR. MIGLIORI: Objection. Misstates</p> <p>18 testimony.</p> <p>19 A. I believe that is exactly what I</p> <p>20 said.</p> <p>21 BY MS. MAINIGI:</p> <p>22 Q. Plaintiffs' counsel reviewed various</p> <p>23 passages from the Rannazzisi letters with you</p> <p>24 in detail, correct?</p> <p>25 A. Yes, ma'am. They did.</p>
<p style="text-align: right;">Page 502</p> <p>1 be speculation. I was only answering the</p> <p>2 question as it was directed to me.</p> <p>3 BY MS. MAINIGI:</p> <p>4 Q. Well, you were asked -- do you</p> <p>5 recall being asked questions, Mr. Wright, about</p> <p>6 what may have been discussed with the</p> <p>7 registrants at the conference?</p> <p>8 A. Based upon the slides that -- that</p> <p>9 he showed.</p> <p>10 Q. Do you know if those slides got</p> <p>11 delivered at the conference?</p> <p>12 A. No, ma'am. Not specifically.</p> <p>13 Q. So you indicating -- you -- you</p> <p>14 reading the slides and telling the plaintiffs'</p> <p>15 counsel what you thought might have been said</p> <p>16 as a result of review of the slide deck, you</p> <p>17 have no idea whether that got communicated to</p> <p>18 the registrants, correct?</p> <p>19 A. Yes, ma'am. That's correct.</p> <p>20 Q. Okay. Now, the person that might</p> <p>21 know and might have some recollection of what</p> <p>22 got said by the DEA to the registrants at that</p> <p>23 September 11th, 2007 conference is Mr. Mapes,</p> <p>24 correct?</p> <p>25 A. Yes, ma'am.</p>	<p style="text-align: right;">Page 504</p> <p>1 Q. And they asked you if you agreed</p> <p>2 that you would have, in fact, said those things</p> <p>3 specifically to distributors in distributor</p> <p>4 briefings.</p> <p>5 Do you recall that?</p> <p>6 MR. MIGLIORI: Objection. Misstates</p> <p>7 the question and answer.</p> <p>8 THE WITNESS: Yes, ma'am.</p> <p>9 BY MS. MAINIGI:</p> <p>10 Q. But sitting here today, Mr. Wright,</p> <p>11 you can't possibly know whether you</p> <p>12 specifically said anything that was in</p> <p>13 Mr. Rannazzisi's letter, which you saw in</p> <p>14 passing after the fact, in the distributor</p> <p>15 briefings that you did for several years, could</p> <p>16 you?</p> <p>17 MR. BENNETT: Objection to form.</p> <p>18 BY MS. MAINIGI:</p> <p>19 Q. "Yes" or "no"?</p> <p>20 A. Then I need the question repeated,</p> <p>21 please.</p> <p>22 Q. Let me start over.</p> <p>23 A. Yes, ma'am.</p> <p>24 Q. Because I probably confused us both.</p> <p>25 I'm sorry.</p>

<p style="text-align: right;">Page 505</p> <p>1        You did the distributor briefings 2 for a number of years, right? 3        A. Yes, ma'am. 4        Q. And you had a very fulsome 5 PowerPoint deck that you utilized as the basis 6 for your briefing, correct? 7        A. Yes, ma'am. 8        Q. And then you also said things out 9 loud at the various briefings, I'm sure, 10 correct, that were not in your PowerPoint? 11       A. Yes, ma'am. 12       Q. Okay. But sitting here today, can 13 you tell me under oath and specifically what 14 you might have said out loud at those briefings 15 that was not necessarily contained in your 16 PowerPoint deck? 17       MR. MIGLIORI: Objection to form. 18       THE WITNESS: To some extent, yes. 19 Because I repeated them quite often. I -- I 20 made sure that they were conveyed to every 21 distributor or to everybody that -- that -- it 22 had to be emphasized. 23       BY MS. MAINIGI: 24       Q. When -- 25       A. I --</p>	<p style="text-align: right;">Page 507</p> <p>1       it. 2       MS. MAINIGI: There's -- there's the 3 machine right there. 4       MR. SHKOLNIK: I don't -- I don't 5 have one. I'm sorry. 6       MS. MCCLURE: I'm sure he'll pass it 7 over. You guys are friends. You're sharing. 8 Just pass it over. 9       BY MS. MAINIGI: 10       Q. Sitting here today, many, many years 11 later, Mr. Wright, unless it is specifically 12 reflected in your PowerPoint, you were at best 13 making an educated guess about what you 14 specifically said to distributors at the 15 distributor briefings, correct? 16       MR. MIGLIORI: Objection. Form. 17       MR. BENNETT: Objection. Form. 18       THE WITNESS: Yes. 19       BY MS. MAINIGI: 20       Q. And maybe after the next break we'll 21 come back and pull out some of the very 22 specific points from the letter you were asked 23 to -- to agree with. 24       MR. MIGLIORI: Is that a question? 25 Form.</p>
<p style="text-align: right;">Page 506</p> <p>1       Q. Go ahead. Finish. 2       A. To be a PowerPoint is just to convey 3 the -- the major concept. Anybody -- I don't 4 like using a PowerPoint to do my job for me. 5       Q. You certainly put into the 6 PowerPoint the stuff you thought was very 7 important, correct? 8       A. Critical. Yes, ma'am. 9       Q. Sitting here today, you can't 10 possibly tell me that you knew for sure that 11 some of the things that were in the Rannazzisi 12 letters were things that you specifically said 13 to all the distributors, can you? 14       MR. BENNETT: Objection. Form. 15       MR. MIGLIORI: Objection. Form. 16       THE WITNESS: Based upon this -- 17 this morning, what you're referring to, I 18 answered those questions when I was asked in 19 the context of this is what I saw in the 20 PowerPoint. That is how I answered those. 21       MR. SHKOLNIK: I'm sorry. Could 22 I've the question and answer read back. 23       MS. MAINIGI: You can do that on 24 your own time. 25       MR. SHKOLNIK: I just couldn't hear</p>	<p style="text-align: right;">Page 508</p> <p>1       BY MS. MAINIGI: 2       Q. Let's take a look at your 3 distributor briefing slides. I believe that 4 they're in your binder. Exhibit 10 -- oh, I'm 5 -- I apologize, Mr. Wright. They're Exhibit 6 10. 7       MR. SHKOLNIK: Can you make sure the 8 exhibits that have been marked are in front of 9 the witness for the last two days. 10       MS. MAINIGI: We -- we can do that. 11       THE WITNESS: Okay. Exhibit which 12 one? 13       MS. MAINIGI: It's Exhibit 10, sir. 14       THE WITNESS: Okay. 15       MS. MAINIGI: It's the -- it's -- 16 it's the -- one of the examples -- 17       THE WITNESS: Got it. 18       MS. MAINIGI: -- of the distributor 19 briefing. 20       BY MS. MAINIGI: 21       Q. By the way, do you recall -- you got 22 asked some questions about -- about Cardinal 23 this morning. 24       Do you recall testifying last week 25 that you did not actually attend the Cardinal</p>

<p style="text-align: right;">Page 509</p> <p>1 distributor briefing?</p> <p>2 A. To the best of my recollection, no.</p> <p>3 Q. And do you recall testifying last</p> <p>4 week that it was actually Mr. Mapes and Ms.</p> <p>5 Seeger that attended the Cardinal briefing?</p> <p>6 A. Yes, ma'am.</p> <p>7 Q. And so sitting here today, you do</p> <p>8 not know yourself what specifically got said</p> <p>9 outside of the PowerPoint by Mr. Mapes or Ms.</p> <p>10 Seeger at the Cardinal distributor briefing,</p> <p>11 correct?</p> <p>12 A. Correct.</p> <p>13 Q. Okay. Now, taking -- feel free to</p> <p>14 refer to the Internet pharmacy data PowerPoint</p> <p>15 that, as I understand it, you used for your</p> <p>16 distributor briefers.</p> <p>17 By the way, you also mentioned last</p> <p>18 week that the early distributor briefings Mr.</p> <p>19 Mapes took the lead on those, and you were an</p> <p>20 attendee.</p> <p>21 Do you recall that?</p> <p>22 A. I do.</p> <p>23 MR. SHKOLNIK: Objection to form.</p> <p>24 BY MS. MAINIGI:</p> <p>25 Q. Was it Mr. Mapes or you or both of</p>	<p style="text-align: right;">Page 511</p> <p>1 to answer. Otherwise, you can answer.</p> <p>2 THE WITNESS: Both.</p> <p>3 BY MS. MAINIGI:</p> <p>4 Q. You worked on both, and he worked on</p> <p>5 both?</p> <p>6 A. On the regulations and that</p> <p>7 discussion, we -- that was both. The -- yes,</p> <p>8 ma'am. Yes, ma'am. Because it -- the whole</p> <p>9 concept of the data -- what we were trying to</p> <p>10 get across. So yes.</p> <p>11 Q. Now, you mentioned something about</p> <p>12 red ink.</p> <p>13 That -- Do you mean that was the</p> <p>14 editing back and forth that naturally occurs?</p> <p>15 A. Yes, ma'am.</p> <p>16 Q. Okay.</p> <p>17 MR. BENNETT: Objection.</p> <p>18 You can answer.</p> <p>19 THE WITNESS: Yes, ma'am.</p> <p>20 MR. BENNETT: I don't want to get</p> <p>21 into the specifics of who was doing red ink or</p> <p>22 where they got advice or -- or the internal</p> <p>23 deliberative process as far as creating this.</p> <p>24 BY MS. MAINIGI:</p> <p>25 Q. Well, let me ask you this,</p>
<p style="text-align: right;">Page 510</p> <p>1 you that actually created the distributor</p> <p>2 briefing, the PowerPoint?</p> <p>3 MR. BENNETT: Objection to the</p> <p>4 extent it goes into internal deliberations.</p> <p>5 But you can answer if you know.</p> <p>6 THE WITNESS: The question again?</p> <p>7 BY MS. MAINIGI:</p> <p>8 Q. Do you recall, Mr. Wright, whether</p> <p>9 the Internet pharmacy data briefing that we</p> <p>10 have been referring to as the distributor</p> <p>11 briefing, whether you actually created this</p> <p>12 PowerPoint or whether Mr. Mapes created it or</p> <p>13 whether you did it jointly?</p> <p>14 A. Jointly.</p> <p>15 Q. Do you remember which pages you</p> <p>16 wrote versus Mr. Mapes?</p> <p>17 A. I remember a lot of red ink. No,</p> <p>18 ma'am.</p> <p>19 Q. Okay. Do you remember whether you</p> <p>20 specifically concentrated on the data examples</p> <p>21 and he concentrated on some of the DEA</p> <p>22 requirements?</p> <p>23 MR. BENNETT: Objection.</p> <p>24 To the extent that would require you</p> <p>25 to disclose internal deliberations, you're not</p>	<p style="text-align: right;">Page 512</p> <p>1 Mr. Wright.</p> <p>2 I don't want to get into those</p> <p>3 details either, but answer this question for me</p> <p>4 "yes" or "no": Do you even recall at this</p> <p>5 point any of the specifics about who edited</p> <p>6 what or what edits you might have made versus</p> <p>7 what edits Mr. Mapes may have been -- may have</p> <p>8 made, or is it just too long ago?</p> <p>9 A. No, ma'am. It's too long ago.</p> <p>10 Q. Okay. Now, I think you testified at</p> <p>11 the H.D. Smith trial that, for whatever reason,</p> <p>12 you deleted your e-mails prior to sometime in</p> <p>13 2010.</p> <p>14 Do you remember testifying to that</p> <p>15 effect?</p> <p>16 A. Yes, ma'am.</p> <p>17 Q. And your e-mails that were deleted</p> <p>18 prior to 2010 would have contained some of the</p> <p>19 back-and-forth red ink that we're talking</p> <p>20 about, right?</p> <p>21 MR. BENNETT: Objection. Form.</p> <p>22 MR. MIGLIORI: Objection. It's</p> <p>23 beyond the scope of prior examination.</p> <p>24 THE WITNESS: I doubt that those</p> <p>25 discussions would have been in those e-mails.</p>

<p style="text-align: right;">Page 513</p> <p>1 But yes, it would have deleted that.  2 BY MS. MAINIGI:  3 Q. Well, they were written discussions  4 or e-mails, right?  5 Red ink would be edits in writing?  6 A. No, ma'am. That would be us sitting  7 across from each other and slamming each other  8 and objecting and doing this. That was most of  9 my discussion with Mr. Mapes.  10 Q. Was just sitting across from him?  11 A. Yes, ma'am.  12 Q. Okay. And was there -- I think you  13 testified at the trial that there was some back  14 and forth about internal discussions in  15 particular about the do-not-ship requirement  16 that were in an e-mail that ultimately got  17 deleted.  18 Do you remember that?  19 A. Yes, ma'am.  20 Q. Okay. And those were internal  21 discussions about whether to -- how to  22 essentially approach the do-not-ship  23 requirement in conversations with distributors,  24 correct.  25 MR. BENNETT: Objection to the</p>	<p style="text-align: right;">Page 515</p> <p>1 question pending. Let's go back and look.  2 The question -- I'll ask the court  3 reporter to read back the question, please.  4 (The record was read as requested.)  5 MR. BENNETT: So I'm going to object  6 to the extent that this question calls for  7 disclosure of internal deliberations and would  8 object to him disclosing any other individuals  9 beyond himself or Mr. Mapes who was involved.  10 But I believe he can say if there were others  11 involved.  12 Do you understand the instruction?  13 THE WITNESS: I understand the  14 instruction.  15 And I'm rethinking the answer. I'm  16 trying to satisfy everybody.  17 Yes.  18 BY MS. MAINIGI:  19 Q. Can you identify those other  20 individuals besides Mr. Mapes?  21 MR. BENNETT: Objection. Internal  22 deliberative process, the individuals who were  23 involved.  24 I'm instructing you not to answer  25 that. I don't believe you are authorized to</p>
<p style="text-align: right;">Page 514</p> <p>1 extent you're asking about prior testimony, he  2 can answer. To the extent you're asking about  3 the contents of internal deliberations, the  4 witness is not authorized to answer that  5 question.  6 THE WITNESS: Yes.  7 BY MS. MAINIGI:  8 Q. And were those discussions just with  9 Mr. Mapes, or did they perhaps include  10 discussions with other folks at DEA?  11 MR. BENNETT: Objection. Same  12 instructions.  13 MR. SHKOLNIK: Just note my  14 objection here. Special Master Cohen was very  15 clear. Reserving time --  16 MS. MAINIGI: I'm sorry. There --  17 there is -- this --  18 MR. SHKOLNIK: No. Reserving time  19 was not meant to do a second deposition. And I  20 think maybe we should go to the special master  21 at the beginning -- when we take the break.  22 MS. MAINIGI: Okay.  23 THE WITNESS: And I apologize again.  24 Would you please repeat the question to me.  25 MS. MAINIGI: I'm not sure there's a</p>	<p style="text-align: right;">Page 516</p> <p>1 disclose that.  2 BY MS. MAINIGI:  3 Q. You were asked -- Mr. Migliori this  4 morning went through the Internet pharmacy data  5 deck with you page by page, practically,  6 correct?  7 A. He did cover quite a bit of the  8 content.  9 Q. And I -- I think he made note of the  10 fact, in fact, that he felt you and I had not  11 the spent enough time on the deck last week.  12 Do you remember that?  13 A. Yes, ma'am.  14 Q. Now, feel free to refer to the deck,  15 but do you recall anything from this deck about  16 the due diligence?  17 A. No, ma'am.  18 Q. Okay.  19 A. It's not mentioned. And it's in  20 that --  21 Q. Do you recall anything about --  22 A. -- terminology.  23 Q. Do you recall anything from this  24 deck about know your customer?  25 A. No, ma'am.</p>

<p style="text-align: right;">Page 517</p> <p>1 Q. But Mr. Migliori asked you a litany 2 of questions about what might have been in 3 these distributor briefings, very specific 4 questions.</p> <p>5 Do you remember that?</p> <p>6 A. Yes, ma'am.</p> <p>7 Q. And you seemed to readily agree with 8 each one of the questions he asked without even 9 looking at the deck that, yes, that was 10 contained in the distributor briefing.</p> <p>11 Do you remember that?</p> <p>12 A. Yes, ma'am.</p> <p>13 Q. Did you go back and look to see if 14 those were actually in the distributor 15 briefing?</p> <p>16 A. No, ma'am.</p> <p>17 Q. And now, sitting here today, you 18 can't recall specifically what you said even in 19 the briefings that you actually did do, right?</p> <p>20 A. I've some recollection of what I 21 said to -- let -- let me answer it this way: 22 The letters was -- and the questions I was 23 asked was consistent with the message that the 24 DEA was putting out at the time.</p> <p>25 Q. So your testimony is the general</p>	<p style="text-align: right;">Page 519</p> <p>1 Q. You don't remember what you 2 specifically said, do you?</p> <p>3 A. Yes, ma'am.</p> <p>4 MR. SHKOLNIK: Objection.</p> <p>5 THE WITNESS: To a certain --</p> <p>6 MR. SHKOLNIK: Was the prior 7 question withdrawn?</p> <p>8 THE WITNESS: Yes, ma'am. I have 9 some recollection.</p> <p>10 BY MS. MAINIGI:</p> <p>11 Q. Okay. What did you specifically 12 say?</p> <p>13 MR. MIGLIORI: Objection to form.</p> <p>14 THE WITNESS: Okay.</p> <p>15 BY MS. MAINIGI:</p> <p>16 Q. That was not in the Internet 17 briefing.</p> <p>18 A. Okay. "You must know your customer 19 on an inmate basis because that customer could 20 get you in trouble."</p> <p>21 And I can certainly guarantee that I 22 probably said that at every briefing.</p> <p>23 Q. The briefing that --</p> <p>24 A. And I know --</p> <p>25 Q. -- you did.</p>
<p style="text-align: right;">Page 518</p> <p>1 gist of what was in the Rannazzisi letters that 2 came after the distributor briefings would have 3 likely been contained in presentations to 4 distributors, right?</p> <p>5 A. Yes, ma'am.</p> <p>6 Q. Okay. But sitting here today, you 7 cannot recall for me specifically what you said 8 to distributors even in the briefings you 9 attended, correct?</p> <p>10 MR. BENNETT: Objection.</p> <p>11 MR. MIGLIORI: Objection. It's been 12 asked and answered four times.</p> <p>13 THE WITNESS: I'm -- I'm not 14 annoying you.</p> <p>15 May I've the question again. I -- I 16 -- I do apologize.</p> <p>17 (The record was read as requested.)</p> <p>18 MR. SHKOLNIK: Objection. Form.</p> <p>19 MR. MIGLIORI: Asked and answered.</p> <p>20 THE WITNESS: Can I have a short 21 recess?</p> <p>22 MS. MAINIGI: Not while the 23 question's pending.</p> <p>24 THE WITNESS: Ah, that's right.</p> <p>25 BY MS. MAINIGI:</p>	<p style="text-align: right;">Page 520</p> <p>1 A. Yes, ma'am.</p> <p>2 MR. MIGLIORI: Don't interrupt.</p> <p>3 THE WITNESS: And I know it's also 4 in the H.D. Smith testimony. And I've stated 5 it in there.</p> <p>6 But I -- the reason I know it is 7 because some people thought that I was -- they 8 didn't like the word "intimacy." I thought it 9 conveyed the extent of what you should do with 10 your -- with your customers.</p> <p>11 So in those things that I've 12 repeated, I have recollection of those.</p> <p>13 BY MS. MAINIGI:</p> <p>14 Q. Anything else --</p> <p>15 MR. BENNETT: Can --</p> <p>16 BY MS. MAINIGI:</p> <p>17 Q. -- that --</p> <p>18 MR. BENNETT: Counsel --</p> <p>19 MS. MAINIGI: Hang on.</p> <p>20 MR. BENNETT: Can we take a break?</p> <p>21 MS. MAINIGI: No. Not -- I'd like 22 to finish this line of questioning and then --</p> <p>23 MR. BENNETT: The witness has asked 24 for a break.</p> <p>25 MS. MAINIGI: I understand. But I</p>

<p style="text-align: right;">Page 521</p> <p>1 think it's very important that we finish this 2 line of questioning. 3 BY MS. MAINIGI: 4 Q. Mr. Wright, I will not keep you much 5 longer, and then I will let you take a break. 6 But do you recall anything else 7 specifically that you would have said at your 8 distributor briefing that's not in the deck? 9 A. The only other thing I can 10 specifically recall is that "Your customer can 11 ruin your business. Get to know them." 12 Q. Anything else? 13 A. That -- not specifically right now. 14 MS. MAINIGI: Okay. Thank you. We 15 can take a break. 16 MR. BENNETT: Thank you, Counsel. 17 THE VIDEOGRAPHER: We are going off 18 the record. 19 This is the end of Media Unit No. 4. 20 The time is 3:58. 21 (A short recess was taken.) 22 THE VIDEOGRAPHER: We are going back 23 on the record. 24 This is the start of Media Unit No. 25 5.</p>	<p style="text-align: right;">Page 523</p> <p>1 MR. SHKOLNIK: Object to the form. 2 MR. BENNETT: Objection. 3 THE WITNESS: I -- I'd have to 4 refresh. 5 BY MS. MAINIGI: 6 Q. Well, when you provided your trial 7 testimony in the H.D. Smith trial in 2011, 8 there was a judge right there, right? 9 A. Yes, ma'am. 10 Q. And he was listening to everything 11 you were saying, correct? 12 MR. BENNETT: Objection. 13 MR. MIGLIORI: Objection. 14 THE WITNESS: I hope so. 15 MR. SHKOLNIK: Don't assume. 16 BY MS. MAINIGI: 17 Q. And you never told the judge that 18 you wanted to change the any of your testimony 19 at that trial, did you? 20 MR. MIGLIORI: Objection. 21 MR. SHKOLNIK: Objection. Form. 22 THE WITNESS: No, ma'am. 23 BY MS. MAINIGI: 24 Q. And you understood that, as an 25 official of the DEA, the judge may rely on what</p>
<p style="text-align: right;">Page 522</p> <p>1 The time is 4:21. 2 You may proceed, Counsel. 3 BY MS. MAINIGI: 4 Q. Mr. Wright, you recall the trial 5 testimony you provided in 2011 relating to 6 H.D. Smith, correct? 7 A. I do. 8 Q. And you recall this morning 9 testifying about the do-not-ship requirement, 10 correct? 11 A. Yes, ma'am. 12 Q. And I think the questions that you 13 got asked by plaintiffs' counsel were very 14 specifically tied to the do-not-ship 15 requirement and any changes in statute or 16 regulation. 17 Do you remember that? 18 MR. MIGLIORI: Object. 19 THE WITNESS: Yes, ma'am. 20 BY MS. MAINIGI: 21 Q. Okay. But do you remember being 22 asked a question related to do-not-ship at 23 trial and you provided that testimony at trial 24 with a judge sitting right there in front of 25 you, right?</p>	<p style="text-align: right;">Page 524</p> <p>1 you testified to under oath at that trial, 2 correct? 3 A. Yes, ma'am. 4 Q. Okay. You testified at that 5 trial -- 6 MR. BENNETT: Counsel, do you have a 7 page and line? 8 BY MS. MAINIGI: 9 Q. -- Mr. Wright, that in 2006 and 2007 10 there was a significant change in DEA policy, 11 DEA guidance, and interpretation of the very 12 issues that are at stake in this litigation, 13 correct. 14 MR. SHKOLNIK: Objection to form. 15 And objection to use of the transcript in this 16 matter. 17 MR. BENNETT: And Counsel, can you 18 give me a page and line where you're reading, 19 please. 20 MS. MAINIGI: 382, 24. 21 BY MS. MAINIGI: 22 Q. Do you recall testifying about the 23 do-not-ship requirement? 24 MR. MIGLIORI: Same Objection. 25 THE WITNESS: Are you asking me did</p>

<p style="text-align: right;">Page 525</p> <p>1 I make that statement?</p> <p>2 BY MS. MAINIGI:</p> <p>3 Q. Yes.</p> <p>4 A. Oh, yes.</p> <p>5 Q. Okay. And you testified, at both</p> <p>6 your deposition and at your trial and last</p> <p>7 week, that there was, in fact, a change in DEA</p> <p>8 policy guidance and interpretation as it</p> <p>9 related to the do-not-ship requirement,</p> <p>10 correct?</p> <p>11 MR. SHKOLNIK: Objection. Asked and</p> <p>12 answered by counsel.</p> <p>13 MR. BENNETT: Objection. Form.</p> <p>14 THE WITNESS: Only in the sense</p> <p>15 of -- from it changing from excessive to</p> <p>16 suspicious. Excessive, it went out;</p> <p>17 Suspicious, it did not.</p> <p>18 BY MS. MAINIGI:</p> <p>19 Q. Okay. And to clarify for the jury</p> <p>20 what that means, what I think you are saying is</p> <p>21 that, when the Excessive Order Program existed,</p> <p>22 which was known by DEA, it was also known by</p> <p>23 DEA that registrants would ship orders out even</p> <p>24 if they were on the excessive order report,</p> <p>25 correct?</p>	<p style="text-align: right;">Page 527</p> <p>1 was enough of a change in policy that confusion</p> <p>2 was created among both distributors and DEA</p> <p>3 investigators, correct?</p> <p>4 MR. SHKOLNIK: Objection to form.</p> <p>5 And asked multiple times.</p> <p>6 THE WITNESS: Yes.</p> <p>7 BY MS. MAINIGI:</p> <p>8 Q. And, in fact, it is because of this</p> <p>9 change in apology that DEA personnel, such as</p> <p>10 yourself, began to conduct distributor</p> <p>11 briefings so that they could familiarize</p> <p>12 distributors with the new policy, right?</p> <p>13 A. Yes, ma'am.</p> <p>14 MS. MAINIGI: Let me give you</p> <p>15 Exhibit 48, Mr. Wright.</p> <p>16 (Deposition Exhibit 48 was marked</p> <p>17 for identification.)</p> <p>18 BY MS. MAINIGI:</p> <p>19 Q. Exhibit 48 is the opinion written by</p> <p>20 the judge in United States versus \$463,497.72</p> <p>21 in U.S. Currency from Best Bank Account dated</p> <p>22 March 30, 2012.</p> <p>23 Do you see that?</p> <p>24 A. Yes, ma'am.</p> <p>25 Q. You could -- have you ever reviewed</p>
<p style="text-align: right;">Page 526</p> <p>1 MR. SHKOLNIK: Objection to the</p> <p>2 form.</p> <p>3 MR. BENNETT: Objection to form.</p> <p>4 THE WITNESS: Yes, ma'am.</p> <p>5 BY MS. MAINIGI:</p> <p>6 Q. When the Suspicious Order Program</p> <p>7 came into existence during a several-year time</p> <p>8 period, what DEA said was "We no longer want</p> <p>9 you to ship out any orders that you don't</p> <p>10 resolve and that remain suspicious," correct?</p> <p>11 MR. SHKOLNIK: Objection to form.</p> <p>12 MR. BENNETT: Objection to form.</p> <p>13 BY MS. MAINIGI:</p> <p>14 Q. Is that correct?</p> <p>15 A. No, ma'am. We had -- we told them</p> <p>16 or stipulated what the suspicious order</p> <p>17 guideline was. And to make that decision based</p> <p>18 upon that. There was --</p> <p>19 Q. With the Suspicious Order Program,</p> <p>20 distributors were told to suspend shipments to</p> <p>21 customers if they identified orders as</p> <p>22 suspicious, correct?</p> <p>23 A. Yes, ma'am.</p> <p>24 Q. It was understood by you, as you've</p> <p>25 testified several times under oath, that that</p>	<p style="text-align: right;">Page 528</p> <p>1 this document before?</p> <p>2 A. Never seen it before.</p> <p>3 Q. Has anyone ever explained to you</p> <p>4 that the judge who took your testimony, who was</p> <p>5 sitting right up there where judges sit,</p> <p>6 absorbed your testimony and ultimately -- and</p> <p>7 absorbed other people's testimony and</p> <p>8 ultimately produced an opinion?</p> <p>9 MR. SHKOLNIK: Objection to form.</p> <p>10 THE WITNESS: Yes, ma'am. I mean</p> <p>11 nobody told me that. But I understand that's</p> <p>12 the process.</p> <p>13 BY MS. MAINIGI:</p> <p>14 Q. Do you remember -- did anyone ever</p> <p>15 tell you about what the outcome was in the</p> <p>16 H.D. Smith case?</p> <p>17 MR. BENNETT: Object to the extent</p> <p>18 that it's conversations with counsel.</p> <p>19 THE WITNESS: Quite frankly, no.</p> <p>20 BY MS. MAINIGI:</p> <p>21 Q. Did you ever wonder or ask anybody</p> <p>22 what happened?</p> <p>23 A. No. It was the worst day of my</p> <p>24 life.</p> <p>25 Q. The actual trial testimony was the</p>

<p style="text-align: right;">Page 529</p> <p>1 worst day of your life?</p> <p>2 A. The deposition.</p> <p>3 Q. How was the trial testimony? That</p> <p>4 was okay?</p> <p>5 A. It was better. But --</p> <p>6 Q. So you never asked what happened?</p> <p>7 MR. SHKOLNIK: Objection. Asked and</p> <p>8 answered.</p> <p>9 THE WITNESS: Most of the time I --</p> <p>10 I moved from one case to the -- to the next.</p> <p>11 This one was done, this is where I have to pick</p> <p>12 up. My workload was --</p> <p>13 BY MS. MAINIGI:</p> <p>14 Q. You --</p> <p>15 A. -- very contiguous.</p> <p>16 Q. If you take a look at page -- it's</p> <p>17 -- it's No. 6 at the bottom right.</p> <p>18 A. 6?</p> <p>19 Q. Yeah. At the -- it's perhaps not</p> <p>20 the 6th page, but 6 at the bottom right.</p> <p>21 And let me know when you're there.</p> <p>22 And I'm going to ask you to read to yourself</p> <p>23 the fourth paragraph down.</p> <p>24 And then when you're done with the</p> <p>25 fourth, please read the fifth paragraph, sir.</p>	<p style="text-align: right;">Page 531</p> <p>1 standard practice in the industry to file</p> <p>2 suspicious order reports while continuing to</p> <p>3 ship products and that practices had been</p> <p>4 approved by the DEA. Derrick testified that he</p> <p>5 knew that it was H.D. Smith's practice to</p> <p>6 routinely ship products after filing suspicious</p> <p>7 orders reports."</p> <p>8 BY MS. MAINIGI:</p> <p>9 Q. You never told the judge,</p> <p>10 Mr. Wright, did you, that what you testified to</p> <p>11 with respect to what the standard practice was</p> <p>12 that had been approved by the DEA -- you didn't</p> <p>13 agree with that testimony in any way, correct?</p> <p>14 MR. SHKOLNIK: Objection to form.</p> <p>15 MR. BENNETT: Objection.</p> <p>16 THE WITNESS: No, ma'am.</p> <p>17 BY MS. MAINIGI:</p> <p>18 Q. You never went back to the judge of</p> <p>19 your attorney in that case and say, "Oh, what I</p> <p>20 testified to in court I don't agree with any</p> <p>21 more," right?</p> <p>22 MR. SHKOLNIK: Objection to form.</p> <p>23 MR. BENNETT: Objection to any</p> <p>24 conversations he had with counsel.</p> <p>25 To the extent you went back to the</p>
<p style="text-align: right;">Page 530</p> <p>1 A. (Witness complied.)</p> <p>2 Q. Let me know when you're ready.</p> <p>3 A. I think I am.</p> <p>4 Q. So you see in this opinion that the</p> <p>5 judge who -- who wrote it, Judge Lawson,</p> <p>6 mentions your testimony, correct?</p> <p>7 A. Yes, ma'am.</p> <p>8 Q. And with respect to your test --</p> <p>9 now, he -- he -- he certainly covered the whole</p> <p>10 issue with your e-mails, right?</p> <p>11 A. He did.</p> <p>12 MR. SHKOLNIK: Objection.</p> <p>13 MR. BENNETT: Objection.</p> <p>14 You can answer.</p> <p>15 MR. SHKOLNIK: Form.</p> <p>16 BY MS. MAINIGI:</p> <p>17 Q. And then at the beginning of the</p> <p>18 fifth paragraph, could you read out loud what</p> <p>19 Judge Lawson said you testified to?</p> <p>20 A. The fifth paragraph.</p> <p>21 Q. Correct.</p> <p>22 MR. BENNETT: Objection.</p> <p>23 You can answer.</p> <p>24 THE WITNESS: "In all events Wright</p> <p>25 testified that the DEA was aware that it was a</p>	<p style="text-align: right;">Page 532</p> <p>1 judge, you can answer.</p> <p>2 BY MS. MAINIGI:</p> <p>3 Q. Did you ever go back to the judge,</p> <p>4 change your hem?</p> <p>5 MR. SHKOLNIK: Objection.</p> <p>6 THE WITNESS: No, ma'am.</p> <p>7 BY MS. MAINIGI:</p> <p>8 Q. Now, before your testimony in this</p> <p>9 matter -- in this, matter, Mr. Wright, you</p> <p>10 received from Mr. Migliori's firm about \$3,000?</p> <p>11 A. I'm sorry. I'm lost in this</p> <p>12 question.</p> <p>13 Q. Well, you're a consultant to -- to</p> <p>14 Summit County, right?</p> <p>15 A. Yes, ma'am.</p> <p>16 Q. And you're a consultant retained</p> <p>17 through the Motley Rice firm, right?</p> <p>18 A. Yes, ma'am.</p> <p>19 Q. And so, prior to your testimony in</p> <p>20 this matter, as a fact witness you have</p> <p>21 received \$3,000 or so from the Motley Rice</p> <p>22 firm, correct?</p> <p>23 MR. BENNETT: Objection.</p> <p>24 MR. MIGLIORI: Asked and answered.</p> <p>25 MR. BENNETT: And also you said "as</p>


1 a fact witness" or as a consultant? 2 MS. MAINIGI: He's testifying here 3 as a fact witness. 4 MR. BENNETT: Correct. 5 But I guess -- objection to form. 6 THE WITNESS: Yes, ma'am. 7 MR. MIGLIORI: As a fact -- 8 MS. MAINIGI: I'm going to go ahead 9 and pass the baton on to one of my colleagues. 10 Shall we go off the record? 11 THE VIDEOGRAPHER: We are going off 12 the record. 13 The time is 4:35. 14 (A short recess was taken.) 15 THE VIDEOGRAPHER: We are going back 16 on the record. 17 The time is 4:36. 18 You may proceed, Counsel. 19 MR. MIGLIORI: Just for a second. 20 Counsel, on the last question you 21 tried to leave it in -- with a question pending 22 that this witness is being paid as a fact 23 witness and knowing that's absolutely not the 24 case and completely inappropriate. 25 I want it to be very clear on this	Page 533 1 "Prior to your testimony in this matter as a 2 fact witness, you have received \$3,000 or so 3 from the Motley Rice firm, correct?" 4 And the impropriety of that is not 5 going to be left without me making a note that 6 that is not the -- however it's interpreted, 7 he's not being paid as a fact witness. He may 8 be a fact witness here. But he's not being 9 paid as a fact witness. 10 Thank you. 11 MR. EPPICH: Thank you. 12 EXAMINATION BY COUNSEL FOR MCKESSON CORPORATION 13 BY MR. EPPICH: 14 Q. Mr. Wright, my name is Chris Eppich. 15 I represent the McKesson defendants in this -- 16 in this litigation. 17 And I would like to return to some 18 testimony you provided about ARCOS. 19 Do you remember testifying about 20 ARCOS earlier today? 21 Do you remember testifying about 22 that? 23 A. No, but -- 24 Q. Not today? There's been a lot of 25 testimony today.	Page 535
1 record that my objection is it totally 2 misstates the record. And it is not true, nor 3 is it consistent with his prior testimony. 4 After all the objections, this 5 record may reflect to the contrary. And I want 6 it to be very clear. He's not be paid as a 7 fact witness by my firm or by any firm. 8 MS. MAINIGI: I believe the 9 questioning reflected, Mr. Migliori, that he 10 was paid for consulting services -- 11 MR. MIGLIORI: That's not what the 12 question says on the realtime. 13 MS. MAINIGI: -- prior to being a 14 fact witness in -- 15 MR. MIGLIORI: I'll -- I'll read -- 16 MS. MAINIGI: Well, we'll go -- 17 we'll -- you know what? 18 MR. MIGLIORI: No, no. I'll read 19 it. 20 MS. MAINIGI: We'll go back and 21 look. 22 MR. MIGLIORI: Because it's very 23 important. 24 MS. MAINIGI: Well, I -- I don't -- 25 MR. MIGLIORI: It says -- it says:	Page 534 1 You testified earlier that you first 2 started to analyze ARCOS data beginning around 3 2005; isn't that correct? 4 MR. BENNETT: Objection. 5 THE WITNESS: Yes, sir. 6 BY MR. EPPICH: 7 Q. And that -- that's when you began 8 working on the distributor initiative? 9 A. Yes, sir. 10 Q. And I guess in 2010 you became 11 what's known as a unit chief of the targeting 12 and analytics unit? 13 A. Analysis. 14 Q. Analysis unit. 15 And in that position you were 16 responsible for the analysis of ARCOS data, 17 correct? 18 A. Correct. 19 Q. And that means you're -- you're 20 actually in charge -- you're in charge of that 21 unit that was responsible for analyzing ARCOS 22 data; is that right? 23 A. Correct. 24 Q. So you and your team or the unit at 25 DEA that -- were tasked with taking all the	Page 536

<p style="text-align: right;">Page 537</p> <p>1 data provided by distributors, by 2 manufacturers, and -- and you were using it 3 to -- to combat diversion. 4 Do I have that right? 5 MR. MIGLIORI: Objection. Misstates 6 testimony. 7 THE WITNESS: Yes, sir. 8 BY MR. EPPICH: 9 Q. Now, you -- you've testified that 10 manufacturers and distributors, they report all 11 of their acquisitions, their dispositions, the 12 inventories of controlled substances into 13 ARCOS; is that right? 14 A. Who? 15 Q. Manufacturers and distributors? 16 A. Yes, sir. 17 Q. And manufacturers and distributors 18 have been submitting this data into ARCOS since 19 you joined with DEA in 1995; isn't that right? 20 A. Correct, sir. 21 Q. And the controlled substances, they 22 were reported in this ARCOS data, and those 23 controlled substances included data on 24 Hydrocodone, oxycodone, fentanyl, other 25 opioids.</p>	<p style="text-align: right;">Page 539</p> <p>1 THE WITNESS: Okay. And after that, 2 can you tell me what you asked? 3 BY MR. EPPICH: 4 Q. I can. 5 Using ARCOS, DEA can generate 6 statistical reports showing drug distribution 7 in grams and dosage units. 8 A. Correct. 9 Q. Now, you've -- you've provided 10 trainings on these statistical reports in the 11 past, haven't you? 12 A. Correct. 13 MR. EPPICH: I'd like to mark as 14 Exhibit No. 49 presentation titled "ARCOS 15 Automation of Reports and Consolidated Order 16 Systems." 17 (Deposition Exhibit 49 was marked 18 for identification.) 19 MR. MIGLIORI: I'm going to object 20 to the question as outside the scope of the 21 direct. 22 BY MR. EPPICH: 23 Q. Now, Mr. Wright, you've seen Exhibit 24 49 before, haven't you? 25 A. I'm looking at it.</p>
<p style="text-align: right;">Page 538</p> <p>1 Do I have that right? 2 A. You have it right. 3 Q. So this -- this ARCOS system, it's a 4 -- it's a robust system, isn't it? 5 MR. BENNETT: Objection to form. 6 BY MR. EPPICH: 7 Q. It has a lot of data in it, doesn't 8 it? 9 MR. SHKOLNIK: Objection to form. 10 THE WITNESS: Yes, sir. 11 BY MR. EPPICH: 12 Q. ARCOS tells you how many pills a 13 manufacturer makes, right? 14 A. How many they sell, yes. 15 Q. How many they sell. 16 ARCOS tells you how many pills have 17 been distributed by a distributor to a 18 pharmacy, doesn't it? 19 A. Correct. 20 Q. And using ARCOS, DEA can generate 21 statistical reports showing drug distributions 22 in grams and in dosage units. 23 They can do that, right? 24 MR. BENNETT: You can answer that 25 question.</p>	<p style="text-align: right;">Page 540</p> <p>1 Q. Do you see your name on the second 2 page of the document? 3 A. It does. 4 Q. And do you recall presenting this -- 5 A. Can I have a moment -- you -- 6 Q. Absolutely. 7 A. Thank you. 8 MR. MIGLIORI: I'm going to repeat 9 my objections. This is beyond the scope. 10 MR. EPPICH: Mr. Bennett, I'll 11 represent to you that this presentation's found 12 on the DEA diversion web site. 13 MR. BENNETT: That's very helpful. 14 Thank you. 15 MR. SHKOLNIK: It was not covered or 16 this topic covered at all on either mine or -- 17 MR. EPPICH: I think you'll see, 18 sir, that the topic was covered. We'll get 19 into that. 20 BY MR. EPPICH: 21 Q. Mr. Wright why don't we go ahead 22 and -- 23 MR. BENNETT: He's still looking, 24 Counsel. Give him a moment, please. 25 MR. EPPICH: I've only got 14.</p>

<p style="text-align: right;">Page 541</p> <p>1       THE WITNESS: Okay.</p> <p>2       BY MR. EPPICH:</p> <p>3       Q. Now, Mr. Wright, do you remember</p> <p>4 giving this presentation in June of 2011 at a</p> <p>5 conference in Fort Worth, Texas?</p> <p>6       Why don't we go ahead and turn to</p> <p>7 page 20. I'll help you out.</p> <p>8       A. Thank you.</p> <p>9       Q. The page is in the bottom-right</p> <p>10 corner.</p> <p>11       And I just want to quickly point out</p> <p>12 to the -- point you to this page.</p> <p>13       Slide 24 is a chart showing the</p> <p>14 purchases of hydrocodone by one pharmacy in</p> <p>15 Texas, isn't it -- excuse me. Yes. On</p> <p>16 slide --</p> <p>17       A. Are you on Page 20?</p> <p>18       Q. I'm going to be on page -- I'm on</p> <p>19 slide -- I'm sorry. You'll have to forgive</p> <p>20 me -- Slide 20.</p> <p>21       A. Okay.</p> <p>22       Q. And slide 20 is a chart showing the</p> <p>23 purchases of Hydrocodone, looks like Arkansas,</p> <p>24 by ZIP code in 2008, isn't it?</p> <p>25       MR. BENNETT: Objection.</p>	<p style="text-align: right;">Page 543</p> <p>1 to show the number of dosage units supplied by</p> <p>2 each distributor to a single pharmacy; isn't</p> <p>3 that true?</p> <p>4       MR. SHKOLNIK: Objection to form.</p> <p>5 And outside the scope.</p> <p>6       THE WITNESS: Yes, sir.</p> <p>7       BY MR. EPPICH:</p> <p>8       Q. Now, you've been able to generate</p> <p>9 these types of reports using ARCOS since at</p> <p>10 least 2005, correct?</p> <p>11       A. Yes, sir.</p> <p>12       Q. And in -- in 2005, when you were</p> <p>13 preparing for distributors briefings, you were</p> <p>14 using these ARCOS reporting tools to identify</p> <p>15 pharmacies having extraordinarily large</p> <p>16 prescriptions of narcotics, weren't you?</p> <p>17       MR. SHKOLNIK: Objection to form.</p> <p>18       THE WITNESS: I'm sorry. I lost</p> <p>19 the -- the last part of your question. Can you</p> <p>20 repeat that, please.</p> <p>21       Q. Let me -- let me try it again.</p> <p>22       A. Thank you, sir.</p> <p>23       Q. In -- when you were preparing for</p> <p>24 the distributor briefings --</p> <p>25       A. Yes, sir.</p>
<p style="text-align: right;">Page 542</p> <p>1       THE WITNESS: I don't know if it's</p> <p>2 Arkansas. But it looks like a state because --</p> <p>3       BY MR. EPPICH:</p> <p>4       Q. The -- the -- but the point is is</p> <p>5 ARCOS reports -- ARCOS reports can be generated</p> <p>6 to show counties having an above-average</p> <p>7 distribution of controlled substances as</p> <p>8 compared to other counties in the state and the</p> <p>9 national average; isn't that true?</p> <p>10       A. Counties --</p> <p>11       MR. SHKOLNIK: Objection. Outside</p> <p>12 the scope.</p> <p>13       THE WITNESS: You -- your question</p> <p>14 is counties in comparison to other counties</p> <p>15 within a state?</p> <p>16       MR. EPPICH: Yes, sir.</p> <p>17       THE WITNESS: Yes.</p> <p>18       BY MR. EPPICH:</p> <p>19       Q. And ARCOS reports can be generated</p> <p>20 to show the number of dosage units dispensed by</p> <p>21 a single pharmacy and compared that -- compare</p> <p>22 that to average pharmacy purchases in the state</p> <p>23 and across the United States; isn't that true?</p> <p>24       A. Yes, it can.</p> <p>25       Q. And ARCOS reports can be generated</p>	<p style="text-align: right;">Page 544</p> <p>1       Q. -- you were using these ARCOS</p> <p>2 reporting tools to identify pharmacies having</p> <p>3 extraordinarily large prescriptions in</p> <p>4 narcotics, and you present that data to the</p> <p>5 distributors, correct?</p> <p>6       A. Yes, sir.</p> <p>7       Q. You didn't -- you didn't need</p> <p>8 distributors' suspicious order reports to do</p> <p>9 that analysis, did you?</p> <p>10       MR. MIGLIORI: Objection. Scope.</p> <p>11       THE WITNESS: No, sir.</p> <p>12       BY MR. EPPICH:</p> <p>13       Q. Now, while you were in the targeting</p> <p>14 and analysis group, one of your</p> <p>15 responsibilities was to analyze the trends of</p> <p>16 controlled substances -- excuse me --</p> <p>17 controlled substance distributions on national,</p> <p>18 state and local levels, correct?</p> <p>19       A. It was one of our functions. I</p> <p>20 don't know if it was a defined responsibility.</p> <p>21       Q. It was one of your functions.</p> <p>22       How were you and your staff using</p> <p>23 ARCOS to conduct and analyze trends of</p> <p>24 controlled substance distributions on a</p> <p>25 national, state and local level, just -- just</p>

<p>1 generally?</p> <p>2 MR. SHKOLNIK: Outside the scope.</p> <p>3 MR. MIGLIORI: Objection to form.</p> <p>4 THE WITNESS: I'd say that the</p> <p>5 easiest answer to that is public reports 1</p> <p>6 through 7.</p> <p>7 BY MR. EPPICH:</p> <p>8 Q. And other than your public reports,</p> <p>9 how were you using ARCOS data to analyze trends</p> <p>10 of controlled substance distributions?</p> <p>11 MR. BENNETT: Objection.</p> <p>12 So you're not --</p> <p>13 MR. MIGLIORI: Same objection.</p> <p>14 MR. BENNETT: You're not authorized</p> <p>15 to --</p> <p>16 MR. SHKOLNIK: Objection. Scope.</p> <p>17 MR. BENNETT: -- discuss specific</p> <p>18 cases on how you used it or confidential law</p> <p>19 enforcement technique. But to the extent you</p> <p>20 can answer generally, you may answer.</p> <p>21 THE WITNESS: My responsibility was</p> <p>22 to provide information to either division --</p> <p>23 first off, the front office and anything that</p> <p>24 they needed, and then to division or regional</p> <p>25 offices or specific offices. They'd send me a</p>	<p>Page 545</p> <p>1 MR. BENNETT: You can answer</p> <p>2 generally.</p> <p>3 THE WITNESS: Yes. Yes. We were</p> <p>4 seeing if -- if there was something, you know,</p> <p>5 grievously outrageous that required further</p> <p>6 attention. Not that we did anything</p> <p>7 specifically with it except for send it out to</p> <p>8 the field office of responsibility.</p> <p>9 BY MR. EPPICH:</p> <p>10 Q. So your testimony is that, when you</p> <p>11 found a suspicious pharmacy or the</p> <p>12 identification of a suspicious pharmacy, you</p> <p>13 would identify that pharmacy to the field</p> <p>14 office; is that correct?</p> <p>15 MR. BENNETT: Objection. Regarding</p> <p>16 what the specific internal practice is with</p> <p>17 individual pharmacies, I'm going to instruct</p> <p>18 the witness he's not authorized at this time to</p> <p>19 answer that. Goes beyond the scope of his</p> <p>20 authorization.</p> <p>21 BY MR. EPPICH:</p> <p>22 Q. In general, when you identified a</p> <p>23 suspicious pharmacy, did you identify that</p> <p>24 pharmacy to the relevant DEA field office?</p> <p>25 MR. BENNETT: Objection.</p>
<p>1 request, and we'd -- depending on whether it</p> <p>2 was an actual case or whether it was just</p> <p>3 background information, we would provide it.</p> <p>4 BY MR. EPPICH:</p> <p>5 Q. Were you ever trying to identify</p> <p>6 pharmacies with order volumes or patterns</p> <p>7 suggesting diversion activity?</p> <p>8 MR. BENNETT: Objection. You're not</p> <p>9 authorized to discuss specific efforts or</p> <p>10 specific techniques.</p> <p>11 THE WITNESS: Yes.</p> <p>12 BY MR. EPPICH:</p> <p>13 Q. Were you using ARCOS to try to</p> <p>14 identify red flags?</p> <p>15 MR. BENNETT: Objection.</p> <p>16 Same instruction.</p> <p>17 THE WITNESS: No.</p> <p>18 BY MR. EPPICH:</p> <p>19 Q. Were you able to identify any</p> <p>20 suspicious pharmacies from your work?</p> <p>21 MR. BENNETT: Objection.</p> <p>22 BY MR. EPPICH:</p> <p>23 Q. Just generally.</p> <p>24 MR. MIGLIORI: Objection. Scope.</p> <p>25 Just generally.</p>	<p>Page 546</p> <p>1 Same instruction. He's not to</p> <p>2 answer that as far as what they did with</p> <p>3 individual pharmacies.</p> <p>4 BY MR. EPPICH:</p> <p>5 Q. In general, what did you do when</p> <p>6 you -- when you learned about a suspicious</p> <p>7 pharmacy?</p> <p>8 MR. BENNETT: Objection.</p> <p>9 BY MR. EPPICH:</p> <p>10 Q. -- from -- from review of the data?</p> <p>11 MR. BENNETT: Objection. He's not</p> <p>12 authorized to answer what the DEA did</p> <p>13 individually in cases internally.</p> <p>14 BY MR. EPPICH:</p> <p>15 Q. Did the DEA shut down the pharmacies</p> <p>16 that you identified?</p> <p>17 MR. BENNETT: Objection.</p> <p>18 MR. SHKOLNIK: Objection. Outside</p> <p>19 the scope.</p> <p>20 MR. BENNETT: And objection. He's</p> <p>21 not authorized to talk about specific cases.</p> <p>22 BY MR. EPPICH:</p> <p>23 Q. Was it your general practice to</p> <p>24 refer the suspicious pharmacies you identified</p> <p>25 through ARCOS to a field office so the field</p>

<p style="text-align: right;">Page 549</p> <p>1 office could shut down that pharmacy?</p> <p>2 MR. BENNETT: Objection. Beyond the</p> <p>3 scope of his authorization. He can't answer</p> <p>4 that.</p> <p>5 MR. SHKOLNIK: And outside the scope</p> <p>6 of examination.</p> <p>7 BY MR. EPPICH:</p> <p>8 Q. What did you do with the</p> <p>9 identification of the suspicious pharmacy after</p> <p>10 you identified it through the ARCOS data?</p> <p>11 MR. BENNETT: Objection. He can't</p> <p>12 answer that. It's outside the scope of his</p> <p>13 authorization.</p> <p>14 BY MR. EPPICH:</p> <p>15 Q. Would you ever follow up with a</p> <p>16 field office to determine whether or not they</p> <p>17 had taken action in response to any</p> <p>18 instructions or guidance or information that</p> <p>19 you'd provide them?</p> <p>20 MR. BENNETT: Objection. He -- he's</p> <p>21 not authorized to answer about specific</p> <p>22 enforcement actions that he took.</p> <p>23 MR. SHKOLNIK: And -- and for the</p> <p>24 record, these were all nice areas to go into on</p> <p>25 the main part of your deposition, not as</p>	<p style="text-align: right;">Page 551</p> <p>1 MR. BENNETT: Counsel, we have about</p> <p>2 five minutes until 5:00.</p> <p>3 MR. EPPICH: Thank you.</p> <p>4 I'd like to mark Exhibit 51.</p> <p>5 This is an e-mail that you received</p> <p>6 from Don Walker on August 14, 2008.</p> <p>7 Notification of suspicious customer, and your</p> <p>8 response on top.</p> <p>9 (Deposition Exhibit 51 was marked</p> <p>10 for identification.)</p> <p>11 BY MR. EPPICH:</p> <p>12 Q. Now, Mr. Wright, in 2008 you're</p> <p>13 familiar with the practice of distributors of</p> <p>14 identifying the names of what they've</p> <p>15 determined to be a suspicious customer after</p> <p>16 they've performed due diligence.</p> <p>17 You're aware of that practice,</p> <p>18 aren't you?</p> <p>19 A. Yes, sir.</p> <p>20 Q. In this e-mail from Mr. Don Walker</p> <p>21 on August 14, 2008, he's identification a</p> <p>22 suspicious customer to you, isn't he?</p> <p>23 A. Yes, sir.</p> <p>24 MR. SHKOLNIK: Objection. Outside</p> <p>25 the scope.</p>
<p style="text-align: right;">Page 550</p> <p>1 reserved for a second deposition. Outside the</p> <p>2 scope.</p> <p>3 MR. EPPICH: Thank you.</p> <p>4 MR. STEPHENS: And for</p> <p>5 clarification, are you instructing him not to</p> <p>6 answer those questions?</p> <p>7 MR. BENNETT: I am indicating that</p> <p>8 he's not authorized to disclose DEA information</p> <p>9 in response to those questions. So he doesn't</p> <p>10 have authorization to answer them.</p> <p>11 BY MR. EPPICH:</p> <p>12 Q. After identifying a suspicious</p> <p>13 pharmacy is in the ARCOS data, did you ever</p> <p>14 inform distributors of the identification of</p> <p>15 that pharmacy?</p> <p>16 MR. SHKOLNIK: Objection. Outside</p> <p>17 the scope of direct.</p> <p>18 MR. BENNETT: Objection to the</p> <p>19 extent that that talks about specific cases.</p> <p>20 However, you can otherwise answer</p> <p>21 that question about information you may have</p> <p>22 provided to distributors about suspicious</p> <p>23 pharmacies as long as it wasn't any specific</p> <p>24 case that was worked.</p> <p>25 THE WITNESS: No.</p>	<p style="text-align: right;">Page 552</p> <p>1 BY MR. EPPICH:</p> <p>2 Q. He's identifying the registrant</p> <p>3 Advanced Doctors Prescription Pharmacy in San</p> <p>4 Antonio, Texas.</p> <p>5 Do you see that?</p> <p>6 A. Yes, sir.</p> <p>7 Q. And you respond: "This is to</p> <p>8 acknowledge receipt of your e-mail. It is</p> <p>9 appreciated if you would continue to provide</p> <p>10 any and all information you have or discover to</p> <p>11 the local DEA office in San Antonio."</p> <p>12 Do you see that?</p> <p>13 A. Yes, sir.</p> <p>14 Q. Now, do you know -- do you know,</p> <p>15 just generally, what the DEA would do with the</p> <p>16 identification of suspicious customers as</p> <p>17 received from distributors during this time?</p> <p>18 MR. BENNETT: Objection. He's not</p> <p>19 authorized to respond to what he's done in</p> <p>20 specific cases internally within the DEA.</p> <p>21 MR. SHKOLNIK: And outside the</p> <p>22 scope.</p> <p>23 BY MR. EPPICH:</p> <p>24 Q. You may answer.</p> <p>25 MR. BENNETT: No. He may not answer</p>

<p style="text-align: right;">Page 553</p> <p>1 what DEA would do with the suspicious order -- 2 this suspicious order. 3 BY MR. EPPICH: 4 Q. Do you recall passing along these 5 suspicious orders to the relevant field 6 offices? 7 MR. BENNETT: Objection. He's not 8 authorized to answer about specific actions 9 taken internally by the DEA in response to this 10 suspicious order report. 11 BY MR. EPPICH: 12 Q. Are you aware that last month the 13 DEA launched a new tool in ARCOS online 14 reporting systems that would allow distributors 15 to view and download the number of distributors 16 and the amount each distributor sold to 17 perspective customers in the last six months? 18 Are you aware of that? 19 MR. SHKOLNIK: Objection. Outside 20 the scope. 21 You asked for an extra two and a 22 half hours of deposition time, and you're just 23 doing a new deposition and not addressing 24 anything we covered. 25 MR. TAYMAN: And you have less than</p>	<p style="text-align: right;">Page 555</p> <p>1 MR. EPPICH: Let's go off the 2 record. 3 THE VIDEOGRAPHER: We are going off 4 the record. 5 The time is 4:58. 6 (A short recess was taken.) 7 THE VIDEOGRAPHER: We are off the 8 record at 5:01 p.m. 9 And This concludes today's testimony 10 given by Kyle Wright. 11 The total number of media units used 12 was five and will be retained by Veritext Legal 13 Solutions. 14 (Whereupon, the proceeding was 15 adjourned at 5:01 p.m.) 16 17 18 19 20 21 22 23 24 25</p>
<p style="text-align: right;">Page 554</p> <p>1 two minutes. 2 MR. BENNETT: And I would join the 3 objection of it being outside the scope of the 4 plaintiffs' cross-examination. 5 THE WITNESS: You -- you said in the 6 last six months? 7 MR. EPPICH: Yes, sir. 8 THE WITNESS: I haven't worked in 9 two years. So I have no idea. 10 BY MR. EPPICH: 11 Q. But DEA, up until 2018, did not 12 permit other distributors to see the ARCOS data 13 so that they could determine how much of a 14 single -- of -- of a controlled 15 substance was being shipped into a pharmacy by 16 another distributor; isn't that correct? 17 MR. SHKOLNIK: Objection. Outside 18 the scope. A waste of your two and a half 19 hours. 20 MR. BENNETT: Objection. 21 MR. EPPICH: I've heard your 22 objection. Thank you. 23 MR. BENNETT: Object to form and 24 also being outside the scope. 25 THE WITNESS: Yes, sir.</p>	<p style="text-align: right;">Page 556</p> <p>1 CERTIFICATE OF NOTARY PUBLIC 2 I, Bonnie L. Russo, the officer before 3 whom the foregoing deposition was taken, do 4 here by certify that the witness whose 5 testimony appears in the foregoing deposition 6 was duly sworn by me; that the testimony of 7 said witness was taken by me in shorthand and 8 thereafter reduced to computerized 9 transcription under my direction; that said 10 deposition is a true record of the testimony 11 given by said witness; that I am neither 12 counsel for, related to, nor employed by any of 13 the parties to the action in which this 14 deposition was taken; and further, that I am 15 not a relative or employee of any attorney or 16 counsel employed by the parties hereto, nor 17 financially or otherwise interested in the 18 outcome of the action. 19 20  21 Notary Public in and for 22 the District of Columbia 23 24 My Commission expires: June 30, 2020 25</p>

<p style="text-align: right;">Page 557</p> <p>1                   Veritext Legal Solutions 1100 Superior Ave 2                   Suite 1820 Cleveland, Ohio 44114 3                   Phone: 216-523-1313 4</p> <p>5                   March 7, 2019</p> <p>6                   To: David Lee Tayman</p> <p>7                   Case Name: In Re: National Prescription Opiate Litigation v.</p> <p>8                   Veritext Reference Number: 3249543</p> <p>9                   Witness: Kyle Wright, Vol II      Deposition Date: 3/4/2019</p> <p>10                  Dear Sir/Madam:</p> <p>11                  Enclosed please find a deposition transcript. Please have the witness 12                  review the transcript and note any changes or corrections on the 13                  included errata sheet, indicating the page, line number, change, and 14                  the reason for the change. Have the witness' signature notarized and 15                  forward the completed page(s) back to us at the Production address 16                  shown 17                  above, or email to production-midwest@veritext.com.</p> <p>18                  If the errata is not returned within thirty days of your receipt of 19                  this letter, the reading and signing will be deemed waived.</p> <p>20                  Sincerely, 21                  Production Department 22</p> <p>23</p> <p>24</p> <p>25                  NO NOTARY REQUIRED IN CA</p>	<p style="text-align: right;">Page 559</p> <p>1                   DEPOSITION REVIEW CERTIFICATION OF WITNESS</p> <p>2                   ASSIGNMENT REFERENCE NO: 3249543</p> <p>3                   CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 3/4/2019</p> <p>4                   WITNESS' NAME: Kyle Wright, Vol II</p> <p>5                   In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me.</p> <p>7                   I have made no changes to the testimony as transcribed by the court reporter.</p> <p>8</p> <p>9                   Date                   Kyle Wright, Vol II</p> <p>10                  Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that:</p> <p>12                  They have read the transcript; 13                  They signed the foregoing Sworn Statement; and 14                  Their execution of this Statement is of their free act and deed.</p> <p>15                  I have affixed my name and official seal</p> <p>16                  this _____ day of _____, 20 _____. 17</p> <p>18                  Notary Public _____</p> <p>19                  Commission Expiration Date _____</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>
<p style="text-align: right;">Page 558</p> <p>1                   DEPOSITION REVIEW CERTIFICATION OF WITNESS</p> <p>2                   ASSIGNMENT REFERENCE NO: 3249543</p> <p>3                   CASE NAME: In Re: National Prescription Opiate Litigation v. DATE OF DEPOSITION: 3/4/2019</p> <p>4                   WITNESS' NAME: Kyle Wright, Vol II</p> <p>5                   In accordance with the Rules of Civil Procedure, I have read the entire transcript of 6 my testimony or it has been read to me.</p> <p>7                   I have made no changes to the testimony as transcribed by the court reporter.</p> <p>8</p> <p>9                   Date                   Kyle Wright, Vol II</p> <p>10                  Sworn to and subscribed before me, a Notary Public in and for the State and County, 11 the referenced witness did personally appear and acknowledge that:</p> <p>12                  They have read the transcript; 13                  They signed the foregoing Sworn Statement; and 14                  Their execution of this Statement is of their free act and deed.</p> <p>15                  I have affixed my name and official seal</p> <p>16                  this _____ day of _____, 20 _____. 17</p> <p>18                  Notary Public _____</p> <p>19                  Commission Expiration Date _____</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 560</p> <p>1                   ERRATA SHEET VERITEXT LEGAL SOLUTIONS MIDWEST</p> <p>2                   ASSIGNMENT NO: 3/4/2019</p> <p>3                   PAGE/LINE(S) /      CHANGE      /REASON</p> <p>4                   _____ 5                   _____ 6                   _____ 7                   _____ 8                   _____ 9                   _____ 10                  _____ 11                  _____ 12                  _____ 13                  _____ 14                  _____ 15                  _____ 16                  _____ 17                  _____ 18                  _____ 19                  _____ 20                  Date                   Kyle Wright, Vol II</p> <p>21                  SUBSCRIBED AND SWORN TO BEFORE ME THIS _____ 22                  DAY OF _____, 20 _____. 23                  _____ 24                  Notary Public _____</p> <p>25                  Commission Expiration Date _____</p>

&	1	499:21 500:17	422:6,17 427:17
& 269:7 270:22 271:7,8 272:3,9 273:9,14,19 274:3 274:8,13	1 278:6 341:6 363:10 387:12 417:6 459:15 467:19 545:5	13 452:13 <b>1301.74</b> 277:17 285:23 343:10 344:13 405:3	<b>1995</b> 279:7 280:3 282:12 301:22 303:12 311:15 329:25 332:8
0	1,500 408:18	407:15 431:5 452:19	340:23,25 346:3 347:25 350:6
<b>00002032-2045</b>	1.2 460:17 467:19	<b>1301.74.</b> 404:24	351:8 354:11
276:23	10 295:7,17,19	<b>13th</b> 386:20	355:9 364:2 369:7
<b>00005987-6045</b>	309:2 363:3 391:5	<b>14</b> 380:7,9 499:15	374:20 377:4,25
277:6	438:7,21 499:15	499:20,24 540:25	379:12 380:3
<b>000088-89</b> 277:24	499:20,24 508:4,6	551:6,21	381:7 382:14
<b>000454261-320</b>	508:13	<b>15</b> 374:25 376:8	487:9 537:19
276:16	<b>10-16-07</b> 276:16	380:8,9 392:20	<b>1996</b> 429:16 432:9
<b>001</b> 276:16	<b>1000</b> 272:16	456:21	434:15
<b>00622468</b> 356:18	<b>10017</b> 270:14	<b>150</b> 453:17	<b>1999</b> 273:15
362:17	<b>10036</b> 271:4	<b>15219</b> 274:14	<b>1:08</b> 454:25
<b>00622468-472</b>	<b>1095</b> 271:4	<b>16</b> 276:13 364:20	<b>2</b>
276:13	<b>10:23</b> 341:7	364:25 365:23	2 280:19 281:3
<b>00837645-648</b>	<b>10:42</b> 341:13	<b>1600</b> 272:3	288:15,17,17
276:9	<b>10th</b> 295:23	<b>16th</b> 356:24	341:12 382:22
<b>00988458-472</b>	<b>11</b> 274:9 376:8	17 268:6,10 276:13	389:2 470:13
276:18	392:2 402:1 453:9	393:11	<b>20</b> 393:18 490:23
<b>01053067-068</b>	500:4	<b>1717</b> 272:22	541:7,17,20,22
276:11	<b>1100</b> 271:13 557:1	<b>1755</b> 271:18	558:16 559:22
<b>01465723</b> 415:20	<b>11937</b> 556:20	<b>17th</b> 271:9 356:24	560:22
<b>01465723-734</b>	<b>11:31</b> 382:23	<b>18</b> 268:12,14	<b>2000</b> 293:20
276:25	<b>11:54</b> 383:4	<b>1800</b> 272:16	386:21 415:1
<b>019076</b> 386:14	<b>11th</b> 270:13,23	<b>1801</b> 274:18	438:10
<b>019076-120</b>	384:20 385:5	<b>1820</b> 557:2	<b>20001</b> 273:11
276:21	386:21 497:18	<b>1875</b> 270:4	<b>20005</b> 272:10
<b>02199</b> 274:5	498:5 500:17,24	<b>18976</b> 274:24	273:20
<b>02203353-357</b>	501:21 502:23	<b>19</b> 438:22,23,24,25	<b>20006</b> 270:5
277:2	<b>12</b> 318:11 336:18	<b>19103</b> 272:4,22	<b>2000s</b> 415:2
<b>03-1134</b> 277:2	386:22 401:10	<b>1970</b> 349:4,6	<b>2001</b> 459:15
<b>034408</b> 459:7	402:1 453:24	<b>1970s</b> 303:7	<b>2002</b> 443:15
<b>03448408-418</b>	<b>12-27-07</b> 276:10	<b>1984</b> 423:18	<b>20036</b> 272:17
277:8	<b>1200</b> 274:19	424:14 427:16	<b>2004</b> 277:4 437:18
	<b>12:06</b> 397:10	434:24	437:25 438:10
	<b>12:12</b> 401:10	<b>1993</b> 415:20	441:11 443:18
	<b>12th</b> 269:8 272:9	417:17 418:9	
	384:20 385:5		

[2005 - 343]

Page 2

<b>2005</b>	279:7 280:4 293:19 294:15,19 295:6,23 296:16 296:21 297:1 302:4 303:20 309:11 318:15 319:15 340:17,22 345:5 348:15 405:12,19 407:18 414:12 421:22 425:24 426:7 427:2 434:14 445:3 489:4 490:12 491:24 492:19 493:15 536:3 543:10,12	551:6,12,21 <b>2010</b> 512:13,18 536:10 <b>2011</b> 428:10 454:8 499:5,7,10,21 500:8 522:5 523:7 541:4 <b>2012</b> 454:8 467:16 527:22 <b>2013</b> 454:9 <b>2015</b> 471:18 <b>2016</b> 453:4 <b>2017</b> 282:13 311:20 330:4 407:24 421:23 453:15,15	<b>212-698-3593</b> 271:5 <b>214-740-8554</b> 273:5 <b>215-241-7910</b> 272:23 <b>215-918-3680</b> 274:25 <b>215-979-3848</b> 272:4 <b>216-523-1313</b> 557:3 <b>216-592-5000</b> 271:14 <b>216-622-3988</b> 270:10 <b>2200</b> 273:4 <b>2203353</b> 429:19 <b>22nd</b> 318:15 <b>23</b> 394:2 <b>24</b> 387:12 524:20 541:13 <b>252</b> 407:6 <b>254</b> 410:19 <b>25701</b> 270:23 <b>26</b> 305:6 306:3,12 307:4,16 310:4 346:21 355:16 436:1,3 <b>2700</b> 274:24 <b>278</b> 276:3 <b>27th</b> 320:19 343:5 <b>28</b> 270:18 <b>2800</b> 273:4 <b>2804</b> 268:5,6 415:20 <b>280400988458</b> 370:14 <b>29464</b> 270:18 <b>2:31</b> 455:6 270:14	<b>2:53</b> 478:9 <b>3</b> <b>3</b> 337:18 349:3 383:3 443:2 454:24 <b>3,000</b> 532:10,21 535:2 <b>3/4/2019</b> 557:8 558:3 559:3 560:2 <b>30</b> 276:9 292:7,14 320:12,15,25 415:7 527:22 556:24 <b>300</b> 274:24 <b>301</b> 274:14 <b>303-592-3197</b> 274:20 <b>304-525-9115</b> 270:24 <b>30th</b> 451:11 <b>31</b> 276:10 341:16 341:19,22 <b>3100</b> 272:21 <b>312-269-4066</b> 271:23 <b>317-236-1313</b> 274:10 <b>32</b> 276:12 356:12 356:13,16 362:15 362:16 <b>322</b> 276:9 <b>3249543</b> 268:25 557:7 558:2 559:2 <b>33</b> 276:14 362:13 362:15,18,19 <b>3355</b> 430:6 <b>3356</b> 430:13 <b>34</b> 276:17 370:5,6 423:19 453:5 <b>343</b> 276:10
<b>2006</b>	319:16 321:9 340:18 345:5 425:25 503:5 524:9	<b>2018</b> 554:11 <b>2019</b> 268:21 278:5 499:8 557:4 <b>202-434-5000</b>	<b>2200</b> 273:4 <b>2203353</b> 429:19 <b>22nd</b> 318:15 <b>23</b> 394:2 <b>24</b> 387:12 524:20 541:13 <b>252</b> 407:6 <b>254</b> 410:19 <b>25701</b> 270:23 <b>26</b> 305:6 306:3,12 307:4,16 310:4 346:21 355:16 436:1,3 <b>2700</b> 274:24 <b>278</b> 276:3 <b>27th</b> 320:19 343:5 <b>28</b> 270:18 <b>2800</b> 273:4 <b>2804</b> 268:5,6 415:20 <b>280400988458</b> 370:14 <b>29464</b> 270:18 <b>2:31</b> 455:6 270:14	<b>274:20</b> <b>304-525-9115</b> 270:24 <b>30th</b> 451:11 <b>31</b> 276:10 341:16 341:19,22 <b>3100</b> 272:21 <b>312-269-4066</b> 271:23 <b>317-236-1313</b> 274:10 <b>32</b> 276:12 356:12 356:13,16 362:15 362:16 <b>322</b> 276:9 <b>3249543</b> 268:25 557:7 558:2 559:2 <b>33</b> 276:14 362:13 362:15,18,19 <b>3355</b> 430:6 <b>3356</b> 430:13 <b>34</b> 276:17 370:5,6 423:19 453:5 <b>343</b> 276:10
<b>2007</b>	276:13 341:25 343:5 356:24 358:5 368:22 369:12 384:21 385:5,15 386:22 402:1 409:19 425:25 444:10,18 445:3 445:19 448:7,8,21 449:13 450:21 491:24 493:2,7 497:18 498:6 499:8 500:4,17,24 501:22 502:23 503:5 524:9	<b>202-662-6000</b> <b>202-695-8147</b> <b>202-778-1800</b> <b>202-879-5907</b> 273:21 <b>2020</b> 556:24 <b>2033</b> 402:2 <b>2035</b> 402:15 <b>2036</b> 404:5 <b>21</b> 277:16,17 343:10 344:7,12 404:24 405:3 407:14 415:20 431:5 452:18 <b>212-397-1000</b> 270:14	<b>272:10</b> <b>202-662-6000</b> <b>202-695-8147</b> <b>202-778-1800</b> <b>202-879-5907</b> 273:11 <b>2020</b> 556:24 <b>2033</b> 402:2 <b>2035</b> 402:15 <b>2036</b> 404:5 <b>21</b> 277:16,17 343:10 344:7,12 404:24 405:3 407:14 415:20 431:5 452:18 <b>212-397-1000</b> 270:14	<b>272:10</b> <b>202-662-6000</b> <b>202-695-8147</b> <b>202-778-1800</b> <b>202-879-5907</b> 273:11 <b>2020</b> 556:24 <b>2033</b> 402:2 <b>2035</b> 402:15 <b>2036</b> 404:5 <b>21</b> 277:16,17 343:10 344:7,12 404:24 405:3 407:14 415:20 431:5 452:18 <b>212-397-1000</b> 270:14
<b>2008</b>	371:21 374:4 376:10,18 377:20 379:22 380:25 442:10,25 443:2 445:19 451:11 452:12 541:24	343:10 344:7,12 404:24 405:3 407:14 415:20 431:5 452:18 <b>212-397-1000</b> 270:14	<b>274:24</b> <b>278</b> 276:3 <b>27th</b> 320:19 343:5 <b>28</b> 270:18 <b>2800</b> 273:4 <b>2804</b> 268:5,6 415:20 <b>280400988458</b> 370:14 <b>29464</b> 270:18 <b>2:31</b> 455:6 270:14	<b>274:24</b> <b>278</b> 276:3 <b>27th</b> 320:19 343:5 <b>28</b> 270:18 <b>2800</b> 273:4 <b>2804</b> 268:5,6 415:20 <b>280400988458</b> 370:14 <b>29464</b> 270:18 <b>2:31</b> 455:6 270:14

[35 - able]

Page 3

<b>35</b> 276:19 386:4,6 386:17 387:10 <b>356</b> 276:12 <b>35th</b> 274:13 <b>36</b> 276:22 401:21 401:22 407:8 429:6 <b>360</b> 270:13 <b>362</b> 276:14 <b>368</b> 499:15,19,24 <b>37</b> 276:24 415:7,8 415:9,16,17 417:7 <b>370</b> 276:17 <b>38</b> 277:2 415:11 423:17 429:8,9,12 429:20,22,23 <b>382</b> 524:20 <b>383</b> 276:4 <b>386</b> 276:19 <b>39</b> 277:3 429:21 437:15 438:3,8 442:19 <b>3900</b> 272:3 <b>395965</b> 437:25 <b>3:07</b> 478:13 <b>3:30</b> 477:13 <b>3:32</b> 477:25 <b>3:32:30</b> 477:15 <b>3:58</b> 521:20	<b>42</b> 277:9 467:7,9 <b>424-332-4764</b> 273:16 <b>429</b> 277:2 <b>43</b> 277:11 471:7,12 <b>437</b> 277:3 <b>44</b> 277:13 473:6,8 <b>44113</b> 270:9 271:14 <b>44114</b> 557:2 <b>442</b> 277:5 <b>45</b> 277:15 456:14 456:17 <b>45005</b> 268:10 <b>45090</b> 268:14 <b>45132</b> 268:12 <b>459</b> 277:7 <b>46</b> 277:16 495:17 495:18 <b>46204</b> 274:9 <b>463,407.72</b> 277:19 <b>463,497.72</b> 527:20 <b>467</b> 277:9 <b>47</b> 277:17 495:20 495:22 <b>472</b> 277:11 <b>473</b> 277:13 <b>478</b> 276:5 <b>48</b> 277:18 527:15 527:16,19 <b>49</b> 277:20 539:14 539:17,24 <b>495</b> 277:16,17 <b>4:21</b> 522:1 <b>4:35</b> 533:13 <b>4:36</b> 533:17 <b>4:58</b> 555:5 <b>4th</b> 278:5	<b>5</b> <b>5</b> 521:25 <b>50</b> 277:22 <b>51</b> 277:23 551:4,9 <b>527</b> 277:18 <b>535</b> 276:6 <b>539</b> 277:20 <b>551</b> 277:23 <b>5732</b> 423:25 424:3 <b>5:00</b> 456:16 458:1 458:14,18 551:2 <b>5:01</b> 555:8,15 <b>5th</b> 453:15	<b>80</b> 454:9 <b>800</b> 274:4 <b>801</b> 270:8 <b>80202</b> 274:19 <b>8158</b> 363:10 <b>823</b> 277:16 285:23 304:15 332:18 334:6,12 344:7 <b>84</b> 423:19,20 425:8 425:23 428:2 <b>842</b> 337:11 <b>843-216-9241</b> 270:19 <b>850</b> 273:10 <b>852</b> 463:15 464:4 <b>852s</b> 463:16 <b>867</b> 465:1 <b>8:00</b> 458:20
		<b>6</b> <b>6</b> 292:7,14 390:6 414:12 426:7 529:17,18,20 <b>60601</b> 271:22 <b>610</b> 271:9 <b>617-951-7000</b> 274:5 <b>650-739-3939</b> 271:19 <b>655</b> 273:20 <b>6th</b> 529:20	<b>9</b> <b>9</b> 374:25 <b>9-27-06</b> 276:9 <b>9-4-08</b> 277:5 <b>90067</b> 273:15 <b>90s</b> 419:5 <b>92660</b> 271:9 <b>94303</b> 271:18 <b>949-823-7963</b> 271:10 <b>95</b> 351:2 418:19 420:6 <b>950</b> 271:13 <b>96</b> 432:21 <b>9:00</b> 458:20 <b>9:09</b> 268:22 278:4
			<b>a</b> <b>a.m.</b> 268:22 278:4 <b>aaron</b> 268:8 <b>abdc</b> 445:6 <b>able</b> 440:4 458:2 482:25 543:8
		<b>8</b> <b>8</b> 390:21 <b>8-14-08</b> 277:24	

546:19	336:5 338:18,23	<b>administration</b>	agreeing 489:24
<b>absent</b> 449:22	340:8 344:20	275:6 321:11	<b>agreement</b> 277:7,9
<b>absolutely</b> 298:14	348:8,15 352:22	329:11 405:8	277:12,14 456:7
298:22 303:4	359:11 361:14	<b>administration's</b>	459:8 465:13
317:5,12 322:8	368:20 369:6	276:20	471:17 473:13
337:4 395:19	396:14 431:17	<b>administrative</b>	<b>agreements</b>
416:12 533:23	448:8,22 456:4	452:14 453:16	413:13 459:22
540:6	476:22 558:14	<b>administrator</b>	463:6
<b>absolve</b> 350:17	559:20	286:14 342:4	<b>ah</b> 439:18 518:24
<b>absorbed</b> 528:6,7	<b>actavis</b> 387:21	<b>advanced</b> 552:3	<b>ahead</b> 280:15
<b>abuse</b> 323:1,12	388:3,9,25 389:1	<b>advice</b> 450:11	294:10 295:1
381:24	<b>action</b> 291:1	511:22	309:19 322:12
<b>accept</b> 291:17	316:11 330:24	<b>advised</b> 425:8	335:20 336:9
492:6 493:16	441:15 491:14,19	<b>affairs</b> 392:15	365:20 393:16
494:12,18	549:17 556:13,18	406:10	398:23 456:25
<b>acceptable</b> 372:21	<b>actions</b> 549:22	<b>affect</b> 370:24	480:9,9 484:8
<b>accepted</b> 487:15	553:8	<b>affirmative</b> 443:10	506:1 533:8
488:23	<b>actiq</b> 466:12 467:1	<b>affixed</b> 558:15	540:21 541:6
<b>accepting</b> 493:20	<b>activity</b> 288:22	559:21	<b>al</b> 268:9,11,13,14
<b>access</b> 473:14	358:18 381:17	<b>afternoon</b> 478:18	<b>allergan</b> 273:18
<b>accommodate</b>	433:21 546:7	<b>ag</b> 457:1	<b>allow</b> 553:14
439:23	<b>actual</b> 279:24	<b>agencies</b> 289:18	<b>allowed</b> 281:24
<b>accomplish</b> 322:17	437:21 474:3	<b>agency</b> 280:6	398:12 399:17,22
<b>account</b> 373:16	528:25 546:2	291:1 292:10,25	448:25
406:19,19 527:21	<b>ad</b> 321:20	297:12 322:15	<b>allowing</b> 343:23
<b>accountability</b>	<b>adapted</b> 382:4	413:10	445:2 448:8
304:13	<b>addiction</b> 300:2	<b>agency's</b> 323:22	<b>alongside</b> 406:22
<b>accounts</b> 406:17	<b>addictions</b> 421:16	<b>agents</b> 422:4	<b>alprazolam</b>
<b>acknowledge</b>	<b>addition</b> 331:9	<b>aggregate</b> 472:10	337:24
552:8 558:11	344:6 357:16	<b>aggressive</b> 357:15	<b>alto</b> 271:18
559:16	440:2	<b>ago</b> 336:18 512:8,9	<b>ama</b> 473:18,20
<b>acquired</b> 290:9,18	<b>additional</b> 327:15	<b>agree</b> 372:9,22	<b>ambiguous</b> 336:7
<b>acquisitions</b>	380:8,10 400:18	373:6,23 375:12	<b>amendment</b>
537:11	<b>address</b> 557:15	376:17 377:19	277:11 471:11,16
<b>act</b> 286:3 297:2	<b>addressed</b> 400:19	379:7 380:24	<b>american</b> 327:2
303:1,6 309:4	<b>addressing</b> 553:23	463:5 490:8	473:24
312:17,23 322:7	<b>adequate</b> 476:4	499:12 507:23	<b>americas</b> 271:4
323:6 324:2,3,12	<b>adhering</b> 451:6	517:7 531:13,20	<b>amerisource</b>
324:23 326:11	<b>adjoining</b> 384:8	<b>agreed</b> 452:13	295:21
328:7,14 329:19	<b>adjourned</b> 555:15	453:5 454:8 464:7	<b>amerisourceberg...</b>
330:10 335:2		504:1	272:19 295:22

[amerisourcebergen - asked]

Page 5

363:3,13 389:9,15	512:3 514:2,4	471:10 501:8	<b>arcos</b> 277:20
389:16 406:10	515:15,24 517:21	556:5	283:5,16 306:23
444:8,18 447:19	530:14,23 532:1	<b>appended</b> 559:11	307:17 316:20
448:6	538:24 545:5,20	559:18	317:9 349:2
<b>amiss</b> 298:10	545:20 547:1,19	<b>applicable</b> 338:24	358:20 535:18,20
<b>amount</b> 300:22	548:2,12 549:3,12	460:25	536:2,16,21
433:10 553:16	549:21 550:6,10	<b>applied</b> 298:18	537:13,18,22
<b>amy</b> 272:2	550:20 552:24,25	315:20 346:20	538:3,12,16,20
<b>analyses</b> 436:14	553:8	365:3	539:5,14 542:5,5
<b>analysis</b> 350:12	<b>answered</b> 296:8	<b>applies</b> 313:21	542:19,25 543:9
351:1 536:13,14	385:8 437:14	<b>apply</b> 298:11,24	543:14 544:1,23
536:16 544:9,14	484:18,21 506:18	299:5 304:23	545:9 546:13
<b>analytics</b> 536:12	506:20 518:12,19	313:12,16 314:4,5	548:25 549:10
<b>analyze</b> 536:2	525:12 529:8	315:6,14,15 316:4	550:13 553:13
544:15,23 545:9	532:24	436:25	554:12
<b>analyzing</b> 536:21	<b>answering</b> 502:1	<b>appreciate</b> 285:13	<b>area</b> 279:23,25
<b>andrew</b> 273:8	<b>answers</b> 462:21	344:2	282:5,18 284:25
274:2	<b>anthony</b> 272:15	<b>appreciated</b>	285:18 287:16
<b>andrew.o'connor</b>	<b>antonio</b> 552:4,11	301:10,13,22	329:12 359:15,17
274:6	<b>anybody</b> 488:7	322:5 552:9	359:20 405:8
<b>anesta</b> 390:22	494:14 506:3	<b>approach</b> 513:22	433:13
<b>angeles</b> 273:15	528:21	<b>appropriate</b>	<b>areas</b> 280:2
<b>annoying</b> 518:14	<b>aoa</b> 473:18,20	326:14 330:24	281:11,18 312:20
<b>anomalies</b> 317:16	<b>apologize</b> 287:19	373:20 376:14	549:24
375:21	295:13 386:10	377:4 379:11	<b>argue</b> 294:7,9
<b>answer</b> 280:15	393:8 471:8 490:5	380:2 381:2,6,8	<b>argument</b> 349:13
292:20 335:14,17	508:5 514:23	399:14	349:16 401:1
355:7 365:20	518:16	<b>approval</b> 346:10	<b>arkansas</b> 541:23
367:25 384:12	<b>apology</b> 527:9	<b>approve</b> 345:11,21	542:2
403:17 437:7,8,10	<b>apparent</b> 433:12	431:6 432:3	<b>arrangement</b>
437:11 445:15	<b>apparently</b> 430:25	490:21,22	482:2
446:16,23 447:5	450:10 501:2	<b>approved</b> 531:4	<b>aruz</b> 272:18
447:11 452:8	<b>appear</b> 362:22	531:12	<b>asked</b> 291:23
460:5 477:3	363:1 500:2	<b>approves</b> 346:12	292:12 296:7
479:15 481:2,7	558:11 559:15	380:18	311:25 329:5
482:5,12,14	<b>appearances</b>	<b>approving</b> 488:22	360:10 361:8
483:15,18 484:4	270:1 271:1 272:1	<b>approximately</b>	363:24 367:21
484:16 487:21	273:1 274:1	282:16 480:18	377:15 384:16
497:12,14 500:18	<b>appears</b> 357:2	481:15,18	385:7 411:23
504:7 506:22	363:18 386:17	<b>arch</b> 272:22	412:10,15 413:19
510:5 511:1,1,18	465:16 470:10		427:10 462:17

[asked - back]

Page 6

478:24 484:21 501:18 502:4,5 503:1 504:1 506:18 507:22 508:22 516:3 517:1,8,23 518:12 518:19 520:23 522:13,22 525:11 527:5 529:6,7 532:24 539:2 553:21 <b>asking</b> 278:23 283:24 292:8 331:21 388:16 398:7,9 440:16 445:10 452:2,7 479:2 514:1,2 524:25 <b>assess</b> 357:22 <b>assessments</b> 496:21 <b>assigned</b> 279:9 323:25 383:24 <b>assignment</b> 558:2 559:2 560:2 <b>assignments</b> 279:10 <b>assistant</b> 286:14 342:4 <b>associated</b> 498:17 <b>association</b> 370:16 370:18 416:21 417:10 418:9 420:24 422:5 424:23 425:7 473:25 493:1 <b>assume</b> 450:4 523:15 <b>assumptions</b> 398:7 <b>assurance</b> 372:18	<b>astanner</b> 273:12 <b>atlantic</b> 388:9 389:1 <b>attached</b> 361:14 364:8 387:1 402:5 442:11 460:20 467:22 559:7 <b>attachment</b> 295:20 468:3 <b>attend</b> 385:13 402:25 500:4,16 500:23 508:25 <b>attendance</b> 385:24 389:1 403:2,20 409:18 <b>attended</b> 404:10 406:23 498:5 499:11 501:6 509:5 518:9 <b>attendee</b> 388:25 390:23 391:7 392:8 393:4,13 394:6 395:3 509:20 <b>attendees</b> 386:19 387:13,17,20 389:25 392:16,22 393:20 402:10 409:13 <b>attending</b> 316:16 384:18,23 389:8 394:19 395:3,11 395:17 <b>attends</b> 403:11 <b>attention</b> 364:7 375:21 473:17 547:6 <b>attitude</b> 432:17 <b>attorney</b> 485:19 486:13,16,19,23 531:19 556:15	<b>attorney's</b> 270:8 275:2 289:16,16 <b>attorneys</b> 370:11 <b>auburn</b> 448:20 <b>audited</b> 336:18 <b>august</b> 295:22 303:20,20 309:11 318:15 499:21 551:6,21 <b>authority</b> 284:3 287:14 328:2,7 490:19 <b>authorization</b> 281:4,8,10,25 283:19 547:20 549:3,13 550:10 <b>authorize</b> 300:1 559:11 <b>authorized</b> 281:12 281:18 282:6,19 284:16 285:1,19 285:24 288:16,20 289:3,11,22 290:7 290:15,23 447:6 447:10 514:4 515:25 545:14 546:9 547:18 548:12,21 549:21 550:8 552:19 553:8 <b>automation</b> 277:21 539:15 <b>available</b> 380:21 463:23 469:24 476:5 <b>avanni</b> 272:5 <b>ave</b> 557:1 <b>avenue</b> 270:8,13 271:4,13 273:4,15 <b>average</b> 433:10 542:6,9,22	<b>avoid</b> 331:11 <b>aware</b> 291:1 323:12 327:14,20 371:20 413:9,14 416:9 417:9,17 418:6,9,13 420:4 425:6,14 441:25 442:1,3 444:7,7,12 447:21 458:17 459:17,21 460:4 461:3 463:21 464:12 474:1 475:1,5 488:12 495:9 530:25 551:17 553:12,18 <b>awry</b> 298:10
<b>b</b>			<b>b</b> 292:7,14 343:10 344:13 405:3 407:15 431:5 460:20,22 467:21 468:17 469:23 494:8,9 <b>bacchus</b> 275:2 <b>back</b> 304:14 305:5 341:9 348:13 349:4,6,11 382:14 382:25 393:7 399:1,4 401:8 409:6 413:9 419:4 422:6,17 425:8,23 428:2 431:9 432:9 434:15 446:9,21 455:2 458:12 462:9 466:9 477:7 478:11 485:12 486:10 497:22 503:2 506:22 507:21 511:14 512:19 513:13 515:1,3 517:13

521:22 531:18,25	429:19 430:6,13	<b>benefits</b> 325:15	548:11,17,20
532:3 533:15	437:23 473:17	<b>bennett</b> 270:7	549:2,11,20 550:7
534:20 557:15	<b>baton</b> 533:9	283:7,13 292:16	550:18 551:1
<b>background</b> 284:2	<b>beach</b> 271:9	295:8,11,14	552:18,25 553:7
323:10 327:15	<b>beck</b> 274:18	320:20,24 321:1	554:2,20,23
373:17 546:3	<b>becoming</b> 316:16	348:25 349:5,8,14	<b>best</b> 315:22 335:23
<b>bailey</b> 270:22	<b>began</b> 346:4	374:5 378:9,11	336:4,21,23
<b>bank</b> 527:21	383:12 458:19	379:24 384:10	383:15 462:21
<b>barker</b> 271:8	492:9,19 493:15	388:6,13,15,19,22	479:23 489:10
<b>barnes</b> 274:8,12	493:18 527:10	396:5 402:17	490:7,13 492:1,2
<b>bartlit</b> 274:18	536:7	403:3 415:8	496:3,6,16,19,25
<b>bartlitbeck.com</b>	<b>beginning</b> 478:24	423:11 424:7,10	500:18,22 507:12
274:20	514:21 530:17	428:12,14,17	509:2 527:21
<b>base</b> 339:13	536:2	429:7,24 430:2	<b>better</b> 457:10
<b>based</b> 281:24	<b>begins</b> 278:6	436:1 440:7,15,20	499:12 529:5
284:3 294:19	<b>begun</b> 458:19	442:15 445:1,3,7	<b>beyond</b> 482:24
317:22 343:11	491:18	445:14,17 446:23	484:21,23 492:10
349:7 355:20	<b>behalf</b> 269:12	447:5,16 452:1	512:23 515:9
361:17 423:14	270:2,7,12,16,21	455:8 457:6 460:2	540:9 547:19
436:6 475:25	271:2,7,16 272:2,6	476:25 480:23	549:2
501:4 502:8	272:14,19 273:2,7	487:20 488:19	<b>big</b> 449:20 451:14
506:16 526:17	273:18 274:2,7,11	490:18 492:12	452:20 453:9
<b>basic</b> 309:3	274:16,21 278:18	496:12 497:2,11	<b>billing</b> 464:10
<b>basically</b> 279:11	284:17 292:10,13	497:15 501:7	<b>binder</b> 498:21
398:8 432:24	292:25 459:15	504:17 506:14	508:4
456:20	<b>beisell</b> 271:20	507:17 510:3,23	<b>bit</b> 367:20 369:23
<b>basing</b> 436:14	<b>believe</b> 292:23	511:17,20 512:21	387:4 492:15
<b>basis</b> 305:12	336:3 371:12	513:25 514:11	499:11 516:7
308:17 309:24	377:3 386:4 402:3	515:5,21 518:10	<b>bless</b> 312:12
331:16 337:10	432:16 433:23	520:15,18,20,23	<b>blessed</b> 291:25,25
347:11 360:21	457:8 492:5 493:5	521:16 523:2,12	487:18 490:14
400:11 464:6	493:13 496:3	524:6,17 525:13	<b>blighted</b> 359:20
465:4,20,22 505:5	498:8 503:14,19	526:3,12 528:17	<b>blind</b> 332:16
519:19	508:3 515:10,25	530:13,22 531:15	334:10
<b>bates</b> 356:17	534:8	531:23 532:23,25	<b>block</b> 463:20
362:15 363:9	<b>benchmark</b>	533:4 536:4 538:5	<b>bmasters</b> 272:12
370:8 386:12	300:20 307:22	538:24 540:10,13	<b>board</b> 284:10
402:2,15 404:5	<b>benchmarks</b>	540:23 541:25	315:17,20 322:14
407:6 410:19	300:20,21 306:5	545:11,14,17	338:25 341:1
415:19 418:1	306:13 307:6	546:8,15,21 547:1	<b>bonnie</b> 268:24
423:25 424:3		547:15,25 548:8	556:2

<b>book</b> 280:20 295:12 <b>border</b> 279:13 <b>boss</b> 342:1 <b>boston</b> 274:5 <b>bottom</b> 387:12 402:15 404:23 424:3 432:13 529:17,20 541:9 <b>boulevard</b> 270:18 <b>box</b> 329:5 <b>boylston</b> 274:4 <b>brad</b> 272:8 <b>brandan</b> 273:2 <b>brandan.montmi...</b> 273:6 <b>break</b> 341:3 382:18,19 454:21 455:9,12 456:5 458:15 484:8 492:15 507:20 514:21 520:20,24 521:5,15 <b>bridgeside</b> 270:18 <b>brief</b> 400:10 494:7 <b>briefed</b> 376:23 493:20 494:8 <b>briefers</b> 509:16 <b>briefing</b> 287:17 303:21 316:16 317:3 318:7 319:15 493:22 494:11 505:6 508:3,19 509:1,5 509:10 510:2,9,11 517:10,15 519:17 519:22,23 521:8 <b>briefings</b> 296:5 297:4 301:19 302:5 311:12 314:22 315:20	316:18 317:14 324:6 328:19 329:20 334:18 337:2,14 340:16 345:5,15 347:21 348:16 350:2,22 352:9 354:5 355:4 356:5 358:11 365:16 367:5 369:11 376:24 492:8,19,25 493:6 493:11,15,18 497:7,8 504:4,15 505:1,9,14 507:15 509:18 517:3,19 518:2,8 527:11 543:13,24 <b>briefly</b> 387:9 <b>bring</b> 364:7 380:7 <b>broad</b> 491:19 <b>brought</b> 338:24 441:16 448:1,2 453:9 <b>bryant</b> 271:3 <b>btlaw.com</b> 274:10 <b>build</b> 494:3,5 <b>building</b> 398:6 <b>bulk</b> 301:1 <b>bullet</b> 314:18 380:11,13 <b>burling</b> 273:9,14 <b>business</b> 298:8 301:1 312:13 336:22 339:11 359:8,16,21 361:5 370:25,25 373:18 390:22 460:24 521:11	<b>c</b> <b>c</b> 274:17 275:5 276:1 278:1 <b>c.f.r.</b> 277:17 <b>c2s</b> 467:1 <b>ca</b> 557:25 <b>cah</b> 276:9,11,18,21 276:25 277:2 370:14 <b>cal</b> 453:22 <b>calendar</b> 468:1 <b>california</b> 271:9 271:18 273:15 453:22,23 <b>call</b> 294:9 385:19 397:4 400:17 457:7,7,7,11 470:24 482:4 484:9 <b>called</b> 292:7 305:7 306:20 370:15 371:17 397:13 435:6 447:9,13 456:8 472:2 <b>calling</b> 400:8 <b>calls</b> 292:17 309:16 354:25 481:11,15,24 482:1,4,9 515:6 <b>capabilities</b> 360:18 <b>capacity</b> 293:1 <b>caps</b> 365:11 366:3 <b>cardinal</b> 272:6 318:12 342:21 343:14 346:22 370:13 386:14 390:7 415:20 429:19 431:2 433:6 448:20 449:15 450:18	451:10 453:4 478:16 508:22,25 509:5,10 <b>care</b> 332:20 334:14,24 <b>carefully</b> 373:19 <b>carolina</b> 270:18 <b>carry</b> 323:25 <b>case</b> 268:6,10,12 268:14 281:12 284:1 285:20 286:8 287:13 289:4 340:4 366:3 400:22 402:4 404:20 441:21 442:22 444:21 498:3 528:16 529:10 531:19 533:24 546:2 550:24 557:6 558:3 559:3 <b>cases</b> 298:4 303:16 303:17 383:21 545:18 548:13,21 550:19 552:20 <b>cash</b> 300:2 <b>catch</b> 410:16 <b>catie</b> 273:19 <b>catie.ventura</b> 273:22 <b>cause</b> 340:3 444:9 449:14 450:17 451:10 <b>center</b> 271:9 274:23 372:3 450:19 451:11 465:8 <b>centre</b> 274:13 <b>cephalon</b> 390:14 390:21,21 459:16 459:18,23,25
---	--	---	--

460:10,13,14,18	523:18 524:10	<b>circumstances</b>	closer 499:7
461:2,6,15,18	525:7 527:1,9	331:15 332:17	<b>cmcnamara</b>
462:5 464:14	532:4 557:13,14	334:11 337:8,19	272:11
<b>ceppich</b> 273:16	559:8 560:3	427:14	<b>code</b> 375:8 541:24
<b>certain</b> 325:17	<b>changes</b> 382:5,9	<b>citation</b> 302:19	<b>cohen</b> 275:1 397:5
353:21 360:22	425:5 522:15	<b>city</b> 268:11	397:12,15 398:22
413:2 460:11	557:12 558:7	<b>citycenter</b> 273:10	399:9 400:15,25
463:20,20 472:14	559:7,9	<b>civil</b> 275:4,5,7	401:4,7 455:25
494:13 519:5	<b>changing</b> 381:17	337:10 452:13	483:11 484:9
<b>certainly</b> 303:11	381:20 415:2	453:5,17 558:5	514:14
353:14 377:1,22	423:21 426:24	559:5	<b>colleague</b> 489:16
428:5 499:7 506:5	497:13 525:15	<b>claimant's</b> 276:22	<b>colleagues</b> 386:8
519:21 530:9	<b>channels</b> 302:24	<b>clarification</b>	533:9
<b>certificate</b> 556:1	304:16 323:24	291:14 550:5	<b>collectively</b> 458:23
559:11	331:14 350:15	<b>clarify</b> 525:19	473:23
<b>certification</b> 558:1	<b>character</b> 463:19	<b>clarity</b> 286:10	<b>colleen</b> 272:7
559:1	<b>characterization</b>	<b>classifiable</b> 289:5	<b>colloquy</b> 399:17
<b>certify</b> 556:4	474:11	<b>classified</b> 289:5	399:19
<b>cfr</b> 285:23 332:4	<b>characterized</b>	<b>clean</b> 400:17	<b>colorado</b> 274:19
343:10 344:12	375:5,10	<b>clear</b> 281:23	453:20
404:24 405:3	<b>characterizing</b>	315:19 354:18	<b>columbia</b> 556:22
407:14 431:5	354:21	361:11 368:7	<b>combat</b> 323:21
452:18	<b>charge</b> 377:14	379:3 388:16	324:24 537:3
<b>chain</b> 277:23	536:20,20	433:4 448:1,5	<b>combinations</b>
298:25 313:7	<b>chart</b> 287:5	456:3 457:18	381:21
325:24 371:2	541:13,22	489:18 490:4,6	<b>come</b> 336:19 382:3
372:4 373:4 395:9	<b>chaverri</b> 270:3	500:22 501:5	421:11 433:5
406:18 414:18	<b>checking</b> 433:9	514:15 533:25	485:12 507:21
417:19 420:11,15	<b>chelsea</b> 275:8	534:6	<b>comes</b> 399:18
466:4 474:3	<b>chemical</b> 277:3	<b>clearly</b> 344:24	413:21,21
<b>chains</b> 385:23	435:6,12 436:7,15	434:14	<b>coming</b> 383:21
425:20 454:6	436:21 437:19	<b>cleveland</b> 268:11	394:10 410:11
472:19	438:8 443:14,18	270:9 271:14	<b>commensurate</b>
<b>chance</b> 342:9	<b>chicago</b> 271:22	557:2	359:21
356:9 499:25	<b>chief</b> 424:15	<b>client</b> 338:24	<b>commentary</b>
<b>chandler</b> 275:3	536:11	339:9	293:8,22 331:21
<b>change</b> 382:4	<b>choosing</b> 456:3	<b>clinic</b> 361:16	468:8
406:1 415:1	<b>chris</b> 535:14	<b>closed</b> 297:8 299:6	<b>commercially</b>
422:25 427:13	<b>christopher</b>	304:24 324:25	467:23
450:2 454:19	273:14	325:24	<b>commission</b>
481:6 494:9			556:24 558:19

## [commission - contents]

Page 10

559:25 560:25 <b>common</b> 389:24 390:3 402:24 406:21 <b>communicated</b> 318:25 458:15 502:17 <b>communication</b> 319:10 455:10,15 <b>communications</b> 292:17 346:8 354:19 <b>community</b> 457:3 <b>companies</b> 317:16 328:13 395:9 396:13 <b>company</b> 317:2,8 325:14 336:24 394:17 469:17 472:11 494:7,7,8 494:10,13,17,19 494:23 496:24 <b>compare</b> 542:21 <b>compared</b> 301:2 542:8,21 <b>comparison</b> 542:14 <b>compilation</b> 435:24 <b>complete</b> 282:9 <b>completed</b> 310:9 368:5,15,16 409:2 440:4 557:15 <b>completely</b> 533:24 <b>completing</b> 350:13 448:23 480:14 <b>compliance</b> 276:17 328:4 370:15 371:17 435:15 452:15	<b>compliant</b> 308:16 330:9 347:4,9 368:19 369:3,5 <b>complied</b> 530:1 <b>comply</b> 328:8,13 328:20 354:24 420:23 476:21 490:15 491:2 <b>complying</b> 336:4 <b>components</b> 325:23 <b>compound</b> 364:17 <b>compulsory</b> 361:2 <b>computer</b> 424:25 <b>computerized</b> 556:8 <b>concentrated</b> 510:20,21 <b>concept</b> 327:24 340:22 366:4,15 366:16 492:24 498:4 506:3 511:9 <b>concepts</b> 338:16 351:15 <b>concern</b> 296:21 380:22 <b>concerning</b> 291:1 335:7 <b>concerns</b> 279:3 296:15 297:1 317:17 <b>concludes</b> 555:9 <b>conclusion</b> 305:24 309:16 379:4 <b>conclusions</b> 312:11 <b>concurrent</b> 331:2 <b>condition</b> 325:3 <b>conditions</b> 460:15 <b>conduct</b> 332:7 350:12 357:15	359:16 527:10 544:23 <b>conducting</b> 298:8 <b>conduit</b> 361:15 <b>conference</b> 358:4 360:2 362:24 384:20,23 385:14 385:20 386:20 387:3 389:10,18 390:24 391:7 392:8,16,23 393:5 393:13,20 394:7 394:22 395:4,11 401:15 402:1,10 403:12 404:9,10 406:11 409:14 456:2 497:18 498:5,18 499:11 500:4,16,24 501:6 501:13,20,21,22 502:7,11,23 541:5 <b>conferences</b> 389:24 406:23 480:11 <b>confidential</b> 480:25 481:6 483:17 545:18 <b>confirm</b> 374:11 <b>confirming</b> 332:20 334:14,24 <b>conflict</b> 330:21,22 <b>confronted</b> 428:10 <b>confused</b> 504:24 <b>confusion</b> 527:1 <b>congress</b> 323:25 324:24 325:25 326:24 328:6 <b>connection</b> 498:13 <b>connolly</b> 269:7 272:9	<b>consequences</b> 328:20 <b>consider</b> 297:25 298:16 299:19 <b>consistent</b> 323:15 324:4 325:7 326:5 327:4 334:16 337:12 338:17 340:14 345:3,13 355:2 358:9 375:15 381:25 418:17 443:17 517:23 534:3 <b>consolidated</b> 277:21 539:15 <b>constant</b> 381:18 <b>constituted</b> 301:1 <b>construed</b> 346:10 <b>consult</b> 484:13 <b>consultancy</b> 482:20 <b>consultant</b> 400:24 532:13,16 533:1 <b>consulting</b> 482:2 483:2 534:10 <b>consummated</b> 310:8,21,22 <b>contact</b> 377:15 <b>contacted</b> 377:13 455:19 457:20 <b>contain</b> 460:19 467:21 <b>contained</b> 374:13 505:15 512:18 517:10 518:3 <b>contains</b> 363:4 <b>content</b> 482:4,23 485:25 516:8 <b>contents</b> 447:21 514:3
--	---	---	--

<b>context</b>	281:22 331:25 340:1 342:15 506:19	405:6 407:17 416:3 431:7 432:4 433:11,23 448:7	<b>corp</b> 390:22 <b>corporate</b> 274:23 406:9	393:21 394:7,12 394:23 395:4 396:3,14 401:13
<b>contiguous</b>	529:15	448:22 452:16	<b>corporation</b>	402:10 403:25
<b>continue</b>	458:2 552:9	466:20 469:2 537:12,21,23	<b>correct</b>	404:14 405:13 407:19,24 411:21
<b>continued</b>	271:1 272:1 273:1 274:1 277:1 278:7 492:6 492:20 493:16	542:7 544:16,17 544:24 545:10 554:14	280:7,11 280:16 282:10,13 282:16 283:13	412:22,24 413:3 414:1,7,22 415:3 416:15 429:23
<b>continuing</b>	531:2	276:14 302:22 304:8,15	284:12 287:5,7,10 287:17,25 288:6	431:10,18 432:9 434:11,15,17,20
<b>contract</b>	469:13 471:9,11 473:11	305:2 315:5 316:10 332:18	288:23 289:1,7,9 289:18,20 290:2,5	441:11 449:9,22 450:5,6,23 451:4
<b>contrary</b>	534:5	334:7,12 344:9	290:11,13,19,21	451:16 452:21
<b>control</b>	276:20 312:7 340:1 342:5 402:9,21 481:3	366:1 404:25 443:5 449:17 450:20 451:12	291:2,4,11 292:2 293:5 294:16,17 294:22 296:5,9,16	453:11 454:15 462:24 464:14 465:13,23 470:18
<b>controlled</b>	276:15 286:2 297:2 299:7 300:16,22 301:3 302:23 303:1 304:24 309:3 312:16 315:3 316:1 322:6,24 323:6,13,24 324:1 324:11,23 325:2 325:16 326:3,11 326:13,25 328:2 328:14 329:9,18 330:10 335:1 336:5 337:22 338:8,18,23 340:2 340:8 343:8 344:12,16,20 348:7,14 350:14 350:19 352:21 358:20 359:11 368:20 369:6 371:8,19 372:7,19 373:3 380:18,20 391:13 396:12	491:13 <b>conversation</b> 445:23 455:21 456:24 457:9	296:17,18 297:19 297:22 298:2 306:25 307:2,6,23 308:1 309:6,8	471:2 476:12 479:6 483:8 484:14 487:10,16 487:19 488:3,14
		<b>conversations</b> 457:13 513:23 528:18 531:24	313:2,3,5,6,7,8,10 313:11,13 314:24 317:10,18,20	488:18 489:8,14 490:16 491:8,14 491:25 492:3,9,21
		<b>convey</b> 360:7 506:2	318:8,14 319:2,6 324:12,14,19,21	493:7,11 494:4 495:5 496:6,11,17
		<b>conveyed</b> 505:20 520:9	325:18 329:25 330:5 335:24	497:1,21 498:6,18 498:24 499:2,5,8
		<b>coordinate</b> 458:4 <b>coordinator</b>	343:25 344:20,22 348:8,16 351:10	501:23 502:18,19 502:24 503:6,10
		318:22	351:20 352:22	503:16,24 505:6
		<b>copies</b> 379:17 386:9 503:3	353:5,7 355:21,23 363:8,13,15 364:3	505:10 506:7 507:15 509:11,12
		<b>copy</b> 320:17,21,23 361:13 423:20	365:8 374:14,15 374:21 383:14	513:24 516:6 518:9 522:6,10
		425:4 431:1 437:4	385:12,15,17,24	523:11 524:2,13
		437:18,24 442:9	386:1 387:6 388:3	525:10,25 526:10
		457:10	388:10 389:10,19	526:14,22 527:3
		<b>core</b> 323:22	390:8,12,16,18,25	530:6,21 531:13
		<b>corner</b> 373:12	391:2 392:3,9,16	532:22 533:4
		541:10	392:23 393:5,13	535:3 536:3,17,18

[correct - data]

Page 12

536:23 537:20 538:19 539:8,12 543:10 544:5,18 547:14 554:16 <b>corrections</b> 557:12 559:17 <b>correctly</b> 333:23 386:19 404:18 406:12,13 407:13 408:7 465:10 471:16 <b>counsel</b> 278:10,12 280:17 288:18 291:7,22 292:18 295:4,8,18 296:11 305:6 310:4 318:13 320:16,20 335:13 341:14 344:1 346:22 355:18 369:18 383:5,6 388:15 398:3 399:18,25 400:3 401:11 402:18 411:24 424:7,10 427:12 428:9,15,22 429:20,24 430:2 437:22 440:16 442:16 448:1,2 455:7 462:18 478:14,15 491:8 498:16 501:19 502:15 503:22 520:18 521:16 522:2,13 524:6,17 525:12 528:18 531:24 533:18,20 535:12 540:24 551:1 556:12,16 <b>counsel's</b> 292:18	<b>counties</b> 542:6,8 542:10,14,14 <b>country</b> 280:2 323:14 <b>county</b> 268:9,13 270:12,16 278:12 278:18 383:6,18 383:20 384:1,7,8 484:13 532:14 558:10 559:15 <b>couple</b> 392:14 454:21 480:10 <b>course</b> 314:2 316:2 325:23 486:11 <b>court</b> 268:2 291:19 303:17 399:5,19 400:11 515:2 531:20 558:7 <b>cov.com</b> 273:12,12 273:13,16 <b>cover</b> 295:19 372:2 430:6 516:7 <b>covered</b> 279:10 285:23 299:23 530:9 540:15,16 540:18 553:24 <b>covering</b> 371:14 <b>covers</b> 305:1 <b>covington</b> 273:9 273:14 <b>crazy</b> 291:19 <b>created</b> 510:1,11 510:12 527:2 <b>creating</b> 511:23 <b>criminal</b> 337:10 381:16 <b>criteria</b> 330:23 352:5 436:22	<b>critical</b> 326:23 336:21 391:6 506:8 <b>cross</b> 322:14 398:11 554:4 <b>csa</b> 327:24 328:5 328:21 332:4 335:8,15 337:11 362:6 375:17 453:7 <b>culminating</b> 279:11 <b>currency</b> 527:21 <b>currently</b> 282:15 323:2 <b>custom</b> 391:6 <b>customer</b> 285:4,8 326:2,13,14 331:4 338:18,23 339:12 339:18 340:5 357:15 359:8,14 359:19 360:22 361:17 373:14,16 373:18,22 374:19 375:7 376:16 377:13,18 379:19 406:15 433:20 440:4 516:24 519:18,19 521:10 551:7,15,22 <b>customer's</b> 373:18 <b>customers</b> 339:22 358:2 361:8 372:8 520:10 526:21 552:16 553:17 <b>cuyahoga</b> 268:9 270:12 383:6,18 383:20,25 384:7 <b>cvs</b> 272:14,14	<b>d</b> <b>d</b> 271:2 278:1 361:23 <b>d.c.</b> 268:20 269:9 270:5 272:10,17 273:11,20 279:15 294:16,22 321:11 416:8 420:18 456:1 461:13 <b>daily</b> 354:21 <b>dallas</b> 273:5 279:9 279:22,23 280:1,8 346:4 377:6 <b>damage</b> 311:6 409:5 <b>dan</b> 268:7 <b>dangerous</b> 340:3 <b>daniel</b> 275:10 <b>data</b> 277:7,9,11,13 283:5,16 295:20 306:23,24 316:20 317:1,2,7,15,23 349:2 413:12 425:1 459:8,14,24 460:11,12,14,18 460:18,22,24 461:3,17 462:6,11 463:7,22 465:6,11 465:19 467:17,19 467:24 469:15 470:15 471:17,17 471:20 472:2,8,10 472:14,21 473:14 473:19,20,25 474:15 475:2,11 475:17 476:5,11 476:20 509:14 510:9,20 511:9 516:4 536:2,16,22 537:1,18,22,23 538:7 544:4 545:9
--	---	---	---

548:10 549:10	286:12 287:5	444:3,8 450:16	<b>dechert</b> 271:3
550:13 554:12	288:22 289:7,15	451:4,9 452:14,17	<b>dechert.com</b> 271:5
<b>database</b> 316:21	290:11 291:11	453:17 459:22	<b>decide</b> 399:16,20
317:9 475:4	292:14,19 293:19	462:9 472:13	414:21
<b>dataset</b> 470:13	295:22 300:8	476:18 487:9,19	<b>deciding</b> 326:2
<b>datasets</b> 469:24	302:17 303:12	488:1,16 489:11	<b>decision</b> 288:5
<b>date</b> 277:5 292:12	304:6 309:12	490:9,14,21 491:8	312:9 336:25
443:1 448:17	311:8,15 313:10	491:11,22 492:6	410:23 431:25
494:13,15 499:4	313:17 315:11	493:16 497:18	432:5 442:4,12
499:16,20 557:8	316:9 323:21,25	498:5,18 500:4,16	526:17
558:3,9,19 559:3	324:2 325:2,15	500:24 502:22	<b>decisions</b> 491:2
559:13,25 560:20	326:19 327:12	510:21 514:10	<b>deck</b> 498:17
560:25	328:6,6,11 329:25	517:24 523:25	502:16 505:5,16
<b>dated</b> 276:9,10	332:8,15 334:9	524:10,11 525:7	516:5,11,14,15,24
277:24 379:17	340:23 343:9	525:22,23 526:8	517:9 521:8
415:20 437:25	344:9 345:10,21	527:2,9 530:25	<b>declared</b> 326:24
527:21	346:4,8,12 347:17	531:4,12 536:25	<b>deed</b> 558:14
<b>dates</b> 377:14 385:2	348:1 350:7 351:3	537:19 538:20	559:20
<b>david</b> 270:3 275:1	351:9 354:12,19	539:5 540:12	<b>deem</b> 376:3
275:4 398:20	355:10 356:23	547:24 548:12,15	408:24
400:14,20 455:25	357:21 358:4,19	550:8 552:11,15	<b>deemed</b> 311:2
484:9 485:1 557:5	361:8,9,11,19,23	552:20 553:1,9,13	330:20 557:19
<b>david's</b> 485:2	364:2 365:25	554:11	<b>defendants</b> 286:8
<b>davidian</b> 392:21	369:2,7 374:20	<b>dea's</b> 285:21 286:1	292:6 458:4
<b>davison</b> 274:3	377:5 378:8	286:4 357:12,14	535:15
<b>day</b> 271:17,21	379:12 380:3,20	360:10 440:19	<b>defense</b> 288:18
278:24 383:12	381:7 382:15	<b>dea07</b> 276:9,11	428:15,22
390:8 411:24	383:23 395:22	<b>dealing</b> 301:22	<b>defined</b> 375:3
412:5 413:18	402:10,25 403:2,8	417:3	544:20
427:12 428:11	403:11 404:7	<b>dealt</b> 414:4	<b>definition</b> 422:6
458:19,19 528:23	406:1,22 407:17	<b>dear</b> 320:3 557:10	<b>definitive</b> 318:24
529:1 558:16	410:3,7,7 414:3	<b>deaths</b> 421:17	<b>deleted</b> 512:12,17
559:22 560:22	415:24 416:7	<b>debra</b> 271:2	513:1,17
<b>days</b> 329:4 460:24	418:19 420:6,17	<b>debra.ogorman</b>	<b>deliberations</b>
461:4 467:25	420:25 421:19	271:5	510:4,25 514:3
480:3 508:9	424:14 425:8,15	<b>decades</b> 426:6	515:7
557:18	428:1 429:17	<b>december</b> 341:25	<b>deliberative</b>
<b>dea</b> 276:12 277:6	430:16,21 431:4,5	343:5 442:9	289:14 511:23
279:7 280:4 282:7	431:10 432:2,7,20	449:13 450:21	515:22
282:10,20,24	433:5,15 434:1,24	453:4	<b>deliver</b> 324:5
284:3,10,11,17,18	438:19 441:11,16		326:3,6 355:25

372:7	529:2 539:17	380:16 415:25	<b>direct</b> 287:10,24
<b>delivered</b> 327:5	549:25 550:1	433:8 443:12	318:4 448:2
340:15 345:4	551:9 553:22,23	549:16 554:13	465:18,19 481:1
347:20 350:2,21	556:3,5,10,14	<b>determined</b>	482:13 483:18
352:8 354:4 355:3	557:8,11 558:1,3	310:19 379:6	539:21 550:17
358:10 409:4	559:1,3	551:15	<b>directed</b> 502:2
502:11	<b>depositions</b> 286:9	<b>determines</b> 353:24	<b>directing</b> 481:7
<b>delivering</b> 338:2	457:15	<b>determining</b>	<b>direction</b> 360:20
338:11 346:14	<b>deputy</b> 286:13	436:24 494:24	556:9
358:4,22 367:5	342:4	<b>detrimental</b> 327:1	<b>directly</b> 286:17
<b>demand</b> 469:25	<b>derived</b> 473:24	<b>developed</b> 380:17	461:18 462:12
<b>demonstrates</b>	<b>derogatory</b> 396:9	<b>deviate</b> 351:24	465:23 469:16
315:4	<b>derrick</b> 531:4	<b>deviated</b> 330:13	474:2
<b>denver</b> 274:19	<b>described</b> 460:12	<b>deviates</b> 352:19	<b>disagree</b> 485:11
<b>department</b> 270:7	460:20 467:21	<b>deviating</b> 329:14	<b>disapprove</b> 431:6
275:2,4,5,6,7	<b>description</b> 282:9	351:16	432:3
281:9,25 285:19	282:23 307:21	<b>deviation</b> 418:11	<b>disclose</b> 329:8
288:14 289:15	377:15 460:17	419:2	344:15 405:5
292:19 322:4	<b>design</b> 309:5 329:8	<b>deviations</b> 418:5	407:16 510:25
370:22 429:18	344:14 345:1	<b>diabetes</b> 300:24	516:1 550:8
442:11 557:22	366:23 380:16	<b>died</b> 382:1	<b>disclosing</b> 515:8
<b>departments</b>	405:4 407:15	<b>difference</b> 408:11	<b>disclosure</b> 515:7
289:17	<b>designated</b> 292:24	410:13	<b>discover</b> 552:10
<b>depending</b> 337:8	<b>designates</b> 399:18	<b>different</b> 458:14	<b>discovered</b> 308:5
546:1	<b>designed</b> 324:24	490:23	309:12,14 310:2
<b>deposition</b> 268:19	452:15	<b>dilaudid</b> 468:20	329:12 347:18
269:1 278:7	<b>desire</b> 460:13	<b>diligence</b> 331:11	348:6 376:7 405:9
280:18 289:12	<b>desired</b> 382:2	331:15,18,25	425:3,11
292:14 320:12	<b>desires</b> 460:10	332:7 347:3	<b>discuss</b> 358:15
341:16 356:13	<b>desk</b> 488:5	357:16 360:11	366:23 370:22
362:19 370:6	<b>despite</b> 398:5	369:20 372:5,13	455:11 460:3
383:12 386:6	<b>destined</b> 432:16	372:17 373:2,14	545:17 546:9
400:1 401:22	<b>detail</b> 503:24	374:3,19 406:16	<b>discussed</b> 363:2,12
402:7 415:17	<b>details</b> 387:3	444:20,24 448:23	424:24 492:9
429:12 437:15	441:24 481:25	449:22 450:23	498:4 501:12
442:5 455:14,15	512:3	451:16 452:21	502:6
455:19 457:5	<b>detect</b> 382:5	453:8 454:1,14	<b>discussing</b> 492:24
459:2 467:9	452:16	476:4 494:23	<b>discussion</b> 327:16
471:12 473:8	<b>determine</b> 309:21	496:4,8,24 497:8	373:13 397:14
495:18,22 514:19	310:16 333:17	516:16 551:16	399:7 415:13
525:6 527:16	350:14 353:16		446:7,18,20

477:24 478:1	<b>distributions</b>	536:8 538:17	371:19,23 402:8
494:22 495:1	538:21 544:17,24	543:2,24 553:16	402:20 405:7
496:9 497:22	545:10	554:16	424:15 430:7
501:11 511:7	<b>distributor</b> 285:3	<b>distributor's</b>	443:6 448:8
513:9	285:7 287:16	331:17 358:16	449:17 450:20
<b>discussions</b> 512:25	296:5 298:8,20,25	375:2,3	451:13 452:16
513:3,14,21 514:8	302:18 303:21	<b>distributors</b> 313:2	491:13 537:3
514:10	304:7 311:9,12	318:8 319:15	540:12 546:7
<b>disjunctive</b> 352:5	314:22 315:5,12	322:25 325:22	<b>diverted</b> 314:12
352:14	315:25 316:12	326:1 327:12,13	331:12 350:15,19
<b>dispensation</b>	322:18 323:16	327:19 328:1	433:24
431:22	324:6,17 325:9	343:9 344:8,11	<b>diverting</b> 315:3
<b>dispense</b> 372:20	326:6 327:6,18	345:4 357:14,22	<b>division</b> 268:3
<b>dispensed</b> 314:10	328:19 329:19	357:25 370:19	275:4 279:9 280:1
316:2 542:20	331:10 332:13,19	371:22 372:4,12	285:5 329:11
<b>dispensers</b> 358:1,1	334:6,7,13,18	372:20 378:1,7	347:17 545:22,24
<b>dispensing</b> 358:17	337:2,13 338:2,11	385:14,24 395:10	<b>dmigliori</b> 270:19
359:4	340:16 345:14	413:11 436:13	<b>doctors</b> 552:3
<b>displayed</b> 295:25	346:16 347:21	441:16 442:12,21	<b>document</b> 268:7
<b>displaying</b> 374:12	350:2,21 352:8,8	449:21 450:3	297:21 305:9
<b>dispositions</b>	354:5 355:3 356:5	451:15 472:20	306:8 332:25
537:11	358:10 359:3	476:3 504:3	333:1 336:14,17
<b>disproportionate</b>	361:16 365:25	506:13 507:14	356:16,19 357:5
338:9	367:5 373:16	513:23 518:4,8	357:10 370:14
<b>dispute</b> 456:10	375:5,6 376:24	526:20 527:2,12	371:15 374:13,16
<b>dissemination</b>	377:17,20 378:19	537:1,10,15,17	376:11 388:17,24
290:1	380:12,14 411:14	543:13 544:5,8	401:21,25 402:3,5
<b>distinction</b> 368:6,8	411:15 412:2,2,12	550:14,22 551:13	404:20 415:16
<b>distinguish</b> 369:12	413:2 414:19	552:17 553:14,15	423:5,17 424:4
<b>distribute</b> 391:21	440:25 443:6,10	554:12	427:16,17 429:6
<b>distributed</b> 315:2	461:17 462:6	<b>district</b> 268:2,2	429:15 435:9
538:17	465:4 466:4 492:8	556:22	442:8 447:20
<b>distribution</b> 297:8	492:18,25 493:6	<b>diversion</b> 276:15	452:7 459:6,7,10
299:6 325:1,16,24	493:10,14,21	276:20 279:8	459:12 467:15,18
326:25 356:25	497:6,7 500:16	285:5 294:21	471:15 474:11
370:16 391:13	504:3,14 505:1,21	302:23 304:8	528:1 540:2
396:12 450:19	507:15 508:3,18	315:5 316:11,16	<b>documentation</b>
451:11 461:5	509:1,10,16,18	323:23 324:24	335:8,16,23 336:3
465:8 475:19	510:1,10 517:3,10	325:6 332:18	369:19 376:10
539:6 542:7	517:14 518:2	334:7,12 337:20	377:11 379:3,20
	521:8 527:10	342:4 344:9 366:2	496:23 497:8

[documented - enactment]

Page 16

<b>documented</b>	271:9 360:19	<b>duty</b>	443:10	<b>effort</b>	322:3
376:12				438:15 439:8	
<b>documents</b>	276:22	<b>e</b>		<b>efforts</b>	322:13,17
429:1 434:20	276:19 280:6	273:8 274:8	275:3 276:1	323:16 467:24	323:16
436:5 501:4	292:10,25 297:11	277:23 278:1,1	332:18 334:6,12	546:9	546:9
<b>doing</b>	321:11 323:1	332:18 334:6,12	457:2,10 512:12	<b>either</b>	292:18
279:7 297:3	324:25 358:19	457:2,10 512:12	512:17,25 513:4	302:17 370:20	302:17
301:19 346:2	370:22 375:8	513:16 530:10	513:16 530:10	411:13 457:12	411:13
359:21 384:24	380:22 381:23,23	551:5,20 552:8	551:5,20 552:8	462:22 512:3	462:22
390:21 397:16,18	381:24 538:21	<b>earlier</b>	363:7	540:16 545:22	540:16
412:22 429:11	539:6	407:10 434:20	407:10 434:20	<b>electronic</b>	460:19
444:19,22,24	<b>druggist</b>	535:20 536:1	535:20 536:1	463:18 467:20	463:18
450:23 452:4	418:9	<b>early</b>	303:7 462:17	<b>electronically</b>	459:24
453:8 454:1,14	419:4 424:23	509:18	509:18	<b>elements</b>	291:8
461:13 462:3	<b>druggists</b>	<b>easiest</b>	<b>easiest</b>	460:20 463:20	460:20
476:18 485:14	416:21	400:23	400:23	467:21	467:21
492:25 494:21	417:10 420:24	<b>eastern</b>	268:3	<b>eleven</b>	439:22
511:21 513:8	425:7	274:16	274:16	<b>eliminate</b>	440:5
553:23	<b>drugs</b>	<b>ecah</b>	276:16	<b>ellis</b>	271:12 273:19
<b>doj</b>	314:10,12	<b>edi</b>	463:15,16,17	<b>email</b>	557:17
446:10,15	315:2 323:13	463:22 464:4	463:22 464:4	<b>emainigi</b>	272:11
<b>don</b>	337:25 381:19,20	465:1	465:1	<b>embarcadero</b>	271:18
278:17 293:7	381:21 409:24	<b>edited</b>	512:5	<b>emphasis</b>	304:6
362:14 365:2	442:3	<b>editing</b>	511:14	<b>emphasized</b>	366:16 505:22
374:10 551:6,20	<b>ds</b>	<b>edits</b>	512:6,7 513:5	<b>emphasizing</b>	421:8
<b>donald</b>	328:5	<b>educated</b>	507:13	<b>employ</b>	494:6
270:16	<b>dtayman</b>	<b>eekhoff</b>	270:17	<b>employed</b>	284:18
<b>door</b>	270:6	<b>effect</b>	327:1 382:2	556:12,16	556:12,16
310:22	<b>due</b>	430:20 512:15	430:20 512:15	<b>employee</b>	358:16
479:18 484:22	285:4 331:11	<b>effective</b>	276:14	556:15	556:15
485:5,7,8	331:15,18,25	302:22 304:8,15	302:22 304:8,15	<b>employees</b>	359:3
<b>dosage</b>	332:7,19 334:13	315:4 316:10	315:4 316:10	491:10	491:10
539:7 542:20	334:23 347:3	332:17 334:6,11	332:17 334:6,11	<b>employment</b>	282:7
543:1	357:15 360:11	344:9 366:1 443:5	344:9 366:1 443:5	282:9	282:9
<b>doubt</b>	369:20 372:5,13	449:17 450:20	449:17 450:20	<b>enacted</b>	303:7
512:24	372:17 373:2,14	451:12 491:12	451:12 491:12	<b>enactment</b>	348:13
<b>download</b>	374:3,19 406:16	<b>effectively</b>	421:15		
553:15	444:20,24 448:23	<b>effectiveness</b>	290:1		
<b>downstream</b>	449:22 450:23				
439:21	451:15 452:20				
<b>draft</b>	453:8 454:1,14				
276:12	476:4 494:23				
356:23 425:4	496:4,8,24 497:8				
<b>draw</b>	516:16 551:16				
312:11	<b>duly</b>				
359:18 445:10	556:6				
<b>drawing</b>	<b>duplicate</b>				
359:24	364:22				
<b>drew</b>	<b>duties</b>				
305:24	282:19				
375:21	290:10,19 327:11				

<b>enclosed</b> 557:11	464:22 474:6,10	493:25 505:21	492:7 493:16
<b>enclosing</b> 425:4	476:8,13,23	515:16	494:12,18 525:15
<b>encompass</b> 383:25	535:11,13,14	<b>evidence</b> 399:17	525:16,21,24
<b>encountered</b> 289:6	536:6 537:8 538:6	470:15	<b>exchanged</b> 461:4
298:6	538:11 539:3,13	<b>ex</b> 455:10 456:24	<b>excuse</b> 288:10
<b>encourage</b> 359:3	539:22 540:10,17	<b>exact</b> 435:23	424:2 541:15
<b>endemic</b> 421:13	540:20,25 541:2	<b>exactly</b> 503:19	544:16
<b>endorse</b> 345:11,22	542:3,16,18 543:7	<b>examination</b> 276:2	<b>executed</b> 559:10
<b>ends</b> 363:9	544:12 545:7	278:12 383:6	<b>execution</b> 558:14
<b>enforce</b> 324:18	546:4,12,18,22	478:15 512:23	559:19
416:15 426:19	547:9,21 548:4,9	535:12 549:6	<b>exercise</b> 331:11,14
<b>enforcement</b>	548:14,22 549:7	554:4	332:19 334:13,23
275:6 276:19	549:14 550:3,11	<b>examining</b> 398:11	<b>exhibit</b> 276:9,10
280:6 285:22	551:3,11 552:1,23	<b>example</b> 299:20	276:12,14,17,19
292:10,25 297:12	553:3,11 554:7,10	306:20 337:22	276:22,24 277:2,3
321:11 324:1,10	554:21 555:1	377:14 380:18	277:5,7,9,11,13,15
328:10 360:17	<b>errata</b> 557:13,18	458:20 464:18	277:16,17,18,20
370:22 545:19	559:7,10,18 560:1	466:2,10 469:15	277:22,23 280:19
549:22	<b>especially</b> 340:1	475:17	280:20 281:3
<b>enforcing</b> 435:10	<b>esq</b> 270:3,7,12,16	<b>examples</b> 303:16	288:15,17 295:6
<b>engaged</b> 279:14	270:17,21 271:2,8	313:19 363:19	295:17,18 305:6
<b>english</b> 272:3	271:11,17,20	508:16 510:20	306:3,12 307:4,16
<b>ensure</b> 325:5	272:2,7,7,8,8,15	<b>exceed</b> 375:9	309:2 310:4
<b>entered</b> 452:14	272:20 273:2,8,8,9	<b>exceeded</b> 305:25	318:11 320:12,15
453:16 459:14	273:14,18,19	<b>exceeds</b> 375:2	320:25 341:16,19
469:14 559:9	274:2,3,8,12,17,22	433:20	341:22 342:20
<b>entire</b> 367:20	275:2,3,4,5	<b>exception</b> 406:18	346:21 355:16
398:15 558:5	<b>essentially</b> 494:4	<b>excess</b> 306:4,13	356:12,13,16
559:5	513:22	307:6,22 408:19	362:13,15,15,18
<b>entitled</b> 415:21	<b>established</b> 359:17	<b>excesses</b> 489:7	362:19 363:3
417:7 459:13	359:22	<b>excessive</b> 306:16	370:4,6 386:3,6,17
473:18	<b>establishing</b>	306:20 310:5	401:21,22 407:7
<b>entity</b> 391:12	433:10	337:21 346:21	415:7,16,17 417:7
<b>enu</b> 272:7	<b>et</b> 268:9,11,13,14	354:23 355:16	423:17,17 424:1
<b>enumerated</b> 288:4	<b>evaluate</b> 357:25	367:2 368:10,14	429:6,12 435:23
<b>envisioned</b> 326:1	361:10	368:18 369:1,4	436:3 437:15
<b>eppich</b> 273:14	<b>event</b> 361:15	410:13,14 420:3	438:1,8 442:5,9
276:6 362:14	460:23	425:2,11 433:9	459:2,6 460:20,22
391:17 392:5,24	<b>events</b> 530:24	487:8,11,14 488:2	467:7,9,21 468:17
393:6,14 452:22	<b>everybody</b> 291:17	488:13 489:8,14	469:23 471:7,12
452:25 454:3	336:23 421:22	490:11 491:24	473:6,8 495:18,22

508:4,5,11,13 527:15,16,19 539:14,17,23 551:4,9 <b>exhibit's</b> 415:11 <b>exhibits</b> 276:8 277:1,25 429:10 508:8 <b>exist</b> 332:7 339:18 340:23 351:2 353:3 <b>existed</b> 340:25 351:6,8 364:2 426:20 525:21 <b>existence</b> 329:24 330:3 482:22 486:1 526:7 <b>existing</b> 380:20 <b>expand</b> 358:19 <b>expect</b> 377:25 <b>expects</b> 357:24 <b>experience</b> 284:2 291:11 297:13 299:24 301:2,12 303:2 305:17 306:2 308:4,10,16 309:13 310:25 311:15,24 312:16 313:14 317:23 322:2,16 324:6 325:8 327:5 328:11 329:18 330:11 334:23 339:6 340:17 345:19 346:15 347:5 348:1 351:3 351:9 361:24 376:1 378:7 382:14 406:23 419:14,17 449:9 489:5,11 490:8	499:2 <b>experiences</b> 298:4 <b>experiencing</b> 421:14 <b>expert</b> 290:8 <b>experts</b> 482:21 <b>expiration</b> 558:19 559:25 560:25 <b>expires</b> 556:24 <b>explain</b> 339:4 <b>explained</b> 281:3 336:13 528:3 <b>explanation</b> 399:12,13 400:10 <b>explicit</b> 346:9 <b>explore</b> 491:19 <b>express</b> 311:24 <b>expressing</b> 432:17 <b>expressly</b> 326:24 <b>extended</b> 433:22 <b>extent</b> 285:23 286:24 287:12 288:2 292:17 332:23,24 333:10 333:11,22 447:8 452:2,6 482:3 485:20 505:18 510:4,24 514:1,2 515:6 520:9 528:17 531:25 545:19 550:19 <b>external</b> 356:24 <b>extra</b> 553:21 <b>extraordinarily</b> 543:15 544:3 <b>extremely</b> 400:9 <b>eye</b> 270:4 332:16 334:10	<b>f</b> <b>f</b> 277:2 <b>face</b> 351:25 353:12 <b>faces</b> 323:2 <b>facets</b> 279:12 <b>facilities</b> 453:19 <b>facility</b> 448:21 449:16 <b>fact</b> 281:11 292:23 297:17 312:8 318:11 328:13 332:14 333:14 334:8 378:5 408:6 408:13 409:16 415:6 420:1 422:21 424:25 425:9 442:3 458:13 463:14 475:20 488:16 492:23 503:16 504:2,14 516:10 516:10 525:7 527:8 532:20 533:1,3,7,22 534:7 534:14 535:2,7,8,9 <b>facts</b> 290:9,17 491:11 <b>factual</b> 284:2 <b>failing</b> 328:20 491:12 <b>failure</b> 316:10 328:8 331:14 334:22,23 337:8 449:16 450:19 451:12 452:15 453:6,18 <b>fair</b> 280:3 333:20 339:25 348:22 395:8 406:2 411:19 412:14 423:1 426:22	450:12 451:24 454:2 463:10 494:7 <b>faith</b> 404:25 <b>fall</b> 493:24 <b>familiar</b> 320:2 342:13 364:12 378:18 403:7 430:9 435:5 441:15 466:23 471:22 472:1 495:3 551:13 <b>familiarize</b> 527:11 <b>far</b> 358:15 425:8 477:15 482:24 485:3 511:23 548:2 <b>farrell</b> 270:21,22 <b>fast</b> 494:15 <b>fda</b> 380:18 <b>federal</b> 289:17 347:4 <b>fedex</b> 391:6,6,11 <b>fee</b> 461:1 <b>feel</b> 282:21 495:8 509:13 516:14 <b>felt</b> 299:25 516:10 <b>fentanyl</b> 537:24 <b>fentora</b> 466:18 <b>fewer</b> 421:16 <b>field</b> 279:9,21 280:1,9 301:23 329:11 346:4 377:5 384:1 405:7 405:20 416:8 419:13 420:17 430:21 431:6 432:2 450:3 487:19 488:1,8,24 547:8,13,24 548:25,25 549:16
--	---	--	---

553:5	454:13 460:8	294:23 301:16,25	<b>forum</b> 395:15
<b>fields</b> 473:20	471:16 480:20	305:18 307:7	<b>forward</b> 399:10
<b>fifteenth</b> 273:20	484:20 536:1	308:8,18 309:15	432:9 434:14
<b>fifth</b> 270:4 529:25	545:23	319:18 342:2	557:15
530:18,20	<b>five</b> 281:11 460:24	354:6 357:15	<b>found</b> 306:7
<b>figure</b> 458:5,23	461:4 467:25	361:1 364:16	540:11 547:11
484:8	486:24,25 551:2	388:13 396:5,21	<b>foundation</b> 301:17
<b>file</b> 531:1	555:12	396:25 397:2	307:8 308:19
<b>filed</b> 447:20	<b>fix</b> 333:21 334:1	398:15 399:15,20	322:9 343:18
<b>filings</b> 531:6	<b>flag</b> 300:9,13	400:10 403:3,15	360:4 367:13
<b>fill</b> 432:15	301:7	406:25 428:12	368:12 391:16
<b>filled</b> 357:23	<b>flags</b> 301:9,21	448:12 452:22,25	396:17 409:21,23
<b>filling</b> 331:11	546:14	454:3,10,16	448:13 453:1
332:21 334:15,25	<b>flash</b> 305:4	465:14 469:20	491:16
348:20 349:25	<b>flip</b> 363:2	474:6 476:8,13,23	<b>four</b> 286:15 287:4
<b>final</b> 285:18 379:4	<b>floor</b> 270:4,13	491:15 497:3	343:24 367:17
<b>finally</b> 290:23	271:9 274:13	500:14 501:7,24	481:17 518:12
379:16	<b>florida</b> 453:21	504:17 505:17	<b>fourth</b> 284:25
<b>finance</b> 273:18	<b>flow</b> 287:4	506:14,15 507:16	529:23,25
<b>financially</b> 556:17	<b>flowed</b> 475:3	507:17,25 509:23	<b>fox</b> 274:23
<b>find</b> 295:9,11,14	<b>flowing</b> 474:15	512:21 518:18	<b>foxrothschild.com</b>
402:18,21 557:11	<b>focus</b> 324:17	519:13 523:1,21	274:25
<b>fine</b> 397:6 400:14	<b>focused</b> 411:25	524:14 525:13	<b>frame</b> 411:2 415:2
400:20 445:19	<b>folded</b> 490:23	526:2,3,11,12	491:25
446:9	<b>folks</b> 514:10	527:4 528:9	<b>francis</b> 275:10
<b>fines</b> 337:10	<b>follow</b> 278:24	530:15 531:14,22	<b>frankly</b> 528:19
<b>finish</b> 468:11	361:12 400:21	533:5 538:5,9	<b>fraud</b> 275:5,7
506:1 520:22	451:21 549:15	543:4,17 545:3	<b>free</b> 509:13 516:14
521:1	<b>following</b> 327:14	554:23	558:14 559:20
<b>finkelstein</b> 275:4	420:16 460:24	<b>format</b> 460:19	<b>freight</b> 391:6
<b>firm</b> 376:14	467:25	463:17,18 467:20	<b>frequency</b> 298:17
532:10,17,22	<b>forbidding</b> 483:5	469:23	329:16 330:13
534:7,7 535:3	<b>foregoing</b> 285:24	<b>formed</b> 400:6	351:18 353:2
<b>first</b> 277:11 280:4	556:3,5 558:13	<b>forming</b> 321:14	<b>frequently</b> 299:25
282:5 311:14	559:18	<b>fort</b> 541:5	460:22
316:13 318:16,18	<b>forgive</b> 541:19	<b>forth</b> 436:23	<b>friends</b> 507:7
321:9 322:22	<b>forgo</b> 440:25	460:22 464:8	<b>front</b> 280:21,25
337:20 346:3	443:10,24	465:3 497:23	364:22 386:23
352:7 378:21	<b>form</b> 282:25	511:14 512:19	495:8,11 498:20
383:11 387:11	283:21 286:20	513:14	508:8 522:24
447:1 453:9,25	291:13 292:15		545:23

<b>fulfill</b> 310:16 312:9,10 340:12 408:22 <b>fulfilled</b> 409:3 <b>fulfilling</b> 311:4 <b>fulfillment</b> 375:7 <b>full</b> 371:16 377:15 <b>fuller</b> 275:9 <b>fully</b> 376:12 <b>fulsome</b> 505:4 <b>function</b> 324:1 325:25 <b>functions</b> 323:23 544:19,21 <b>fundamental</b> 443:4 <b>furnish</b> 337:9 <b>further</b> 399:4,4 443:8 460:12 478:15 547:5 556:14	<b>generated</b> 436:6 542:5,19,25 <b>geoffrey</b> 273:8 <b>geographic</b> 433:13 <b>geriatric</b> 300:24 <b>getting</b> 405:19 462:5 469:15 476:2 479:16 <b>ghobart</b> 273:12 <b>gist</b> 412:10 518:1 <b>gitchel</b> 424:16 <b>give</b> 281:12 285:20 303:16 313:19,20 336:13 343:20 349:18 371:16 386:5 403:13 404:13 424:7 429:5 437:3 442:15 466:10 524:18 527:14 540:24 <b>given</b> 282:8,21 328:2 334:5 377:14 403:8 451:3 493:22 555:10 556:11 <b>gives</b> 302:18 404:8 <b>giving</b> 283:25 284:1 286:3 289:4 290:8 302:5 323:10 329:19 334:17 357:17 366:11 450:11 451:22 494:14 541:4 <b>go</b> 280:15 281:15 288:19 294:1,10 295:1 296:11 304:14 308:23 309:19 311:5 313:23 316:17	322:12 329:1 335:20 336:9 342:24 361:7 365:20 382:14 387:3,9,15,18 389:23 390:6,13 390:20 391:4 392:1,13,20 393:2 393:7,11,18 394:2 394:16 395:22 397:3 398:22 399:1,10 401:14 407:5 408:3 423:25 430:16 445:22 446:5,9,21 447:1 456:25 463:20 466:9 473:18 477:18 478:5 480:9,9 484:8 485:3,3 506:1 514:20 515:1 517:13 532:3 533:8,10 534:16,20 540:21 541:6 549:24 555:1 <b>goal</b> 395:13 <b>god</b> 292:21 <b>goes</b> 332:12 337:19 348:13 351:14 379:2 399:3 419:24 433:19 464:25 510:4 547:19 <b>going</b> 278:4 280:23 290:16 291:7 294:3 305:4 309:20 329:1 339:10,13 341:4,9 359:3 372:2 374:11 381:23	382:3,20,25 383:21 393:16 397:4,10 401:8,20 402:18,19 415:6 415:11,11,15 423:16 424:13 428:1 429:5,15 430:12 434:6 437:5 438:9 441:20 442:8,22 445:23 446:15,17 452:1 454:18,22 455:2 456:5 457:5 459:5,9,10 460:16 467:6,7 468:2,6 470:16 471:6 473:5 478:7,11 479:13,15 481:1 484:6 485:11 494:18 496:21 515:5 521:17,22 529:22 533:8,11 533:15 535:5 539:19 540:8 541:18 547:17 555:3 <b>good</b> 278:3,15,16 336:4 367:17 374:3,7 379:21 383:9 396:3 397:8 400:3,6 404:25 423:22 424:11 428:20 438:14 439:7 442:24 478:18 <b>gotten</b> 498:1 <b>government</b> 292:9 348:22 417:3 455:16,20,21 456:13,15
--	---	--	--

<b>grams</b> 538:22 539:7 <b>grant</b> 274:14 <b>granular</b> 472:12 <b>gray</b> 274:3 <b>greater</b> 301:1 372:18 <b>greene</b> 270:22 <b>grievously</b> 547:5 <b>grounds</b> 315:13 <b>group</b> 389:9,16 409:13 410:7 417:19 422:5 544:14 <b>groups</b> 313:13 <b>growing</b> 323:14 <b>guarantee</b> 316:9 519:21 <b>guess</b> 483:9 507:13 533:5 536:10 <b>guidance</b> 371:21 373:13 375:12 376:10 377:19 379:12,21 380:3 380:24 381:9 451:3 524:11 525:8 549:18 <b>guided</b> 418:10 <b>guideline</b> 526:17 <b>guidelines</b> 276:18 370:15 371:17 <b>guys</b> 477:22,24 507:7 <b>gx</b> 274:2	<b>half</b> 481:23 553:22 554:18 <b>hand</b> 386:2 401:20 415:11,15 442:8 459:5,9 464:9 473:5 <b>handed</b> 386:16 437:18 <b>handle</b> 328:2 <b>handler's</b> 277:3 <b>handlers</b> 325:1 435:6,12 436:7,15 436:22 437:19 438:8 443:15,18 <b>hands</b> 310:15 <b>hang</b> 402:17 446:25 520:19 <b>happen</b> 320:20 399:23 <b>happened</b> 292:2 455:14,24 482:21 528:22 529:6 <b>happening</b> 293:9 493:11 <b>happenstance</b> 482:21 <b>happy</b> 368:3 370:10 397:21 <b>hard</b> 456:15 458:1 458:13,18 494:15 <b>harm</b> 340:4 409:4 <b>hbc</b> 274:11 <b>hda</b> 356:1 <b>hdma</b> 276:12 356:1,6,23 357:8 358:4,23 360:2 362:23 369:24 370:1,17 371:3,8 371:20 372:17,23 373:7,24 375:1	<b>376:9,10,18</b> 377:10,20 379:8 379:21 380:9,25 493:1 <b>hds</b> 276:13,23 402:2 <b>he'll</b> 507:6 <b>headquarter</b> 280:6 <b>headquarters</b> 287:5 295:22 321:10 487:19 488:12 <b>heads</b> 333:16 <b>health</b> 272:6 277:13 323:14 327:2 342:21 343:14 370:14 386:14 390:7 429:19 431:2 448:20 449:15 453:4 472:2,5 473:14 478:16 <b>health's</b> 450:18 451:10 <b>healthcare</b> 370:16 373:24 <b>hear</b> 299:16 395:24 506:25 <b>heard</b> 416:20 424:21 458:14 554:21 <b>hearing</b> 427:2 <b>heart</b> 300:25 <b>held</b> 269:1 282:20 282:24 399:7 415:13 <b>help</b> 298:1 359:7 359:10 361:4 372:6 402:21 448:4 475:25	<b>476:2,20 541:7</b> <b>helped</b> 296:4 428:3 <b>helpful</b> 398:2 462:2,2,8 540:13 <b>helps</b> 387:19 <b>hem</b> 532:4 <b>henry</b> 273:2 356:19 392:14 <b>hereof</b> 460:21 467:22 <b>hereto</b> 460:20 467:22 556:16 <b>high</b> 282:23 472:11,13 <b>higher</b> 287:4 360:11 <b>highlight</b> 404:20 <b>highlighted</b> 356:21 357:13 <b>highlighting</b> 365:3 374:12 433:4 <b>history</b> 282:7,10 294:21 309:13 <b>hit</b> 395:24 <b>hmm</b> 400:5 <b>hobart</b> 273:8 <b>honest</b> 423:6,10 <b>hope</b> 292:21 354:7 387:25 523:14 <b>horrible</b> 429:10 <b>hour</b> 456:21 481:21,23 <b>hours</b> 435:10 553:22 554:19 <b>house</b> 390:8,15 <b>houston</b> 384:20 385:6,14 386:21 389:18 390:23 391:8 392:23 402:1 404:9
<b>h</b>			
<b>h</b> 290:4 321:20 <b>h.d.</b> 274:7 392:2 402:3 498:24 512:11 520:4 522:6 523:7	356:1,6,23 357:8 358:4,23 360:2 362:23 369:24 370:1,17 371:3,8 371:20 372:17,23 373:7,24 375:1	282:24 399:7 415:13 <b>help</b> 298:1 359:7 359:10 361:4 372:6 402:21 448:4 475:25	

409:19 497:20 498:12 500:17,25 <b>houtz</b> 274:17 <b>hsi</b> 356:17 362:16 <b>huh</b> 349:5 408:21 <b>hunter</b> 270:12 278:21 383:10 397:18 457:23 478:20 484:22 <b>huntington</b> 270:23 <b>hydrocodone</b> 279:19 337:23 449:18 450:21 451:13 537:24 541:14,23 <b>hysingla</b> 471:21 471:22	<b>identifier</b> 473:22 <b>identify</b> 281:11 309:6 366:24 414:6 419:2 443:7 443:24 453:18 483:1 515:19 543:14 544:2 546:5,14,19 547:13,23 <b>identifying</b> 483:6 550:12 551:14 552:2 <b>ii</b> 268:18 270:7 278:7 468:21 470:4 557:8 558:4 558:9 559:4,13 560:20 <b>illegal</b> 326:25 489:6,13 490:10 <b>illicit</b> 323:24 432:16 438:13 439:6 440:23 <b>illicitly</b> 381:19 <b>illinois</b> 271:22 453:20 <b>illustrate</b> 364:19 <b>imf</b> 473:14 <b>immediate</b> 444:9 445:8 448:19 449:14 450:17 454:7 <b>immediately</b> 316:3 418:5,12 419:1 422:13 <b>impaired</b> 290:2 <b>implement</b> 324:2 <b>implementing</b> 420:12 <b>implicit</b> 346:9 <b>importance</b> 299:11 304:10	406:15 <b>important</b> 299:13 299:19 300:17 359:2 366:3,16 506:7 521:1 534:23 <b>impossible</b> 362:4 <b>impoverished</b> 359:20 <b>impressing</b> 434:7 <b>impression</b> 436:5 <b>impressions</b> 291:23 <b>improper</b> 489:6 489:12 490:10 <b>impropriety</b> 535:4 <b>ims</b> 277:13 472:2,2 472:4,5,25 473:14 473:23 474:14,19 475:1,4 <b>inappropriate</b> 399:21 533:24 <b>incentive</b> 328:4 <b>include</b> 313:1 329:13 353:10 358:20 360:24 377:11 379:3 380:12 404:25 464:8 470:14 514:9 <b>included</b> 277:25 406:18 455:21 465:2,7 537:23 557:13 <b>includes</b> 313:4 <b>including</b> 289:15 313:7 379:5 380:15 471:19 <b>inclusive</b> 298:6 352:6	<b>incompatible</b> 443:23 <b>incorporated</b> 393:4 411:4 559:12 <b>increase</b> 353:22 <b>independent</b> 331:1 350:12 351:1 <b>independently</b> 370:21 373:21 <b>indiana</b> 272:14 274:9 <b>indianapolis</b> 274:9 <b>indicated</b> 397:22 491:11 <b>indicates</b> 344:24 <b>indicating</b> 354:23 502:13 550:7 557:13 <b>indication</b> 380:19 <b>indicative</b> 337:20 <b>individual</b> 361:25 474:4 547:17 548:3 <b>individually</b> 548:13 <b>individuals</b> 404:11 480:4 515:8,20,22 <b>industrial</b> 331:14 <b>industry</b> 276:17 301:14 312:21 313:22 316:4,7 347:1 360:17 362:10 370:15 371:17 384:19 385:20,22 386:20 396:11 401:15 402:9 406:21 409:17 410:8 417:1,18,19 419:3 419:4,19 420:5
<b>i</b>			
<b>idea</b> 333:2 397:23 413:20 442:24 502:17 554:9 <b>identifiable</b> 473:21 <b>identification</b> 320:13 341:17 356:14 362:20 370:7 377:12 386:7 401:23 415:18 429:13 437:16 442:6 459:3 467:10 471:13 473:9 495:19,23 527:17 539:18 547:12 549:9 550:14 551:10,21 552:16 <b>identified</b> 287:1 375:21,24 414:20 473:22 526:21 547:22 548:16,24 549:10			

427:2 428:1 448:9 454:13 463:22 531:1 <b>industrywide</b> 314:14 315:7,9,15 342:22 <b>influenced</b> 400:23 <b>inform</b> 329:10 343:9 347:17 405:7 431:4 452:17 550:14 <b>information</b> 288:21 289:6,13 289:24 290:9,17 294:19 316:20 318:12 343:21 361:15 373:17,19 373:20 377:16,17 379:18 380:21 395:14 413:2 447:9,13 462:4,10 463:15 464:8 465:3 470:2 472:12 473:20 474:3 545:22 546:3 549:18 550:8,21 552:10 <b>ingredient</b> 305:7 306:4,12 355:17 435:22 <b>initiative</b> 287:17 322:18 323:17 324:18 325:10 326:7 327:6,18 328:19 329:20 334:18 337:2,14 338:2 340:16 345:15 346:16 347:21 350:21 352:9 355:4 356:5 358:11 492:8	536:8 <b>initiatives</b> 338:12 <b>ink</b> 425:5 510:17 511:12,21 512:19 513:5 <b>inmate</b> 519:19 <b>inquiry</b> 405:1 <b>inside</b> 400:1 <b>insightful</b> 462:15 <b>inspect</b> 361:12 <b>inspections</b> 360:25 488:17 <b>institutional</b> 426:16 <b>instruct</b> 547:17 <b>instructed</b> 447:17 <b>instructing</b> 515:24 550:5 <b>instruction</b> 366:10 515:12,14 546:16 548:1 <b>instructions</b> 514:12 549:18 <b>insurance</b> 299:23 299:24 <b>insurances</b> 299:24 <b>intelligence</b> 289:25 <b>intend</b> 326:14 372:20 <b>intended</b> 373:5 438:13 439:6 456:23 <b>interact</b> 285:11 <b>interaction</b> 285:2 361:19 <b>interactions</b> 285:12 <b>interchange</b> 301:18	<b>interest</b> 302:21 315:13 370:25 375:1,6,11,19 <b>interested</b> 556:17 <b>internal</b> 289:13 510:4,25 511:22 513:14,20 514:3 515:7,21 547:16 <b>internally</b> 548:13 552:20 553:9 <b>internet</b> 279:14,16 279:19 295:20 296:16,20 298:11 302:10,14 303:18 304:18 313:22 314:4,13,19 315:6 315:14 316:5 509:14 510:9 516:4 519:16 <b>interpretation</b> 285:21 286:1,4 436:6 452:3 524:11 525:8 <b>interpretations</b> 292:1 <b>interpreted</b> 421:19 535:6 <b>interrupt</b> 520:2 <b>interrupted</b> 468:19 <b>interviews</b> 477:2 <b>intimacy</b> 520:8 <b>introduced</b> 288:18 383:11 <b>introduction</b> 372:3 <b>invalid</b> 314:10 <b>inventories</b> 537:12 <b>inventory</b> 277:7,9 277:11 459:8,13 459:24 460:11	461:3 467:8,12,17 469:24 471:16 <b>investigate</b> 373:21 427:3 <b>investigated</b> 379:5 <b>investigation</b> 279:14,17,18,20 288:22 316:15 336:16 376:13 379:4,20 384:11 441:21 443:11 444:20 445:6,13 447:10,14,19,22 452:3 460:5 477:4 <b>investigations</b> 279:11 280:10 301:23 376:11 378:12 384:6 406:16 447:7 460:3 477:2 <b>investigative</b> 289:25 <b>investigator</b> 279:8 430:7 <b>investigators</b> 488:21 527:3 <b>involved</b> 280:10 339:10 340:17 360:17 441:25 457:9,13,18 515:9 515:11,23 <b>involving</b> 455:20 <b>irresponsibility</b> 432:18 <b>irs</b> 336:18 <b>issue</b> 299:19 300:5 369:18 413:19 448:2 457:1 485:2 495:4 530:10 <b>issued</b> 444:8,10 448:6 449:15
---	---	--	---

[issued - larger]

Page 24

450:16 451:9	<b>jonesday.com</b>	<b>klockenga</b> 275:8	371:3,9 426:16
454:8 479:17	271:23	<b>knew</b> 350:18	436:12,19 462:22
<b>issues</b> 297:25	<b>joey</b> 341:24	394:9 410:10	462:23 466:21
298:5,16 302:4	<b>jr</b> 270:21	422:16 425:22	476:17 489:10
417:2,4 524:12	<b>judge</b> 268:7	426:6 491:11	490:7,13 491:22
<b>it'd</b> 354:1	522:24 523:8,17	506:10 531:5	492:1,2 493:16
<b>items</b> 298:5,7	523:25 527:20	<b>know</b> 279:4	<b>knowledgeable</b>
<b>j</b>	528:4 530:5,5,19	280:17 281:2	316:17
<b>j</b> 268:19 269:1	531:9,18 532:1,3	291:6 293:7 331:3	<b>known</b> 328:18
270:12 271:17,20	<b>judges</b> 528:5	336:20 338:17,22	350:18 426:5,13
276:2	<b>july</b> 459:14	339:18,22 340:5,5	441:10 458:12
<b>james</b> 270:7 349:6	<b>jump</b> 460:16	342:18 343:2	525:22,22 536:11
354:7	468:2	369:25 373:13	<b>knows</b> 400:11
<b>james.bennett4</b>	<b>june</b> 415:20 541:4	389:25 396:17,20	<b>krnceanic</b> 271:11
270:10	556:24	400:5 403:2	<b>kyle</b> 268:19 269:1
<b>janssen</b> 271:7	<b>jurisdictional</b>	412:22 416:15	276:2 278:8
<b>january</b> 277:4	279:25	422:3,22 423:9	357:11 358:15,18
437:25 451:11	<b>jury</b> 525:19	424:17 427:25	361:10,14 555:10
453:15	<b>justice</b> 270:7	435:9 441:24	557:8 558:4,9
<b>jbarker</b> 271:10	275:2,4,5,6,7	445:19,21 456:11	559:4,13 560:20
<b>jeffrey</b> 271:8	281:9 282:1	463:4,16,20	<b>kyle's</b> 361:13
<b>jennifer</b> 272:8	285:19 288:14	472:18 473:3	<b>l</b>
273:18	289:15 292:19	474:14,20 475:10	<b>l</b> 268:24 556:2
<b>jennifer.levy</b>	429:18 442:11	481:4,5,25,25	<b>l.p.</b> 268:9,11,13
273:21	<b>justification</b> 301:6	484:22 486:14	271:2
<b>jersey</b> 450:18	<b>jwicht</b> 272:12	488:20,23 494:5	<b>labeled</b> 340:2
453:20	<b>k</b>	496:19 499:17	355:20
<b>job</b> 268:25 415:25	<b>k</b> 273:14	501:16,16 502:10	<b>laboratories</b>
416:14 462:3	<b>kaitlyn</b> 270:17	502:21 504:11	393:12 395:2
506:4	<b>keekhoff</b> 270:20	509:8 510:5	<b>lack</b> 315:4 462:23
<b>jodie</b> 275:8	<b>keep</b> 337:9 399:3	516:24 519:18,24	<b>lacks</b> 307:7
<b>joe</b> 320:6 321:14	468:6 485:11	520:3,6 521:11	<b>lakeland</b> 449:15
503:4	521:4	529:21 530:2	<b>land</b> 339:11
<b>johnson</b> 271:7,7	<b>kelly</b> 274:24	534:17 542:1	<b>lane</b> 270:3
<b>join</b> 554:2	<b>kept</b> 421:15	544:20 547:4	<b>language</b> 312:23
<b>joined</b> 357:11	<b>ketchum</b> 270:22	552:14,14	329:4,17 330:4
487:9 537:19	<b>key</b> 325:23	<b>knowing</b> 406:15	343:5 344:17
<b>jointly</b> 510:13,14	<b>kind</b> 300:4	533:23	348:7 353:9
<b>jones</b> 271:17,21	<b>kirkland</b> 273:19	<b>knowledge</b> 319:2	<b>large</b> 543:15 544:3
<b>jonesday</b> 271:19	<b>kirkland.com</b>	319:14 322:3	<b>larger</b> 364:22
	273:21,22	342:25 349:1,9,11	457:3

<b>lasted</b> 481:20	342:7,13 343:5,7	<b>limited</b> 284:19	<b>loading</b> 398:18
<b>late</b> 480:19 484:1	343:12,17 354:16	302:9,13 314:13	<b>lobbying</b> 422:5
<b>latitude</b> 482:22	424:4,14,22,24	314:18 337:21	<b>local</b> 347:17
<b>launched</b> 553:13	434:24 442:10	338:7 352:15	544:18,25 552:11
<b>law</b> 347:4 406:1	494:17 503:15	386:9	<b>located</b> 279:22,24
545:18	504:13 507:22	<b>limits</b> 360:18	<b>location</b> 358:17
<b>lawful</b> 326:4	557:19	<b>line</b> 411:16 520:22	376:14 401:17
<b>lawson</b> 530:5,19	<b>letters</b> 319:22	521:2 524:7,18	<b>locations</b> 359:5
<b>lawyer</b> 394:18	320:2,3 503:4,9,23	557:13 559:7	373:5
<b>lead</b> 360:16	506:12 517:22	560:3	<b>locke</b> 273:3
433:22 509:19	518:1	<b>lines</b> 499:15,20,24	<b>lockelord.com</b>
<b>leading</b> 367:22	<b>letting</b> 311:5	<b>list</b> 281:17 386:19	273:6
<b>learn</b> 482:21	<b>level</b> 282:23	387:13,17 388:25	<b>logan</b> 272:21
<b>learned</b> 294:20	360:11 372:18	389:24 435:22	<b>long</b> 435:10
548:6	421:15 461:17	466:21 468:16	441:10 455:11
<b>leave</b> 533:21	465:7 470:6,16,25	<b>listed</b> 318:5 559:7	481:18 484:2
<b>lee</b> 270:3 557:5	472:11,11,13,22	559:17	486:22 512:8,9
<b>left</b> 477:12 535:5	474:8,15 475:2,19	<b>listening</b> 523:10	550:23
<b>legal</b> 309:16	475:20 490:21	<b>listing</b> 559:7	<b>longer</b> 346:12
327:11,14,18	544:25	<b>lists</b> 380:9	467:24 478:1
328:2 491:8	<b>levels</b> 297:9	<b>litany</b> 517:1	494:11,18 521:5
555:12 557:1	385:21 544:18	<b>literally</b> 320:22	526:8
560:1	<b>levy</b> 273:18	<b>litigation</b> 268:6	<b>look</b> 298:7 301:5
<b>legally</b> 372:21	<b>lexington</b> 270:13	278:20 292:11	317:1 321:3
<b>legislation</b> 417:3	<b>liaison</b> 318:23	356:20 370:23	322:22 341:23
<b>legitimacy</b> 332:20	<b>license</b> 277:7,9,11	383:20,22 441:23	357:3 358:16
334:14,24 361:4	459:8,14 460:10	524:12 535:16	359:4 363:10
<b>legitimate</b> 302:24	460:14 461:1	557:6 558:3 559:3	373:12 399:10,19
311:10 314:11	467:8,12,17 471:1	<b>little</b> 287:20 291:6	417:6 429:17
325:1 330:23	471:17	369:23 381:25	430:5 499:14
331:13 340:10	<b>lies</b> 411:11	387:4 482:23	508:2 515:1
350:15 353:20	<b>lieu</b> 344:6	492:15 496:19	517:13 529:16
443:13	<b>life</b> 528:24 529:1	<b>llc</b> 270:17 272:14	534:21
<b>lester</b> 274:17	<b>liked</b> 419:18	273:18 274:2	<b>looked</b> 375:22
<b>lester.houtz</b>	420:22 426:5,12	388:9	378:5 402:7 435:3
274:20	427:24 428:8,25	<b>llp</b> 269:7 270:3,22	443:17
<b>letter</b> 276:9,10	<b>limit</b> 305:7,25	271:3,8,12 272:9	<b>looking</b> 299:11,18
277:5 281:19	306:1,1,2,4,12	272:15,21 273:3,9	317:7 352:17
290:4 321:14	355:17	273:14,19 274:3,8	391:5 399:2 423:5
322:23 331:8	<b>limitation</b> 285:14	274:13,18,23	491:18 517:9
337:6,18 341:23			539:25 540:23

<b>looks</b> 390:6 541:23 542:2	517:16 518:5 519:3,8 520:1	313:15,24 314:7 314:15,23 315:8	369:15 370:2,11 371:4,10,24
<b>lord</b> 273:3	522:11,19 523:9	315:16,21 316:6	372:10,14,24
<b>los</b> 273:15	523:22 524:3	316:23 317:4,11	373:8,25 374:6,22
<b>losses</b> 405:2	526:4,15,23	317:19,25 319:3,8	375:13,18 376:2
<b>lost</b> 287:20 464:10 474:22 532:11 543:18	527:13,24 528:10 530:7 531:16 532:6,15,18 533:6	319:17,24 320:4 320:16 321:23 322:8,19 323:7,18	376:19,25 377:7 377:21 378:2,10 378:22 379:9,13
<b>lot</b> 510:17 535:24 538:7	<b>machine</b> 507:3	324:7,13,20	379:23 380:4
<b>loud</b> 505:9,14 530:18	<b>madam</b> 557:10	325:11,19 326:8	381:3,11,15
<b>low</b> 472:11	<b>mail</b> 277:23 457:2 457:10 513:16	326:15 327:7,21 328:15,23 329:21	382:10,16 384:2,9 384:25 385:16,25
<b>lower</b> 366:3 421:15	551:5,20 552:8	330:1,6,15,19	386:11 387:22
<b>lunch</b> 455:1,9,12 456:5 458:12,15	<b>mails</b> 512:12,17,25 513:4 530:10	331:5,19 332:1,9 333:6 334:19	388:1,5,11 389:4 390:2,9 391:15,23
<b>m</b>			
<b>m</b> 272:2,15,16 274:12 275:4 281:19	<b>main</b> 271:13 449:16 549:25	335:3,10,17,25 336:6 337:3,15	392:4,11,17 393:23 395:18
<b>ma'am</b> 478:22 479:10 480:6 486:9,17,21 487:2 487:6,13,17,23 488:10,15 489:9 489:15,19,20,23 491:5 492:4,22 493:4,8,12 495:2,6 496:7 497:4,10,24 498:7,19,25 499:3 499:6,9,13 500:1 502:12,19,25 503:7,11,13,25 504:8,23 505:3,7 505:11 506:8 509:6 510:18 511:8,8,15,19 512:9,16 513:6,11 513:19 516:13,17 516:25 517:6,12	<b>mainigi</b> 272:7 276:5 282:2,25 283:21 284:5,13 284:22 285:15 286:5 287:6,18 288:7,10,24 289:8 289:19 290:3,12 290:20 291:3,12 292:3,15 293:6,23 294:8,13,23 296:18,22 297:5 297:15,20 298:13 298:21 299:2,8,21 300:6,10 301:16 301:25 302:6,11 303:3,8,13,24 304:11,20,25 305:14,18 306:6 306:14,18 307:1,7 307:18,24 308:7 308:13,18 309:7 309:15,25 310:7 310:23 311:1,16 311:21 312:1,5,18	338:4,13,19 339:1 339:7,20 340:9,19 340:24 342:10,14 342:19 343:1,15 343:22,25 344:21 345:7,16,24 346:5 346:17,23 347:6 347:12,22 348:2 348:10,17,21 349:4,6,10,18 350:3,8,23 351:4 351:11,21 352:2 352:10,23 353:6 353:13,19,25 354:6,13 355:5,11 355:14,22 356:2 357:18 358:6,12 358:24 359:6,13 360:3,12 361:1,21 362:2,9 363:14,22 364:4 365:1,18 366:6,12,17 367:6 367:12,18,23 368:11,23 369:8	396:4,15,22 397:1 397:6,18 398:13 399:2 400:14,20 401:2,18 402:11 403:4,14 404:1,15 405:14,21 406:3 407:1,20,25 408:8 408:15 409:9,22 410:9 411:3,9,17 411:20 412:6,16 412:23 413:4,16 413:24 414:8,13 414:23 415:4 416:4,11,16,25 417:14,23 418:15 418:21 419:7,12 419:20 420:7,19 421:2,6,25 422:7 422:18 423:2,12 424:18 425:12,16 426:2,8,14 427:7 427:21 428:4,13 428:21 429:4 430:22 431:13,19

432:10,22 433:16	501:9,17 502:3	<b>man</b> 410:3	509:4,9,19,25
434:2,9,16,21	503:21 504:9,18	<b>management</b>	510:12,16 512:7
435:1,17 436:8,16	505:23 506:23	370:16	513:9 514:9 515:9
437:1,7,11 438:21	507:2,9,19 508:1	<b>manner</b> 435:14	515:20
439:12 440:6,14	508:10,13,15,18	464:7	<b>mapes's</b> 404:14
441:4,12 443:19	508:20 509:24	<b>manor</b> 274:23	408:4 410:21
444:4,15 445:1,5,9	510:7 511:3,24	<b>manual</b> 277:3	<b>march</b> 268:21
445:12,15,18,25	513:2 514:7,16,22	430:7,8,9,20 431:1	278:5 471:18
446:4,9,12,15,19	514:25 515:18	431:16 435:6,12	527:22 557:4
446:25 447:4	516:2 518:22,25	436:7,15,22,23	<b>marcus</b> 274:13,15
448:15 449:1,5,10	519:10,15 520:13	437:19,21 438:8	<b>mariama</b> 275:5
449:24 450:7,13	520:16,19,21,25	443:15,18	<b>mark</b> 415:7
450:24 451:5,17	521:3,14 522:3,20	<b>manufactured</b>	423:17 467:7
451:25 453:12	523:5,16,23 524:8	469:9	539:13 551:4
455:22 457:16,22	524:20,21 525:2	<b>manufacturer</b>	<b>marked</b> 320:12
458:9 461:7,21	525:18 526:5,13	411:14 412:2,11	341:16,19,22
462:13,25 463:11	527:7,14,18	412:21 414:19	356:13 362:19
463:24 464:15,21	528:13,20 529:13	459:25 462:4	370:6 386:3,6,17
465:15,24 466:6	530:16 531:8,17	463:8 464:13	401:21,22 415:16
466:15,22 467:4	532:2,7 533:2,8	465:23 466:3,12	415:17 429:12
468:22 469:4,10	534:8,13,16,20,24	470:3,17 471:1	437:15 442:5,9
469:18 470:8,19	<b>maintain</b> 297:7	474:2 475:18	459:2,6 467:9
471:3,23 472:6,9	304:8,15 316:10	538:13	471:12 473:8
472:23 473:1	332:17 334:6,11	<b>manufacturers</b>	495:18,22 508:8
474:17,21 475:7	344:8 366:1 443:5	313:9 328:1 343:8	527:16 539:17
475:12,21 476:7	450:19 451:12	344:8,10 371:7	551:9
476:14,24 477:11	452:15 491:12	385:23 391:22	<b>market</b> 272:3
477:16,25 478:5	<b>maintaining</b> 325:3	395:10 413:11	409:7 432:16
478:17 479:18,20	<b>maintenance</b>	436:11,13 450:3	<b>markets</b> 440:23
481:4,9 482:7,15	302:22	462:10,18,24	<b>marking</b> 429:6
482:19,25 483:5,9	<b>major</b> 319:15	465:12 475:10	473:6
483:12,19,24	506:3	476:2 537:2,10,15	<b>markings</b> 423:21
484:7,10,18,25	<b>maker</b> 288:5	537:17	<b>martin</b> 274:22
485:4,10,15,22	<b>making</b> 312:9	<b>mapes</b> 286:19,22	<b>maryland</b> 453:21
486:4 487:24	367:10 370:23	287:9,9,12,24	<b>massachusetts</b>
489:3 490:2,25	404:25 410:22	318:5,6,13 384:23	274:5 453:22
491:6,21 492:13	431:25 432:5	395:12,12 403:21	<b>master</b> 275:1
492:17 495:12,14	440:3 491:1	403:24,25 404:8	294:9 397:5,12,15
495:16,20,24	507:13 535:5	409:12 411:1	398:22 399:9
496:15 497:5,16	<b>mallinckrodt</b>	449:19 451:22	400:15,25 401:4,7
499:19,23 500:20	274:2 392:21	501:5,11 502:23	455:11,19 457:14

483:10 514:14,20	<b>md</b> 268:6	<b>medications</b>	<b>messages</b> 334:17
<b>masters</b> 272:8	<b>mdl</b> 268:5 276:9	300:25 338:10	337:13 358:10
<b>material</b> 363:5	276:11,13,23	<b>meet</b> 330:23 453:7	<b>messaging</b> 345:14
<b>matter</b> 384:7	277:8 356:17	483:13,20 485:16	<b>met</b> 375:9 383:13
487:4 524:16	362:16 370:14	485:19 486:12,15	422:11,16 426:23
532:9,9,20 535:1	402:2 459:7	<b>meeting</b> 276:12	479:1,6,9,12,21,25
<b>matters</b> 370:23	<b>mdl2804</b> 276:18	295:21 319:1	480:5,12 483:2
<b>mcarter</b> 272:3	276:25 277:2	332:2 356:23	<b>methamphetamine</b>
<b>mcarter.com</b>	<b>mean</b> 309:23	357:12 397:23	279:12
272:5	316:13 331:25	398:1 403:12	<b>methamphetami...</b>
<b>mcclure</b> 272:20	346:12 352:13	480:16 483:25	280:11 301:24
280:12 284:6	356:4 392:7	484:2 485:25	<b>method</b> 299:12,19
286:20 288:25	395:21 396:8	486:1	<b>michael</b> 318:5,13
293:21 296:7	406:21 414:11	<b>meetings</b> 338:3	403:24
299:14 300:11,18	416:14 421:19	346:16 425:20	<b>michigan</b> 453:21
307:25 308:6,12	440:5,13 441:8	457:2	<b>mid</b> 388:9 389:1
309:17 310:13	449:3 463:6	<b>meets</b> 375:2	415:2
320:8 321:17	477:22 511:13	<b>meghan</b> 273:9	<b>middle</b> 318:17
331:20 332:22	528:10	<b>member</b> 423:7	329:3 404:23
333:10,17,22,25	<b>meaning</b> 385:20	<b>members</b> 369:25	<b>midwest</b> 381:25
342:2 364:16	449:19	371:8 377:20	557:17 560:1
365:2,6,9 370:8	<b>means</b> 309:14	417:11,21 418:6	<b>migliori</b> 270:16
374:10 381:10	327:25 381:16,18	420:11 425:6	276:3 278:11,14
385:7 388:12	440:11 489:24	<b>memory</b> 499:10	278:17 280:14
389:11,20 393:24	525:20 536:19	<b>mentioned</b> 481:10	282:4 283:2,11,14
403:15 406:25	<b>meant</b> 422:13	496:13 509:17	283:23 284:8,15
409:20 431:11	439:20 441:3	511:11 516:19	284:24 285:17
437:22 441:5,18	451:2,20 514:19	<b>mentions</b> 530:6	286:7,23 287:8,21
444:13,25 448:12	<b>mechanisms</b>	<b>merely</b> 349:24	287:23 288:8,13
463:1 468:4,7,12	328:11	<b>meridian</b> 274:9	289:2,10,21 290:4
468:23 469:5,19	<b>media</b> 278:6 341:6	<b>message</b> 314:21	290:6,14,22 291:5
470:9,20 471:4	341:11 382:22	324:4 325:8 326:5	291:15,21 292:5
473:2 474:9 475:8	383:2 454:24	327:4 337:1 338:1	292:22 293:10,14
475:13,22 507:6	455:4 521:19,24	338:11 340:15	293:15 294:1,11
<b>mck</b> 277:24	555:11	345:3,4 346:15	294:14 295:1,3,10
<b>mckesson</b> 273:7	<b>medical</b> 302:24	347:20 350:1,20	295:13,15 296:10
392:22 452:12	304:15 314:11	352:7 354:4 355:2	296:19,25 297:10
453:16 535:12,15	331:13 340:11	355:25 356:10	297:16,23 298:15
<b>mckesson's</b> 393:3	353:20 393:3	357:17 358:3,23	298:23 299:4,10
<b>mcnamara</b> 272:7	473:24	360:1 367:4	299:17 300:3,7,14
		517:23	301:8,20 302:3,8

302:15 303:5,10	351:13,23 352:4	518:11,19 519:13	<b>monaghan</b> 273:9
303:15,25 304:4,9	352:12,25 353:8	520:2 522:18	<b>monitor</b> 324:18
304:17,22 305:3	353:15,23 354:3	523:13,20 524:24	330:12
305:16,21 306:9	354:10,15 355:6	532:24 533:7,19	<b>monitoring</b> 276:25
306:15,22 307:3	355:15,24 356:3	534:9,11,15,18,22	375:4 380:15
307:12,15,20	356:11,15 357:20	534:25 537:5	381:1 415:22
308:2,9,14,22	358:8,14 359:1,9	539:19 540:8	416:3 417:8,12,21
309:9,19,22 310:3	359:25 360:8,14	544:10 545:3,13	461:14 476:21
310:11,18,24	361:6,22 362:5,12	546:24	<b>month</b> 306:25
311:7,18,23 312:3	362:16,21 363:16	<b>migliori's</b> 532:10	307:22 348:20
312:14,22 313:18	363:23 364:6,18	<b>mike</b> 275:9	480:18 553:12
313:25 314:9,17	365:5,8,10,13,19	<b>million</b> 452:13	<b>monthly</b> 305:12
314:25 315:10,18	366:8,14,19 367:8	453:5,17 454:9	306:24 308:17
315:24 316:8,25	367:15,21,24	<b>mind</b> 304:4 468:14	309:24 347:11
317:6,13,21 318:2	368:17,25 369:10	496:16	354:22 419:25
319:5,11,21 320:1	369:17 370:4,10	<b>mine</b> 540:16	<b>months</b> 553:17
320:5,11,14,18,22	370:13 371:1,6,13	<b>minimum</b> 377:10	554:6
320:25 321:2,19	372:1,11,16 373:1	<b>minute</b> 281:16	<b>montminy</b> 273:2
322:1,11,21 323:9	373:10 374:2,8,15	349:19 454:21	<b>morning</b> 278:3,15
323:20 324:9,15	374:18,24 375:14	<b>minutes</b> 361:7	278:16,22,23
324:22 325:13,21	375:23 376:5,21	456:14,17,21	383:9 384:17
326:10,18,22	377:2,9,23 378:4	478:2 486:24,25	398:15 458:17
327:9,23 328:17	378:16,24 379:1	551:2 554:1	496:9 497:17
328:25 329:23	379:15 380:1,6	<b>missed</b> 283:8	503:15 506:17
330:8,17,25 331:7	381:5,13 382:6,12	<b>mission</b> 297:19	508:23 516:4
331:23 332:5,11	382:18 398:15	<b>misstates</b> 280:12	522:8
333:2,8,12,20,24	479:8,9,12,13,22	294:24 296:22	<b>motley</b> 270:17
334:1,3,21 335:5	479:25 480:17	320:8 332:25	275:9 480:5,12,20
335:12,19 336:2,8	481:12 482:10,12	336:6 431:11	481:11,16 482:2,8
337:5,17 338:6,15	482:17,20 483:4,6	448:13 503:17	483:1,7,14 484:12
338:21 339:3,16	483:8,15,22 484:1	504:6 534:2 537:5	532:17,21 535:3
339:24 340:13,21	484:3,12,15,20	<b>mistaken</b> 435:20	<b>motleyrice.com</b>
341:2,15,18,20	485:1,8,13 490:1	<b>mmonaghan</b>	270:19,20
342:6,12,17,23	490:17,19 491:4	273:13	<b>mouth</b> 367:20
343:3,19,24 344:2	491:15 492:9,10	<b>moa</b> 452:14	396:19
344:4,23 345:9,18	492:24 497:23	453:16 454:9	<b>move</b> 362:14
346:1,7,19,25	498:15 500:14	<b>model</b> 339:11	<b>moved</b> 529:10
347:8,14,24 348:4	503:17 504:6	359:8	<b>movement</b> 470:17
348:12,19 349:7	505:17 506:15	<b>moment</b> 321:3	472:21
349:12,16,20,22	507:16,24 512:22	540:5,24	
350:5,10,25 351:7	516:3 517:1		

<b>moving</b> 472:15 <b>mt</b> 270:18 <b>multidistrict</b> 278:19 <b>multiple</b> 527:5 <b>mutilated</b> 490:23 <b>mutually</b> 464:7 <b>myers</b> 271:8 <b>mylan</b> 393:12 <b>myriad</b> 279:10	<b>ndc</b> 465:9 <b>neal</b> 271:17 <b>nebraska</b> 453:21 <b>necessarily</b> 407:3 499:1 505:15 <b>necessary</b> 336:4 <b>necessity</b> 353:21 <b>need</b> 279:3 293:7 340:11 367:18 429:10 458:5 486:14 496:1 497:12 504:20 544:7 <b>needed</b> 380:23 545:24 <b>needing</b> 339:14 <b>needs</b> 339:22,23 399:10,11,23,24 445:18 <b>neither</b> 471:9 556:11 <b>never</b> 307:8 322:9 383:13 477:7 479:6 489:5 490:20,22 494:14 523:17 528:2 529:6 531:9,18 <b>new</b> 270:14,14 271:4,4 302:4 323:4 338:24 340:22 373:16 374:19 380:18,19 380:21 406:17,19 406:19 410:14 414:11 422:22 423:9 425:24 426:18,24 434:13 450:18 453:20 471:19 494:4 527:12 553:13,23	<b>newport</b> 271:9,9 <b>nice</b> 549:24 <b>night</b> 457:3 <b>noncontrolled</b> 300:16,23,23 338:10 <b>nonmedical</b> 323:12 <b>nonpublic</b> 290:9 290:17,25 <b>normal</b> 329:15 351:17 352:19 <b>northern</b> 268:2 <b>notarized</b> 557:14 <b>notary</b> 556:1,21 557:25 558:10,18 559:15,23 560:23 <b>note</b> 293:11 366:5 366:9,22,25 367:9 367:10 368:12 458:11 497:7 514:13 516:9 535:5 557:12 <b>noted</b> 358:18 457:16 <b>notes</b> 364:9,10,13 364:14,23 365:15 367:14 <b>notice</b> 269:12 280:18 292:8 343:4 402:16,24 403:8,13 404:7,13 <b>noticed</b> 286:9 292:6 <b>notification</b> 551:7 <b>novelty</b> 441:16 442:3,12,21 <b>november</b> 371:21 448:21 <b>nstephens</b> 271:19	<b>number</b> 277:2 356:17 370:9 386:12 397:23,24 403:20 418:2 424:3 429:19 435:24 436:3 437:23 438:2 493:10 503:2 505:2 542:20 543:1 553:15 555:11 557:7,13 <b>numbered</b> 304:1 402:15 407:6,7 415:19 423:25 430:13 <b>numbers</b> 386:9 465:23 559:7 <b>nutshell</b> 297:7 <b>nwda</b> 276:24 415:21 417:8
			<b>o</b> <b>o</b> 276:1 278:1 <b>o'connor</b> 274:2 390:17 391:1 393:22 395:5 <b>o'gorman</b> 271:2 <b>o'melveny</b> 271:8 <b>oath</b> 335:18 397:25 480:2 485:17,19 505:13 524:1 526:25 <b>object</b> 291:13 307:7 319:18 333:25 342:2 354:6 364:16 388:13 392:5 398:14 406:25 452:2,22,25 454:3 454:10,16 455:17 465:14 468:7 469:20 474:6,10

476:8,13,23	325:11,19 326:8	384:10,25 385:1,7	441:4,5,12,18
479:13 515:5,8	326:15,20 327:7	385:16,25 388:1,5	443:19 444:4,13
522:18 523:1	327:21 328:15,23	388:6,11,12 389:4	444:14,15,25
528:17 539:19	329:21 330:1,6,15	389:11,20 390:2,9	448:12,15 449:1,5
554:23	330:19 331:5,19	390:17 391:1,15	449:10,24 450:7
<b>objecting</b> 513:8	331:20 332:1,9,22	391:17,23 392:4	450:13,24 451:5
<b>objection</b> 280:12	333:11 334:19	392:11,17,24	451:17,25 453:12
282:2,25 283:7,21	335:3,10,17,25	393:6,14,22,23,24	461:7,8,21 462:13
284:5,6,13,22	336:6 337:3,15	394:4,8,20,24	462:25 463:1,11
285:15 286:5,20	338:4,13,19 339:1	395:5,18 396:4,5	463:24 464:15,21
287:6,18 288:7,11	339:7,20 340:9,19	396:15,21,25	464:22 465:15,24
288:24,25 289:8	340:24 342:10,14	397:1,19 398:14	466:6,15,22 467:4
289:19 290:3,12	342:19 343:1,15	399:11,14,14,20	468:22,23 469:4,5
290:20 291:3,12	344:21 345:7,16	399:24 400:4,9,12	469:10,18,19
291:17 292:3,15	345:24 346:5,17	401:18 402:11	470:8,9,19,20
292:16 293:6,11	346:23 347:6,12	403:3,4,14 404:1	471:3,4,23 472:6,9
293:21 294:23	347:22 348:2,10	404:15 405:14,21	472:23 473:1,2
296:7,22 297:5,15	348:17 350:3,8,23	406:3 407:1,20,25	474:9,17,21 475:7
297:20 298:13,21	351:4,11,21 352:2	408:8,15 409:9,20	475:8,12,13,21,22
299:2,8,14,21	352:10,23 353:6	409:22 410:9,11	476:7,14,24,25
300:6,10,11,18	353:13,19,25	411:3,9,17,20	480:22,23 482:3
301:15,16,25	354:13 355:5,11	412:6,16,23 413:4	482:10,11 483:16
302:1,6,11 303:3,8	355:14,22 356:2	413:16,24 414:8	483:22,23 484:3,6
303:13,24 304:11	357:18 358:6,12	414:13,23 415:4	484:15,17 485:20
304:20,25 305:14	358:24 359:6,13	416:4,11,16,25	487:20 488:19
305:18,19 306:6	360:3,12 361:1,21	417:14,23 418:15	490:1,17,18 491:4
306:14,18 307:1	362:2,9 363:14,22	418:21 419:7,12	491:15 492:10,12
307:18,24,25	364:4 365:1,18	419:20 420:7,19	496:12 497:2,3
308:6,7,8,18,19	366:6,12,17 367:6	421:2,6,25 422:7	500:14 501:7,24
309:7,15,16,17,25	367:12 368:11,23	422:18 423:2,11	503:17 504:6,17
310:7,13,23 311:1	369:8,15 370:2	423:12 424:18	505:17 506:14,15
311:16,21 312:1,5	371:4,10,24	425:12,16 426:2,8	507:16,17 509:23
312:18 313:15,24	372:10,14,24	426:14 427:7,21	510:3,23 511:17
314:7,15,23 315:8	373:8,25 374:5,6	428:4,12,13,18	512:21,22 513:25
315:16,21 316:6	374:22 375:13,18	429:4 430:22	514:11,14 515:21
316:23 317:4,11	376:2,19,25 377:7	431:11,13,19	518:10,11,18
317:19,25 319:3,8	377:21 378:2,9,10	432:10,22 433:16	519:4,13 523:2,12
319:17,24 320:4,8	378:22 379:9,13	434:2,9,16,21	523:13,20,21
321:17,23 322:8	379:23,24 380:4	435:1,17 436:8,16	524:14,15,24
322:19 323:7,18	381:3,10,11,15	437:1 439:12	525:11,13 526:1,3
324:7,13,20	382:10,16 384:2,9	440:6,7,14,15,21	526:11,12 527:4

528:9 529:7	<b>occasion</b> 318:9	383:25 384:6	525:5,19 529:4
530:12,13,22	383:14 384:5	453:22 557:2	539:1 541:1,21
531:14,15,22,23	481:13	<b>okay</b> 278:25 279:1	<b>oklahoma</b> 279:13
532:5,23 533:5	<b>occasions</b> 479:11	279:6,16 280:17	<b>old</b> 410:13
534:1 536:4 537:5	<b>occurring</b> 411:16	281:22 282:1	<b>omm.com</b> 271:10
538:5,9 541:25	<b>occurs</b> 511:14	283:3,11 286:17	<b>once</b> 375:24
542:11 543:4,17	<b>october</b> 276:13	286:24 288:14	407:14 409:7
544:10 545:3,11	356:24 358:5	292:23 293:10	446:3 458:3,5
545:13,16 546:8	383:21	295:18 296:2,13	466:2 473:10
546:15,21,24	<b>od</b> 318:14	300:15 313:23	493:25
547:15,25 548:8	<b>odds</b> 400:2	321:8,20 343:4	<b>ones</b> 467:14
548:11,17,18,20	<b>offer</b> 290:16	365:14 371:7	<b>online</b> 553:13
549:2,11,20	<b>offered</b> 361:14	378:24 387:17	<b>onus</b> 312:20
550:16,18 551:24	<b>office</b> 270:8 275:3	388:18 397:3	326:16 411:10
552:18 553:7,19	276:20 280:9	401:2,7 410:20	<b>op</b> 268:10,12,14
554:3,17,20,22	289:17 292:19	415:10 419:10	<b>opana</b> 381:24
<b>objections</b> 308:12	346:4 347:17	423:16,20 424:22	<b>open</b> 485:6,8
308:13 397:17	402:8,20 405:7	430:3 431:24	<b>opened</b> 479:19
534:4 540:9	416:8 488:1,8,25	435:11 438:7	484:22 485:5
<b>obligation</b> 309:3	491:7 545:23	439:1,14 440:13	<b>opening</b> 373:15
312:17 323:21	547:8,14,24	442:2 445:21	<b>operate</b> 309:5
326:12 331:1,3	548:25 549:1,16	447:4 457:23	329:8 344:14
338:17 339:17	552:11	458:25 477:16	345:1 366:24
340:11 414:16,21	<b>officer</b> 556:2	479:5,8 480:4,14	405:4 407:16
427:3 443:5,24	<b>offices</b> 431:6 432:2	483:9 484:7	<b>operated</b> 336:22
<b>obligations</b> 286:2	487:19 545:25,25	485:10 486:8,10	<b>operating</b> 378:6
322:6 323:5	553:6	486:18,22 487:3,7	378:19
324:16 325:17	<b>official</b> 284:11	487:14 488:11	<b>operation</b> 424:15
332:3 335:1	290:10,19 403:1	492:5,15 493:13	<b>operational</b>
338:22 344:19	523:25 558:15	494:16 495:12	279:25
352:21 359:11	559:21	497:15 498:15,22	<b>operations</b> 280:6
360:23 368:20	<b>oh</b> 295:13 349:12	499:14,22 500:2	<b>operative</b> 329:4,17
369:2,5,13 375:25	371:15 394:14,15	501:4 502:20	330:4
414:4 453:7	424:21 428:16	503:1,14 505:12	<b>opiate</b> 268:6 557:6
476:22	437:11 438:22	508:11,14 509:13	558:3 559:3
<b>observations</b>	439:14 478:3	510:19 511:16	<b>opinion</b> 277:19
301:2	495:10 500:11	512:10 513:12,20	443:1,16 527:19
<b>observe</b> 420:15	508:4 525:4	514:22 516:18	528:8 530:4
<b>obtain</b> 325:2	531:19	518:6 519:11,14	<b>opinions</b> 290:16
373:17 381:18	<b>ohio</b> 268:2,11,13	519:18 521:14	<b>opioid</b> 383:22
	270:9 271:14	522:21 524:4	461:18 466:13

## [opioids - participants]

Page 33

<b>opioids</b> 436:25 537:25	<b>orders</b> 277:21 303:22 309:6,12	<b>outcome</b> 528:15 556:18	398:9 404:5 417:6 418:1 424:2
<b>opportunity</b> 400:16	310:6 317:18 329:9,12,13,14,14	<b>outlining</b> 402:9	430:15,17 433:2
<b>order</b> 276:24 283:5,17 298:17 298:17 304:6 308:15 310:12,14 310:17,19 311:4,9 312:10 330:12,20 330:23 332:15 334:9 347:2 350:16 352:18 353:4,11 354:2,18 354:21 355:1,19 365:24 368:2,4,5,9 368:16,16 372:6 375:1,2,5,7,9,10 375:11,19,20 379:5 381:1 408:12,16,17,18 414:6,20 415:21 417:8,12 419:2 433:9 438:13 439:6 443:1,7 444:8,9 445:8,15 448:6,20 449:14 449:15 450:16,17 451:9 454:7 461:14 464:9 469:25 476:21 493:17 494:12,18 494:24 525:21,24 526:6,16,19 531:2 539:15 544:8 546:6 553:1,2,10	<b>output</b> 472:14	438:7,20 442:19	
<b>ordered</b> 338:10	<b>original</b> 365:7 374:14	<b>outrageous</b> 547:5	466:9 499:15,19
<b>ordering</b> 337:21 337:23,24 338:7 339:15 359:15	<b>organizations</b> 356:9	<b>outside</b> 279:22 301:4 305:14,19 308:7 309:17 316:2 339:18 477:4 509:9 539:20 542:11 543:5 545:2 548:18 549:5,12 550:1,16 551:24 552:21 553:19 554:3,17,24	499:24 516:5,5 524:7,18 529:16 529:20 540:2 541:7,9,12,17,18 557:13,15 559:7 560:3
		<b>oversee</b> 297:7	<b>pages</b> 296:12 499:19 510:15
		<b>oxford</b> 274:13	<b>paid</b> 454:9 533:22 534:6,10 535:7,9
		<b>oxycodone</b> 537:24	<b>palo</b> 271:18
		<b>oxycontin</b> 468:20 469:8 470:5,17,24	<b>paper</b> 336:19
			<b>par</b> 272:2
			<b>paragraph</b> 318:16
			318:18 322:22 332:13 337:7
			344:5 406:7 408:4
			438:9 460:9,9,17 468:18 529:23,25 530:18,20
			<b>paraphrase</b> 500:12
			<b>park</b> 271:3
			<b>part</b> 290:9,18
			293:9 302:25 322:3 348:7 371:2
			379:19 415:24 416:14 449:3,20
			460:21 467:22 501:23 543:19 549:25 559:9
			<b>parte</b> 455:10 456:24
			<b>participants</b> 389:10

<b>participate</b> 458:7	<b>pennsylvania</b> 272:4,22 274:14	349:1,9,11	413:3 414:17,18
<b>participated</b> 295:7	274:24	<b>personally</b> 489:4	420:11 425:20
391:12		558:11 559:15	454:6 462:6 463:6
<b>participating</b>	<b>people</b> 299:22	<b>personnel</b> 527:9	466:4 469:16
390:1	327:3 370:12	<b>perspective</b>	471:2 472:19
<b>particular</b> 302:23	390:16 392:15,15	395:22 405:25	509:14 510:9
312:19 346:10	395:14,16 403:20	553:17	516:4 538:18
353:21 365:22	403:21 406:22,22	<b>pharma</b> 268:9,11	541:14 542:21,22
376:15 385:22	422:16 428:1	268:13 271:2	543:2 547:11,12
433:13 441:22	429:11 432:8	467:17 472:18	547:13,23,24
513:15	520:7	<b>pharmaceutical</b>	548:7 549:1,9
<b>particularly</b>	<b>people's</b> 317:23	313:9 384:19	550:13,15 552:3
320:10	528:7	385:20,21 386:20	554:15
<b>parties</b> 269:13	<b>percentage</b> 300:15	389:18 390:23	<b>phenomenon</b>
456:19 556:13,16	<b>perfectly</b> 400:22	392:23 395:9	414:11
<b>party</b> 473:19	<b>perform</b> 360:23	402:9 404:10	<b>phentermine</b>
<b>pass</b> 507:6,8 533:9	372:5,13 494:23	409:14	337:23
<b>passages</b> 503:23	<b>performance</b>	<b>pharmaceuticals</b>	<b>philadelphia</b>
<b>passing</b> 321:25	290:10,18	271:7 272:2	272:4,22
322:10 503:16	<b>performed</b> 496:5	393:19	<b>phone</b> 370:12
504:14 553:4	551:16	<b>pharmacies</b>	481:15 557:3
<b>patrick</b> 271:20	<b>performing</b> 347:3	279:24 296:16,20	<b>physical</b> 358:17
<b>pattern</b> 301:5	<b>period</b> 293:19	303:18 313:4,7,20	359:5
315:2 329:15	319:23 460:25	314:19 315:3,7,15	<b>physically</b> 389:7
330:13 351:17	493:9,17 503:5	363:19 371:2	480:12
352:20	526:8	395:10 406:18	<b>physician</b> 473:21
<b>patterns</b> 546:6	<b>periodic</b> 380:14,25	413:11 417:19,20	473:25 474:15
<b>paul</b> 270:21	<b>periodically</b> 382:8	420:11,15,16	475:2
<b>pay</b> 300:2 453:5	<b>periods</b> 433:22	436:13 461:5	<b>physicians</b> 474:5
453:17,17	<b>permit</b> 554:12	462:12,24 474:3	<b>pick</b> 529:11
<b>paying</b> 299:25	<b>person</b> 288:4	474:16 475:3	<b>pills</b> 538:12,16
<b>payment</b> 299:12	292:9,13 332:14	476:3 543:15	<b>pinon</b> 394:22
299:18 300:1	334:8 388:10	544:2 546:6,20	<b>pittsburgh</b> 274:14
<b>pbeisell</b> 271:23	433:23 438:12	547:17 548:3,15	<b>place</b> 414:4,17
<b>pen</b> 425:4	439:5 480:20	548:24 550:23	434:15 484:1
<b>penalties</b> 337:10	483:25 491:1	<b>pharmacist</b>	487:8 493:7
<b>penalty</b> 452:13	502:20	377:14 412:12	<b>placed</b> 408:17
453:5,18	<b>personal</b> 283:3,15	<b>pharmacy</b> 295:20	<b>places</b> 396:3
<b>pending</b> 515:1	284:19 285:1,10	298:9,20 299:1	<b>placing</b> 332:14
518:23 533:21	285:11,12,20	361:16 385:23,23	334:9 339:19
	286:3 290:16	411:15 412:3,22	

<b>plaintiff</b> 276:23 458:3	524:10 525:8 527:1,12	509:9,14 510:2,12 <b>powerpoints</b> 295:5 387:2	<b>prescriptions</b> 314:1,11 472:21 474:4 543:16 544:3
<b>plaintiffs</b> 270:21 278:13,19 383:7 383:19 398:3 400:24 456:14 458:4 498:3,16 501:19 502:14 503:22 522:13 554:4	<b>polite</b> 489:17,21 489:22 <b>polster</b> 268:8 <b>populated</b> 359:15 <b>portion</b> 332:23 387:1 <b>position</b> 287:2 349:15 357:14 432:20 455:23 456:13,14,15,22 536:15	<b>pplpc00400032...</b> 277:10 <b>pplpc03100127...</b> 277:14 <b>pplpc03400104...</b> 277:12 <b>practically</b> 516:5 <b>practice</b> 314:2 316:3,14 374:4 390:4 419:14,18 <b>positions</b> 282:20 282:24 <b>possession</b> 463:9 <b>possibility</b> 373:3 <b>possible</b> 401:16 <b>possibly</b> 395:15 433:24 504:11 506:10 <b>post</b> 443:23 <b>potential</b> 316:14 316:15 317:17 328:21 339:23 340:3 359:19 373:21 409:4	<b>present</b> 269:12 275:1 356:18 357:7 384:18 455:16 544:4 <b>presentation</b> 297:18 301:11 303:19 311:12 318:12 327:17 344:18 357:7,12 361:13 362:23 363:13 364:1,9,21 364:22 366:11 368:22 387:6 390:15,24 403:23 404:14 410:22 452:5 539:14 541:4 <b>presentation's</b> 540:11
<b>played</b> 293:18			<b>presentations</b> 384:19,24 411:5 434:7 444:22 449:4,20 451:23 461:13 518:3
<b>playing</b> 293:5			<b>presented</b> 318:7 387:2 404:9 429:1 434:8
<b>pleasant</b> 270:18 499:2			<b>presenting</b> 316:19 318:14 395:12,13 540:4
<b>please</b> 281:2,2 306:8 378:15 396:20 406:12 437:23 446:6,22 477:7,18 478:6 486:3 504:21 514:24 515:3 524:19 529:25 540:24 543:20 557:11,11			<b>president</b> 406:9 424:6
<b>llc</b> 270:13 275:8 275:8			<b>pretty</b> 282:8
<b>point</b> 309:10 317:15 367:11 369:12 380:11,13 400:8 409:7 458:8 461:11 465:6 512:5 541:11,12 542:4			<b>prevent</b> 323:23 452:16
<b>pointed</b> 489:16			<b>preventing</b> 371:18 371:23
<b>points</b> 364:1 507:22			
<b>policing</b> 361:25			
<b>policy</b> 318:23 377:4 417:11			

[previous - purpose]

Page 36

<b>previous</b> 501:2	<b>procedure</b> 377:4	<b>project</b> 280:23	<b>prudential</b> 274:4
<b>previously</b> 368:13	443:22 558:5	339:14	<b>pseudoephedrine</b>
397:24 424:24	559:5	<b>promulgated</b>	280:11 301:23
<b>primarily</b> 280:9	<b>procedures</b> 283:4	417:11	<b>public</b> 302:21
293:18	283:10,16 349:2	<b>promulgating</b>	315:12 452:6
<b>primary</b> 327:25	378:6,19	417:20	545:5,8 556:1,21
328:4 352:16	<b>proceed</b> 278:10	<b>properly</b> 325:25	558:10,18 559:15
<b>principals</b> 364:1	341:14 383:5	<b>proposed</b> 291:1	559:23 560:23
<b>principles</b> 327:14	401:11 455:7	370:23 417:3	<b>publicly</b> 447:20
327:19	478:14 522:2	443:12	<b>published</b> 321:25
<b>printout</b> 402:8	533:18	<b>prospective</b> 326:2	371:21
419:25 424:25	<b>proceeding</b> 555:14	<b>protect</b> 297:7	<b>pull</b> 399:6 409:6
<b>prior</b> 279:14	<b>process</b> 287:14	340:10	507:21
294:19 330:14	289:14 391:13	<b>provide</b> 285:10	<b>purchase</b> 306:16
331:21 332:21	511:23 515:22	331:16 372:18	306:20 310:5
334:15,25 335:22	528:12	459:23 464:3,4	346:21 355:17
336:1,7 350:13	<b>processes</b> 406:19	465:7,18 474:14	368:10,14,18
421:20 431:12	496:22	475:2 545:22	369:1,4 372:19
443:9 448:13	<b>produce</b> 292:9	546:3 549:19	465:19 472:20
489:4 490:12	<b>produced</b> 356:16	552:9	487:8,14 488:3,14
501:4 512:12,18	356:19 402:3	<b>provided</b> 281:8	489:8,14 490:11
512:23 514:1	459:12 528:8	285:9 317:2	491:24 492:7
519:6 532:19	<b>product</b> 300:24	319:15 337:11	<b>purchased</b> 298:18
534:3,13 535:1	311:5 340:3 375:8	357:12 377:17	<b>purchases</b> 307:5
<b>priority</b> 319:20	439:24 440:22	379:18 460:25	307:22 310:6
<b>priorprod</b> 276:9	465:8 469:8	461:2 462:3	354:23 367:3
276:11	471:19 472:15	467:13 470:3	541:14,23 542:22
<b>privilege</b> 325:18	<b>production</b> 276:22	471:10 473:11	<b>purchasing</b> 462:11
481:3 482:17	557:15,17,22	485:17 487:23	474:2 475:11
<b>privileged</b> 480:24	<b>products</b> 298:18	522:5,23 523:6	<b>purdue</b> 268:9,11
481:5 482:16	300:23 339:13	535:18 537:1	268:13 271:2
483:16	443:9 460:1,13	539:9 550:22	393:19 467:17
<b>probably</b> 356:8	461:19 464:5	<b>provides</b> 472:11	469:9,14,15 470:4
504:24 519:22	465:2 466:10	<b>providing</b> 317:8	471:1,10,18
<b>problem</b> 279:12	468:16,21 470:4	324:25 406:16	473:12,13 474:2
323:1,14,22	531:3,6	461:16,17 465:1	<b>purpose</b> 281:10
396:11 397:20	<b>professional</b> 314:2	465:22 471:20	302:25 314:12
421:13	316:3 473:25	485:18	322:23 339:8
<b>problems</b> 316:15	<b>program</b> 294:21	<b>provisions</b> 313:12	343:6,13 456:2
421:16	323:4 452:15	324:11 328:14	476:12 483:2
	525:21 526:6,19	335:16 380:13,22	

[purposes - recall]

Page 37

<b>purposes</b> 286:10 296:5 326:4 372:21 374:10 438:13 439:7 443:13 469:17 <b>pursuant</b> 269:12 314:10 471:1 <b>put</b> 294:5 296:4 364:15 367:19 396:18 398:14 437:2 457:24 495:7 506:5 <b>puts</b> 312:17 326:11 <b>putting</b> 517:24	<b>q</b> <b>qualitest</b> 393:19 <b>quantities</b> 337:21 338:8 339:14 <b>quantity</b> 338:9 464:10 469:25,25 469:25 470:14 <b>question</b> 287:20 293:24,25 294:2 306:8 307:14 308:21,25 331:22 333:13 344:1 348:21 363:17 367:25 378:15 387:22 397:21 398:8,9,21 399:21 400:6 437:5,10,12 445:16 446:16 447:8,11,12 448:4 468:4,9,11,25 474:23 477:5,7 479:3,14 481:8 486:3 492:14 500:15 502:2 504:7,20 506:22 507:24 510:6	<b>r</b> <b>r</b> 270:7 278:1 <b>range</b> 298:18 <b>rannazzisi</b> 286:9 286:13,25 320:7 321:14 327:10 332:12 334:4 341:24 347:15 350:11 351:14 354:17 503:5,23 506:11 518:1 <b>rannazzisi's</b> 286:11 337:6,18 503:9,15 504:13 <b>raymond</b> 271:11 <b>raymond.krncevic</b> 271:15 <b>rbarnes</b> 274:15 <b>reach</b> 339:12 373:4,5 456:6 477:13 <b>reached</b> 356:8 455:25 <b>read</b> 303:23 304:2 305:13 332:23 333:7,8,14,23 366:25 370:8 372:2 386:11 397:21 398:21 399:8 407:13 408:7 423:14 424:13 427:11 437:23 438:9 439:3 442:22 460:8 477:6,9 500:11 506:22 515:3,4 518:17 529:22,25 530:18 534:15,18 558:5,6 558:12 559:5,6,17	<b>readily</b> 517:7 <b>reading</b> 333:1,18 404:18 406:11,12 465:10 467:19 468:6,18 471:15 502:14 524:18 557:19 <b>ready</b> 457:21 530:2 <b>really</b> 395:24 400:5 409:6 422:24 <b>realtime</b> 534:12 <b>reask</b> 400:6 <b>reason</b> 283:24 291:18 353:22 357:24 432:15 456:6 512:11 520:6 557:14 559:8 560:3 <b>reasonable</b> 325:4 433:23 438:14 439:8 467:23 <b>reasonably</b> 458:6 <b>reasons</b> 401:14 <b>recall</b> 311:11 316:22 319:25 335:14 345:19 356:7 357:17 358:22 360:1,9,15 361:18 365:14,17 365:21 366:7,10 367:10,14 369:21 371:5,11 412:4 413:22 432:19 437:20 441:23 467:5 479:2 492:23 494:10,14 494:16 497:19,22 498:13,23 501:11 502:5 504:5
---	---	---	--

## [recall - registrants]

Page 38

508:21,24 509:3	420:5,16,23	reduce 373:3	registered 389:8,9
509:21 510:8	421:24	reduced 556:8	389:17,25 390:11
512:4 516:15,21	<b>recommendations</b>	reed 272:21	390:14,22 391:7
516:23 517:18	290:25 380:8,10	<b>reedsmith.com</b>	392:7,8,14,22
518:7 521:6,10	451:3,7,21	272:23	393:4,12,20 395:3
522:4,8 524:22	<b>recommended</b>	<b>refer</b> 509:14	<b>registrant</b> 309:4
540:4 553:4	380:12 422:12	516:14 548:24	312:24 313:4
<b>receipt</b> 552:8	<b>record</b> 278:4,9	<b>reference</b> 376:9	317:10 320:3
557:18	291:16 293:22	495:25 557:7	324:16 326:17
<b>receipts</b> 464:11	294:6 319:2 320:9	558:2 559:2	329:7,9,10,13
<b>receive</b> 431:20	331:21 332:24	<b>referenced</b> 496:9	332:15 334:9
<b>received</b> 354:2	341:5,10 365:2	558:11 559:15	338:25 339:17
360:2 461:1	370:9 374:11	<b>referencing</b>	344:14,15 345:1
488:24 532:10,21	382:21 383:1	443:14 445:5	347:1,16,19 348:6
535:2 551:5	386:12 397:4,10	<b>referred</b> 300:8	350:17,18 354:2
552:17	397:14 399:7,8	310:4 320:3 406:8	354:20,23,25
<b>receives</b> 326:13	401:9 415:14	435:21 468:17	362:11 368:21
<b>recess</b> 341:8	437:23 445:22	<b>referring</b> 281:1	375:25 377:25
382:24 397:11	446:6,8,10,13,21	506:17 510:10	378:7 392:2 394:6
455:1 478:10	447:1,3,25 454:23	<b>reflect</b> 534:5	394:19 405:4,5,6,9
518:21 521:21	455:3,8,23 457:24	<b>reflected</b> 507:12	407:15 411:11
533:14 555:6	457:25 458:1,11	534:9	414:5 420:2 423:7
<b>recognition</b> 403:1	468:8 477:9,18	<b>reflection</b> 300:1	425:1 431:3
<b>recollect</b> 387:19	478:6,8,12 490:4,6	500:3	439:16 489:5,12
<b>recollection</b> 283:4	515:4 518:17	<b>refresh</b> 357:5	490:9 552:2
283:15 284:19	521:18,23 533:10	387:19 448:5	<b>registrant's</b> 335:1
285:2,12,21 286:4	533:12,16 534:1,2	523:4	<b>registrants</b> 285:3
293:17 315:23	534:5 549:24	<b>regard</b> 415:3	297:3 299:5
318:22 343:11,16	555:2,4,8 556:10	<b>regarding</b> 285:21	311:25 313:1,10
357:6 383:16	559:9	288:21 290:17	313:17 318:7
384:14,22 410:5	<b>record's</b> 388:16	380:21 417:12,21	319:23 322:4
432:8 448:5	433:4 457:18	420:13 455:19	327:12 331:3
461:23 462:22	<b>recorded</b> 278:7	457:14 459:25	342:25 343:13
479:7,24 494:20	<b>records</b> 337:9	461:14,18 472:21	345:20 349:23
500:19,23 502:21	376:12,15	474:4 476:4	350:11 354:18
509:2 517:20	<b>red</b> 300:9,13 301:7	547:15	361:9,13 376:23
519:9 520:12	301:9,21 510:17	<b>region</b> 383:25	378:20 382:11
<b>recollections</b>	511:12,21 512:19	<b>regional</b> 381:24	385:22 395:16,23
292:1	513:5 546:14	545:24	401:16 422:10
<b>recommendation</b>	<b>redirect</b> 400:17	<b>register</b> 399:24	425:20 431:3
418:25 419:3,19			432:14 433:12

434:8 435:13,14	<b>reiterated</b> 327:15	493:3 495:1 498:9	418:5 422:13
438:18 439:11,25	<b>reiterating</b> 421:7	498:11 510:15,17	537:22
440:1 444:23	<b>reiteration</b> 323:5	510:19 512:14	<b>reporter</b> 291:14
459:19 476:19	<b>rejected</b> 451:2	513:18 516:12	291:19 399:6
488:2,13,17	<b>relate</b> 303:17	517:5,11 519:1	415:9 515:3 558:7
491:12,23 493:17	304:18	522:17,21 528:14	<b>reporting</b> 304:5
494:3 502:7,18,22	<b>related</b> 286:25	535:19,21 541:3	308:15 331:9
503:4 525:23	290:8 448:22	<b>remembers</b>	345:12,22 346:11
<b>registerate</b> 354:20	482:1 522:22	388:19	348:5 350:16
<b>registration</b>	525:9 556:12	<b>remind</b> 460:2	354:17 357:16
302:21 312:7	<b>relates</b> 268:7	<b>reminded</b> 349:23	358:20 365:24
315:11 325:3,4,5	297:19 359:10	<b>renee</b> 275:2	368:9,10,19 369:1
325:15 327:25	453:7	<b>repeat</b> 283:12	369:4 371:18
328:3,22 331:17	<b>relating</b> 283:5,16	291:15 306:8	410:15 420:2
347:16 361:10	285:22 376:15	365:20 368:1,3	466:11 543:14
391:21 442:13	460:12 522:5	378:15 385:2	544:2 553:14
<b>registrations</b>	<b>relationship</b> 285:4	486:3 514:24	<b>reports</b> 277:21
302:18 328:8,12	285:8 286:11	540:8 543:20	283:6,17 306:21
<b>regulate</b> 439:21	298:19,24 485:9	<b>repeated</b> 504:20	310:5 346:21
<b>regulated</b> 438:12	<b>relative</b> 280:10	505:19 520:12	354:22 355:1,1
439:5,15,19,20,25	287:3 289:5 297:2	<b>repeatedly</b> 311:13	425:9 440:3
<b>regulation</b> 344:24	335:23 363:25	345:25 426:23	487:15,18 488:3
406:1 426:17	369:13 371:22	<b>rephrase</b> 388:20	488:14,24 489:8
490:16 495:21	556:15	403:5 416:5	489:14 490:12
496:2,11 497:1	<b>relatively</b> 362:4	<b>report</b> 286:18	491:24 492:7
522:16	<b>select</b> 285:11	305:7,11 306:4,12	493:17 494:12,19
<b>regulations</b> 324:2	<b>relevant</b> 288:9	306:17 307:4,9	531:2,7 538:21
328:6 344:10	377:12 400:7	308:17 309:11,24	539:6,10,15 542:5
414:3 415:3	547:24 553:5	344:11 347:10	542:5,19,25 543:9
416:10 418:19	<b>relieve</b> 304:6	349:25 354:24	544:8 545:5,8
426:20 435:16	365:25 420:1	355:17,17,20	<b>represent</b> 298:3
444:2 491:3 495:4	425:1,10	369:14 376:4,6	383:18 389:16
511:6	<b>rely</b> 332:14 334:8	405:1,1 408:5,24	405:24,25 484:13
<b>regulatory</b> 328:5	523:25	409:15 418:10	535:15 540:11
392:15 406:9	<b>remain</b> 311:19	419:1 425:2,10,23	<b>representative</b>
416:1	526:10	427:4 430:18	284:11 377:13
<b>reintroduce</b>	<b>remains</b> 458:8	432:14 435:23	<b>representatives</b>
383:17	<b>remember</b> 305:6,8	453:6,18 525:24	389:17 409:18
<b>reiterate</b> 322:24	335:9 346:14	537:10 553:10	<b>represented</b> 390:7
327:18 343:7	435:23 478:21	<b>reported</b> 268:24	<b>request</b> 276:22
	480:18 486:6	286:17,21 308:3	277:2 310:15

408:17 433:20	<b>reserved</b> 550:1	545:21 547:8	<b>revision</b> 380:17
455:18 546:1	<b>reserving</b> 514:15	<b>responsible</b>	<b>revocation</b> 328:12
559:9,11	514:18	536:16,21	328:21 331:16
<b>requested</b> 399:8	<b>resolution</b> 330:22	<b>responsive</b> 457:4	442:13
477:9 515:4	<b>resolve</b> 311:3	<b>rest</b> 329:2 451:22	<b>revoke</b> 328:7
518:17	330:21 359:8	466:24	<b>revoked</b> 315:12
<b>requesting</b> 368:6	361:4 438:15	<b>restate</b> 307:13	<b>rice</b> 270:17 275:9
<b>requests</b> 377:16	439:8 485:2	468:24	480:5,12,21
<b>require</b> 335:15	526:10	<b>rests</b> 410:23 432:5	481:11,16 482:2,8
344:10 353:1	<b>resolving</b> 330:22	<b>result</b> 316:11	483:1,7,14 484:13
510:24	<b>resources</b> 361:11	502:16	532:17,21 535:3
<b>required</b> 309:5	361:19,24	<b>retail</b> 298:25	<b>right</b> 282:18 288:2
330:18 337:9	<b>respect</b> 280:5	371:2 406:17,18	291:22,24 293:14
340:12 353:17	293:18 360:10	470:14	295:4 296:3 309:4
374:20 431:4	396:12 530:8	<b>retained</b> 376:13	318:17 319:12
440:3 452:18	531:11	379:19 484:11	320:11 329:1,3
496:10 497:1	<b>respectfully</b>	532:16 555:12	333:7,9 341:2
547:5 557:25	455:18	<b>rethinking</b> 515:15	343:19 351:14
<b>requirement</b>	<b>respective</b> 269:13	<b>retired</b> 282:13,15	367:15 373:12
305:12 334:5	<b>respond</b> 552:7,19	330:4	397:15 399:9
340:7 344:7 351:2	<b>respondents</b>	<b>retirement</b> 311:20	418:8 432:21
351:5 354:24	443:22	405:12 407:24	442:20 445:24
355:13 361:3,3	<b>response</b> 370:3	418:20 421:23	446:20 454:18
366:23 408:5	393:25 399:22	432:21	463:7 465:12
409:14 425:22	426:23 427:5	<b>retrospect</b> 458:16	469:16 470:25
430:18 438:18	489:17 549:17	<b>return</b> 535:17	472:22 475:19
439:11 450:4	550:9 551:8 553:9	<b>returned</b> 557:18	483:4 489:25
513:15,23 522:9	<b>responsibilities</b>	<b>reveal</b> 289:13,24	494:1 503:12
522:15 524:23	280:5,9 322:24	<b>review</b> 342:9	505:2 507:3
525:9	332:3,6 343:7	373:18 380:14,25	512:20 513:4
<b>requirements</b>	544:15	382:8 443:6,23	517:19 518:4,24
328:5,9 332:3	<b>responsibility</b>	499:25 502:16	521:13 522:24,25
375:16 416:1	287:16 304:7,13	548:10 557:12	523:8,8 527:12
426:17 510:22	312:20 326:17,23	558:1 559:1	528:5 529:17,20
<b>requires</b> 332:19	331:10 344:25	<b>reviewed</b> 321:4,5	530:10 531:21
334:13 335:8	349:24 350:17	501:5 503:22	532:14,17 536:22
344:13 347:16	362:8 366:1 382:8	527:25	537:4,13,19 538:1
407:15 438:14	382:13 410:22	<b>reviewer</b> 379:17	538:2,13,23 541:9
439:7	411:11 420:2,12	<b>reviewing</b> 317:23	<b>risk</b> 285:4
<b>rescheduling</b>	425:2,10 431:25	357:5 400:11	<b>road</b> 271:18
458:7	432:4 544:20		274:24

[robert - seen]

Page 41

<b>robert</b> 274:12 275:3 <b>robust</b> 538:4 <b>role</b> 286:11 287:15 293:4,16,17 297:11 321:8,13 324:10 339:11 360:10 <b>room</b> 457:19 486:7 <b>ropes</b> 274:3 <b>ropesgray.com</b> 274:6,6 <b>ross</b> 273:4 <b>rothschild</b> 274:23 <b>roughly</b> 321:21 <b>routinely</b> 432:14 531:6 <b>ruin</b> 521:11 <b>ruiz</b> 272:15 <b>rule</b> 370:23 405:11 482:18,24 <b>rules</b> 417:20 426:24 431:9 453:10 558:5 559:5 <b>ruling</b> 446:2 479:16 <b>run</b> 312:12 477:14 <b>running</b> 293:8 484:6 <b>russo</b> 268:24 275:10 556:2 <b>rx</b> 272:14	<b>sale</b> 304:23 310:21 325:16 347:10 350:13 368:4,5,15 408:25 409:2 410:15 <b>sales</b> 298:12 302:10 304:19 307:5 310:9 313:22 314:5,5,8 314:14 316:5 367:3 369:13 396:12 408:6,12 409:16 420:1 424:25 433:10 462:5,11 463:5 465:4,11 470:14 470:24 <b>san</b> 552:3,11 <b>sat</b> 453:25 <b>satisfy</b> 305:12 515:16 <b>save</b> 349:12,16 354:8 <b>saw</b> 302:17 321:24 322:9,10 434:19 457:2 488:4,5 503:15 504:13 506:19 <b>saying</b> 316:22 333:4,6 409:8 422:25 494:10 523:11 525:20 <b>says</b> 295:20 297:25 302:17,20 303:22 309:11 310:1 314:18 315:1,25 322:23 325:22 327:12 329:7 331:8 334:4 337:7 343:6 344:6 345:10 347:15	350:11 353:9 357:10,21 366:2 372:3 373:2,15 376:11 380:11 387:12 388:17 402:16,20 403:19 403:22,24 404:24 408:5 409:2 418:2 430:7,16,17 431:3 431:24 432:13 434:24 440:2 443:4 460:10,17 464:9,25 465:6 466:12 471:16,20 473:19 534:12,25 534:25 <b>schedule</b> 457:7 468:21 470:4 <b>schein</b> 273:2 356:19 392:14 <b>scheme</b> 327:11 <b>scientific</b> 331:13 <b>scope</b> 305:15,19 308:8 309:18 314:16 479:14 484:23 490:17 492:11 512:23 539:20 540:9 542:12 543:5 544:10 545:2,16 546:24 547:19 548:19 549:3,5,12 550:2,17 551:25 552:22 553:20 554:3,18,24 <b>screen</b> 280:24 305:5 333:5,15,18 356:22 363:11 <b>sea</b> 415:1 422:25 450:2	<b>seal</b> 558:15 559:21 <b>second</b> 281:17 282:18 341:23 344:5 354:16 402:17 408:3 424:8 429:25 442:15 455:13 460:9 477:8,20 514:19 533:19 540:1 550:1 <b>section</b> 275:5,7 277:16,17 303:19 332:18 334:5,12 363:6 404:23,24 424:15 430:17 442:22 473:18 <b>security</b> 372:6 404:25 406:9 <b>see</b> 281:13,20 301:5 349:10 365:3 374:16 387:12,19 389:2 412:11,12,13 419:14 420:10 429:16 458:5 496:18,20 503:9 503:12 517:13 527:23 530:4 540:1,17 552:5,12 554:12 <b>seeger</b> 318:14,20 509:5,10 <b>seeing</b> 305:8 437:20 547:4 <b>seen</b> 307:8 321:6 321:20 344:17 364:10 407:10 419:18 420:22 438:5 528:2 539:23
<b>s</b>			
<b>s</b> 276:1 278:1 557:15 559:8,8 560:3 <b>sacramento</b> 453:23	310:1 314:18 315:1,25 322:23 325:22 327:12 329:7 331:8 334:4 337:7 343:6 344:6 345:10 347:15	355:1,25 366:2 372:3 373:2,15 376:11 380:11 387:12 388:17 402:16,20 403:19 403:22,24 404:24 408:5 409:2 418:2 430:7,16,17 431:3 431:24 432:13 434:24 440:2 443:4 460:10,17 464:9,25 465:6 466:12 471:16,20 473:19 534:12,25 534:25 <b>screen</b> 280:24 305:5 333:5,15,18 356:22 363:11 <b>sea</b> 415:1 422:25 450:2	321:20 344:17 364:10 407:10 419:18 420:22 438:5 528:2 539:23

<b>sees</b> 412:13	<b>shannon</b> 272:20	388:23 389:5,13	435:2,19 436:2,10
<b>self</b> 398:10	<b>shape</b> 367:17	389:22 390:5,10	436:18 437:2,9,13
<b>sell</b> 310:16 463:7	<b>shapira</b> 274:13	390:19 391:3,19	437:17,24 438:3,4
538:14,15	<b>shapira.com</b>	391:25 392:6,12	438:22,25 439:2
<b>selling</b> 316:1	274:15	392:19 393:1,7,10	439:14,17 440:9
411:14,15 439:24	<b>shared</b> 413:12	393:16,17 394:1,5	440:18,24 441:7
464:13 465:11	<b>sharing</b> 277:14	394:9,11,21 395:1	441:14,19 442:7
<b>send</b> 319:22	413:13 417:2	395:7,20 396:7,16	442:17,18,24
408:17 457:10	473:14 507:7	396:20,24 397:3,7	443:3,21 444:6,17
488:2,13 545:25	<b>sheet</b> 557:13 559:7	398:6,11,17,20,24	445:4,11,21 446:1
547:7	559:10,18 560:1	399:5 400:13	446:5,11,14,17
<b>sending</b> 343:13	<b>ship</b> 347:2 375:6	401:3,6,12,20,24	447:15,25 448:3
494:16	410:23,23 413:21	402:13,19,23	448:16 449:2,7,12
<b>sense</b> 525:14	414:5,22 427:4	403:5,6,16 404:3	450:1,9,15 451:1,8
<b>sensitive</b> 430:16	431:25 432:5	404:17,19,22	451:19 452:9,23
<b>sent</b> 292:8 310:22	448:10 450:4,23	405:16,23 406:5	453:3,14 454:5,11
321:25 342:16,18	451:15 452:21	407:4,22 408:2,10	454:18 457:17
424:5,14 431:2	453:25 454:14	409:11 410:1,10	458:25 459:4
<b>sentence</b> 421:19	513:15,22 522:9	410:17 411:6,12	460:7 461:10,24
<b>september</b> 320:19	522:14,22 524:23	411:18,22 412:8	462:16 463:3,13
321:9 384:20	525:9,23 526:9	412:18,25 413:6	464:1,17,24
385:5 386:21,22	531:3,6	413:17,25 414:10	465:17 466:1,8,17
402:1 442:10	<b>shipment</b> 375:1	414:15,25 415:6	466:25 467:6,11
443:2 497:18	421:20 422:14	415:10,15,19,23	468:5,10,13,15,24
498:5 500:4,17,24	<b>shipments</b> 431:7	416:5,6,13,18	469:1,7,12,22
501:21 502:23	432:3 526:20	417:5,16,25	470:12,22 471:6
<b>series</b> 501:18	<b>shipped</b> 433:11	418:16,23 419:9	471:14,25 472:7
<b>serious</b> 323:13	465:5 554:15	419:15,23 420:9	472:17,24 473:5
<b>serve</b> 292:12	<b>shipping</b> 413:20	420:21 421:4,9	473:10,15 474:7
<b>serves</b> 328:3	443:9 444:10,19	422:2,9,20 423:4	474:13,18,24
<b>services</b> 272:14	444:20,23 448:22	423:13,16,24	475:9,15,24
534:10	449:22 453:8	424:9,12,19	476:10,16 477:6
<b>serving</b> 398:10	<b>shitty</b> 399:21	425:13,18 426:4	477:19,23 478:3
<b>set</b> 306:1,13	<b>shkolnik</b> 270:12	426:10,21 427:9	478:20,24 479:19
436:22 456:8	270:13 275:8,8	427:23 428:7,16	485:5,6 497:3
457:11 460:22	276:4 278:21	428:20,23,24	498:1,16 499:16
464:8 465:3	383:8,10 384:4,15	429:5,9,14,22	501:24 506:21,25
<b>setting</b> 456:2	385:4,9,11,18	430:1,4,24 431:15	507:4 508:7
<b>setup</b> 406:19	386:2,8,13,15	431:21 432:12,23	509:23 514:13,18
<b>seven</b> 454:12	387:14,16,24	433:3,7,18 434:4	518:18 519:4,6
	388:2,8,14,18,20	434:10,18,23	523:1,15,21

524:14 525:11	<b>sigh</b> 435:8	328:16,24 329:22	408:1,7,9 411:21
526:1,11 527:4	<b>signature</b> 321:15	330:2,7,16 331:6	412:7,17 413:5,15
528:9 529:7	556:20 557:14	332:10 334:20	413:23 414:9,12
530:12,15 531:14	<b>signed</b> 341:24	335:4,11,21	414:14,24 415:5
531:22 532:5	379:17 467:13	336:10 337:16	416:17 417:15,24
538:9 540:15	558:13 559:18	338:5,14,20 339:2	418:14,22 419:8
542:11 543:4,17	<b>significance</b> 411:7	340:20 342:11	419:11,21 420:8
545:2,16 548:18	<b>significant</b> 405:2	344:3,22 345:8,17	420:20 421:1
549:5,23 550:16	524:10	346:6,18,24 347:7	422:1,8,11,19,21
551:24 552:21	<b>signing</b> 557:19	347:13,23 348:3	423:3,5,8,15
553:19 554:17	<b>similar</b> 334:4	348:11,18 350:4,9	425:17 426:3,9
<b>short</b> 341:8 382:24	348:23	350:24 351:12,22	427:8,22 428:3
397:11 478:10	<b>simple</b> 448:17,17	352:3,11,24 354:9	429:3 430:10,11
518:20 521:21	<b>simply</b> 330:9	354:14 355:8	430:23 431:14,23
533:14 555:6	332:14 334:8	357:19 358:7,13	432:11,25 433:17
<b>shorthand</b> 556:7	363:17 426:19	358:25 361:20	434:3,12,15,22
<b>show</b> 297:24	<b>sincerely</b> 557:21	362:25 363:15,21	435:3,4,7,18
308:24 320:14	<b>singer</b> 483:13,20	364:5 365:12	436:17,19 438:6
321:15 336:12	<b>single</b> 418:2,4	366:13,18 367:7	439:13 440:12
341:18 356:11,17	420:3 542:21	368:24 369:9,16	441:8,13 443:20
362:12 424:4,13	543:2 554:14	369:22 371:25	444:5,7,16 448:18
427:16,18 428:9	<b>sir</b> 279:6 280:22	372:15,25 373:9	449:6,9,11,23,25
429:15 444:9	281:7,14,21 282:3	374:1,23 376:20	450:8,14,25
449:14 450:16	282:11,14,17	377:8 378:3	451:18 452:11
451:9 464:2 471:6	283:1,22 284:7,14	379:10,14,25	453:2,13 454:4,17
542:6,20 543:1	284:23 285:16	380:5 381:4,12	459:20 460:6
<b>showed</b> 280:18,19	286:6 287:11	382:17 383:15,23	461:9 463:2,12,25
291:7 295:4,18	288:1,12 291:20	384:3 386:16,24	464:16,23 465:25
318:13 346:22	292:4 293:13	386:25 387:7	466:5,7,14,16
355:18 502:9	295:2 296:2	388:4,7,22 389:3	467:5 469:6,11,21
<b>showing</b> 341:21	297:14 299:9	389:12,21 390:12	470:11,21 471:5
538:21 539:6	302:2,7,12 303:9	390:18 391:2,10	471:24 472:3
541:13,22	303:14 304:21	391:18,24 392:10	474:12 475:6,14
<b>shown</b> 426:16	305:10,20 307:10	392:18,25 393:9	475:23,25 476:9
435:21 503:3	307:19 308:11	393:15 394:12,13	476:12,15 477:10
557:16	310:1 311:17,22	394:25 395:6	486:23 495:17,21
<b>shows</b> 336:15,17	312:2,25 316:24	396:6 401:19	508:13 529:25
<b>shut</b> 548:15 549:1	318:1,10,19 319:4	402:12 403:9,18	536:5,9 537:7,16
<b>sic</b> 449:16	321:12 323:8,19	404:2,16 405:15	537:20 538:10
<b>side</b> 366:22	324:8 325:12,20	405:22 406:4	540:18 542:16
	326:9,21 327:8,22	407:19,21,24	543:6,11,22,25

544:6,11 551:19 551:23 552:6,13 554:7,25 557:10 <b>sit</b> 293:2 528:5 <b>site</b> 360:24 540:12 <b>site's</b> 358:17 <b>sites</b> 359:4 <b>sitting</b> 500:21,23 501:10 504:10 505:12 506:9 507:10 509:7 513:6,10 517:17 518:6 522:24 528:5 <b>situated</b> 372:5,13 <b>situations</b> 412:20 412:21 413:1,7,9 <b>six</b> 553:17 554:6 <b>size</b> 298:17 329:14 330:13 351:16,24 353:2,10,11,22 418:4,11 419:2 433:12 <b>skip</b> 393:16 <b>skipped</b> 277:15,22 <b>slamming</b> 513:7 <b>slide</b> 297:24 298:1 298:3 303:22 305:13 308:24 309:1,10 311:8 365:22 367:1 403:22 408:4 410:21 502:16 541:13,16,19,20 541:22 <b>slides</b> 297:18 318:4 364:24 502:8,10,14 508:3 <b>slow</b> 439:4 <b>smclure</b> 272:23	<b>smith</b> 272:21 274:7 276:2 392:2 402:3 498:24 512:11 520:4 522:6 523:7 528:16 <b>smith's</b> 531:5 <b>snicker</b> 501:14 <b>sold</b> 470:1 553:16 <b>sole</b> 344:25 362:7 <b>solomon</b> 275:10 <b>solution</b> 400:22 <b>solutions</b> 555:13 557:1 560:1 <b>somebody</b> 292:24 399:24 <b>sophisticated</b> 372:4 <b>sorry</b> 299:15 302:13 303:25 306:10 307:10 308:21 318:17 393:7 404:11 407:7 418:7 423:19,20 428:14 429:7,9 432:1,1 436:12 437:2 438:10,22 440:10 442:10 452:18 460:9 461:16 462:7 468:25 480:9 486:2 504:25 506:21 507:5 514:16 532:11 541:19 543:18 <b>sort</b> 396:1 412:9 456:24 491:14 <b>sounds</b> 445:9 <b>source</b> 325:6 472:2	<b>south</b> 270:18 274:9 <b>spaeder</b> 272:15 <b>sparsely</b> 359:15 <b>speak</b> 281:18,24 282:6,19 283:19 284:16 285:1 290:24,24 292:9 292:13,24 356:6 384:11 406:22 456:9 486:18,22 487:3 <b>speaking</b> 284:9 285:6 288:3 289:12 364:10,12 412:20 <b>speaks</b> 294:24 297:21 333:1 335:18 <b>spears</b> 275:5 <b>spec</b> 274:2 <b>special</b> 275:1 294:9 397:4,12,15 398:22 399:9 400:15,25 401:4,7 431:20 455:11,18 457:14 483:10 514:14,20 <b>specialist</b> 275:10 <b>speciality</b> 339:10 <b>specialty</b> 389:16 <b>specific</b> 279:21 285:24 288:22 345:11,22 346:13 375:8 378:12 384:11 441:21 445:2 447:7,9,13 452:3 460:3,5 472:15 473:21 477:1,4 507:22 517:3 545:17,25	546:9,10 547:16 548:21 549:21 550:19,23 552:20 553:8 <b>specifically</b> 288:15 335:15 342:21 344:13 356:7 384:6 417:2 496:14 501:12 502:12 504:3,12 505:13 506:12 507:11,14 509:8 510:20 517:18 518:7 519:2,11 521:7,10,13 522:14 547:7 <b>specifics</b> 447:18 511:21 512:5 <b>speculation</b> 501:22 502:1 <b>speculative</b> 448:14 <b>speech</b> 398:25 <b>spended</b> 490:23 <b>spent</b> 516:11 <b>spoke</b> 286:1 335:22 406:10 480:21 482:24 484:22 496:3,4,5 <b>square</b> 272:21 <b>sshkolnik</b> 270:15 <b>staff</b> 318:21 544:22 <b>stafford</b> 451:10 <b>stake</b> 524:12 <b>stamped</b> 277:5 490:22 <b>standard</b> 347:2,3 378:6,18 531:1,11 <b>standpoint</b> 452:24 <b>stanner</b> 273:8
---	---	---	--

<b>stars</b> 273:15	<b>stating</b> 385:13	<b>straight</b> 398:8	316:1 322:7 323:6
<b>start</b> 287:22	397:16,19 401:14	407:23	323:24 324:2,11
341:11 348:15	414:2	<b>stream</b> 413:12	324:23 325:2
352:16 374:7	<b>statistical</b> 538:21	<b>street</b> 269:8 270:4	326:11,13,25
383:2 455:4	539:6,10	270:23 272:3,9,16	328:14 329:10,18
457:21 494:6	<b>statute</b> 351:6,19	272:22 273:10,20	330:10 335:2
504:22 521:24	351:25 355:12	274:4,9,14,18	336:5 337:22
<b>started</b> 279:2	495:3,17 496:1,10	409:25	338:8,18,23 340:2
280:4 282:12	497:1 522:15	<b>stressed</b> 406:14	340:8 344:12,16
294:15 301:22	<b>statutes</b> 491:3	<b>strike</b> 285:11	344:20 348:8,15
303:12 398:18	<b>statutory</b> 327:11	308:25 335:13	350:14,19 352:21
420:6 444:21	331:10,16	369:3	358:21 359:11
451:14 452:20	<b>stay</b> 381:17	<b>strings</b> 463:19	368:20 369:6
454:13 536:2	<b>stayed</b> 381:25	<b>stuff</b> 506:6	371:8,19 372:7
<b>starting</b> 293:24	<b>steeped</b> 421:12	<b>subject</b> 358:19	373:4 391:13
459:1 494:13	<b>stenographic</b>	<b>submission</b> 419:25	396:13 405:6
<b>startling</b> 426:18	415:14	<b>submit</b> 308:16	407:17 432:4
<b>state</b> 444:2 455:23	<b>stephens</b> 271:17	491:23	433:11 448:7,22
542:2,8,15,22	291:13 301:15	<b>submitted</b> 307:17	452:17 466:20
544:18,25 558:10	302:1 319:18	310:15 354:22	469:2 537:12,21
559:15	326:20 385:1	<b>submitting</b> 305:11	537:23 542:7
<b>stated</b> 368:13	394:4,8,20,24	489:7,13 490:11	544:16
520:4	429:20 438:1	537:18	<b>substantial</b> 327:1
<b>statement</b> 372:9	454:10,16 461:8	<b>subparagraph</b>	353:22
372:22 373:6,23	465:14 469:20	357:1	<b>substantially</b>
376:17 379:3,7,16	550:4	<b>subscribed</b> 558:10	329:15 351:16
406:2 411:5,8,19	<b>steps</b> 325:4 361:9	559:14 560:21	352:19
412:14 423:1	<b>sticker</b> 437:3	<b>subset</b> 307:16	<b>substantively</b>
450:12 451:24	<b>stipulated</b> 332:4	<b>substance</b> 322:25	457:8
454:2 463:10	496:20 526:16	325:16 326:3	<b>suburban</b> 359:17
489:24 492:3	<b>stock</b> 408:23 465:4	328:3 343:8	<b>succinct</b> 400:9
500:5,7,9 525:1	<b>stone</b> 274:23	372:19 380:19,20	<b>sufficiently</b> 495:9
558:13,14 559:19	<b>stop</b> 316:3 357:22	416:3 431:7 432:1	<b>suggested</b> 317:16
559:19	374:25 456:15	433:24 544:17,24	361:3 436:14
<b>statements</b> 398:10	458:1,14 484:9	545:10 554:15	<b>suggesting</b> 465:21
<b>states</b> 268:2 270:8	<b>store</b> 461:17	<b>substances</b> 276:15	546:7
275:2,2,3,4,5,7	465:18,19 470:6	286:2 297:2 299:7	<b>suggests</b> 388:25
277:18 281:9	470:16,25 472:22	300:16 301:3	389:6 469:24
289:14,16 309:2	474:8 475:19	302:23 303:1	<b>suite</b> 270:9 271:13
527:20 542:23	<b>stores</b> 465:12	304:24 309:4	272:3,16,21 273:4
		312:8,17 315:4	274:19,24 557:2

<b>summary</b>	276:12 313:20 315:1,25 323:4 356:23 363:19,25 464:5	507:6 508:7 514:25	368:9,15 369:14 371:18,22 375:20	344:14 345:2,12 345:22 346:10,13
<b>summit</b>	268:13 270:16 278:12,18 384:7 484:13 532:14	<b>surgical</b> 393:3 <b>surprise</b> 419:6,11 <b>surprising</b> 418:24 <b>suspected</b> 310:20 <b>suspects</b> 438:12 439:5	376:4 379:6 380:15 381:1 403:25 405:1,5,8 407:14,16 408:5,6 408:12,12,16,20 408:24 409:15,15	366:24 375:4 380:13,14,16 381:1 382:4 405:4 407:16 410:13,14 415:22 417:8,13 439:22 441:9 487:8 488:17 494:4 538:3,4
<b>superior</b>	270:8 557:1	<b>suspend</b> 328:7 374:25 526:20	410:14,15 414:6 414:20 415:21	<b>systems</b> 417:13 440:23 539:16 553:14
<b>supervisor</b>	286:16 287:10,25 318:5 320:6 323:11	<b>suspension</b> 328:12 328:21 331:17 444:9 445:8 448:6	417:8,12,22 418:3 420:3,13 425:3,11 430:18 431:4	<b>t</b>
<b>supplement</b>	497:12	448:20 449:14 450:17 454:7	432:14 433:21 436:24 438:15	<b>t</b> 276:1,1 341:24
<b>supplied</b>	460:18 467:19 543:1	<b>suspicion</b> 311:3	443:7,24 444:11	<b>tail</b> 301:7
<b>supplier</b>	410:24 431:7 432:3,6 433:8	<b>suspicions</b> 438:16 439:9 440:5	444:19 448:11 452:17 453:6,19	<b>tails</b> 298:9 300:12 301:9,21 317:16 333:16 359:23
<b>suppliers</b>	440:1	<b>suspicious</b> 276:24 283:5,17 303:22	461:14 476:4,21 494:24 525:16,17	<b>take</b> 296:12 321:3 325:4 330:24 341:3 357:3 358:16 361:9 382:18,19 429:17
<b>supply</b>	274:21 372:4 373:4 460:21,23 467:24	304:5 308:15 309:6,12,21	526:6,10,16,19,22 531:2,6 544:8	430:5 454:20 463:19 483:10 491:14 499:14 508:2 514:21 520:20 521:5,15 529:16
<b>support</b>	322:16 372:6	310:12,20 311:3 317:18 329:9,12	546:20 547:11,12 547:23 548:6,24	<b>taken</b> 341:8 346:12 366:10 382:24 397:11
<b>supportive</b>	323:16	329:13 330:12,21 331:9,12 332:15	549:9 550:12,22 551:7,15,22	455:1 478:10 521:21 533:14
<b>supports</b>	322:13	332:16 334:9,10	552:16 553:1,2,5 553:10	549:17 553:9 555:6 556:3,7,14
<b>supposed</b>	293:4 450:22	343:9 344:11,15	<b>swedesboro</b> 450:18	<b>talk</b> 288:16 378:12 378:13 428:15 447:6,18,21 457:8 477:1 486:14
<b>supreme</b>	303:17	345:12,23 346:11	<b>sweet</b> 349:21	
<b>sure</b>	281:1,23 291:9 295:10 306:10 307:12 308:23 322:4 326:12 363:24 378:17 407:11 418:8 424:9 430:1 445:17 474:25 486:5 490:3,6 505:9,20 506:10	347:2,10,18 348:5 349:1,25 350:13 350:16 351:2 352:1,18 353:4,9 353:12,17 354:18 354:21,25 355:1 355:19 357:2,11 357:13,24 358:18 361:17 362:1 363:7 364:25 365:23,24 366:22 366:24 367:2	558:10,13 559:14 559:18 560:21	
			<b>synopsis</b> 404:8,13 <b>system</b> 276:25 277:21 297:8 299:6 304:24 309:5 314:6 324:25 325:24 329:8 336:22	

489:1 501:15	422:11 423:19	289:23	401:3,6 402:22
548:21	461:15 476:19	<b>testifying</b> 486:6	409:1 424:10
<b>talked</b> 363:7	479:14 485:24,25	498:23 508:24	430:2 447:4 458:9
457:25	505:13 506:10	509:3 512:14	468:10 480:14
<b>talking</b> 280:24	528:15 539:2	522:9 524:22	486:8 492:16
345:20 364:20	<b>telling</b> 345:20	533:2 535:19,21	498:22 521:14,16
369:19,23 371:15	409:13,17 421:22	<b>testimony</b> 280:13	535:10,11 540:7
399:3 428:18,21	422:21 425:24	281:12 283:25	540:14 541:8
491:25 499:18	432:8 444:22	285:9,20 286:25	543:22 550:3
512:19	451:14 452:20	289:4 290:8	551:3 554:22
<b>talks</b> 311:8 327:10	454:13 488:21	294:24,24 296:6	<b>that'd</b> 412:24
365:24 406:7	494:17 502:14	296:14,23 335:7	<b>thick</b> 435:24
550:19	<b>tells</b> 538:12,16	335:22 336:1,7	<b>thing</b> 288:16 294:4
<b>targeting</b> 536:11	<b>ten</b> 367:16 399:13	367:20 427:11,13	399:23 423:22
544:13	<b>tenth</b> 273:10	427:20,25 428:10	521:9
<b>tasked</b> 536:25	<b>term</b> 300:4 310:21	431:12 448:13	<b>things</b> 299:12
<b>tayman</b> 270:3,3	<b>terminated</b> 285:3	478:25 480:2	300:25 352:16
438:20 457:23	361:16	485:17,18 497:17	370:24 382:3
480:22,24 482:3	<b>termination</b> 285:7	498:8,21 499:4,15	400:17 458:14
482:11,13 483:16	<b>terminology</b>	499:20,25 501:2	476:1 489:2
483:23 484:17	464:19 516:22	503:18 514:1	501:15 504:2
485:20,24 553:25	<b>terms</b> 287:15	517:25 520:4	505:8 506:11,12
557:5	415:2 416:2	522:5,23 523:7,18	520:11
<b>team</b> 451:22	436:23 460:14	528:4,6,7,25 529:3	<b>think</b> 282:22
536:24	472:8 480:16	530:6 531:13	283:7,9 294:13
<b>tears</b> 287:4	496:5	532:8,19 534:3	302:16 309:2
<b>technique</b> 545:19	<b>test</b> 530:8	535:1,18,25 537:6	316:19 318:11
<b>techniques</b> 290:1	<b>testified</b> 288:21	547:10 555:9	319:12 329:4
546:10	294:18 295:7	556:5,6,10 558:6,7	349:10 352:17
<b>tedious</b> 291:6	316:19 319:13	559:6,9,12	360:5 367:18
<b>teleconference</b>	343:16 397:25	<b>teva</b> 277:8 459:7	388:14 394:15
270:22 271:12,21	427:15,19 484:12	459:13	398:2,12,13 399:3
273:3 274:12,22	487:7 492:5,18	<b>texas</b> 273:5 279:13	399:25 400:3,4
275:9	493:5 503:8	385:6 386:21	402:6 406:8 407:7
<b>telephone</b> 480:10	512:10 513:13	451:10 500:25	407:9 411:25
480:11 481:11	524:1,4 525:5	541:5,15 552:4	428:21 435:22
482:9 483:21	526:25 530:19,25	<b>thank</b> 278:11	442:20,25 456:24
486:19	531:4,10,20 536:1	320:24 321:1	457:1 462:20
<b>tell</b> 279:6 283:9	537:9	333:24 341:15	473:7 477:16
291:10 305:23	<b>testify</b> 281:4	349:20 365:9	478:1 479:18
311:9 406:12	287:13,14 289:23	388:22 400:13	485:4 493:1

498:20 501:25	341:7,13 349:17	289:24 293:2	<b>trade</b> 422:5,12
512:10 513:12	368:21 382:23	374:17 381:23	493:1
514:20 516:9	383:4 397:10	458:6 486:11,20	<b>traditional</b> 298:19
521:1 522:12	399:16 401:10	487:1,5 500:21,23	<b>trails</b> 457:2
525:20 530:3	407:3 410:7 411:2	501:10 504:10	<b>training</b> 488:25
540:17	415:2 421:8,14	505:12 506:9	<b>trainings</b> 539:10
<b>third</b> 283:3 380:10	424:20,21 425:21	507:10 509:7	<b>transaction</b> 443:8
380:13 473:19	426:6 429:2	517:17 518:6	443:11,13,23
<b>thirty</b> 557:18	433:22 446:8	535:20,24,25	472:12
<b>thompson</b> 275:8	454:25 455:6,13	<b>today's</b> 485:18	<b>transactions</b>
<b>thornburg</b> 274:8	455:18 456:4,8,21	555:9	306:24 307:17
<b>thoroughly</b> 357:25	457:4 458:8,17,25	<b>told</b> 376:22 422:4	440:3 441:1 443:8
<b>thought</b> 428:18	461:11 477:8,12	426:7 427:2 428:1	443:25 463:15
435:15 445:7	477:15 478:9,13	436:12 448:9,24	464:5 465:2
446:1,2 498:9	479:23 480:1	449:19 450:5,22	<b>transcribed</b> 558:7
502:15 506:6	485:14 491:25	453:10 456:12,12	<b>transcript</b> 277:25
520:7,8	493:9,18,24 499:7	456:13 479:5	499:17 524:15
<b>thousands</b> 501:15	503:5 506:24	488:16 489:5,11	557:11,12 558:5
<b>three</b> 271:3 272:21	514:15,18 516:11	490:9 491:23	558:12 559:5,11
286:15 287:4	517:24 521:20	493:13 523:17	559:17
343:24 353:3,3	522:1 526:7 529:9	526:15,20 528:11	<b>transcription</b>
390:15 451:13,15	533:13,17 547:18	531:9	556:9
452:19,20 453:10	552:17 553:22	<b>tom</b> 424:16	<b>transferred</b>
<b>threshold</b> 375:3,9	555:5	<b>tomorrow</b> 458:2	279:15
433:20	<b>timed</b> 478:3	<b>tool</b> 553:13	<b>transition</b> 493:24
<b>thresholds</b> 380:16	<b>times</b> 282:23	<b>tools</b> 543:14 544:2	494:15
380:22	318:6 425:19	<b>top</b> 373:12 402:16	<b>transmission</b>
<b>throwing</b> 426:18	479:21 498:12	430:15 458:18	464:7
<b>thursday</b> 278:25	518:12 526:25	493:24 551:8	<b>transmitted</b>
288:18 289:23	527:5	<b>topic</b> 285:6 403:22	463:18 464:6
383:11,14 384:17	<b>timing</b> 452:7,10,24	540:16,18	465:3
462:17 464:19	<b>title</b> 344:12 356:22	<b>topics</b> 285:24	<b>treated</b> 473:23
486:7,19,25 487:4	371:16 407:14	287:1,3 288:3,6	<b>trends</b> 544:15,23
<b>tied</b> 522:14	459:8	454:19	545:9
<b>tiers</b> 286:15	<b>titled</b> 539:14	<b>total</b> 555:11	<b>trial</b> 383:21
<b>ties</b> 280:1	<b>titles</b> 377:11	<b>totally</b> 489:18	427:11,16 498:21
<b>time</b> 291:16	<b>tlclawfirm.com</b>	534:1	498:24 499:20
293:19 296:12,15	270:6	<b>tower</b> 274:4	512:11 513:13
299:23 301:10	<b>today</b> 280:18	<b>town</b> 359:20	522:4,23,23 523:6
303:11 308:4	281:5 283:20	439:22	523:7,19 524:1,5
319:23 321:21	284:11 285:10		525:6 528:25

529:3	<b>tweel</b> 270:22	348:9,14 352:20	542:23
<b>tried</b> 326:6 491:14	<b>two</b> 279:12 282:16	353:18 355:21	<b>units</b> 375:8 538:22
491:17 533:21	283:11 329:4	360:21 362:7	539:7 542:20
<b>trouble</b> 519:20	341:22 397:24	368:19 369:2,7	543:1 555:11
<b>true</b> 303:6,11	478:1 479:1	370:19 375:16	<b>unrelated</b> 460:4
311:14,19 312:4	481:23 508:9	376:1 382:7	<b>unsigned</b> 471:9
335:16 346:3	553:21 554:1,9,18	405:10,18 407:18	473:11,12
347:25 350:6	<b>type</b> 279:17	407:23 408:14	<b>unusual</b> 329:14,16
354:11 355:9	389:23 402:16,24	409:16 410:6,25	351:15,17 353:2,2
374:15 534:2	403:7 420:12	412:19 416:24	353:10,11 418:4
542:9,23 543:3	470:2 484:23	418:18 430:19	418:11 419:2
556:10	<b>types</b> 543:9	431:8 432:24	<b>usc</b> 285:22 337:11
<b>truly</b> 300:20	<b>u</b>	433:14,25 435:12	344:7
<b>trusted</b> 326:3	<b>u.s.</b> 270:7 289:16	438:17 439:10	<b>usdoj.gov</b> 270:10
<b>try</b> 297:6 395:13	527:21	440:17,19 441:3	<b>use</b> 310:21 323:12
401:15 402:18,20	<b>u.s.c.a.</b> 277:16	444:1 455:9 462:1	380:19 467:23
415:25 416:9	<b>uh</b> 408:21	472:4 476:1	485:13 524:15
439:3 490:5	<b>ultimately</b> 513:16	487:22	<b>uses</b> 327:24
543:21 546:13	528:6,8	<b>understood</b>	<b>usual</b> 314:2
<b>trying</b> 322:14,17	<b>unable</b> 443:12	284:12 285:8	<b>utilized</b> 325:6
324:5,18 325:9	<b>uncommon</b> 407:2	297:12 301:10	403:11 421:12
340:4 360:6,16,19	<b>underneath</b> 364:9	303:1 308:4 322:5	435:13 505:5
367:19 381:18	364:23,24 366:2	360:6,18 398:4	<b>v</b>
396:10,18 398:2	366:22	487:25 495:16	<b>v</b> 268:9,13 557:6
410:3,7 416:15	<b>understand</b> 281:6	523:24 526:24	558:3 559:3
426:19 456:25	283:18 284:1,4,21	<b>undoubtedly</b>	<b>vague</b> 336:7
457:11 511:9	285:13,25 291:9	323:12	<b>vaguely</b> 385:10
515:16 546:5	308:20 312:7	<b>unfortunately</b>	416:22
<b>tucker</b> 271:12	323:3 339:21	467:13 498:25	<b>valid</b> 314:3
<b>tuckerellis.com</b>	343:12 355:19	<b>unilaterally</b> 456:4	<b>vanni</b> 272:2
271:15	359:10 386:18	<b>uniquely</b> 372:5,12	<b>variables</b> 300:21
<b>turn</b> 332:16	405:18 440:11	<b>unit</b> 278:6 341:6	<b>variation</b> 488:5
334:10 364:20	447:12,23,24	341:11 382:22	<b>variations</b> 488:9
366:20 373:11	455:22 456:22	383:2 454:24	<b>variety</b> 337:22
376:8 389:14	458:22 509:15	455:4 521:19,24	338:7 370:24
402:14 404:4	515:12,13 520:25	536:11,12,14,21	<b>various</b> 282:20,23
410:18 416:19	528:11	536:24	383:19 385:21
418:1 430:13	<b>understanding</b>	<b>united</b> 268:2 270:8	503:4,22 505:9
433:1 438:7	293:3 312:15	275:2,2,3,4,5,7	<b>vein</b> 334:5
442:19 473:16	313:14 330:11	277:18 281:9	<b>vendor</b> 464:3,4,6
541:6	331:24 347:5	289:14,16 527:20	465:1,18,19

<b>vendors</b> 467:20	469:17 470:6,24	395:21,22 396:2	491:25
<b>ventura</b> 273:19	475:18	400:16 407:11	<b>web</b> 540:12
<b>verbally</b> 318:25	<b>visible</b> 333:19	408:18 441:24	<b>week</b> 283:20 285:9
<b>verbatim</b> 500:11	<b>vol</b> 557:8 558:4,9	446:7 456:18	291:23 302:17
<b>verify</b> 373:20	559:4,13 560:20	457:12,24 467:14	316:22 335:6,18
<b>veritext</b> 555:12	<b>volume</b> 268:18	481:25 489:21,22	346:22 355:18
557:1,7 560:1	278:6	500:11 511:20	369:19 458:17
<b>veritext.com.</b>	<b>volumes</b> 546:6	512:2 526:8	468:1 493:6,14
557:17	<b>vs</b> 268:11 277:18	533:25 534:5	508:24 509:4,18
<b>version</b> 407:10	<b>w</b>		
438:11	<b>wacker</b> 271:22	541:11	516:11 525:7
<b>versus</b> 300:22	<b>wagmdl003959...</b>	<b>wanted</b> 325:14	<b>week's</b> 485:17
367:2 408:12	277:4	456:17 523:18	<b>weekly</b> 354:22
510:16 512:6	<b>wait</b> 477:19,19	<b>wants</b> 357:21	464:6 465:4,20,22
527:20	<b>waites</b> 275:7	358:19 403:13	<b>welcomed</b> 419:22
<b>vice</b> 406:9 424:5	<b>waived</b> 557:19	<b>warning</b> 479:16	<b>welfare</b> 327:2
<b>vickie</b> 318:14,20	<b>walgreen</b> 274:16	<b>warrant</b> 331:15	<b>went</b> 321:21
<b>video</b> 278:7	274:16 394:17	<b>warrington</b>	322:10 342:21
446:11	459:15,18 460:11	274:24	358:15 410:16
<b>videographer</b>	460:21,23 461:1	<b>washington</b>	430:20 457:25
275:10 278:3	467:16 470:3	268:20 269:9	503:9 516:4
341:4,9 382:20,25	471:9,18 473:13	270:5 272:10,17	525:16 531:18,25
397:9 401:8 447:2	<b>walgreens</b> 394:3	273:11,20 294:15	<b>west</b> 270:8,23
454:22 455:2	437:25 454:6	294:21 321:10	271:22 453:23
477:12,14,21	459:23,24 460:13	405:12,19 461:13	<b>wewatta</b> 274:18
478:7,11 521:17	461:5,16 464:3,4	<b>waste</b> 554:18	<b>whatsoever</b>
521:22 533:11,15	464:12 465:1,8,11	<b>watch</b> 358:18	321:18
555:3,7	466:11 467:23	<b>watson</b> 395:2	<b>whichever</b> 411:15
<b>videotaped</b> 268:19	469:14 470:7	<b>way</b> 333:14 396:9	<b>wholesale</b> 357:24
269:1	471:2 473:24	406:6 421:18	406:17 416:20
<b>view</b> 322:25	<b>walked</b> 498:16	425:22,23 433:3	417:10 418:7,8
553:15	<b>walker</b> 551:6,20	457:12 470:5,16	419:4 420:10,11
<b>viewed</b> 433:21	<b>walmart</b> 271:16	475:3 476:1	420:24 424:23
<b>vigilant</b> 326:1	<b>want</b> 281:22 291:8	508:21 509:17	425:7 465:20,22
<b>violating</b> 448:7,21	294:6 296:12	517:21 531:13	466:4
<b>violation</b> 334:25	297:24 304:2	<b>ways</b> 490:24	<b>wicht</b> 272:8
452:18	313:21 339:12	<b>wc.com</b> 272:11,11	<b>widgets</b> 408:18
<b>virginia</b> 270:23	340:5 341:18	272:12,12	<b>william</b> 274:3,8
<b>visibility</b> 411:25	364:7 368:1	<b>we've</b> 287:1,1	<b>william.davison</b>
412:1 462:19,23	373:11 378:11	288:3 344:17	274:6
464:20 466:3	382:18 387:18	369:23 394:17	<b>william.padgett</b>
		402:6 463:14	274:10

[williams - witness]

Page 51

<b>williams</b> 269:7	319:4,9,19,25	382:11,17 384:3	463:25 464:16,23
272:9	320:10 321:18,24	384:13 385:2,10	465:16,25 466:7
<b>wisconsin</b> 453:20	322:20 323:8,19	385:17 386:1	466:16,23 467:5
<b>wish</b> 458:16	324:8,14,21	388:7 389:12,21	469:6,11,21
500:13	325:12,20 326:9	390:3,18 391:2,18	470:10,21 471:5
<b>withdraw</b> 387:8	326:16,21 327:8	391:24 392:18,25	471:24 472:10
404:12 410:4	327:22 328:16,24	393:9,15,25	473:3 474:12,22
413:8 420:13	329:22 330:2,7,16	394:25 395:6,19	475:14,23 476:9
428:17 436:19	330:20 331:6	396:6 397:22	476:15 477:5,10
437:5,6,13 440:20	332:2,10 334:20	398:12 400:23	482:6 486:2
442:4 462:7	335:4,11 337:4,16	401:19 402:12	487:22 488:20
492:14	338:5,14,20 339:2	404:2,16 405:15	490:20 491:5,17
<b>withdrawn</b> 464:10	339:8,21 340:10	405:22 406:4	492:16 495:13,15
519:7	340:20,25 342:3	407:2,21 408:1,9	496:13 497:4,13
<b>withdrew</b> 437:9	342:11,15,20	408:16 409:10,24	499:22 500:15
<b>witness</b> 270:2	343:2 344:3,22	410:12 411:4,10	501:8,25 504:8
282:3 283:1,22	345:8,17,25 346:6	411:21 412:7,17	505:18 506:16
284:7,14,23	346:18,24 347:7	412:24 413:5	507:18 508:9,11
285:16 286:6,21	347:13,23 348:3	414:9,14,24 415:5	508:14,17 510:6
287:7,19 288:12	348:11,18 350:4,9	416:12,17 417:1	511:2,19 512:24
289:1,9,20 290:5	350:24 351:5,12	417:15,24 418:22	514:4,6,23 515:13
290:13,21 291:4	351:22 352:3,11	419:8,13,21 420:8	518:13,20,24
291:20 292:4,7,21	352:24 353:7,14	420:20 421:3,7	519:5,8,14 520:3
293:13 295:2	353:20 354:1,9,14	422:1,8,19 423:3	520:23 522:19
296:9,24 297:6,22	355:12,23 357:19	425:17 426:3,9,15	523:3,14,22
298:14,22 299:3,9	358:7,13,25 359:7	427:8,22 428:5	524:25 525:14
299:15,22 300:12	359:14 360:5,13	430:23 431:14,20	526:4 527:6
300:19 301:18	361:2 362:3,10	432:11 433:17	528:10,19 529:9
302:2,7,12 303:4,9	363:15 364:5	434:3,17,22	530:1,24 531:16
303:14 304:2,5,12	365:12 366:7,13	435:18 436:9,17	532:6,20 533:1,3,6
304:21 305:1,20	366:18 367:7	438:24 439:1,13	533:22,23 534:7
306:7,19 307:2,10	368:12,13,24	439:15 440:8,22	534:14 535:2,7,8,9
307:13,19 308:1	369:9,16 370:3,18	441:6,13 443:20	536:5 537:7
308:20 309:8,20	371:5,11,25	444:5,16 446:24	538:10 539:1
310:1,8,14 311:2	372:15,25 373:9	447:6,24 449:6,11	541:1 542:1,13,17
311:17,22 312:2,6	374:1,7,23 375:19	449:25 450:8,14	543:6,18 544:11
312:19 313:16	376:3,20 377:1,8	450:25 451:6,18	545:4,21 546:11
314:8,16,24 315:9	377:22 378:3,14	453:2,13 454:4,17	546:17 547:3,18
315:17,22 316:7	378:23 379:10,14	456:16 457:14	550:25 554:5,8,25
316:24 317:5,12	379:25 380:5	460:2,6 461:9,22	556:4,7,11 557:8
317:20 318:1	381:4,12,16	462:14 463:2,12	557:11 558:1,4,11

559:1,4,15	504:10 507:11	507:10 554:9
<b>witness's</b> 280:13	508:5 510:8 512:1	<b>york</b> 270:14,14
396:19	521:4 522:4 524:9	271:4,4
<b>witnesses</b> 455:20	527:15 530:24	<b>z</b>
<b>witness'</b> 557:14	531:10 532:9	<b>zachary</b> 274:22
<b>wonder</b> 528:21	535:14 539:23	<b>zimmerman</b> 406:8
<b>word</b> 282:22 283:8	540:21 541:3	406:14
367:16 395:21,25	551:12 555:10	<b>zip</b> 541:24
396:9,10 399:12	557:8 558:4,9	<b>zmartin</b> 274:25
400:10 401:15	559:4,13 560:20	<b>zoom</b> 387:14
410:2,6 491:20	<b>wright's</b> 447:10	404:5
520:8	<b>writes</b> 354:17	<b>zuckerman</b> 272:15
<b>words</b> 343:24	<b>writing</b> 513:5	<b>zuckerman.com</b>
367:19 396:18	<b>written</b> 314:1	272:18
399:13 472:14	379:18 459:22	
<b>work</b> 339:5 384:5	513:3 527:19	
400:21 458:23	<b>wrong</b> 291:24	
476:18,19 477:22	437:3 498:2	
489:1 546:20	<b>wrote</b> 323:11	
<b>worked</b> 318:23	368:12 372:17	
431:9 511:4,4	375:1 377:10	
550:24 554:8	424:22 510:16	
<b>working</b> 365:14	530:5	
384:1 405:11,20	<b>wva</b> 277:24	
411:1 416:2,7	<b>y</b>	
420:25 462:9	<b>yeah</b> 398:22	
488:18 536:8	402:19 428:16	
<b>workload</b> 529:12	438:21,25 440:18	
<b>works</b> 294:12	442:17,24 445:4	
<b>worst</b> 528:23	529:19	
529:1	<b>year</b> 382:1 480:19	
<b>worth</b> 541:5	484:1 499:5 526:7	
<b>wright</b> 268:19	<b>years</b> 282:16	
269:1 278:8	284:17 286:12	
341:21 357:11,13	288:9 336:18	
383:9 401:13	383:23 414:2	
436:21 447:17	451:14 452:19	
458:6,13,18 459:5	453:9,24 454:13	
459:9 478:18	461:12 487:16	
490:8 497:11	492:20 495:15	
500:3,10,22 502:5	504:15 505:2	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF SEPTEMBER 1, 2016. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS  
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at [www.veritext.com](http://www.veritext.com).